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Kainate receptors (KARs) are glutamate-gated ion channels that regulate 
neuronal excitability and network function in the brain. They can signal through 
both canonical ionotropic and a non-canonical metabotropic pathway. They 
regulate neuronal excitability by undergoing plasticity themselves while also 
regulating plasticity of other receptors. Most KARs contain the subunit GluK2 
and the precise properties of these GluK2-containing KARs are determined by 
additional factors including ADAR2-mediated mRNA editing of a single codon 
that changes a genomically encoded glutamine (Q) to an arginine (R), which 
affects their assembly, trafficking and channel properties.  
I initially set out to study the role of KARs in various forms of plasticity including 
long term potentiation (LTP) and long term depression (LTD) of AMPA 
receptors (AMPAR) and homeostatic scaling of KARs themselves. I was 
unable to reliably replicate previous data showing transient KAR stimulation 
leads to their increased surface expression which in turn increases AMPAR 
surface expression. Interestingly however, I discovered that sustained KAR 
stimulation decreased AMPAR surface expression leading to AMPAR LTD.  
In addition, I identified that KARs undergo homeostatic plasticity whereby they 
upscale and downscale in response to changes in the network activity. My 
findings show that ADAR2-dependent Q/R editing of GluK2 is dynamically 
regulated during homeostatic plasticity elicited by the suppression of synaptic 
activity. This suppression of synaptic activity decreases ADAR2 levels by 
enhancing their proteasomal degradation, which selectively reduces the 
numbers of GluK2 subunits that are edited. This loss of editing results in 
increased KAR oligomerisation and ER exit to increase the surface expression 
of GluK2-containing KARs. Furthermore, I show that partial ADAR2 
knockdown phenocopies and occludes TTX-induced scaling of KARs. These 
data indicate that activity-dependent regulation of ADAR2 levels and GluK2 
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1.1 Synaptic transmission 
1.1.1 Synapses 
Neurones are specialised cells in the brain comprising of a cell body that 
projects out long neurites; which can be axons or dendrites. These neurites 
can extend great lengths into the neighbouring brain regions to form synapses. 
Synapses are specialised structures that allow neurones to receive and 
transmit information in the form of chemical or electrical signal. Synapses are 
junctions where a pre-synaptic membrane of a neurone (axon), that passes 
the signal, comes into proximity with the post-synaptic membrane of 
neighbouring neurone (dendrites), which receives the signal [Figure 1-1]. A 
neurone can form around 10,000 such synapses, all of them highly dynamic 
and responsive (Choquet and Triller 2013, Alberts 2015, Henley and Wilkinson 
2016). 
1.1.2 Chemical synapses and transmission 
Chemical synapses consist of pre- and post-synaptic terminals separated by 
the synaptic cleft, which is filled with matrix that allows these terminals to 
adhere. The pre-synaptic terminal (axons) consists of synaptic vesicles (SVs) 
containing neurotransmitters either as part of the readily releasable pool or as 
part of the recycling/reserve pool (Denker and Rizzoli 2010). Neurones 
express voltage-gated sodium and potassium-permeable channels on their 
plasma membrane that generate action potentials once the depolarisation of 
the membrane reaches above the threshold level (Catterall 1995, Lodish H 
2000).   
The action potential is then propagated along the axon and upon reaching the 
axon terminal leads to Ca2+ influx through the opening of voltage-gated Ca2+ 
channels (Llinas, Steinberg et al. 1981). This influx triggers exocytosis 
whereupon the SVs fuse with the pre-synaptic membrane to release the 
neurotransmitters into the synaptic cleft (Heuser, Reese et al. 1979, 
Heidelberger, Heinemann et al. 1994, Hilfiker, Pieribone et al. 1999), which 
then diffuse across and bind to their specific ionotropic and/or metabotropic 
receptors on the post synaptic membrane (dendrites) (Wilcox, Buchhalter et 
al. 1994).  
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Activation of these ionotropic and metabotropic receptors via neurotransmitter 
binding results in ion flow or second-messenger signalling cascade in the case 
of metabotropic receptors (Pin and Duvoisin 1995, Conn and Pin 1997) 
[Figure 1-1]. This triggers changes in the post-synaptic membrane potential 
and conductance. If the membrane potential changes are above the threshold 
level, action potential is triggered, and the chemical signal is converted to an 
electrical signal.  
 
Figure 1-1: Synaptic structure.  
Synapse is a specialised structure where a pre-synaptic membrane (axon) is near the 
post synaptic membrane (dendrites), separated by the synaptic cleft. Upon receiving 
action potential, the pre-synaptic terminal releases neurotransmitters into the synaptic 
cleft, which diffuses across and bind to their specific ionotropic and/or metabotropic 
receptors in the post synaptic membrane. This results in downstream signalling 
cascades, triggering changes in the post synaptic membrane potential and 
conductance which generates the action potential, thus allowing information transfer.  
1.1.3 Excitatory and inhibitory transmission 
Depending on the type of neurotransmitters being released and the 
subsequent receptor activation, the effect can be excitatory or inhibitory in the 
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postsynaptic neuron. The excitatory axon terminals typically synapse on to the 
dendritic spines, which are small protrusions from dendrites; while the 
inhibitory axon terminals predominantly synapse onto the dendritic shafts 
(Kandel 2000, Megias, Emri et al. 2001).  
Ionotropic glutamate receptors mediate the excitatory neurotransmission, 
which contribute to the excitatory postsynaptic potential (EPSP) (Wisden and 
Seeburg 1993). On the other hand, majority of the inhibitory transmission is 
mediated by inhibitory receptors such as Gamma-AminoButyric Acid (GABA) 
receptors (GABAAR and GABABR), which generate the inhibitory postsynaptic 
potential (IPSP) (Connors, Malenka et al. 1988, Wilcox, Buchhalter et al. 1994, 
Sigel and Steinmann 2012). 
1.1.4 Measuring synaptic transmission 
Excitatory post-synaptic potential (EPSP) is triggered by the momentary 
depolarisation of cell following the flow of positively charged ions into the 
postsynaptic cell, which can potentially lead to generation of action potential. 
Excitatory post synaptic currents (EPSCs) are the flow of ions that cause 
EPSP. These changes in either the amplitude or frequency of EPSCs can be 
measured using electrophysiological techniques. Typically, changes in the 
EPSC frequency are attributed to altered presynaptic neurotransmitter release 
probability and/or altered numbers of synapses. Changes in the peak 
amplitude is an indication of altered numbers of postsynaptic receptors and 
the number of neurotransmitters released in each quantum (2015). 
EPSC recordings can be generated with experimental stimulation (evoked) or 
without experimental stimulation; which can be spontaneous(s) or 
miniature(m) EPSCs. sEPSC is generated by release of neurotransmitters 
which can be both  action-potential-dependent and independent while 
mEPSCs are detected in the absence of presynaptic action potentials, solely 
due to spontaneous SVs release (Holz RW 1999, Kandel 2000, Mozrzymas 
2008, Pinheiro and Mulle 2008).   
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1.2 Ionotropic glutamate receptors 
Ionotropic glutamate receptors (iGluRs) mediate almost all of the excitatory 
neurotransmission in the central nervous system (CNS) (Wisden and Seeburg 
1993). They are multi-subunit receptors where each subunit is made up of 
extracellular N-terminus, 3 membrane spanning domains, one re-entrant loop 
and an intracellular carboxy-terminal domain (C-terminal) (Henley and 
Wilkinson 2016) [Figure 1-2]. These subunits assemble into a tetramer 
forming the ion channel which upon glutamate binding is opened to pass ions 
into the post-synaptic membrane (Safferling, Tichelaar et al. 2001). 
There are three main types of glutamate receptors: 
• α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR) 
• Kainate Receptor (KAR) 
• N-methyl-D-Aspartate receptor (NMDAR) 
 
Figure 1-2: General iGluR subunit structure and topology.  
iGluRs share similar structure and topology to an extent. Each subunit consists of 3 
membrane spanning domains (TMI, III and IV), extracellular N-terminus, one re-
entrant loop (TMII) and intracellular carboxy-terminal (C-terminus).  
Delta family of ionotropic glutamate receptors (GluD1 and GluD2) also exist 
however, they do not show typical agonist induced ion channel currents 
(Yamazaki, Araki et al. 1992, Lomeli, Sprengel et al. 1993). They are 
unresponsive to glutamate but bind neurotransmitters D-serine and glycine 
(Naur, Hansen et al. 2007) and have been shown to have an important role in 
synaptogenesis by interacting with pre-synaptic proteins such as Neurexins  
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(Yuzaki and Aricescu 2017). For instance, GluD2, which is predominantly 
expressed in cerebellar Purkinje cells, was shown to bind to Cerebellin 1 
(Cbln1) which in turn binds to presynaptic receptor neurexin 1 in parallel fibre 
terminals. Mice lacking GluD2 had reduced number of these purkinje cells-
parallel fibre synapses and restoring GluD2 levels restored normal level of 
these synapses (Yuzaki 2013). GluD1 was also shown to be able to induce 
synapse formation by binding to Cbln 1 and Cbln 2 which interacts with 
neurexin in vitro (Matsuda, Miura et al. 2010, Yasumura, Yoshida et al. 2012).  
1.2.1 AMPARs 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) 
AMPARs are tetrameric assemblies made up of four possible subunits; GluA1, 
GluA2, GluA3 and GluA4 (previously referred to as GluR1-4), encoded by the 
genes GRIA1-4 respectively. They assemble predominantly as heterodimers 
(Hollmann and Heinemann 1994) but can also assemble as homodimers 
(Wenthold, Petralia et al. 1996, Lu, Shi et al. 2009).  
1.2.1.1 AMPAR subunit diversity 
The AMPAR subunits are highly homologous in their domains, with ~70% 
amino acid residue identity while their C-terminal is the most variable region 
(Collingridge, Isaac et al. 2004). Additional factors such as alternative splicing 
and RNA editing add further diversity to the AMPAR subunits. Alternative 
splicing leads to the so-called flip/flop exon variants being produced that cause 
alterations in the receptor desensitisation rate and the channel closing kinetics 
(Lambolez, Ropert et al. 1996, Pei, Huang et al. 2009). This flip/flop alternative 
splicing occurs in the connecting loop in between transmembrane region TMIII 
and IV at the C-terminal end (Sommer, Keinanen et al. 1990). There are other 
forms of post-transcriptional modifications (RNA editing) that occur such as 
Q/R editing and R/G editing adding further diversity to the subunits and altering 
their functional ionotropic properties such as Ca2+ permeability and 
desensitisation properties [Figure 1-3]. (Sommer, Kohler et al. 1991, Lomeli, 
Mosbacher et al. 1994) [RNA editing discussed in detail in section 1.5]. 




Figure 1-3: Schematic of an AMPAR subunit.  
The N-terminal region in combination with the region between TMIII and TMIV form 
the ligand binding domain. The variable C-terminal region allows for subunit specific 
protein-protein interactions. Alternative splicing leads to the flip/flop exon variants. 
GluA2 subunit also undergoes RNA editing process, such as the Q/R editing, which 
occurs in the TMII region (black arrow).  
1.2.1.2 AMPAR expression 
AMPARs are enriched at the post synaptic membrane in the excitatory 
synapses (Henley and Wilkinson 2016). GluA1/A2 form the predominant 
AMPAR heteromeric complex in adult CA1 hippocampal neurones (Wenthold, 
Petralia et al. 1996, Shi, Hayashi et al. 2001, Lu, Shi et al. 2009). GluA3 is 
thought to be expressed at only 10% of the levels compared to GluA1 and 
GluA2 (Sans, Vissel et al. 2003). However, studies have indicated GluA2/A3 
along with GluA1/A2 to be predominant heteromers in rat hippocampus and 
cortex (Wenthold, Petralia et al. 1996, Lu, Shi et al. 2009). GluA4 is highly 
expressed during early developmental stages but is expressed sparsely in the 
adult brain (Zhu, Esteban et al. 2000), though they play a key role in 
transmission in parvalbumin-containing inhibitory interneurons, where reduced 
GluA4 expression has been shown to cause a reduction in AMPAR function in 
these interneurons and hence reduced feedforward inhibition. This resulted in 
imbalance in excitatory/inhibitory transmission promoting epileptic activity and 
deficit in spatial learning memory  (Bernard, Somogyi et al. 1997, Pelkey, 
Barksdale et al. 2015).  
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1.2.1.3 Regulation of AMPAR trafficking and localisation 
The variable C-terminal domain of AMPAR subunits allow for subunit specific 
protein-protein interactions and post-translational modifications that regulates 
the function and trafficking of the resultant tetramer (Huganir and Nicoll 2013, 
Henley and Wilkinson 2016). These protein-protein interactions are mostly 
mediated by the PDZ domain containing proteins such as Protein Interacting 
with C-Kinase 1 (PICK1) (Hanley 2014), Glutamate receptor-interacting 
protein 1 (GRIP1) (Dong, O'Brien et al. 1997) and sorting nexin 27 (SNX27) 
(Hussain, Diering et al. 2014, Loo, Tang et al. 2014), all of which bind to one 
or more specific AMPAR subunits to maintain their synaptic localisation either 
basally or during plasticity. Other proteins such as multimeric ATPase N-
ethylmaleimide sensitive factor (NSF) (Nishimune, Isaac et al. 1998, Gardner, 
Takamiya et al. 2005) has been shown to be important in synaptic 
incorporation of GluA2-AMPARs. AMPAR auxiliary subunits such as the family 
of transmembrane AMPA receptor regulatory proteins (TARPs) (stargazin and 
γ3-8) was shown to promote synaptic trapping by binding to post synaptic 
density protein 95 (PSD-95), a post-synaptic adhesion protein (Tomita, 
Adesnik et al. 2005, Opazo, Labrecque et al. 2010, Jackson and Nicoll 2011). 
Moreover, post-translational modifications also regulate the interactions 
between these proteins and AMPAR subunits. For instance, Protein Kinase C 
(PKC) can phosphorylate GluA2 in its PDZ region in the C-terminus inhibiting 
GluA2 binding to GRIP1 but increasing GluA2 binding to PICK1. Figure 1-4 is 
a cartoon schematic of majority of known AMPAR interactors.  




Figure 1-4: Cartoon diagram of scaffolding and trafficking proteins implicated in 
AMPAR trafficking and localisation.  
Proteins such as PICK1, GRIP1, NSF and SNX27 regulate AMPAR endocytosis and 
exocytosis. AMPAR auxiliary subunits such as TARPs enhance AMPAR synaptic 
trapping. Signalling proteins such as protein kinases and phosphatases regulate 
receptor trafficking. PSD structural complex including PSD-95 interact with other 
proteins to regulate structure and function of the synapse. Figure taken from (Huganir 
and Nicoll 2013). 
1.2.1.4 AMPARs function 
AMPARs mediate majority of the fast-excitatory neurotransmission in the 
central nervous system as such regulating AMPAR surface expression and 
localisation underlies the ultimate mechanism that regulates plasticity of 
majority of excitatory neurotransmission (Chater and Goda 2014). The 
number, composition and/or properties of AMPARs on the post-synaptic 
surface can be altered and regulated to respond to the incoming stimulus. The 
mechanisms regulating AMPAR properties, trafficking and localisation are 
reinforced to allow AMPARs to fulfil their role in plasticity. These also include 
properties that regulate AMPAR diversity for instance Ca2+ permeability of 
AMPARs via GluA2 Q/R editing [see section 1.5.4]. In fact, AMPAR regulation 
provides basis of plasticity mechanisms such as Long Term Potentiation 
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(LTP), Long Term Depression (LTD) and homeostatic scaling [more detail on 
plasticity in Section 1.3] (Huganir and Nicoll 2013, Henley and Wilkinson 
2016).    
1.2.1.5 AMPARs in diseases 
Due to the vastly important role of AMPARs in synaptic function, any defect in 
their trafficking, subunit composition or activity can result in neurological 
disorders and neurodegenerative diseases (Henley and Wilkinson 2016). For 
instance, reduced synaptic AMPARs and aberrations in LTP and LTD are the 
early hallmarks of dementia in Alzheimer’s disease (Walsh and Selkoe 2007, 
Shankar, Li et al. 2008). Reports have shown that soluble amyloid-β (Aβ) 
oligomers disrupts AMPAR trafficking (Zhao, Santini et al. 2010) while 
intracellular Aβ also causes enhancement of synaptic Ca2+ permeable 
AMPARs resulting in excitotoxicity (Whitcomb, Hogg et al. 2015). Moreover, 
other pathological conditions such as in epilepsy, alterations in AMPAR 
subunit compositions are also observed where loss of GluA1 containing 
AMPARS occur (Grigorenko, Glazier et al. 1997) while cocaine exposure 
causes increase in levels of Ca2+ permeable AMPARs (Heshmati 2009).     
1.2.2 Kainate Receptors 
Kainate Receptors (KARs) are ionotropic glutamate receptors that play key 
roles in regulating synaptic function and neuronal network activity (Evans, 
Gurung et al. 2017). They are involved in processes ranging from neuronal 
development and differentiation to neuronal cell death and neurodegeneration 
(Lerma and Marques 2013). Functional KARs are tetrameric assemblies 
composed of five possible subunits: low-affinity (for kainate ligand) GluK1, 
GluK2, GluK3 and high-affinity GluK4 and GluK5 (previously named as GluR5, 
GluR6, GluR7, KA1 and KA2 respectively), encoded by gene GRIK1-5 
respectively (Collingridge, Olsen et al. 2009). 
Studies using recombinant proteins have shown that GluK1, GluK2 and GluK3 
can form functional ion channels as homomeric assemblies while GluK4 and 
GluK5 can only form functional ion channels as heteromeric assemblies with 
GluK1-3 (Ayalon and Stern-Bach 2001). GluK4 and GluK5 have ER retention 
sequences and so cannot be released from ER and express on the surface 
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without forming heteromers with GluK1-3 (Gallyas, Ball et al. 2003, Ruiz, 
Sachidhanandam et al. 2005, Vivithanaporn, Yan et al. 2006, Ball, Atlason et 
al. 2010). Moreover, at least one of the GluK4/5 subunit is needed for KAR’s 
ionotropic function (Fernandes, Catches et al. 2009). Interestingly, along with 
their canonical ionotropic function, KARs can also signal through a non-
canonical metabotropic pathway where KARs signal through coupled 
heterotrimeric G-proteins and second messengers (Contractor, Mulle et al. 
2011). This metabotropic signalling pathway regulates various neurological 
functions of KARs which will be explored below.  
1.2.2.1 KAR subunit diversity 
KAR subunits undergo alternative splicing in their N- and C-terminal domains 
adding to their subunit diversity. GluK1 can produce two N-terminal variants 
(GluK11-2), where GluK11 has an insertion of 15-amino-acid (aa) cassette in its 
N-terminus, and 4 C-terminal alternative splice variants (GluK1a-d) (Bettler, 
Boulter et al. 1990, Sommer, Burnashev et al. 1992, Pinheiro and Mulle 2006). 
GluK2 and GluK3 can also undergo editing in their C-terminal region to 
produce splice variants (GluK2a-c and GluK3a-b respectively) (Schiffer, 
Swanson et al. 1997, Jaskolski, Coussen et al. 2004) [Figure 1-5]. For GluK2, 
GluK2a-b, which differs in their C-terminus domain, can equally co-assemble in 
native receptors and are found to be expressed within the same brain regions, 
while GluK2c consists of exon insertion in the C-terminus and have only been 
described in humans as of yet. For GluK3a, the whole of C-terminus is replaced 
by an unrelated 55aa sequence (Pinheiro and Mulle 2006). Similar to the 
AMPARs, the C-terminal variations in KARs affect KAR trafficking, regulation, 
interaction and expression (Pahl, Tapken et al. 2014). 
In addition, GluK1 and GluK2 subunits of KAR can undergo RNA editing 
adding to their diversity. These editing processes include I/V, Y/C and Q/R 




   





Figure 1-5: Structure and Topology of GluK2 KAR subunit.  
The N-terminal region in combination with the region between TMIII and TMIV form 
the ligand binding domain. The C-terminal region is prone to splicing producing 
alternatively spliced variants. GluK2 along with GluK1 subunit also undergoes RNA 
editing process such as the Q/R editing site which occurs in the TMII region. Figure 
adapted from (González‐González 2012).     
1.2.2.2 KAR subunit expression  
mRNA studies have shown high expression of KAR subunits throughout the 
brain and spinal cord (Wisden and Seeburg 1993, Bahn, Volk et al. 1994, 
Bettler and Mulle 1995). Within the CA3 region and in dentate gyrus cells, 
there are high levels of GluK2, GluK4 and GluK5. GluK1 is thought to express 
predominantly in the CA3 interneurons and GluK3 in the dentate granule cells 
(Bahn, Volk et al. 1994, Bureau, Bischoff et al. 1999, Paternain, Herrera et al. 
2000). Lack of reliable specific antibodies have limited the expression studies 
of KARs to mRNA levels. However, GluK2-GluK5 heteromeric complex is 
thought to be the most abundant KAR complex in the adult hippocampus 
(Petralia, Wang et al. 1994, Kumar, Schuck et al. 2011).  
1.2.2.3 Post-translational regulation of KARs 
Activity-dependent regulation of KARs has been shown in many previous 
studies (Martin and Henley 2004, Martin, Bouschet et al. 2008, Gonzalez-
Gonzalez and Henley 2013) [see Chapter 3.1]. Post translational modifications 
such as palmitoylation, phosphorylation, SUMOylation and ubiquitination 
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regulate both KAR trafficking and their post-synaptic localisation [Figure 1-6], 
discussed below.  
Small Ubiquitin like Modifier (SUMO) proteins are small 97 residue proteins 
(11kDa), which covalently conjugate to the lysine residue of the target proteins 
altering the protein stability, inducing conformation changes and/or altering 
protein interactions either by masking or introducing new interaction sites 
(Wilkinson and Henley 2010). In the case of GluK2, it’s SUMOylation in the 
intracellular C-terminus, K886, allows agonist-induced internalisation of 
GluK2-containing KARs (Martin, Nishimune et al. 2007).  
Phosphorylation is the major post translational modification mechanism 
through which protein function is regulated in response to various stimuli. 
GluK2 phosphorylation by PKC at S846 and S868 site has been shown to 
regulate GluK2 trafficking through the secretory pathway by reducing ER exit 
and hence their surface expression (Evans, Gurung et al. 2017). Basally, 
phosphorylation at S846 promotes internalisation of GluK2-containing KARs 
while both the serine sites are also phosphorylated in response to the agonist 
stimulation, with the phosphorylation at S868 in particular being required for 
agonist-induced endocytosis. Interestingly, phosphorylation at S868 also 
enhances GluK2 SUMOylation to allow basal and activity-induced 
internalisation of GluK2-containing KARs. However, in the absence of 
SUMOylation GluK2 phosphorylation at S868 leads to the recycling of 
endocytosed GluK2 back to the plasma membrane (Nasu-Nishimura, Jaffe et 
al. 2010, Konopacki, Jaafari et al. 2011, Chamberlain, Gonzalez-Gonzalez et 
al. 2012, Wilkinson, Konopacki et al. 2012). This suggests the role of 
phosphorylation in both insertion and removal of KARs from the plasma 
membrane.  
Palmitoylation is another form of post-translational modification where palmitic 
acid is added to specific cysteine residues regulating protein trafficking and 
function, acting as a form of reversible lipid modification (Fukata and Fukata 
2010). Palmitoylation of GluK2 (C858 and C871) was shown to promote its 
interaction with scaffolding protein 4.1N resulting in stable KAR surface 
expression while phosphorylation of GluK2 inhibited this interaction and 
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enhanced KAR endocytosis instead (Pickering, Taverna et al. 1995, Copits 
and Swanson 2013). This also shows existence of dynamic crosstalk between 
these various forms of post translational modifications that regulate KAR 
surface expression.   
Ubiquitin on the other hand is a highly conserved 76-amino acid protein, which 
tags target proteins for degradation in the proteasomes (Hallengren, Chen et 
al. 2013). GluK2 containing KARs are also targeted for ubiquitination and 
degradation by various E3 ubiquitin ligases. Cullin 3 (Cul3) interacts with the 
C-terminus of GluK2 via an adaptor protein actinofilin (Salinas, Blair et al. 
2006). Recently, it was shown that another E3 ubiquitin ligase, Parkin, can 
ubiquitinate GluK2 in its C-terminus. Loss of Parkin increases GluK2 surface 
expression which results in increased susceptibility of the hippocampal 
neurones to kainate-induced excitotoxicity (Maraschi, Ciammola et al. 2014). 
While above mentioned modifications have focused on GluK2 containing 
KARs, other subunits of KAR can also be regulated by post translational 
modifications. For instance, CaMKII has been shown to phosphorylate the C-
terminal domain of GluK5 which is required for KAR-LTD at MF-CA3 synapses 
by antagonising GluK5 interaction with the post synaptic adhesion protein 
PSD95 (Carta, Opazo et al. 2013). Hence, posttranslational modification of 
KARs play a major role in KAR localisation and function both basally and 









Figure 1-6: Post translational modifications regulating GluK2-KAR surface 
expression.  
Agonist induced phosphorylation of GluK2-KAR by PKC at S868 enhances GluK2-
KAR SUMOylation at K886 leading to KAR endocytosis (1). Phosphorylation at S868 
in the absence of SUMOylation leads to receptor recycling back to the plasma 
membrane, increasing the surface expression of KAR (2). PKC phosphorylation of 
GluK2 at S846 and S868 reduces ER exit of GluK2 basally (not shown). 
Palmitoylation of KAR enhances its surface expression by interaction with 4.1N 
scaffolding protein (3). PKC mediated phosphorylation of KAR inhibits this interaction 
and promotes endocytosis (4). Finally, ubiquitination of GluK2-KAR by Parkin or Cul3 
has been shown to mediate KAR internalisation and degradation (5).  
1.2.2.4 Regulation of KAR localisation 
Various mechanisms have been shown to regulate KAR synaptic positioning. 
This includes subunit dependent regulation, protein-protein interactions and 
post-translational modifications as mentioned above.  
1.2.2.4.1 Protein-protein interactions  
Many KAR protein interactors have been identified which play a major role in 
their post-synaptic localisation. Single pass transmembrane proteins Neto1 
and Neto2 have been shown to bind to GluK1-3 subunits (Zhang, St-Gelais et 
al. 2009, Straub, Hunt et al. 2011). Neto1 is highly expressed in the 
hippocampus while Neto2 is more expressed in the cerebellum (Evans, 
Gurung et al. 2017). However, there is contradiction in terms of whether Netos 
do play a role in trafficking and targeting of GluK2-containing KARs as some 
studies have reported enhanced GluK2 surface expression with 
overexpression of Neto1 and Neto2 (Palacios-Filardo, Aller et al. 2016) and 
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reduction in synaptic GluK2 in Neto2 knockout (Wyeth, Pelkey et al. 2014). 
Other studies have reported no difference in GluK2-KAR responses in CA1 
pyramidal neurones when co-expressed with Neto1 or Neto2 (Sheng, Shi et 
al. 2015). Interestingly for GluK1, expressing Neto1 or Neto2 along with GluK1 
in CA1 pyramidal cells enhanced synaptic targeting of GluK1 containing KARs 
(Copits, Robbins et al. 2011). However, importance of Neto proteins in vivo 
have not been examined as of yet. While Netos role in KAR localisation remain 
debatable, the association of Netos to KAR has been shown to mediate the 
slow deactivation kinetics of KARs, which is not detected on recombinant 
KARs (Tomita and Castillo 2012).  
Recently, C1q-like protein (c1ql), a synaptically secreted soluble factor 
(Matsuda 2017), was reported to be a key contributor in KAR localisation in 
mossy fibre synapses in the CA3 neurones (Matsuda, Budisantoso et al. 2016, 
Straub, Noam et al. 2016) [Figure 1-7]. C1ql2 and 3 were shown to bind to N-
terminal domain of GluK2, GluK4 (Matsuda, Budisantoso et al. 2016) and 
GluK5 (Straub, Noam et al. 2016) while the pre-synaptic adhesion molecule 
neurexin 3 binds to c1ql2/3. Interestingly, using co-cultures of HEK293T cells 
expressing neurexin 3 and c1ql2/3 with neurones, the neurexin3-c1ql-KAR 
complex could be isolated (Matsuda, Budisantoso et al. 2016). Other adhesion 
molecules such as N-cadherin and PSD95 also binds KAR subunits and 
maintain their postsynaptic localisation, interaction of which are mediated by 
the PDZ ligand (Garcia, Mehta et al. 1998, Coussen, Normand et al. 2002, 
Hirbec, Francis et al. 2003).    
PSD95, synaptic scaffolding protein has been shown to interact with the C-
terminal PDZ ligands of GluK1, GluK2 and GluK5 subunits of KARs (Garcia, 
Mehta et al. 1998). While it is not known whether this binding is direct or not, 
PSD95 knockout mice showed decreased synaptic KAR component in MF-
CA3 synapses, showing their importance in KAR synaptic localisation (Suzuki 
and Kamiya 2016). Similarly, expression of dominant negative N-cadherin, 
which is a neuronal cell adhesion protein, and knockdown of N-cadherin both 
reduce KAR synaptic components in the MF-CA3 synapses. The C-terminal 
region of GluK2 again has been shown to mediate KAR interaction with N-
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cadherin, identifying it to be important for GluK2 incorporation in MF-CA3 
synapses [Figure 1-7] (Fievre, Carta et al. 2016).  
 
Figure 1-7: Protein-protein interactors that regulate KAR post synaptic localisation. 
Soluble c1ql proteins secreted from the pre-synaptic terminal cluster the post synaptic 
KARs and pre-synaptic neurexin 3. N-cadherin and PSD95 also interact with the C-
terminus of KAR subunits promoting KAR synaptic incorporation and maintenance. 
Figure adapted from (Evans, Gurung et al. 2017).   
1.2.2.4.2 Subunit mediated regulation 
The GluK2 C-terminus itself also plays an important role in synaptic stability of 
KARs but not necessarily in KARs surface expression in general (Yan, 
Yamasaki et al. 2013, Straub, Noam et al. 2016). Ablating Neto2 or GluK5 had 
no effect on the postsynaptic density abundance of GluK2/Neto2 or 
GluK2/GluK5. However, mice lacking C-terminus of GluK2 lacked synaptic 
responses in mossy fibre-CA3 synapses but had no effect on surface or total 
levels of GluK2 in the cerebellum thus suggesting, their importance in synaptic 
stabilisation of KARs, which is most likely through interaction with synaptic 
adhesion proteins.  
Interestingly however, the study did show the importance of subunits GluK4 
and GluK5 in providing synapse specificity in hippocampus. GluK4/5 knockout 
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mice showed lack of postsynaptic KARs at MF-CA3 synapses (Fernandes, 
Catches et al. 2009). Furthermore, the GluK2 subunit was observed to be 
redistributed in more distal dendrites within the CA3 pyramidal neurones 
(Straub, Noam et al. 2016). This was suggested to be via GluK5 ability to bind 
c1q-like proteins, which is present in abundance in mossy fibre synapses, 
through the N-terminal region of GluK5. Therefore, GluK2 C-terminus was 
shown to be important for synaptic localisation but the high affinity GluK4/5 are 
needed for KAR synapse specificity (Straub, Noam et al. 2016).   
1.2.2.5 Forward trafficking of KARs 
We have recently shown that GluK2 containing KARs can use local secretory 
pathways to be delivered to the cell surface and its trafficking itself can be 
regulated in various activity contexts (Evans, Gurung et al. 2017). Briefly, we 
showed that KARs can use local secretory pathways to be delivered to the cell 
surface and this can be activity dependently regulated as activating surface 
KARs using kainate stimulation results in a negative feedback mechanism 
where less de novo KARs are trafficked to the surface. Moreover, the PDZ 
ligand mediated interaction of GluK2 was shown to be important for this 
regulation however, the interactors are not known as of yet (Evans, Gurung et 
al. 2017). Finally, GluK5 also regulates KAR trafficking as its heteromerization 
with GluK2 and binding to 14-3-3ζ promotes KAR forward trafficking 
(Vivithanaporn, Yan et al. 2006).  
1.2.2.6 KAR in excitatory neurotransmission 
KARs are expressed at both pre- and post-synaptic membranes where they 
fulfil distinct functional roles (Contractor, Mulle et al. 2011).  
1.2.2.6.1 Pre-synaptic KARs 
Pre-synaptic KARs can bidirectionally modulate glutamate release to regulate 
excitatory neurotransmission. At MF-CA3 synapses they can decrease 
glutamate release upon stimulation with relatively high (>100nM) 
concentration of kainate (Vignes, Clarke et al. 1998, Contractor, Swanson et 
al. 2000, Kamiya and Ozawa 2000, Schmitz, Frerking et al. 2000). Both 
metabotropic and ionotropic functions of KAR have been implicated in its 
function to regulate this release. It has been proposed that KAR activation at 
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these concentrations of kainate may inactivate the sodium and Ca2+ channels 
and promote electrical shunting, which in turn depresses the evoked glutamate 
release by reducing the terminal excitability (Kamiya and Ozawa 2000, 
Schmitz, Mellor et al. 2001). However, KAR mediated depression of glutamate 
release was also sensitive to the treatment of pertussis toxin (PTx) which 
inhibits the Gi/o pathway, thus suggesting it to be a metabotropic function 
instead (Rodriguez-Moreno and Sihra 2004). This second messenger 
signalling cascade involved adenylate cyclase(AC)/cAMP/PKA activation 
[Figure 1-8 A].  
 
Figure 1-8: Pre-synaptic KARs regulate bi-directionally modulate glutamate release.  
Pre-synaptic KARs can both depress (A) and enhance glutamate release (B). KARs 
depress glutamate release via its metabotropic function activating G-protein and 
downstream signalling cascade of AC/cAMP and PKA. Pre-synaptic KARs can also 
enhance glutamate release by inducing Ca2+ release from internal stores, which 
results in Ca2+-calmodulin complex formation thereby activating PKA. Figure taken 
from (Sihra and Rodriguez-Moreno 2013). 
Interestingly when activated at lower kainate concentrations, pre-synaptic 
KARs can facilitate glutamate release in the MF-CA3 synapses (Schmitz, 
Mellor et al. 2001). Subsequent studies also showed the role of presynaptic 
KARs in the facilitation of glutamate release (Lauri, Bortolotto et al. 2001, 
Lauri, Bortolotto et al. 2003, Pinheiro, Perrais et al. 2007, Andrade-Talavera, 
Duque-Feria et al. 2013). This release action was shown to be dependent on 
the increase in cytosolic Ca2+ concentration, potentially through the Ca2+ 
permeable KARs (Lauri, Bortolotto et al. 2003, Pinheiro, Perrais et al. 2007, 
Andrade-Talavera, Duque-Feria et al. 2013). Interestingly, downstream 
signalling mechanism for this pathway also involves the adenylate 
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cyclase/cAMP/PKA signalling cascade, similar to the pathway of inhibiting 
glutamate release, but the facilitation is not dependent on the G-protein 
activation as it is not sensitive to the inhibitors of G-protein function (Negrete-
Diaz, Sihra et al. 2006, Negrete-Diaz, Sihra et al. 2007) . It is instead thought 
that the intracellular Ca2+ increase by KAR activation directly leads to the 
activation of the adenylate cyclase (Andrade-Talavera, Duque-Feria et al. 
2013) [Figure 1-8 B].       
1.2.2.6.2 Post synaptic KARs 
Post synaptic KARs upon activation through synaptically released glutamate 
yields EPSCs which have small amplitudes and characteristic slow kinetics i.e. 
slow activation and deactivation (Castillo, Malenka et al. 1997), potentially 
providing unfulfilled integrative capacities for information transfer (Frerking 
and Ohliger-Frerking 2002, Pinheiro, Lanore et al. 2013). KAR EPSCs have 
been found in few central synapses for instance the MF-CA3 pyramidal 
neurones. This is unlike that of the AMPARs and NMDARs, which are localised 
in majority of postsynaptic glutamatergic synapses in the brain (Castillo, 
Malenka et al. 1997, Vignes and Collingridge 1997). Along with this long-
lasting depolarisation, KARs also regulate the slow afterhyperpolarization 
current (ISAHP) (Melyan, Wheal et al. 2002, Melyan, Lancaster et al. 2004). AHP 
is the state post action potential generation which can last up to several 
seconds and has several phases; fast, medium and slow, each being 
generated due to activation of different potassium channels. The slow AHP 
has relatively slower kinetics in that it has slow rising phase and lasts up to 
several seconds and is easily detected after a train of action potentials (Storm 
1990, Sah 1996). The noncanonical metabotropic signalling of KARs were 
shown to be responsible for regulating the ISAHP. This metabotropic 
downstream signalling pathway activates Gi/o protein leading to PKC activation 
(Melyan, Wheal et al. 2002) and potentially PKA and MAP kinases activation 
(Grabauskas, Lancaster et al. 2007). Together, these characteristics of post 
synaptic KARs regulate the neuronal excitability.    
Moreover, postsynaptic KARs can undergo plasticity themselves undergoing 
LTD that can be induced by various stimulation protocols whilst also 
undergoing activity-dependent up- or down-regulation on the surface upon 
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agonist activation (Martin, Bouschet et al. 2008, Carta, Opazo et al. 2013, 
Chamberlain, Sadowski et al. 2013). Recently, studies in our lab have shown 
that activation of postsynaptic KARs at CA3-CA1 synapses induces a novel 
form of AMPAR-LTP via its noncanonical metabotropic signalling pathway 
(Petrovic, Viana da Silva et al. 2017). 
KAR role in excitatory synaptic transmission is further explored in Chapter 3.1.  
1.2.2.7 KARs in inhibitory neurotransmission 
While KARs are known to mediate excitatory neurotransmission [Chapter 3.1, 
(Evans, Gurung et al. 2017)], they can also regulate inhibitory transmission. 
Pre-synaptic KARs regulate pre-synaptic GABA release from interneurones 
(Rodriguez-Moreno and Lerma 1998). This pertussis toxin (PTx) sensitive 
pathway was mediated by downstream signalling through G-protein coupled 
receptors activating kinases Phospholipase C (PLC) and PKC, which reduces 
the inhibitory postsynaptic currents (IPSCs) (Rodriguez-Moreno and Lerma 
1998).  
Moreover, KARs mediate activation of potentiated extrasynaptic GABAA 
receptors via intracellular PKC pathway while depressing the synaptic GABAA 
receptors. It is thought that the potentiation of extrasynaptic GABAA receptors 
may depress feedforward and feedback inhibition thereby facilitating LTP 
induction. On the other hand, depression of synaptic GABAA receptors have a 
protective effect by preventing neuronal over-excitation (Jiang, Kang et al. 
2015).  
Furthermore, KARs also control the surface expression of chloride transporter 
KCC2 (potassium(K+)-chloride(Cl-) co-transporter) (Pressey, Mahadevan et al. 
2017). KCC2 is required to maintain low intracellular Cl- concentration. This is 
important to attain the required electrochemical gradient that allows GABAARs 
signalling to maintain postsynaptic inhibition (Woodin, Ganguly et al. 2003). 
KCC2 and KAR were shown to exist in a macromolecular complex, and KAR 
itself was shown to be required for KCC2 oligomerisation and surface 
expression (Mahadevan, Pressey et al. 2014). In particular, the 
phosphorylation in the GluK2 C terminal residues S846 and S868 was shown 
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to regulate GluK2 mediated increase in KCC2 surface expression through 
enhanced recycling of KCC2 to the surface (Pressey, Mahadevan et al. 2017).  
Hence, it is becoming increasingly evident that KARs can regulate both 
excitatory and inhibitory neurotransmission and is a likely key regulator of 
excitation-inhibition balance. 
1.2.2.8 KAR signalling through non-canonical metabotropic pathway 
As well as signalling through the canonical ionotropic receptors, KARs can 
also signal via an additional non-canonical metabotropic signalling pathway, 
which I have alluded to in previous sections. This non-canonical signalling is 
G-protein receptor mediated [Figure 1-9] and is pertussis toxin-sensitive. This 
metabotropic signalling pathway is known to be involved in KAR modulation of 
GABA release within the inhibitory synapses in the CA1 hippocampal region, 
which is prevented by the inhibition of PKC or PLC activation (Rodriguez-
Moreno and Lerma 1998). This signalling also regulates KAR mediated 
inhibition of the slow after-hyperpolarizing potential (ISAHP) resulting in 
continuing enhancement of neuronal excitability (Melyan, Wheal et al. 2002).  
While the metabotropic signalling is essential for various KAR functions, the 
mechanism behind this is not fully known and is a subject of some controversy. 
KAR subunits such as GluK2, GluK1 and GluK5 have all been implicated in 
this function (Fisahn, Heinemann et al. 2005, Ruiz, Sachidhanandam et al. 
2005, Gonzalez-Gonzalez and Henley 2013, Rutkowska-Wlodarczyk, Aller et 
al. 2015). The kainate evoked upregulation of KAR surface expression was 
shown to require metabotropic signalling via a GluK2-dependent mechanism 
(Gonzalez-Gonzalez and Henley 2013). Similarly, the metabotropic regulation 
of ISAHP was absent in GluK2-/- mice but retained in GluK1-/- mice (Fisahn, 
Heinemann et al. 2005, Ruiz, Sachidhanandam et al. 2005). However, other 
studies suggested interactions between GluK5 and Gαq to be involved in KAR 
metabotropic regulation of its ISAHP (Ruiz, Sachidhanandam et al. 2005) while 
another proteomic study suggested interactions between GluK1 subunit and 
Go proteins to mediate the metabotropic signalling (Rutkowska-Wlodarczyk, 
Aller et al. 2015). Recently, KAR signalling that regulates AMPAR surface 
expression was attributed to its metabotropic signalling mediated by the GluK2 
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subunit (Petrovic, Viana da Silva et al. 2017). It is also not known if a KAR 
subunit can signal via both metabotropic and ionotropic pathways. Despite 
these unknowns, it is well accepted that KAR metabotropic signalling regulates 
various neurological functions of KARs.  
 
Figure 1-9: Metabotropic Signalling by KARs.  
GluK1, GluK2 and GluK5 have all been shown as potential metabotropic signalling 
subunit of KAR. While it is not known if the interaction with the G-protein is direct or 
adaptor protein mediated, the downstream signalling pathway involves PLC mediated 
Ca2+ signalling which activates the PKC pathway. This metabotropic signalling is 
pertussis toxin sensitive, and inhibiting PLC and PKC activation inhibits the G-protein 
downstream signalling. 
1.2.2.9 KARs during development 
KARs have been shown to play key roles in development by controlling 
filopodial motility, growth cone dynamics and synapse formation/stabilisation 
(Bahn, Volk et al. 1994, Cherubini, Caiati et al. 2011). KARs can enhance 
axonal motility in immature rat hippocampal slices but inhibit motility in mature 
slices (Tashiro, Dunaevsky et al. 2003). KARs are also expressed early during 
development in thalamocortical synapses, which are slowly replaced by 
AMPARs via NMDAR mediated Ca2+ entry (Kidd and Isaac 1999). Having 
KARs early on in development is thought to help integrate synaptic inputs over 
longer period in young synapses as KARs have longer lifetime per individual 
current flow (Frerking and Ohliger-Frerking 2002). 
KARs are also known to drive the network activity during development. For 
instance, during development in early neonatal hippocampus KARs regulate 
Chapter 1  General Introduction 
24 
 
both GABAergic and glutamatergic synaptic transmission and thus control the 
neuronal network by regulating the balance between these two forms of 
transmission (Lauri, Segerstrale et al. 2005). Moreover, in neonatal CA3 
synapses, presynaptic KARs can be activated by endogenous glutamate 
which regulates the frequency of mEPSCs and spontaneous network activity 
(Lauri, Segerstrale et al. 2005). KARs in CA1 synapses were also shown to be 
activated by ambient glutamate which also developmentally regulates 
glutamatergic transmission by regulating the probability of release (Lauri, 
Vesikansa et al. 2006). Moreover, mice lacking the GluK2 subunit were shown 
to have transient reduction in their synaptic strength during development as 
they had delayed functional and structural maturation at MF-CA3 synapses 
compared to the WT mice (Lanore, Labrousse et al. 2012). Therefore, there 
are increasing evidences supporting KAR role during development in 
regulating synaptic function and network activity.      
1.2.2.10 KARs in diseases 
KARs have been linked to many neurodegenerative disorders including 
epilepsy, schizophrenia and autism, where KAR mutations have been 
associated with increased susceptibility to these conditions (reviewed in 
(Lerma and Marques 2013)). Application of kainate induces acute seizures like 
those found in the temporal lobe epilepsy (TLE) patients (Ben-Ari and Cossart 
2000). Intriguingly, study in in vitro and in vivo models of TLE showed that 
mice lacking GluK2 or by treating with GluK2/GluK5 receptor antagonist, mice 
exhibit reduced seizure-like activity (Peret, Christie et al. 2014). Moreover, 
using hypoxia model in neonatal mice, it was shown that the KARs lacking 
GluK2 subunit or blockade of KAR ionotropic function decreased their seizure 
susceptibility, implying the role of GluK2-KARs in mediating hypoxic seizures 
particularly during the reoxygenation period (Grosenbaugh, Ross et al. 2018). 
Additionally, both gain or loss of GluK2 function have led to Autism spectrum 
like disorder (ASD) phenotypes (Lanore, Labrousse et al. 2012, Micheau, 
Vimeney et al. 2014, Guzman, Ramsey et al. 2017). Studies on GluK2 KO 
mice showed abnormalities in CA3 functional maturation, where both 
structural and functional maturation of MF-CA3 synapses were delayed in the 
GluK2 KO mice (Lanore, Labrousse et al. 2012). This was followed by 
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behavioural analysis on the GluK2 KO mice where the mice displayed 
phenotypes similar to the ASD phenotypes in the social and cognition tasks. 
For instance, social interaction behavioural task performed on the GluK2 KO 
mice showed these mice to be less sociable and have reduced locomotor 
activity (Micheau, Vimeney et al. 2014). However, a patient study associated 
the gain of function mutation in the GRIK2 (A657T) gene to be associated with 
neurodevelopmental abnormalities in the patient displaying characteristics of 
intellectual disability and speech and motor delay. KARs with this single point 
mutation were also shown to be constitutively active in their channel function 
(Guzman, Ramsey et al. 2017).  
Recently, it was shown that complete knockout of all kainate receptor subunits 
in mice results in compulsive and obsessive behaviours such as over-
grooming while also displaying motor problems (Xu, Marshall et al. 2017). 
These observations support the importance of KARs in higher brain function 
as their disruption can lead to various neurological disorders.   
1.3 Synaptic plasticity 
Synaptic plasticity is the biological process in which functional and structural 
changes in synapses cause changes in synaptic transmission. Hebbian 
Plasticity and Homeostatic plasticity represent the two most studied forms of 
synaptic plasticity.  
1.3.1 Hebbian plasticity 
Hebbian form of plasticity refers to activity dependent long-lasting changes in 
the synaptic efficacy resulting in either enhancement of synaptic transmission 
(Long-term Potentiation (LTP)) or depression of synaptic transmission (Long-
term depression (LTD)) (Morris 1999). These synaptic changes are 
associative, rapidly induced and input specific. Together, LTP and LTD form 
the cellular models of cognition, learning and memory, as these processes 
allow the information to be built and retained in the neurones by strengthening 
connections in between cells (Citri and Malenka 2008) and are implicated in 
many physiological and pathological processes (Malenka and Bear 2004).  
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1.3.1.1 Long Term Potentiation (LTP) 
LTP, which is the enhancement of synaptic transmission, was first described 
using high frequency stimulation (HFS) in the dentate area of hippocampus 
which was stable over months (Bliss and Lomo 1973). A classical LTP 
induction involves the activation of NMDARs. Typically, HFS leads to sodium 
influx through AMPARs, depolarising the postsynaptic compartment and 
activating NMDARs. NMDAR activation involves magnesium dissociation, 
allowing Ca2+ influx through the Ca2+ permeable NMDAR ion channel leading 
to a rise in the intracellular Ca2+ levels (Collingridge, Kehl et al. 1983, Mayer, 
Westbrook et al. 1984, Kauer, Malenka et al. 1988, Bliss and Collingridge 
1993, Malenka and Nicoll 1993). NMDAR activation can also be induced 
chemically by bath application of NMDAR co-agonist glycine (chem-LTP) (Lu, 
Man et al. 2001). One of the main characteristic change that occurs during 
LTP is the increase in the number of AMPARs inserted in the post-synaptic 
membrane which strengthens the synapse [Figure 1-10]. AMPARs can be 
inserted either via lateral diffusion (Makino and Malinow 2009, Penn, Zhang et 
al. 2017) and/or by increased AMPAR exocytosis (Lu, Man et al. 2001, 
Pickard, Noel et al. 2001). The Ca2+ influx also leads to kinase mediated 
activation of proteins involved in AMPAR trafficking and insertion. For 
instance, Ca2+ calmodulin–dependent kinase II (CaMKII) is transiently 
activated following LTP induction, which leads to phosphorylation of C termini 
of AMPAR subunits which in turn alters the single channel conductance and 
trafficking of AMPARs (Hayashi, Shi et al. 2000, Soderling and Derkach 2000, 
Lee, Escobedo-Lozoya et al. 2009). CaMKII can also phosphorylate 
scaffolding proteins in the post synaptic density to accommodate for additional 
AMPARs i.e. creating slots (Tomita, Stein et al. 2005, Lisman, Yasuda et al. 
2012). Moreover, CaMKII also regulates the actin cytoskeleton to physically 
enlarge spines supporting increased synaptic efficiency (Patterson and 
Yasuda 2011, Bosch, Castro et al. 2014). These alterations combined with 
additional protein synthesis allows the LTP to be maintained over a longer 
period of time (Reymann and Frey 2007).  




Figure 1-10: NMDAR mediated Long-Term Potentiation (LTP) and Long-Term 
Depression (LTD).  
Both LTP and LTD inducing protocols release the magnesium block from the 
NMDARs, resulting in Ca2 ion flow. In LTP, the Ca2 ion flow activates CaMKII kinase 
resulting in insertion of more AMPARs on the post-synaptic surface. In contrast the 
LTD protocol results in lower Ca2+ influx, activating protein phosphatase cascade 
instead, causing internalisation of AMPARs from the post-synaptic surface.  
NMDAR independent forms of LTP have also been reported. For instance, 
mGluR dependent LTP was first described in the hippocampal region where a 
group I/II mGluR antagonist blocked both NMDAR dependent and 
independent forms of LTP (Bashir, Bortolotto et al. 1993). mGluRs belong to 
the G-protein coupled receptor superfamily, which are activated by 
neurotransmitters such as glutamate resulting in intracellular signalling 
cascade through interactions with G-proteins (Niswender and Conn 2010). It 
has however been a matter of controversy since, as to whether these 
receptors can directly induce LTP (Fitzjohn, Bortolotto et al. 1998, Doherty, 
Palmer et al. 2000, Mellor and Nicoll 2001, Bortolotto, Collett et al. 2005), and 
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so is not as well accepted. It has nevertheless been suggested that mGluRs 
can act as a molecular switch whereupon their activation is important to induce 
LTP in a pathway that has not previously experienced LTP induction 
(Bortolotto, Collett et al. 2005). 
KARs have also been shown to induce LTP whereupon they can undergo 
plasticity themselves and have recently been shown to regulate AMPAR 
expression independently of NMDARs [discussed in Chapter 3.1.2].  
1.3.1.2 Long Term Depression (LTD) 
LTD on the other hand, is weakening of synapses and like LTP, is classically 
generated by NMDAR activation (Dudek and Bear 1992). This can be induced 
either by low frequency stimulation (LFS) or bath application of NMDA (chem-
LTD) (Lee, Kameyama et al. 1998). LFS triggers prolonged NMDAR activation, 
but below the threshold levels that induces LTP. While both LTP and LTD are 
generated by postsynaptic Ca2+ influx, the strength and the length of the Ca2+ 
accumulation impacts on the plasticity direction (Lee, Kameyama et al. 1998). 
The spatio-temporal nature of the Ca2+ rise during LTD induction activates 
protein phosphatase cascade (Mulkey, Herron et al. 1993, Mulkey, Endo et al. 
1994). It is thought that the signalling pathways with higher Ca2+ affinity are 
activated (Mulkey, Endo et al. 1994). Upon NMDAR activation, downstream 
Ca2+ sensing molecules such as calcineurin and their phosphoprotein 
substrate; inhibitor-1 and PP1 are activated. This triggers AMPARs removal 
by targeted dephosphorylation events causing reduction in the synaptic 
strength. GluA1 is one of the downstream substrates that are 
dephosphorylated at serine 845 (S845) site causing their endocytosis and 
decrease in channel conductance of AMPARs (Lee, Takamiya et al. 2010). 
Moreover, it was shown that AKAP interaction with calcineurin is also 
important for NMDAR mediated LTD (Jurado, Biou et al. 2010). Other 
interactions such as clathrin adaptor AP2 with GluA2 (Lee, Liu et al. 2002) and 
phosphorylation mediated interaction of GluA2 with PICK1 (Kim, Chung et al. 
2001, Steinberg, Takamiya et al. 2006, Rocca, Martin et al. 2008) also induces 
internalisation of these GluA2-AMPARs during NMDAR mediated LTD [ 
Figure 1-10].  
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Like LTP, NMDAR-independent forms of LTD can also occur and mGluR-LTD 
is a well-studied form of LTD (Palmer, Irving et al. 1997, Fitzjohn, Kingston et 
al. 1999). Activation of these receptors using DHPG (potent agonist of group I 
mGluRs) induces removal of AMPARs like that of NMDAR-dependent LTD 
(Snyder, Philpot et al. 2001). While both forms of LTD can coexist, they follow 
mechanistically distinct routes to induce LTD (Oliet, Malenka et al. 1997, 
Bhattacharyya, Biou et al. 2009). mGluR pathway also involves post synaptic 
Ca2+ release, though in this case through mGluR-dependent G protein 
signalling through Gq (Luscher and Huber 2010) leading to activation of 
downstream signalling cascades such as NCS-1 and PICK1 (Jo, Heon et al. 
2008). While both pathways involve internalisation of AMPARs, AMPAR 
internalisation in the presence of both NMDA and DHPG is additive (Casimiro, 
Sossa et al. 2011), in that they target distinct populations of AMPARs.  
KARs can also undergo LTD themselves independent of NMDARs and 
AMPARs, which will be also explored in chapter 3.1.3.  
1.3.1.3 LTP and LTD associated with learning and memory 
Both LTP and LTD are key cellular processes that underlie learning and 
memory. It was initially shown that inhibiting NMDAR using antagonist APV 
into hippocampus impaired learning (Morris, Anderson et al. 1986). Moreover, 
preventing CaMKII activation (T286A CaMKII knock-in mice which prevents 
autophosphorylation), showed normal NMDAR function but LTP was absent 
which in turn impaired learning and memory in these mice (Giese, Fedorov et 
al. 1998). Alternative approaches where LTP was studied during learning 
using processes such as fear-conditioning in amygdala (a type of associative 
learning) (Rogan, Staubli et al. 1997) and one-trial inhibitory avoidance 
learning in CA1 hippocampus (Whitlock, Heynen et al. 2006) also showed LTP 
induction.  
LTD, while initially proposed to underlie forgetting (Tsumoto 1993), have also 
been implicated in promoting memory formation. Blocking in vivo exocytosis 
in the perihinal cortex was shown to prevent visual memory formation 
(Griffiths, Scott et al. 2008, Cazakoff and Howland 2011). Another interesting 
study using fear conditioning in amygdala showed that associative learning 
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can be inactivated and reactivated by LTD and LTP respectively (Nabavi, Fox 
et al. 2014). Hence, these studies show interplay between these different 
forms of plasticity and highlights their importance in synaptic learning and 
memory processes.  
1.3.2 Homeostatic plasticity  
Because they are both potentially positive-feedback systems the synaptic 
changes induced by LTP and LTD can lead to destabilization of the neuronal 
circuits. Therefore, compensatory mechanisms exist to account for these 
changes in the network activity and maintain global stability. This phenomenon 
is referred to as homeostatic plasticity or scaling which acts as a negative 
feedback mechanism to allow neurones to globally scale up or down their 
synaptic strength relative to the input. This stabilises neuronal firing within a 
usable range necessary for information processing and storage (Turrigiano, 
Leslie et al. 1998, Turrigiano 2008, Pozo and Goda 2010). This also prevents 
runaway excitation thereby maintaining synaptic stability, critical to network 
formation, development and stability and defects in this process has been 
implicated in neurological diseases such as epilepsy and schizophrenia 
(Wondolowski and Dickman 2013).  
1.3.2.1 Glutamate receptors in synaptic scaling 
Homeostatic synaptic response was first demonstrated in visual cortical 
cultures which were treated with various channel blockers chronically over 
period of 48 hours. Treatment with tetrodotoxin (TTX), which blocks voltage 
gated sodium channels, thus dampening the network activity (Narahashi 
2008), increased the mEPSC amplitude, resulting from an increase in synaptic 
AMPARs. On the other hand, treatment with bicuculline, GABAA blocker 
(Straughan, Neal et al. 1971) which enhances the network activity, decreased 
this AMPAR mEPSC amplitude (Turrigiano, Leslie et al. 1998). Hence, the 
synaptic AMPARs were altered to counteract the external changes in activity 
[Figure 1-11]. This activity-dependent bidirectional changes to adjust the 
strength of neuronal excitatory synapses to stabilise firing is also termed as 
‘synaptic scaling’ (Turrigiano 2008). Importantly, these scaling processes 
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retain the changes in the original strength of the connections to maintain the 
input-specific LTP and LTD information (Chater and Goda 2014). 
  
Figure 1-11: Role of glutamate receptors in homeostatic scaling.  
Chronic decrease or increase in network activity can be induced following treatments 
with TTX or bicuculline respectively. Based on decrease or increase in network 
activity, the surface expression of glutamate receptors (mainly AMPARs) increase or 
decrease respectively to compensate for the changes in the synaptic activity, bringing 
the activity level back to basal.  
Regarding glutamate receptors role in homeostatic scaling, predominant 
studies have focused mainly on the changes in AMPAR expression and 
composition. Majority of the post synaptic changes that occur during 
homeostatic plasticity are due to changes in the composition and abundance 
of AMPARs (Pozo and Goda 2010, Chater and Goda 2014, Henley and 
Wilkinson 2016). Both GluA1 and GluA2 subunit-containing AMPARs are 
known to scale up or down (Watt, van Rossum et al. 2000). However, there 
are some controversies on which AMPAR subunit plays the more important 
role. Both GluA1 and GluA2 have been shown to be upregulated in response 
to chronic activity changes (O'Brien, Kamboj et al. 1998, Wierenga, Ibata et al. 
2005) while some studies have suggested GluA2 to have a more prominent 
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role during homeostatic up-scaling (Cingolani, Thalhammer et al. 2008). For 
instance, overexpressing GluA2 C-terminal domain peptide blocked 
homeostatic scaling in cultures, most likely by acting as a dominant negative 
and GluA2 KD was also shown to occlude synaptic scaling (Gainey, Hurvitz-
Wolff et al. 2009). Particularly, GluA2 C-terminal interaction with GRIP1 was 
shown to be important for this as WT GluA2 could rescue the loss of synaptic 
scaling but not a mutant form of GluA2 (Y876E) that cannot bind GRIP1 
(Gainey, Tatavarty et al. 2015) . Another study also showed the importance of 
GluA2 C-terminal on synaptic scaling, however emphasised more on the 
importance of GluA2 proximal C-terminal domain (residues A841 and A843). 
Nevertheless, the study showed that GluA2 subunit is both necessary and 
enough for synaptic scaling (Ancona Esselmann, Diaz-Alonso et al. 2017). 
However, other reports show postsynaptic enhancement of GluA1 recruitment, 
but not necessarily of GluA2, during synaptic scaling (Ju, Morishita et al. 2004, 
Thiagarajan, Lindskog et al. 2005, Sutton, Ito et al. 2006). Nonetheless, 
despite these discrepancies that remain to be resolved, it is well accepted that 
changes in AMPAR accumulation administers synaptic scaling. 
NMDARs at the post synapses also upscale or downscale in response to 
opposing changes in the network activity (Rao and Craig 1997, Watt, van 
Rossum et al. 2000, Mu, Otsuka et al. 2003). In cortical neurones, it was shown 
that they can both upscale and downscale in proportional manner to that of 
AMPARs thereby maintaining the ratio of NMDA to AMPA receptors at 
individual synapses (Watt, van Rossum et al. 2000). Furthermore, increased 
forward trafficking through the early secretory pathway of newly synthesised 
NMDARs was shown to increase their surface expression during chronic 
inactivity (Mu, Otsuka et al. 2003) 
Scaling responses can also be induced by locally perturbing synapses as 
opposed to globally altering network activity. Local enhancement of 
homeostatic plasticity can be achieved by simultaneously blocking 
postsynaptic firing with TTX and blocking NMDARs. This was shown to 
selectively increase GluA1, by relieving the brake on local (dendritic) protein 
synthesis to promote insertion of GluA1 (Sutton, Wall et al. 2004, Sutton, Ito 
et al. 2006). This local dendritic protein synthesis was mediated by regulating 
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phosphorylation state of eukaryotic elongation factor-2 (eEF2). The 
dephosphorylated eEF2, which is the active form, was activated upon chronic 
silencing promoting dendritic protein synthesis (Sutton, Taylor et al. 2007). 
This also suggests distinct mechanisms for LTP and homeostatic up-scaling 
as LTP is caused by NMDAR activation while scaling can be induced by 
NMDAR blockade (Ju, Morishita et al. 2004, Thiagarajan, Lindskog et al. 2005, 
Sutton, Ito et al. 2006).    
In contrast to AMPARs and NMDARs, prior to our work there are very few 
reports in the literature for the homeostatic scaling of KARs, which is 
summarised in Chapter 3.1.4.  
1.3.2.2 Homeostatic plasticity mechanisms 
The cellular and molecular properties of homeostatic plasticity have been 
studied intensively (Turrigiano, Leslie et al. 1998, Shepherd and Huganir 
2007). The compensatory changes in the surface expression of postsynaptic 
glutamate receptors in particular AMPARs are governed by multiple cellular 
processes such as endo/exocytosis, lateral diffusion of receptors in between 
synaptic and extrasynaptic sites and changes in protein-protein interactions 
that deliver and/or stabilise synaptic AMPARs (Bredt and Nicoll 2003, 
Collingridge, Isaac et al. 2004, Harms, Tovar et al. 2005, Ehlers, Heine et al. 
2007, Shepherd and Huganir 2007). 
1.3.2.2.1 Protein interactions 
On an individual level, many cellular processes and their signalling molecules 
have been identified that play a role in homeostatic plasticity [Figure 1-12]. 
For instance, the transcriptional regulator Arc/Arg3.1 can basally upregulate 
or downregulate synaptic strength when removed or overexpressed from the 
system respectively (Shepherd, Rumbaugh et al. 2006, Craig, Jaafari et al. 
2012). Furthermore, secretory molecules such as BDNF and TNF-α (Leslie, 
Nelson et al. 2001, Leonoudakis, Zhao et al. 2008); cell adhesion molecules 
such as N-cadherin/β-catenin complex and integrins and AMPAR interactors 
such as PICK1, GRIP1, PSD93 and PSD95 regulate synaptic AMPARs during 
scaling, also summarised in Table 1-1 (Okuda, Yu et al. 2007, Cingolani, 
Thalhammer et al. 2008, Frank, Pielage et al. 2009, Anggono, Clem et al. 
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2011, Sun and Turrigiano 2011, Tan, Queenan et al. 2015). Interestingly, like 
LTP and LTD, Ca2+ dependent signalling pathways such as CaMKIV also play 
a role in scaling up and down of synaptic AMPARs (Thiagarajan, Lindskog et 
al. 2005, Ibata, Sun et al. 2008). Moreover, post-translational modifications 
such as phosphorylation and SUMOylation of effector proteins can each 
regulate synaptic AMPARs during homeostatic scaling (Noritake, Fukata et al. 
2009, Craig, Jaafari et al. 2012). For instance, PKA levels are increased during 
chronic inactivity resulting in increased GluA1 S845 phosphorylation resulting 
in increased AMPAR up-scaling (Diering, Gustina et al. 2014). Suppression of 
network activity increases SUMOylation of Arc resulting in their increased 
stability which in turn increases AMPAR surface expression (Craig, Jaafari et 
al. 2012). 




Figure 1-12: Various molecular players implicated in homeostatic scaling.  
Upon chronic alterations in the synaptic activity, certain intracellular signalling 
pathways are activated which can either activate gene expression enhancing local 
protein synthesis or secrete soluble factors that enhances or reduces receptor 
abundance on the surface. Equally, these intracellular signalling pathways can also 
act by altering post-synaptic anchoring proteins to either enhance or reduce 
glutamate receptor abundance on the surface. Figure adapted from (Pozo and Goda 
2010).  
Chapter 1  General Introduction 
36 
 
Table 1-1: Regulators of AMPAR mediated Homeostatic Plasticity. Table adapted 
from (Fernandes and Carvalho 2016). 
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1.3.2.2.2 Proteome changes 
Studies have also looked at global level compensatory changes during 
scaling. Translation of over 300 proteins were differentially regulated during 
up-scaling and down-scaling including proteins involved in regulation of 
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cellular processes such as axon guidance and neurite outgrowth, excitatory 
synapses and glutamate receptor complexes. Interestingly, rather than 
individual proteins, opposing pathways were targeted to adjust the proteome 
(Schanzenbächer, Sambandan et al. 2016). Furthermore, comparing early (2 
hour) to late set responses (24 hour) during scaling, there was no overlap in 
newly synthesised proteins, rather there were overlaps in functional groups 
that were regulated in early and later phases (Schanzenbacher, Langer et al. 
2018). This suggests instead of altering specific proteins, set of proteins with 
functional overlap are regulated variably during ‘early’ and ‘late’ phase of 
synaptic scaling. These functional groups included voltage gated Ca2+ 
channels, synaptosomes, cell adhesion, actin cytoskeleton, polarity and 
protein kinases and phosphatases (Schanzenbacher, Langer et al. 2018). 
1.3.2.2.3 Protein turnover 
In addition, a quantitative study in the post synaptic density (PSD) fraction 
showed that ubiquitination targeted degradation plays a key role in regulating 
PSD molecular reorganisation during chronic activity changes. For instance, 
in response to increased activity, certain postsynaptic proteins and scaffolding 
proteins get ubiquitinated and degraded rapidly, which would in turn alter the 
global molecular character and signalling properties of the post synaptic 
membrane (Ehlers 2003).  
Understanding how the interplay between all these cellular processes are 
regulated globally during scaling, will help give clearer understanding of 
mechanisms that regulate synaptic scaling.  
1.3.2.2.4 Post-transcriptional modifications  
Post transcriptional processes also play a role in scaling. Interestingly for 
NMDARs, their forward trafficking at the endoplasmic reticulum regulates their 
synaptic accumulation during chronic activity blockade. ER export of NR1 
subunit of NMDARs were shown to be accelerated by their alternatively spliced 
C2’ domain and slowed by the C2 splice cassette. C2’ variant was shown to 
be predominant during activity blockade which enhances their recruitment to 
ER exit sites by binding of a divaline motif within C2’ to COPII coats, thus 
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allowing their increased surface expression. On the other hand, increased 
chronic activity, increased C2 variant abundance (Mu, Otsuka et al. 2003).  
1.3.2.3 Physiological relevance and diseases associated with 
homeostatic plasticity 
While majority of the work has been performed in dissociated cultures, several 
reports have investigated the physiological relevance of this form of synaptic 
plasticity. Homeostatic scaling has been studied in visual cortex in in vivo 
model where network activity was blocked by intraocular injection of TTX or 
exposing and depriving animals of light (altering sensory inputs) to induce 
experience dependent scaling of glutamate receptors. Depriving animals of 
light increased the glutamatergic quantal size which correlated with increased 
AMPAR abundance, and re-introducing light reversed these changes (Desai, 
Cudmore et al. 2002, Goel, Jiang et al. 2006).  A recent study showed that 
homeostatic down-scaling functions during sleep to remodel synapses in 
rodents for memory consolidation. During sleep, synapses were shown to 
undergo weakening by removal of AMPARs (Diering, Nirujogi et al. 2017). This 
further demonstrates the importance of homeostatic scaling in intact brain.   
Unsurprisingly, inability of the system to balance the network activity can have 
many pathological consequences. For instance, it has been proposed that the 
neural excitability disorder epilepsy is thought to be a pathological 
consequence of synaptic imbalance (Treiman 2001). The balance of excitation 
and inhibition needs to be maintained to avoid epileptogenic states (Swann 
and Rho 2014). Interestingly, global scale changes in translation during 
homeostatic scaling uncovered changes in over 166 proteins that are 
implicated in various neural diseases such as epilepsy (960 genes), 
Alzheimer’s disease (66 genes), Parkinson’s disease (39 genes) and 
schizophrenia (71 genes) (Schanzenbächer, Sambandan et al. 2016). In 
addition, molecular links to diseases such as Autism spectrum disorders, 
Fragile X syndrome, schizophrenia and Alzheimer’s disease are also 
becoming increasingly evident (Soden and Chen 2010, Blackman, Djukic et 
al. 2012, Wondolowski and Dickman 2013, Jang and Chung 2016). Hence, 
homeostatic scaling does play a key role in both physiological and 
pathophysiological function in the brain and defining the molecular 
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mechanisms behind homeostatic scaling will help better understand the 
underlying physiology and pathology. 
1.4 Adenosine to Inosine RNA editing by ADARs 
Glutamate receptors undergo the process of Adenosine to Inosine (A to I) RNA 
editing which adds further diversity to their subunits. Both AMPAR and KAR 
subunits have been shown to undergo various RNA editing processes, all of 
which are named based on the resultant amino acid alterations; Q/R editing 
(Glutamine to Arginine), R/G (Arginine to Glycine), I/V (Isoleucine to Valine) 
and Y/C (Tyrosine to Cysteine). This editing is mediated by the family of 
enzymes called Adenosine Deaminases acting on RNA (ADARs) (Nishikura 
2016).  
1.4.1 Adenosine Deaminases Acting on RNA (ADAR) 
Adenosine Deaminases acting on RNA (ADARs) are enzymes that convert 
adenosine bases to inosine in double stranded RNA by hydrolytic deamination 
at the C6 position (Bass and Weintraub 1988, Wagner, Smith et al. 1989) 
[Figure 1-13]. The resultant inosine is read as guanosine by the cellular 
translational machinery, base-pairing it with cytosine and allowing 
incorporation of amino acids that are not genomically encoded.  
These ADAR family members are conserved in the animal kingdom and are 
essential for normal development in mammals (Jin, Zhang et al. 2009, 
Nishikura 2016). There is one ADAR found in D. melanogaster (dADAR) and 
two found in C. elegans (CeADAR1-2). In vertebrates, there are three families 
of ADARs known: ADAR1, ADAR2 and ADAR3 (Kim, Wang et al. 1994, 
Melcher, Maas et al. 1996, Chen, Cho et al. 2000, Bass 2002, Barraud and 
Allain 2012).  
 




Figure 1-13: Catalytic conversion of Adenosine to Inosine.  
Adenosine is hydrolytically deaminated to an inosine, which is read as guanosine by 
the cellular translational machinery. Figure taken from (Slotkin and Nishikura 2013). 
Studies using KO mice have demonstrated the importance of ADAR1 and 
ADAR2 for survival. Lack of ADAR1 is embryonically lethal, showing 
overproduction of interferons and hematopoietic failures (Hartner, Schmittwolf 
et al. 2004, Hartner, Walkley et al. 2009). ADAR2 KO mice are viable however 
are increasingly seizure prone and die post birth (Higuchi, Maas et al. 2000).  
Along with editing protein coding sequences, ADARs also have other 
substrates such as precursors of certain primary microRNAs (pre-mRNA), 
regulating the expression and function of non-coding miRNAs (Nishikura 
2016).  
1.4.2 ADAR structure  
All three ADARs share common functional domains [Figure 1-14]. The double 
stranded RNA binding domain (dsRBD) is roughly 65 aa long and consists of 
α-β-β-α configuration which allows ADARs to interact with its double stranded 
RNA substrate (Stefl, Xu et al. 2006). ADAR1 consists of three dsRBDs while 
ADAR2 and ADAR3 consists of two dsRBDs each. The deaminase domain, 
which lies in the carboxy-terminal region, allows the enzymatic catalysis to 
occur.  




Figure 1-14: Structure of ADARs.  
All ADARs consist of a deaminase domain, various numbers of dsRNA binding 
domains and nuclear localisation signal. ADAR1 consists of additional nuclear export 
signal and Z-DNA-binding domains while ADAR3 consists of arginine-rich single-
stranded RNA binding domain (R-domain). Figure adapted from (Slotkin and 
Nishikura 2013). 
In addition, all ADARs have putative nuclear localisation sequence (NLSs). 
ADAR1 also consists of two additional Z-DNA-binding domains (Zα and Zβ) 
(Herbert, Alfken et al. 1997), while ADAR3 has an Arginine(R)-rich domain in 
its amino-terminal region (R-domain) (Chen, Cho et al. 2000). While the 
functional significance of these two regions are not fully understood, it is 
thought that the R-domain in ADAR3 allows ADAR3 to bind single-stranded 
RNA (ssRNA) (Chen, Cho et al. 2000) and also aid nuclear localisation of 
ADAR3 (Maas and Gommans 2009). On the other hand, amongst the Z-DNA 
binding domains in ADAR1, the Zα domain has been shown to  successfully 
bind Z-DNA structures. As Z-DNA structures are usually formed upstream of 
an active RNA polymerase, additional binding of ADAR1 to Z-DNA is thought 
to assist efficient mRNA binding by ADAR1 before splicing (Barraud and Allain 
2012). Zβ domain however cannot bind Z-DNA but has been suggested to 
have a role in ADAR1 dimerisation instead (Athanasiadis, Placido et al. 2005). 
Interestingly for Zα domain it is also thought to allow ADAR1 to bind Z-RNA 
structures (Placido, Brown et al. 2007). 
Studies in flies and mammalian ADARs shows ADARs to act as a dimer (Cho, 
Yang et al. 2003, Gallo, Keegan et al. 2003). Mammalian ADAR1 and ADAR2 
form homodimers, needed for its editing activity in vitro (Cho, Yang et al. 
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2003). Homodimerisation is mediated by the dsRBDs in both ADAR1 (it’s third 
dsRBD) (Ota, Sakurai et al. 2013) and ADAR2 (it’s first dsRBD) (Poulsen, 
Jorgensen et al. 2006, Ota, Sakurai et al. 2013). However, binding to the 
dsRNA substrate itself is not required for their dimerisation (Valente and 
Nishikura 2007). Interestingly, FRET analysis showed that ADAR1 and 
ADAR2 could also form heterodimers, suggesting heterodimerisation of 
ADAR1 and ADAR2 could play a regulatory role in their editing activity 
(Chilibeck, Wu et al. 2006). ADAR3, unlike 1 and 2, cannot homodimerise 
(Cho, Yang et al. 2003, Cenci, Barzotti et al. 2008).  
1.4.3 ADAR isoforms 
ADAR2 can undergo multiple splicing events that generate several isoforms 
(ADAR2a-f) (Lai, Chen et al. 1997, Rueter, Dawson et al. 1999, Filippini, Bonini 
et al. 2018). This creates various lengths of ADAR2 affecting their ability to 
interact with and edit its substrates. The first splicing event is self-editing 
producing 2e and 2f isoforms that have no catalytic domain or RNA binding 
domains (Rueter, Dawson et al. 1999). Isoform 2c and 2d have shorter C 
terminus disrupting the deaminase domain and as such display no editing 
activity (this is only known to occur in human). The final splicing event leads 
to an inclusion of 30 nucleotides in rat and mouse (120nt in human) producing 
isoforms ADAR2a and 2b (Gerber, O'Connell et al. 1997). ADAR2a and 2b are 
the only known functional and active isoforms of ADAR2 and they differ with 
each other by 10aa. ADAR2b includes the additional 10aa cassette. Study in 
rat cortical cultures showed ADAR2a to be the more active isoform, showing 
higher editing activity compared to the b isoform. The extra 10aa loop is 
thought to interfere with the RNA binding. However, both display the same 
level of substrate specificity and dimerisation properties (Filippini, Bonini et al. 
2018). Moreover, they were shown to be equally expressed in rat cortical 
cultures, but their relative expression levels have not been studied in vivo 
(Filippini, Bonini et al. 2018). Additional splicing variants for ADAR2 have also 
been detected, one of which has extended open reading frames, referred to 
as ADAR2R. This extension also consists of sequence motif similar to the R-
domain of ADAR3 and shows the highest expression in the cerebellum, but 
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their functional significance has not been explored yet (Maas and Gommans 
2009).        
ADAR1 has two main isoforms generated due to alternative splicing at exon 1 
producing an interferon induced 150kDa protein and a constitutively 
expressed 110kDa protein, where the N-terminal portion of the protein 
including the first Z-DNA binding domain is absent (Patterson and Samuel 
1995).  
1.4.4 ADAR tissue expression and cellular localisation 
ADAR1 and ADAR2 is ubiquitously expressed but ADAR2 is highly expressed 
in the brain and has many targeted substrates there (Kim, Wang et al. 1994, 
Melcher, Maas et al. 1996). ADAR3 on the other hand is expressed exclusively 
in the brain (Melcher, Maas et al. 1996).     
ADARs are usually nuclear localised where they interact with their pre-mRNA 
substrates. For ADAR3, importin alpha KPNA2 (importin subunit alpha 2) 
interacts with its R-domain, acting as a classical NLS, allowing controlled 
nuclear import. On the other hand, ADAR2 which is entirely nuclear retained, 
consists of NLS that interacts with KPNA1 (importin subunit alpha-5) and 
KPNA3, but not KPNA2 (Maas and Gommans 2009). A later study also 
showed specific interaction of ADAR2 with importin subunit-alpha 4 (KPNA3) 
to regulate ADAR2 import during cortical development (Behm, Wahlstedt et al. 
2017). However, ADAR2R isoform which consists of ADAR3-like NLS due to 
the presence of R-domain, allows ADAR2 to interact with importin alpha 
KPNA2 (Maas and Gommans 2009). This further shows the role of ADAR3 R-
domain in allowing specific interactions with importins.  
On the other hand, ADAR1 lacked any binding to all the importins. However, 
nonconventional import pathways for ADAR1 into the nucleus has been 
suggested where nonclassical NLS within the third dsRBD of ADAR1 is 
recognised by nuclear import factor transportin-1 (Fritz, Strehblow et al. 2009). 
Interestingly, ADAR1 also consists of nuclear export signal (NES) within its Zα 
binding domain that allows it to shuttle between the nucleus and cytoplasm 
(Poulsen, Nilsson et al. 2001). Moreover, the first dsRBD of ADAR1 has also 
been implicated in its cytoplasmic localisation (Strehblow, Hallegger et al. 
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2002). As the NES signal is missing within the p110 isoform of ADAR1 
(constitutively expressed form and lacking the Zα binding domain), it is mostly 
localised in the nucleus but can still export out to the cytosol to an extent 
through interaction with transportin-1 and exportin-5 through its first dsRBD 
(Fritz, Strehblow et al. 2009).  
Finally, both ADAR1 and ADAR2 can shuttle in and out of the nucleoplasm 
and nucleoli, along with ADAR1 (Desterro, Keegan et al. 2003, Sansam, Wells 
et al. 2003). 
1.4.5 ADAR substrate preference and specificity 
ADARs bind to dsRNA and efficiently deaminate specific adenosines in the 
duplex RNA without modifying other adenosines within the sequence (Li, 
Levanon et al. 2009). It is generally thought that the ADARs can bind to any 
dsRNA regardless of the sequence, but it is the deaminase domain that 
confers the specificity of target adenosine after binding (Wong, Sato et al. 
2001). The variable number of copies of dsRNA binding domains in different 
ADARs is also thought to contribute to the substrate binding affinity and 
selectivity from other non-ADAR RNA Binding domains (Liu, Lei et al. 2000, 
Stephens, Haudenschild et al. 2004).  
Following these speculations many studies have investigated the preferences 
and specificities of ADAR1 and ADAR2 activity as certain sites are edited 
exclusively by either ADAR1 or ADAR2. However, there are many other sites 
that can be edited equally by both ADAR1 and ADAR2 [see Table 1-2] 
(Nishikura 2016). Moreover, ADAR1 and ADAR2 can act on the same protein 
but at different sites [Table 1-2]. While ADAR1 edits majority of the substrates 
in the mammals, it has been shown to predominantly edit repetitive sites while 
ADAR2 accounts for more non-repetitive coding sites editing (Tan, Li et al. 
2017). There is a preference to edit adenosine in neighbouring 5’ uridine for 
both ADAR1 and ADAR2 but preferential 3’ guanosine editing for ADAR2 
(Lehmann and Bass 2000).  
Further specificity to editing target substrates by ADARs are mostly mediated 
through secondary structures formed by the substrate mRNA. These 
secondary structures could include terminal and internal loops, bulges and/or 
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mismatches (Barraud and Allain 2012).  For instance, Q/ R editing of glutamate 
receptors are more specific to ADAR2 editing [see section 1.5.1] while the Zα 
binding domain in ADAR1 is thought to target ADAR1 to sites that are likely to 
form Z-RNA structures (Placido, Brown et al. 2007). Due to the importance of 
RNA structures, the dsRBDs are thought to play a more important role in the 
target specificity.   
Recently, structural studies also revealed RNA-binding loops within the 
catalytic domain of ADAR1 and ADAR2. This loop was conserved in the family 
of ADAR2 but varied among other family of ADARs (Matthews, Thomas et al. 
2016). This difference in RNA binding loop was later shown to contribute to 
the ADARs specificity as chimeric human ADAR1, where it’s RNA binding loop 
was replaced with the loop from human ADAR2, showed ADAR2-like 
selectivity in editing of target substrates (Wang, Park et al. 2018). Thus, both 
the catalytic domains and the RBDs are important in ADAR’s editing 
specificity.  
1.4.6 Potential co-factor involvement in the deamination 
Structural study of human ADAR2 bound to dsRNA revealed important 
catalytic domains (His394, Glu396, Cys451 and C516) that coordinate the zinc 
ion in the active site and form the catalytic centre (Macbeth, Schubert et al. 
2005). The adenosine to be deaminated is thought to be targeted to the 
catalytic pocket by a base-flipping mechanism (Matthews, Thomas et al. 
2016). Base-flipping is a well-studied mechanism where a single nucleotide 
within the double helix is rotated outside to allow access to the enzymes to the 
site of reaction (Roberts and Cheng 1998). This study also showed that inositol 
hexakisphosphate (IP6) acts as a potential co factor in the enzyme core to aid 
the protein fold, important for its enzyme activity (Macbeth, Schubert et al. 
2005). As of now, no such studies have been performed using ADAR1.  
1.4.7 ADAR3 lacks catalytic activity 
While both ADAR1 and ADAR2 act on many substrates (Kim, Wang et al. 
1994, Melcher, Maas et al. 1996, Barbon and Barlati 2011), ADAR3 has not 
been shown to have any functional role as it’s deaminase domain is inactive 
as such it cannot edit the substrates (Melcher, Maas et al. 1996, Chen, Cho et 
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al. 2000, Schneider, Wettengel et al. 2014). ADAR3 is thought to play a more 
regulatory role by altering availability of various ADAR substrates as it can still 
bind the substrates through its RNA binding domain (Oakes, Anderson et al. 
2017). While both ADAR1 and ADAR2 have conserved arginine residue within 
their RNA-binding loop, this is absent within ADAR3, which may add to its 
catalytic inactivity (Matthews, Thomas et al. 2016, Wang, Park et al. 2018). 
Moreover, ADAR3 lack of ability to form dimers may also be contributing to 
their lack of activity (Cho, Yang et al. 2003, Cenci, Barzotti et al. 2008).  
Recently, behavioural study has shown that mice expressing ADAR3 which 
lacks the dsRBDs have increased anxiety levels and are deficient in short-term 
and long-term memory formation (Mladenova, Barry et al. 2018). This is likely 
due to its inability to sequester substrates from ADAR1 and ADAR2 and thus 
provides a novel role of ADAR3 in cognitive processes.   
1.5 Q/R editing of glutamate receptor by ADARs 
Q/R editing is the process in which a genomic codon encoding for a glutamine 
(Q) (CAG) is altered post-transcriptionally to code for an arginine (R) (CGG). 
The arginine codon is introduced by converting the adenosine base to inosine 
(A to I) which is read as guanosine by the cellular machinery. The AMPAR 
subunit GluA2 (at 607amino acid) and KAR subunits GluK1 (at 636 amino 
acid) and GluK2 (at 621 amino acid) undergo this process of Q/R editing. 
Table1-2 shows the list of Q/R editing sites present in both AMPAR and KAR 
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Table 1-2: List of known glutamate receptor RNA editing sites and the ADARs 
implicated. 
Gene Protein Editing Implicated 
ADARs 
GRIK1 GluK1 (KAR) Q to R ADAR2 
ADAR1  
GRIK2 GluK2 (KAR) Q to R ADAR2 
GRIK2 GluK2 (KAR) I to V ADAR1 
ADAR2 
GRIK2 GluK2 (KAR) Y to C ADAR2 
GRIA2 GluA2 (AMPAR) Q to R ADAR2 
GRIA2 GluA2 (AMPAR) R to G ADAR1 
ADAR2 
GRIA3 GluA3 (AMPAR) R to G ADAR1 
ADAR2 
GRIA4 GluA4 (AMPAR) R to G ADAR1 
ADAR2 
1.5.1 ADAR2 in Q/R editing of KARs and AMPARs 
Among the two functional ADARs, ADAR2 is the key mediator of Q/R editing 
for both GluK2 and GluA2 (Melcher, Maas et al. 1996, Belcher and Howe 
1997, Lai, Chen et al. 1997). In vivo studies in ADAR2 KO mice (which had 
intact ADAR1 levels) exhibited huge deficiencies in GluA2 editing (reduced 
from 98% to 10%) and in GluK2 editing (reduced from ~86% to 29%). There 
was comparatively lower decrease in the GluK1 editing (reduced from 64% to 
40%) (Higuchi, Maas et al. 2000). ADAR1 can also mediate the Q/R editing of 
these substrates (but to a much lower extent compared to ADAR2) as there 
are also in vitro studies showing a role for ADAR1 in Q/R editing of both GluK2 
and GluA2 (Dabiri, Lai et al. 1996, Herb, Higuchi et al. 1996). This perhaps 
explains the remaining low levels of editing of GluA2 and GluK2 observed in 
ADAR2 KO mice. Nevertheless, all the available evidence points to ADAR2 
being the predominant mediator of Q/R editing. 
Q/R editing by ADAR2 for both AMPAR and KAR subunits require 
intramolecular dsRNA structure mediated by the interaction between exonic 
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sequences surrounding the editing site and the editing site complementary 
sequence (ECS) downstream in the adjacent intron [Figure 1-15]. These 
exonic and the intronic regions where the base pairing occurs do not 
necessarily need to occur nearby. In the case of GluK1 and GluK2 Q/R editing 
site, the ECS is as far as 1900 nucleotides (nt) down the Q/R site (Herb, 
Higuchi et al. 1996). In contrast for GluA2, nearby ECS sites in the intronic 
region, ~310 nucleotides distal of the 5’ splice sites, is recruited for base 
pairing (Higuchi, Single et al. 1993). These findings are consistent with the 
RNA editing being a nuclear event that occurs in the pre-mRNA prior to the 
splicing. This also provides examples of the secondary structure of ds(pre-
)mRNA allowing for substrate editing specificity, which was eluded to earlier in 
the section 1.4.4.  
As the ECS site is required for ADAR2 activity in Q/R editing, this intronic 
region has been manipulated to produce GluK2 editing deficient mice. 
However, these mice showed residual 5% edited GluK2 despite the deletion 
of the ECS site, perhaps suggesting a minor mechanism of ECS-independent 
editing of GluK2 as ADAR1 also requires this ECS site to deaminate (Vissel, 
Royle et al. 2001). The intronic ECS region required for the GluA2 editing has 
also targeted to produce GluA2 editing deficient mice, whereby this region was 
replaced by loxP. As expected, these mice completely lacked in Q/R editing, 
further showing the ECS element to be crucial for the GluA2 Q/R editing 
(Brusa, Zimmermann et al. 1995, Feldmeyer, Kask et al. 1999).   




Figure 1-15: Interaction between dsRNA and ADAR2.  
The adjacent intronic region of AMPAR and KAR consist of editing complementary 
site (ECS) which forms dsRNA with the exon consisting of the Q/R editing site. This 
can be as close as 350nt and as far as 1900nt. Upon binding of the ADAR2 enzyme, 
it’s deaminase domain recognises and edits the adenosine to inosine within the 
glutamine coding sequence in the Q/R site.  
 
1.5.2 Effects of Q/R editing on glutamate receptor 
properties 
Q/R editing occurs in the transmembrane II (TMII) region of both AMPAR and 
KAR subunits. As arginine is positively charged, its presence in the inner 
channel pore forming region results in reduction in the Ca2+permeability along 
with low single channel conductance and a linear current voltage relationship 
of the resultant tetramer in AMPARs (Sommer, Kohler et al. 1991, Burnashev 
and Rozov 2000, Cull-Candy, Kelly et al. 2006) [Figure 1-16].    
Similar to AMPARs, KARs with edited GluK1 and GluK2 have reduced Ca2+ 
permeability (Egebjerg and Heinemann 1993, Köhler, Burnashev et al. 1993), 
channel conductance (Swanson, Feldmeyer et al. 1996, Vissel, Royle et al. 
2001) and linear current voltage relationship while the unedited KARs display 
inwardly rectifying response (Bowie and Mayer 1995, Kamboj, Swanson et al. 
1995) [Figure 1-16].  
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Q/R editing also affects receptor oligomerisation, assembly and trafficking 
properties. This was shown to be the case for GluA2 and GluK2 subunits of 
AMPARs and KARs respectively (Greger, Khatri et al. 2002, Greger, Khatri et 
al. 2003, Ball, Atlason et al. 2010). The Q/R editing for both GluA2 and GluK2 
reduces its assembly/oligomerisation, with the edited subunits accumulating 
mostly as a monomer/dimer and as a result are more likely to be ER retained 
(Greger, Khatri et al. 2002, Greger, Khatri et al. 2003, Ball, Atlason et al. 2010).  




Figure 1-16: Glutamate receptor Q/R editing regulates their ionotropic function.  
The Q/R editing occurs in the channel pore forming region (A). As arginine is 
positively charged (C), this alters their ionotropic properties by altering Ca2+ 
permeability (B and D), channel conductance and current voltage relationship. As 
arginine is positively charged, its incorporation next to the channel pore region (D) 
prevents Ca2+ flow altering ion permeability of the resultant tetramer.  
1.5.3 Q/R editing of GluA2 is important for survival 
ADAR2 KO mice show increased seizure activity and premature death. Adding 
back edited GluA2 in this system by replacing the alleles for GluA2 with alleles 
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encoding the edited version exonically rescued the lethal phenotype (Higuchi, 
Maas et al. 2000). Similar results were obtained in GluA2 editing deficient 
mice, which expressed AMPARs with increased Ca2+ permeability resulting in 
mice developing seizures followed by death within 3 weeks (Brusa, 
Zimmermann et al. 1995). Moreover, studies in mouse models which express 
unedited AMPARs at different levels, were shown to be capable of inducing 
inappropriate/excessive NMDAR-independent LTP in hippocampal pyramidal 
connections and suffered from neurological dysfunctions such as epilepsy and 
deficient dendritic architecture (Feldmeyer, Kask et al. 1999). All these studies 
show that ADAR2 mediated Q/R editing in mice is important for brain function 
and survival.     
1.5.4 Developmental and plasticity role of Q/R editing in 
AMPARs  
In contrast to KAR Q/R editing, GluA2 is fully edited (>99%) before birth, 
however the developmental stage at which this editing occurs is not fully 
known (Burnashev, Monyer et al. 1992, Higuchi, Single et al. 1993, Wahlstedt, 
Daniel et al. 2009). There have been some reports of the potential importance 
of unedited GluA2 during development, as ~60% unedited GluA2 Q/R 
transcripts are present in human neuronal progenitor cells (Whitney, Peng et 
al. 2008). However, contradicting this, a study in neuroepithelial precursor cells 
found fully edited GluA2 present throughout, implying the lack of significance 
of unedited GluA2 during development. Perhaps this discrepancy in cell lines 
could be due to their variable expression of ADAR2 (Pachernegg, Munster et 
al. 2015). Furthermore, a study from mice engineered to constitutively express 
arginine (R) (edited site) at GluA2 Q/R site, did not produce any obvious 
defects and displayed a normal phenotype (Kask, Zamanillo et al. 1998), 
hence suggesting the lack of importance of unedited GluA2. Moreover, a 
zebrafish model lacking Q/R editing at GluA2 site showed abnormal neural 
development (Li, Chen et al. 2014). Thus, the functional relevance of these 
unedited GluA2 is not well understood and it is a mystery as to why the critical 
arginine residue in the GluA2 Q/R site is generated via site-selective RNA 
editing and not by exon coding. 
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Because over 99% of GluA2 are edited in adults, GluA2 containing receptors 
in adults are mostly Ca2+ impermeable and incorporation of single edited 
GluA2 subunit in the receptor tetramer assembly causes the entire AMPAR 
complex channel to be Ca2+ impermeable (Hollmann, Hartley et al. 1991, 
Burnashev, Monyer et al. 1992). As such, many studies on synaptic plasticity 
have explored the importance of incorporation of GluA2-lacking Ca2+ 
permeable (CP) and GluA2-containing Ca2+ impermeable receptors. It is 
generally thought that the CP-AMPARs are required for the initial stage of 
activity induction but not necessarily for the maintenance of plasticity (Man 
2011, Henley and Wilkinson 2016). The CP-AMPARs are replaced by Ca2+ 
impermeable GluA2 containing AMPARs post activity induction. For instance, 
LTP studies have shown that CP-AMPARs initially recruited during LTP 
stimulation are soon replaced by GluA2-containing AMPARs (Plant, Pelkey et 
al. 2006, Jaafari, Henley et al. 2012). This was also suggested in homeostatic 
plasticity where activity blockade showed a rapid increase in the surface 
expression of CP-AMPARs in the early stages followed by the increase in 
GluA2-containing AMPARs (Leonoudakis, Zhao et al. 2008). However, the 
role of Ca2+ permeable and impermeable AMPARs in homeostatic scaling is 
controversial, as other studies have also specified the importance of 
incorporation of GluA2 containing AMPARs for scaling induction itself (Gainey, 
Hurvitz-Wolff et al. 2009). Nevertheless, Q/R editing of GluA2 plays an 
important role in plasticity while its role in development is not known. 
1.5.5 Developmental and plasticity role of Q/R editing in 
KARs 
GluK1 and GluK2 are edited at low-levels during development in the Q/R site 
and increases up to 40% and 80% respectively, within the first few days after 
birth (Belcher and Howe 1997, Paschen, Schmitt et al. 1997, Bernard, Ferhat 
et al. 1999). There are also regional differences in the extent of GluK1 and 
GluK2 editing. Studies on rat hippocampus showed GluK2 to reach its maximal 
editing of ~80% by P10, which remains stable through to adulthood, while at 
E18 the editing is at only 20%. On the other hand, GluK1 in hippocampus at 
E18 and P0 stage is edited ~15% which increases up to 40% by P4 and is 
stabilised through to adulthood (Bernard, Ferhat et al. 1999).  
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Since, unedited GluK1 and GluK2 are present at significantly higher levels in 
early life, it is thought that they play an important role during development. A 
study focusing specifically on GluK2 editing deficient mice showed that these 
mice continue to display a juvenile form of NMDAR-independent LTP in 
adulthood (Vissel, Royle et al. 2001). One possibility suggested was that this 
is an important unedited KAR-dependant mechanism for LTP induction in early 
development that is lost in the wildtype mice. Moreover, KAR containing 
synapses during development in thalamocortical synapses are modified in an 
activity dependent manner, whereby the KAR contribution to transmission 
decreases during experience dependent plasticity (Kidd and Isaac 1999). The 
increased editing of GluK2 could be playing a role in this decreased 
transmission. Therefore, GluK2 editing seems to have more significant role 
during development, while its role in plasticity in adult brain is not as well 
characterised.  
GluK1 Q/R editing deficient mice, on the other hand, did not show any 
developmental abnormalities, behavioural defects or any obvious effects to 
kainate induced seizures (Sailer, Swanson et al. 1999). Hence their role is not 
fully understood. However, a study into pre-synaptic KARs showed that the 
Ca2+ permeable unedited GluK1-KARs have a potential role in increasing 
functional presynaptic release sites as suggested by increased synaptophysin 
(pre-synaptic protein) puncta (Sakha, Vesikansa et al. 2016). 
1.5.6 GluK2 Q/R editing and seizures    
While GluK2 editing deficient mice are fully viable, their increased vulnerability 
to induced seizures suggests that increased GluK2 editing during 
development can act as a critical regulator in reducing seizure vulnerability in 
adults. This is in line with previously suggested ideas that editing dysregulation 
can be the pathological mediator of seizure generation (Bernard, Ferhat et al. 
1999) and unedited GluK2 may be playing a major role in seizure generation 
in developing brain (Johnston 1996), further demonstrating the role of KARs 
in epilepsy (Mulle, Sailer et al. 1998, Bernard, Ferhat et al. 1999, Vincent and 
Mulle 2009). This shows that GluK2 Q/R editing play important role in plasticity 
and in pathological processes.   
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1.6 Other forms of Glutamate receptor RNA editing 
The AMPAR subunits GluA2, GluA3 and GluA4 also undergo RNA editing at 
the R/G (Arginine to Glycine) site, in the extracellular domain close to the 
glutamate binding site, preceding the flip/flop splice site (GluA2 at 764aa, 
GluA3 at 769 aa and GluA4 at 765aa) [Figure 1-17, Table 1-2]. Editing at this 
site has been shown to be functionally important for AMPAR kinetic properties. 
The G-edited subunits were shown to have enhanced rate of recovery from 
desensitisation. As this editing site occurs close to the neurotransmitter 
binding site, the channel of unedited GluA2 receptor complex at this site exhibit 
rapid responses to the new glutamate stimulus (Lomeli, Mosbacher et al. 
1994). This editing site is also shown to work in coordination with the flip/flop 
splice site (Laurencikiene, Kallman et al. 2006). During neuronal cell 
maturation, R/G editing increases (Orlandi, La Via et al. 2011). Moreover, 
editing at this site was also shown to be regulated during neuronal activity 
[(Sanjana, Levanon et al. 2012, Balik, Penn et al. 2013), Chapter 4].  
The KAR GluK2 subunit also undergoes editing at two additional sites; I/V (at 
567aa) (Isoleucine to Valine) and Y/C (Tyrosine to Cysteine) at (571aa) 
[Figure 1-17]. These editing occur at the transmembrane domain I (TMI) of 
GluK2. They regulate the ion permeability of the GluK2 containing KARs along 
with the Q/R site and are associated with finer modification of ionic properties 
(Köhler, Burnashev et al. 1993, Burnashev, Zhou et al. 1995). Editing at Y/C 
site increases during development reaching up to 90% in rat brain while the 
I/V site was found to be edited up to 60% in adult rat brain (Belcher and Howe 
1997). However, the function and relevance of these editing sites is not well 
studied.  




Figure 1-17: RNA editing sites in glutamate receptors.  
Q/R editing for GluK1, GluK2 and GluA2 occurs at the TMII region as shown while 
GluA2/A3 and A4 undergo R/G editing in the loop connecting TMIII and TMIV. GluK2 
can also undergo additional I/V and Y/C site editing in the TMI region. 
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1.7 Glutamate receptor RNA editing in diseases 
Dysfunction of ADAR1 and ADAR2 have been implicated in range of cancers 
and viral infections (Gallo and Locatelli 2012, Fritzell, Xu et al. 2017). 
Moreover, as ADAR2 is highly enriched in the brain, the majority of the 
pathological consequences of alterations in ADAR2 editing is mediated by 
changes in the CNS substrates GluA2 and GluK2 (Filippini, Bonini et al. 2017). 
Some of these neurological diseases are also mediated by alterations in 
ADAR1 editing (Slotkin and Nishikura 2013). Many neural pathological 
conditions have been identified in which glutamate receptor RNA editing has 
been shown to be altered.  
ADAR2 mediated editing of GluK2 and GluA2 has been implicated in a range 
neurological disease (Barbon and Barlati 2011, Slotkin and Nishikura 2013). 
As RNA editing is very important for learning, memory and behaviour, its 
dysregulation is altered in diseases such as epilepsy (Brusa, Zimmermann et 
al. 1995, Higuchi, Maas et al. 2000). GluA2 Q/R editing, mediated by ADAR2, 
for instance was shown to be altered in forebrain ischemia (Peng, Zhong et al. 
2006), amyotrophic lateral sclerosis (ALS) (Kawahara, Ito et al. 2004), 
schizophrenia (Akbarian, Smith et al. 1995), Alzheimer’s disease (Gaisler-
Salomon, Kravitz et al. 2014) and in tumors such as glioblastoma (Ishiuchi, 
Yoshida et al. 2007) and astrocytoma (Cenci, Barzotti et al. 2008).  
While majority of ADAR2 dysfunction is thought to be mediated via alterations 
in GluA2 Q/R editing, ADAR2 mediated GluK2 Q/R editing have also been 
implicated particularly in epilepsy (Kortenbruck, Berger et al. 2001), spinal cord 
injury (Caracciolo, Fumagalli et al. 2013) and schizophrenia (Barbon, 
Fumagalli et al. 2007). Alterations in GluK2 editing has also been observed in 
hippocampal and neocortical tissue of epileptic patients (Grigorenko, Bell et 
al. 1998). Interestingly, increased GluK2 editing was observed in murine model 
of schizophrenia (phenylcyclidine-treated rats) (Barbon, Fumagalli et al. 2007). 
Another study also reported a slight decrease in GluK2 Q/R editing following 
kainate-induced seizures (Bernard, Ferhat et al. 1999). This is interesting as 
GluK2 editing deficient mice have increased susceptibility to kainate induced 
seizures (Vissel, Royle et al. 2001). A similar observation of reduced GluK2 
editing has also been reported following cerebral ischemia (Paschen, Schmitt 
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et al. 1996). While not fully known, it can be speculated that increased calcium 
conductance through increased unedited receptors during ischemia, 
contributes to the ischemic cell damage and death (Zhu, Kong et al. 2014).  
Other forms of A-to-I RNA editing such as GluA2 R/G editing has been 
implicated in spinal cord injury (Barbon, Fumagalli et al. 2010), excitotoxicity 
(Bonini, Filippini et al. 2015), and Alzheimer’s diseases (Khermesh, D'Erchia 
et al. 2016). Similarly, I/V and Y/C site editing of GluK2 have also been linked 
to spinal cord injury (Caracciolo, Fumagalli et al. 2013) and bipolar disorder 
(Silberberg, Lundin et al. 2012).  
All these links are from varieties of studies performed in murine models and/or 
cell culture model of diseases and samples from human patients. While most 
of the studies have linked these editing deficiencies to the changes in ADAR2 
(in some cases ADAR1) levels, not all studies show the editing deficiency to 
be consequential. Nevertheless, all these studies highlight the key role of 
ADAR2 (and ADAR1) mediated RNA editing plays in brain function and 
dysfunction of this leads to neurological disorders.  
1.8 Objectives 
Kainate receptors play a major in synaptic plasticity. They undergo plasticity 
themselves and can be activity dependently regulated while also mediating 
plasticity. This has been studied to an extent in Hebbian forms of plasticity: 
LTP and LTD. However, their role in homeostatic plasticity is not as well 
explored.  
Building on recently published work showing that KARs regulate AMPAR 
plasticity, I wanted to determine how KAR signalling can regulate AMPAR 
expression. I also wanted to determine what role if any do KARs play in 
homeostatic scaling.  
Finally, ADAR2-mediated (Q/R) RNA editing has been shown to be an 
important regulator of KAR diversity, trafficking and physiological and 
pathological function. I also wanted to explore its potential function in KAR 
plasticity. So, my project objectives were to address the following questions: 
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• Can KARs mediate AMPAR plasticity (LTP and LTD)? If so, what are 
the mechanisms? 
• Do KARs play a role in homeostatic plasticity? If so, what are the 
mechanisms? 
• Do Q/R editing of GluK2 play a role in KAR plasticity? If so, is this 








































 MATERIALS AND METHODS 
  






All reagents were purchased from Sigma-Aldrich Company limited unless 
stated otherwise.  
All acids were purchased from Fisher Scientific unless stated otherwise.  
2.1.2  Bacterial reagents 
2.1.2.1 Escherichia Coli (E.Coli) 
Table 2.1 consists of all the E. coli strains used: 
Table 2-1: E.Coli strains used. 
Strain Purpose Supplier Genotype 
DH5α Cloning and 
amplification 
Thermo Fisher Φ80 lacZΔ M15 
supE44 Δlac U169 
hsdR17 recA1 endA1 
gyrA96 thi-1 relA1 
XL1-
Blue 






recA1 endA1 gyrA96 
thi-1 hsdR17 supE44 
relA1 lac [F´ proAB 
lacIq ZΔM15 Tn10) 
*Competent DH5α were bought from the indicated suppliers originally and 
were made in house (protocol described in (Inoue, Nojima et al. 1990)).  
*Commercial XL1-blue competent cells (Agilent) were used for cloning into 
viral vector purposes. 
2.1.2.2 Bacterial growth media and agar plates 
E.coli bacteria were grown in in house Luria Bertani (LB) media (University of 
Bristol central stores) for cloning and amplification of DNA stocks. Agar plates 
to culture E.coli were made using LB and 1.5% agar under sterile conditions. 
Bacterial growth media and agar plates were supplemented with appropriate 
antibiotics: Ampicillin (100µg/ml diluted from 100mg/ml stock in 50% ethanol; 
Sigma-Aldrich) and kanamycin (25µg/ml diluted from 10mg/ml stock; Sigma).  




2.1.3 Molecular biology reagents 
2.1.3.1 Plasmids 
Following plasmids were used for cloning purposes: 
• pcDNA3.1 (Invitrogen) 
• pEGFP-N1 (Clontech) 
• pSUPER-neo-GFP (OligoEngine) 
2.1.3.2 Restriction endonucleases 
All restriction enzymes and their compatible buffers used were supplied by 
New England Biolabs (NEB) and stored at -20oC. 
2.1.3.3 Other enzymes 
T4 DNA ligase to ligate vector and inserts was purchased from Takara 
(BioWhittaker). Calf Intestinal Alkaline Phosphatase (CIP) was purchased 
from NEB. 
2.1.3.4 Polymerase Chain Reaction (PCR) kit 
KOD Hot Start DNA Polymerase kit was purchased from Merck Millipore which 
included KOD Hot start polymerase, 10x buffer, dNTPs and MgSO4. DMSO 
was also added to PCR mixture obtained from Sigma. 
2.1.3.5 Agarose gel DNA  
Agarose gels (0.8%, 1.5% or 4%) for gel electrophoresis were made in house 
using ultra-pure agarose (Bioline). 1kb and 50bp DNA ladder were purchased 
from Thermo Scientific. Ethidium Bromide added to the agarose gel to 
visualise the DNA were purchased from Sigma. 
2.1.3.6 DNA purification  
DNA purification was performed using GeneJETTM Gel extraction, Miniprep 
and Midiprep kits obtained from Thermo Scientific.  
2.1.3.7 RNA extraction and cDNA synthesis 
RNA extraction kit was obtained from Qiagen and cDNA synthesis kit from 
ThermoFisher Scientific.  




2.1.3.8 Primers and sequencing 
All primers were ordered from Sigma-Aldrich synthesised as oligonucleotides 
and resuspended in 1xTE (10 mM Tris-HCl pH8.0, 1mM EDTA) buffer made 
in house. Plasmids were sequenced using Eurofins MWG Services. 
2.1.4 Protein biochemistry reagents 
cOmpleteTM Protease inhibitor tablets were obtained from Roche, 
resuspended in 2ml of distilled water to make 20x stock and stored at 4oC. 
Phosphatase inhibitor cocktail solution 2 was obtained from Sigma. 30% v/v 
acrylamide was obtained from Geneflow limited to make SDS-PAGE gels. For 
protein transfer, Polyvinylidene difluoride (PVDF) 0.45µM immobilin 
membrane was obtained from Millipore and WhatmanTM Grade 3MM Chr 
Cellulose Chromatography Papers from GE Healthcare Life Sciences. 
PageRuler protein ladder was obtained from ThermoScientific. For membrane 
blocking, non-fat milk powder from The Co-operative own brand and Bovine 
Serum Albumin (BSA) from Sigma-Aldrich were obtained. Following HRP 
Substrates were used to develop western blot images: 
• SuperSignal® West Pico Enhanced Chemiluminescence (ECL)- 
Thermo Scientific 
• LuminataTM Crescendo- Merck Millipore 
• LuminataTM Forte- Merck Millipore 
• West Femto ECL- Thermo Scientific 
CL-XposureTM Xray Film was obtained from ThermoScientific and 
HypercasetteTM from Amersham Biosciences. The fixer and developer 
solutions were from Fixaplus. 
EZ-Link® Sulfo-NHS-SS-Biotin were obtained from ThermoScientific and 
Streptavidin-Agarose from Streptomyces Avidinii beads were from Sigma. 
GFP Trap beads were obtained from Chromotek and BCA Assay kit from 
Pierce ThermoFisher Scientific. 




2.1.5 Mammalian clonal cell line reagents 
Human Embryonic Kidney (HEK) 293T cells lines were obtained from The 
European Collection of Cell Cultures (ECACC). Stocks were maintained in 1% 
DMSO and stored in liquid nitrogen. 
Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained from Lonza or 
Sigma-Aldrich and were supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Sigma-Aldrich), 1% Glutamine (Gibco, Invitrogen) and 1000 
units Penicillin and 0.1mg Streptomycin (Gibco). Poly-L-Lysine (PLL) was from 
Sigma-Aldrich and Lipofectamine® 2000 transfection reagent from 
ThermoFisher.  
2.1.6 Electronic equipment 
Sterile cell culture hoods were set up by Holten LaminAir and cell culture 
incubators and shaking bacterial incubators were from LTE Scientific and New 
Brunswick Scientific respectively. Mini bacterial incubator was from IKA® KS 
3000i control. Bench top microcentrifuges were from Biofuge and Eppendorf. 
High speed Centrifuges and rotors were from Beckman-Coulter or Jouan. Low 
speed centrifuges were from Jouan and Hettick. Electrophoresis power pack 
for western blot were from Bio-Rad Laboratories, agarose gel electrophoresis 
tank from Takara and thermal cycler PCR was from MJ Research PTC-2000. 
The X-Ray film developer was from Konica (SRX-101A automatic medical X-
ray film developer) and Odyssey Fc detection system was from LI-COR. 
Microscopes for dissection were from Leica and for fixed cell imaging Leica 
SP5-II confocal laser scanning microscope attached to Leica DMI 6000 
inverted epifluorescence was used. Plate reader was from Versamax 
Microplate reader, Molecular devices. Heat block was from Eppendorf, 
waterbath from Grant and Benchtop UV Transilluminator from BioDoc-ItTM 
Imaging System. 
2.1.7 Plasticware and glassware 
Non-sterile plastic pipette tips (10µl to 1000µl) were from StarLabs and Gel 
loading tips from Fisher. Stripettes (5ml to 25ml) from CellStar. 25mm glass 
coverslips and glass slides were from VWR International.Cell culture 
plasticware were from Cellstar. PCR tubes (0.5ml and 0.2ml) were from 




Starlab. 0.5ml and 1.5ml tubes from Eppendorf and 15ml and 50ml tubes from 
Falcon. Syringes and Needles from Sarotorius and BD MicrolanceTM3 
respectively. RNAse free 1.5ml microfuge tubes were from Ambion.  
2.1.8 Fixed cell imaging reagents 
16% Formaldehyde stock was obtained from Electron Microscopy Sciences 
and Fluoromount-G mountingTM media with DAPI from Thermo Fisher. 
2.1.9 Antibodies used 
2.1.9.1 Primary antibodies 
Following primary antibodies were used for western blotting (WB) and 
immunocytochemistry (ICC). All the primary antibodies for WB were diluted in 




















Table 2-2: List of primary antibodies used for WB and ICC. 
Antibody 
Use 






Rabbit Sigma SAB4500090 1:1000 Polyclonal 
ADAR2 
ICC 
Rabbit Abcam Ab64830 1:400 Polyclonal 
ADAR1 
WB 
Mouse SantaCruz sc73408 1:1000 Monoclonal 
Actin Mouse Sigma A5441 1:10000 Monoclonal 
EGFR WB Rabbit Abcam Ab52894 1:1000 Monoclonal 
Fibrillarin 
ICC 
Mouse Abcam Ab4566 1:400 Monoclonal 
GAPDH Mouse Abcam Ab8245 1:10000 Monoclonal 
GluA1 WB Rabbit Millipore Ab1504 1:1000 Polyclonal 
GluA1 ICC Mouse Millipore Mab2263 1:100 Monoclonal 
GluA2 WB Rabbit Synaptic 
Systems 
182103 1:1000 Polyclonal 
GluA2 ICC Mouse Millipore MAB397 1:70 Monoclonal 
GluK2 WB Rabbit Millipore 04-921 1:1000 Monoclonal 
GluK5 WB Rabbit Millipore 06-315 1:1000 Polyclonal 
GFP WB Rat Chromotek 3h9-100 1:10000 Monoclonal 
GFP ICC Chicken Abcam Ab13970 1:1000 Polyclonal 
HA WB Mouse Sigma 43663 1:2000 Monoclonal 
HA ICC Mouse Sigma 43663 1:600 Monoclonal 
LaminB Goat SantaCruz Sc-6217 1:1000 Polyclonal 
Pin1 WB Mouse Santacruz G-8 1:1000 Monoclonal 
RhoGDI Rabbit Abcam Ab133248 1:1000 Monoclonal 
WWP2 
WB 
Rabbit Abcam Ab86544 1:500 Polyclonal 




2.1.9.2 Secondary antibodies 
HRP conjugated anti-mouse (raised in Goat), anti-rabbit (raised in Goat), anti-
rat (raised in Rabbit) and anti-goat (raised in rabbit) were all from Sigma-
Aldrich and used at a dilution of 1:10000 in 5% milk and PBS-T.  
All secondary antibodies Cy2, Cy3 and Cy5 (raised in Donkey) for 
immunocytochemistry were from Jackson ImmunoResearch and used at 
1:400 in 3% BSA in PBS. 
2.1.10 Plasmid constructs 
Plasmid constructs generated are listed in table below.    
Table 2-3 List of plasmid constructs used. 
Protein Species Backbone Tag Cloning Sites 
ADAR2 WT Rat pcDNA3.1 HA 5’KpnI 3’XbaI 
ADAR2 T32A Rat pcDNA3.1 HA 5’KpnI 3’XbaI 







































Rat pXLG3-Wpre HA 5’SpeI 3’BamHI 
ADAR2 T32A 
rescue 
Rat pXLG3-wpre HA 5’SpeI 3’BamHI 






Rat pXLG3-wpre HA 5’SpeI 3’BamHI 
GluK2 621Q * Rat pcDNA3.1 YFP 
Myc 
 
GluK2 621R * Rat pcDNA3.1 YFP 
Myc 
 
shGluK2* Rat pXLG3-100bp 
stuffer 
GFP 5’KpnI 3’KpnI 
Pin1 Rat peGFP-N1 GFP 5’EcoRI 3’BamHI 
Wwp2 Rat pcDNA3.1 HA 5’KpnI 3’XbaI 




GFP 5’BglII 3’XhoI 





GFP 5’BglII 3’XhoI 
shwwp2 1 Rat, 
mouse 
pXLG3-wpre GFP 5’PacI 3’XhoI 
shwwp2 2 Rat, 
mouse, 
human 
pXLG3-wpre GFP 5’PacI 3’XhoI 
*GluK2 621Q was made by Dr. Stephane Martin (Martin, Nishimune et al. 
2007) and GluK2 621R was made by Dr. Ash Evans by using Quickchange 
Mutagenesis. shGluK2 was prepared by Dr. K.A.Willkinson. 
2.1.11 Drugs 



















40mM 40µM DMSO Sigma 
Bortezomib 
(BTZ) 




100mg/ml 25-50µg/ml DMSO Sigma 
GYKI53655 10mM 40µM ddH2O Abcam 








1mM 0.5-1µM ddH2O Tocris 
Bioscience 
2.2 Molecular biology methods 
2.2.1 Polymerase Chain Reaction (PCR) 
High fidelity Hot KOD polymerase, purified from Thermococcus 
kodakaraensis, were used for conventional PCR. Each PCR reaction was 











Table 2-5: List of components added to the PCR reaction mixture 




10x Buffer 5 10x 1x 
dNTP mix 5 2mM 0.2mM 
MgSO4 3 25mM 1.5mM 
Forward primer 1.5 10µM 0.3µM 
Reverse primer 1.5 10µM 0.3 µM 
Template DNA 10 1ng/µl 0.2ng/µl 
ddH2O 20.5   
DMSO 2.5   
KOD Hot Start 
Polymerase 
1 1unit/µl 0.02unit/µl 
 Total = 50µl   
 
PCR was then performed using a thermal cycler with the following settings: 
Table 2-6: PCR reaction thermocycler setup 
Polymerase 
activation 
95oC for 2 minutes (mins) 
Denature DNA 95oC for 20 seconds 















Repeat Cycles Repeat steps 2-4, 25 times 
Final extensions 70oC for sec/min (per step 4) 
Cooling 10oC for 10 mins 
 
Site Directed Mutagenesis (SDM) was used to introduce point mutations. For 
this, long primers were designed which were oppositely coded and annealed 
to the region of interest with desired point mutation. The desired mutation site 
was kept in the middle during primer design with complementary 21bp added 




either side. PCR was then performed to copy the whole plasmid. PCR was 
performed with mostly Table 2-6 settings, except polymerase extension at 
70oC 25s/kb (length of whole vector + insert) and repeat steps 2-4 were 
performed 18-22 times.  
2.2.2 Agarose gel electrophoresis 
Agarose gels were prepared by mixing either 0.8% or 1.5% agarose with 0.5x 
TAE buffer (40mM Tris acetate, 1mM EDTA) and heated to dissolve the 
agarose. The mixture is then cooled (but not set) and ethidium bromide 
(0.5µl/ml) was added, swirled to mix and poured into mould with the well 
setting combs added beforehand. The gels were then allowed to set.  
In a Mupid®-eXu gel tank, the agarose gels were submerged in 0.5x TAE. 
Samples were mixed with 6x loading dye (ThermoScientific) and loaded into 
the agarose gel wells. Typically, 5µl of sample would be mixed with 1µl loading 
due to load 6µl total volume. 5µl of 1kb Hyperladder (Bioline) was also loaded 
to identify the DNA size. Electrophoresis was run at 135 volts (V) for 20 
minutes to allow the DNA to resolve and gels were imaged using a UV 
transilluminator. 
2.2.3 PCR purification 
A GeneJETTM Gel extraction kit was used to purify the PCR products. Binding 
buffer was added in a ratio of 5 times the volume of the product to be purified, 
vortexed briefly and added to a purification column. The column was spun at 
16100g for 1 min on a bench-top centrifuge. The flow-through was discarded. 
Wash buffer was added to the column and spun at max speed for 1 min on 
bench-top centrifuge. Flow through was discarded and wash step repeated, 
after which the column was spun again to discard residual wash buffer from 
the column. The column was transferred into a fresh 1.5ml Eppendorf tube 
and 50µl ddH2O was added to the column and incubated for 2 mins before 
spinning at 16100g for 2 mins.   
2.2.4 Restriction enzyme digestion 
50µl of purified PCR product and 5µg of vector DNA were digested with 20units 
of restriction endonucleases in appropriate NEB buffer and made up to a final 




volume of 100µl with ddH2O. For vector DNA digestion, 20 units of Calf 
Intestinal Alkaline phosphatase (CIP) was also added to remove the 5’ 
phosphate groups and prevent vector re-ligation. The digest mixture reactions 
were incubated at 37oC for 2 hours and purified using GeneJETTM Gel 
Extraction kit as explained in section 2.1.3.6. 
For SDM, PCR product was not purified and digested straight using DpnI 
restriction endonuclease for 2 hours at 37oC. DpnI is used to digest methylated 
DNA to remove the original template DNA and not the PCR product. After 
digestion, the mutated vector was purified again (see section 2.2.3) and eluted 
twice using the same 10µl volume of ddH2O.  
2.2.5 DNA ligation  
The digested and purified DNA and vector were run on an agarose gel (see 
section 2.1.3.5) to ensure the vector was linearised and help determine 
vector:insert molar ratio. The vector DNA was diluted in appropriate volume of 
ddH2O to obtain 3:1 molar ratio with the insert when mixed in 1:1 ratio. 1µl of 
insert DNA was then mixed with 1µl diluted vector DNA along with 2µl T4 ligase 
solution 1 (Takara). Control ligation was set up where ddH2O was used instead 
of insert to determine the amount of vector-ligation. The ligation mixture was 
left at room temperature (rt) for 30 mins.     
2.2.6 Bacterial transformation 
Chemically competent E.coli were grown in lab and aliquots stored in -80oC. 
DH5α E.coli were used for general transformation and amplification while XL1-
Blue E.coli was specifically used for pXLG3 based transformation and 
amplification for lentivirus purposes due to their low recombinase activity.  
The 4µl of ligation mixture added to 40µl of E.coli (thawed on ice) in a 1.5ml 
Eppendorf tube and incubated on ice for 20 mins.  
Agar plates containing the appropriate antibiotics was pre-warmed in the 37oC 
bacterial incubator. Cells were heat shocked for 90 seconds in 42oC waterbath 
and transferred on ice for 2 mins. For commercial XL1-Blue, the cells were 
heat shocked for only 45 seconds. After 2 mins, 100µl of warm LB broth was 
added to the bacteria. The bacterial cells were then added to the agar plate 




and spread evenly using a sterile hockey spreader stick. For kanamycin 
resistance genes, 200µl of LB broth was added to the E.coli after heat-shock 
and incubated for an hour at 37oC to allow for expression of genes before 
plating on the agar plate. The agar plate was then incubated at 37oC overnight 
with the lid facing down so that the condensation does not drip onto the plate 
and disrupt growing bacteria. For site-directed mutagenesis, the 10µl of 
purified digested product was added to 40µl of E.coli and above protocol was 
followed. 
2.2.7 Bacterial amplification and plasmid DNA 
purification 
Single colonies on LB agar plates were picked and cultured in 3ml of LB Broth 
overnight supplemented with the appropriate antibiotics in a 37oC shaking 
incubator. Plasmid DNA was extracted and purified the next day using 
GeneJETTM Plasmid Miniprep Kit according to the manufacturer’s instructions 
and eluted in 50µl of elution buffer. DNA concentrations were measured using 
a NanoDrop ND-1000 (LabTech) at an absorbance wavelength of 260nm. The 
successful colonies were PCR screened and sent for sequencing.  
The correct miniprep DNA were amplified using Midiprep for transfection 
purposes. For this, bacterial transformation was carried as section 2.2.6, 
where 1µl of miniprep DNA was transformed in 10µl of E.Coli and plated on 
appropriate antibiotic coated agar plate overnight at 37oC to pick clonal 
population. The next day, single colony was picked and grown in 100ml of LB 
Broth supplemented with appropriate antibiotic in a shaking incubator at 37oC. 
The following day DNA was extracted and purified using a GeneJETTM 
Plasmid Midiprep kit according to manufacturer’s instructions (following the 
high-speed protocol) and was eluted in 500µl of elution buffer. DNA 
concentration was measured and stored at -20oC till use.      
2.2.8 Colony screening 
After single bacteria clones were amplified using Miniprep kit, they were PCR 
screened to test for positive colonies with the desired insert. Appropriate 
forward and reverse primers were used to perform PCR with same methods 
as mentioned before. However, the PCR volume was scaled down to 10µl 




instead of 50µl volume and all the product was run on an agarose gel and PCR 
products visualised to confirm ligation.  
The positive preps were then sent for full sequencing to MWG Eurofins using 
appropriate primers either available from MWG or using pre-made primers.  
2.2.9 shRNA synthesis 
Forward and reverse complementary oligonucleotides consisting of the full 
shRNA hairpin sequence with 5’ BamHI and 3’ XhoI overhangs were ordered 
from Sigma-Aldrich. The oligonucleotides were diluted to 100µM in 1x TE 
buffer (10mM Tri-HCl, 1mM EDTA, pH 8). 2µl of each oligonucleotide were 
mixed together in an Eppendorf tube and heated to 95oC in a heat block for 4 
mins and left to cool after for 30 mins at rt to allow annealing to occur. The 
annealed oligonucleotides were diluted to 250µl with ddH2O. 1µl of diluted 
oligonucleotide was ligated with 1µl pSUPER-neo-GFP (cut with BglII and 
XhoI minus the CIP), transformed and plated onto ampicillin-containing LB 
agar plates.  
Once successfully cloned pSUPER was identified, the shRNA including the 
H1 promoter from pSUPER was subcloned into lentiviral vector pXLG-3 
(Demaison, Parsley et al. 2002). For the knockdown vector, flanking KpnI 
restriction sites were introduced via primers. For knockdown rescue vectors 
(pXLG3-wpre), flanking 5’ PacI and 3’ XhoI was introduced via primers to ligate 
the shRNA cassette. Ligation, transformation and screening was performed as 











Table 2-7: shRNA target sequences for protein knockdown 







shADAR2 Partial pXLG3-100bp 
stuffer 
AACAAGAAGCTTGCCAAGGCC 
shGluK2  pXLG3-100bp 
stuffer 
GCCGTTTATGACACTTGGA 
shwwp2 1 pXLG3-wpre TGCCCAATGGGCGTGTCTATT 
shwwp2 2 pXLG3-wpre GCAGCACTTCAGCCAAAGATT 
wpre: Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory 
Element 
*shGluK2 was designed and prepared by Dr. K.A Wilkinson. 
2.2.10 Lentivirus production 
HEK293T cells for lentivirus production was grown using Complete Sigma 
DMEM media (Plain Sigma DMEM ((with L-glutamine) and supplemented with 
10% FBS) and all transfections were also performed using this media.  
2.2.10.1 Plating HEK293T cells 
HEK293T cells were cultured in Complete DMEM media and passaged as 
described in section 2.3.1 and 2.3.2. 6.5 x 106 cells were plated in a 10cm cell 
culture dish (not pre-treated with PLL) containing 7ml of Sigma complete 
DMEM media. The cells were incubated overnight to allow them to adhere and 
grow.   
2.2.10.2 HEK293T cell transfection 
The next day, the HEK293T cells were transfected. For this, required amount 
of plain DMEM media was sterile filtered using 0.2µM syringe filter. For 
knockdown vector, 20µl of XLG viral vector containing the shRNA under H1 
promoter (pXLG3-100bp stuffer) and promoter was mixed with 5µg pDMD2.G 
packaging vector (Addgene) and 15µg of p8.91 helper vector (Addgene) into 
a sterile bijou vile containing 2.5ml of sterile filtered Sigma plain DMEM media. 




In a 15ml falcon tube, 2.5ml of plain DMEM media was mixed 4.8% 1mg/ml 
polyethylenimide (PEI) by inverting several times. The PEI mixture solution 
was sterile filtered using 0.2µM syringe filter into a fresh 15ml falcon tube, left 
to stand in rt for 2-3 mins and inverted to mix several times again. The PEI-
DMEM mixture was then added to the bijou vile containing the earlier prepped 
DNA mixture, inverted to mix several times and left to stand in rt for 30 mins.  
During this incubation period, the plated HEK293T cells were carefully washed 
with 6ml of plain DMEM media twice. After second wash the media was 
aspirated and the 5ml of transfection solution was slowly added to the cells 
and incubated at 37oC for 4 hours. After the incubation, the transfection 
mixture media was aspirated from cells and replaced with 7ml of neuronal 
feeding media (sterile filtered with 0.2µM filter and warmed to 37oC). The cells 
were the placed back in the 37oC incubator.   
For pXLG3-wpre vector (for knockdown and rescues) above protocol was used 
for HEK293T transfection with slight variances in concentrations of vectors and 
PEI:  
• 10µg of viral vector was added to 2.5µg pDMD2.G and 7.5µg of 
p8.91 vector.  
• 2.4% 1mg/ml PEI was added to make the transfection mixture.  
• After 4 hours of incubation, 7ml of complete DMEM was added 
to the HEK293T cells instead of the feeding media.  
2.2.10.3 Lentivirus harvesting 
60-72h post-transfection, the virus containing media was collected into 15ml 
falcon tube and centrifuged at 3000g for 10 minutes at 4oC to pellet any 
remaining dead cells in the media. The supernatant was syringe filtered 
(0.45µM) into a fresh 15ml falcon tube. The syringe filter was pre-wetted with 
neuronal plating media beforehand. The sterile filtered virus containing media 
was then aliquoted to required volume (500µl to 1ml) before being stored at -
80oC.  
For XLG-wpre vector (knockdown under H1 promoter but rescue/GFP under 
SFFV promoter), the virus-containing media was harvested 40-48 hours post-




transfection and the syringe filter was pre-wetted with complete DMEM media. 
Otherwise, the protocol was same as above.   
2.2.11 RNA extraction and cDNA synthesis 
RNA extraction was performed using Qiagen RNeasy Mini Kit as per 
manufacturer’s instructions. The surface and all required equipment for this 
process were sprayed and wiped with RNAseZapTM RNase decontamination 
solution (InvitrogenTM) spray. RNAse free 1.5ml microcentrifuge tubes and 
filter pipette tips were used throughout the process and the whole process was 
carried out in rt.  
Briefly, after required treatments 350µl of buffer RLT supplemented with β-
mercaptoethanol (β-ME) 1:100 were added per 1 million cells. Cells were 
scraped and collected in a RNAse free 1.5ml microcentrifuge tube. The 
solution was spun at 16100g in a benchtop centrifuge to remove any 
undissolved pellet. The supernatant was transferred in to a fresh tube and the 
RNA was precipitated using 70% ethanol, pipetted to mix and transferred onto 
the RNeasy Mini Spin Column. Wash steps were followed per manufacturer’s 
instructions and the RNA was eluted into a fresh RNAse free microcentrifuge 
with 25µl of RNase-Free water. RNA concentration was measured using 
Nanodrop at 260nm wavelength.    
cDNA synthesis was performed using RevertAid First Strand cDNA synthesis 
kit (Thermo Scientific) following manufacturer’s instructions. 1µg of extracted 
RNA was used along with oligo(dT)18 primer and other components shown in 










Table 2-8: Components of the reaction mixture for cDNA synthesis. 




Template RNA - As needed 1µg 0.05µg/µl 
Primer 1µl 100µM 5µM 
Water, nuclease-
free 
To make to 12ul 
with template 
RNA and Primer 
 - 
Reaction Buffer 4µl 5x 1x 
RiboLock RNase 
Inhibitor  
1µl 20units/µl 1unit/µl 





1µl 200units/µl 10units/µl 
 Total = 20µl   
The mixture was pipetted to mix, spun down briefly and then heated at 42oC 
on a heatblock for an hour before heating at 70oC for 5 mins to inactivate the 
reverse polymerase enzyme.  
No RT control and ddH2O control was also prepared to ensure no genomic 
DNA contamination occurred. 
2.2.12 BbvI restriction enzyme assay and analysis 
For BbvI restriction enzyme Assay, once cDNA was synthesised per condition, 
primers spanning the TMII region of GluK2 and GluA2 were used as follows to 
perform PCR. 
GluK2 F: 5’-GGTATAACCCACACCCTTGCAACC-3’ 
GluK2 R: 5’-TGACTCCATTAAGAAAGCATAATCCGA-3’ 
 
GluA2 F: 5’-GTGTTTGCCTACATTGGGGTC-3’ 
GluA2 R: 5’-TCCTCCTACACGGCTAACTTA-3’ 




To set up PCR, 6µl of cDNA synthesised was used per condition with the same 
set up as Table 2-5, but ddH2O volume adjusted to make up to 50µl total 
volume. PCR amplification set up was the same as described in Table 2-6, 
except the repeat steps 2-4 were performed for 35 times. The resultants PCR 
product was purified as described in section 2.1.3.6 and eluted in 25µl of 
ddH2O.  
For BbvI digestion, the 15µl of the purified PCR product was incubated with 
20 units of BbvI enzyme (NEB) and 2µl of CutSmart Buffer (NEB) made up to 
20µl volume with ddH2O and incubated at 37oC for 2 hours. All the 20µl of 
digested product was run on a 4% agarose gel and the ethidium bromide 
stained bands were imaged using UV transilluminator and quantified using FIJI 
ImageJ (NIH). Densitometry was calculated using the Gel Analysis Tool in FIJI 
ImageJ (NIH). The relative pixel intensity was calculated as the area under 
each peak and the percentage of editing was determined as below: 
For GluK2; 
[Intensity of 376(edited)/(Intensity of (376 (edited)+269(unedited))] * 100.  
The band at 76bp present in both edited and unedited products allowed to 
determine equal loading.    
The above protocol for GluK2 was adapted from (Bernard, Ferhat et al. 1999). 
For GluA2; 
[Intensity of 231 (edited)/Intensity of 131 (unedited)] * 100.  
2.2.13 Obtaining sequencing chromatographs 
To obtain sequence chromatographs to highlight the dual peaks at the region 
of editing, the 2µl of purified PCR product was diluted in 13µl of ddH2O and 
sent for sequencing to MWG Eurofins. The resultant chromatographs were 
downloaded from the Eurofins webpage and opened and imaged using the 
free version of Chromas (Technelysium, version 2.6.2).  
2.2.14 Genotyping and PCR 
Ear Notch samples from mice (rough 2mm volume) were received from Animal 
Unit Breeding Team as requested. KAPA Mouse Genotyping Kit (Sigma) was 




used to extract the genomic DNA following manufacturer’s protocol. DNA 
extraction was performed per extraction in 100µl volume with 88µl PCR-grade 
water, 10µl 10x KAPA Express extract Buffer and 1U/µl KAPA Express Extract 
Enzyme added to the mouse tissue in a 1.5ml Eppendorf tube. The mixture 
was pipetted up and down to mix the solution and heated to 75OC for 10 
minutes on a heat block for lysis followed by enzyme inactivation at 95OC for 
5 mins. The samples were centrifuged briefly to pellet cellular debris. The 
supernatant (DNA) was moved to a fresh 1.5ml Eppendorf tube and diluted 
10-fold with 10mM Tris-HCl pH 8.0 (crude extract). 
To set up PCR, following components were mixed per individual PCR tube 
and mixed well. 







PCR-grade water 7.75 N/A N/A 
2xKAPA2G Fast (HotStart) Genotyping 
Mix with dye 
12.5 2x 1x 
Forward Primer 1.25 10µM 0.5µM 
Reverse Primer 1.25 10µM 0.5µM 
Reverse Primer 2 1.25 10µM 0.5µM 




 Total=25µl   
 
Following PCR cycling settings were used.  
  




Table 2-10: PCR cycling protocol for genotyping samples. 
Polymerase 
activation 
95oC for 3 mins 
Denature DNA 95oC for 15 seconds 
Annealing primers 60oC for 15 seconds 
Polymerase 
extension 
72oC for 30 seconds 
Repeat Cycles Repeat steps 2-4, 30 times 
Final extensions 72oC for 2 mins 
Cooling 10oC for 10 mins 
 
The PCR products were run on a 4% agarose gel and visualised using UV 
transilluminator.  
2.3 Cell culture methods 
All cell culture work was performed under sterile hood conditions and all the 
cells were incubated at 37oC, 5% CO2 and 95% O2. 
2.3.1 Culturing HEK293T cells 
HEK293T cells stored in liquid nitrogen cryostore (10% DMSO in DMEM 
media) were thawed in 37oC waterbath before mixing them with 10ml 
Complete DMEM media (Plain DMEM supplemented with 10% FBS, 1% L-
glutamine and 1% Penicillin/Streptomycin) in a 15ml falcon tube. The cells 
were resuspended and centrifuged at 1500g for 2 minutes at rt. The 
suspension media was removed, and the cell pellet was resuspended in 1ml 
of Complete DMEM to remove any DMSO. The resuspended cells were 
transferred to a T25 flask along with additional 5ml of complete media and 
incubated overnight. The cells were passaged the next day into T75 flask 
containing 15ml complete DMEM media. Cells in culture were regularly 
passaged for experimental use. 
2.3.2 Passaging HEK293T cells 
The HEK293T cells were passaged regularly when 70-90% confluency was 
reached. In a T75 flask, cells were gently washed with 10ml of 1x PBS (10x 




PBS (Gibco) diluted in sterile cell culture grade water (HycloneTM HyQPAK)) 
before adding 1ml of 0.05% typsin-EDTA to the cells. The cells were incubated 
for 2-3 mins at 37oC to allow the adherent cells to detach from the flask. The 
trypsin was deactivated by adding 10ml of Complete DMEM to the flask and 
collecting the cells in to a 15ml falcon tube. The cells were centrifuged at 
1500g for 2 minutes at rt. The supernatant was aspirated, and the cell pellet 
was resuspended in 10ml of complete DMEM media by triturating with a 10ml 
serological pipette. 1ml of the cell suspension was added to a new T75 flask 
containing 15ml of complete DMEM media and incubated till the next passage. 
2.3.3 Plating HEK293T cells 
To plate HEK293T cells for experiments, wells of a cell culture 6-well dish or 
3cm dishes were coated with PLL to aid cell adhesion to the dish. For this, PLL 
diluted to 0.1mg/ml in sterile cell culture grade water was added to cover the 
wells/dish, incubated at 37oC for at least 1 hour and washed three times with 
2ml of sterile cell culture grade water before adding 2ml of transfection DMEM 
media (Plain DMEM media supplemented with 10% FBS and 1% L-glutamine). 
Cells in a T75 flask was passaged and counted using haemocytometer. 
200,000 cells per well of a 6 well dish was added or 1 million cells per 3 cm 
dish was added and incubated overnight to allow them to adhere.     
2.3.4 Counting cells 
To count cells, the resuspended cells were diluted 1:10 in 0.4% Trypan Blue 
solution (Gibco). The trypan blue-cell mixture was pipetted into a 
haemocytometer and counted to determine concentration of cells in million per 
ml.  
2.3.5 Transfecting HEK293T cells 
For transfection, appropriate amount of DNA (as per the experiment) was 
added to 100µl of plain DMEM media in a 1.5ml Eppendorf tube. In another 
1.5ml Eppendorf tube, 1.5µl of Lipofectamine® 2000 per µg of DNA was added 
to another 100µl of plain DMEM media. The solutions were vortexed briefly 
and left to incubate in rt for 5 minutes. The Lipofectamine® tube was added to 
the DNA tube and vortexed briefly again and allowed to incubate in rt for 25 
mins. After 25 mins, the tubes with the transfection mixtures were vortexed 




again and added to the wells/dishes in dropwise manner. The transfection was 
left to incubate for either 48 hours for overexpression constructs or 72 hours 
for knockdown constructs before lysing the cells. If both overexpression and 
knockdown constructs were used at the same time, the transfection was left 
on for 72 hours.         
2.4 Primary neuronal cell culture 
2.4.1 Preparation of glass coverslips 
25mm glass coverslips (~50) were placed in a large glass beaker, submerged 
in nitric acid and incubated overnight with gentle agitation at rt. The next day, 
the nitric acid was removed carefully, and the coverslips were washed with 
distilled water (3 quick washes followed by 3 x 30 mins washes). The 
coverslips were then transferred to 140mm plastic cell culture dish and 
sterilised in 70% ethanol for at least 2 hours with gentle agitation at rt. After 
the incubation, the coverslips were given three quick washes and 3 x 30 
minutes washes with sterile cell culture grade water. All the washes after 
ethanol incubation were done in sterile laminar flow hood. The coverslips were 
then stored in cell culture grade water at rt.  
2.4.2 Preparation of sterile borate buffer 
To prepare borate buffer, required grams of Borax and Boric acid powders was 
added to a 50ml falcon tube to achieve a final concentration of 10mM Borax 
and 50mM Boric acid in 500ml volume. 50ml sterile cell culture grade water 
was added to the powder mixture under sterile laminar flow hood and left to 
dissolve on a rotating wheel at rt for 2 hours. The dissolved borax and boric 
acid were then sterile filtered using vacuum filtration system with 0.2µM pore 
membrane and made up to volume of 500ml with sterile cell culture grade 
water. The sterile borate buffer was then stored at rt for future use.  
2.4.3 Coating glass coverslips and plastic plates with 
Poly-L-lysine (PLL) 
To prepare dishes were cell culture, the plastic wells of 6-well dish were coated 
with 0.5mg/ml PLL diluted in sterile borate buffer. Prepared glass coverslips 




were placed in 35mm plastic dishes and washed three times with sterile cell 
culture grade water before adding 1mg/ml PLL diluted in sterile borate buffer. 
Plates and dishes were left to incubate overnight in a 37oC incubator, after 
which they were washed three times with sterile cell culture grade water and 
replaced with 2ml of plating media (Neurobasal® medium supplemented with 
5% Horse serum, 2% B27 and 1% Glutamax) and stored in a 37oC incubator 
until needed.  
2.4.4 Rat embryonic dissection 
All dissection tools and work place were cleaned with 70% ethanol in distilled 
water before use. Pregnant E18 Han Wistar rats were anaesthetised using 
isoflurane with pure oxygen flow and humanely sacrificed using cervical 
dislocation under Home Office Schedule 1 regulations. The skin of the animal 
was sterilised with 70% ethanol in distilled water and cut through to extract 
embryos from the womb. The embryos were kept in Hank’s Buffered Salt 
Solution (HBSS) (Gibco) at rt once extracted and throughout the dissection. 
Embryos were immediately removed from their sacks and decapitated. Under 
a dissection microscope, the brains were removed from severed heads using 
sharp forceps. The left and right brain hemispheres were separated, and the 
cerebellum, midbrain and meninges were removed and discarded. The 
hippocampus was excised from each hemisphere to prepare hippocampal 
cultures while the rest was kept for cortical cultures.  
2.4.5 Tissue dissociation, plating and feeding neurones 
After dissection, the rest of the procedures mentioned here were carried out in 
a sterile laminar flow hood using aseptic techniques. The dissected 
hippocampi and cortices were transferred to sterile 15ml and 50ml falcon tubes 
respectively. The cortical tissues were cut into smaller pieces using sterile 
scalpel blade. Both the tissues were washed three times with HBSS (10ml 
HBSS for hippocampi and 30ml HBSS for cortices). Hippocampi were the 
incubated in 10ml HBSS containing 0.005% trypsin-EDTA for 9 minutes and 
cortices in 30ml HBSS containing 0.005% trypsin-EDTA for 15 minutes at 
37oC. The trypsinised tissues were washed three times in HBSS volumes 
mentioned before and washed once with 1ml and 5ml plating media for 




hippocampi and cortices respectively. The hippocampal cell suspension was 
pipetted up and down several times using 1ml pipette to dissociate 
hippocampal cells while the cortices were triturated with 5ml serological 
pipette. The hippocampal cell suspension was diluted with 4ml plating media 
and the cortical cell suspension was diluted in 25ml plating media. 
The cells were counted and for biochemistry 500,000 cortical or hippocampal 
cells per well of a 6 well dish were plated. For imaging, 200,000 cells per 25mm 
coverslips were plated and incubated at 37oC incubator overnight. 
24 hours after plating, the plating media was replaced with 3 ml of feeding 
media (Neurobasal® medium supplemented with 2% B27 and 1% Glutamax) 
and replaced in 37oC incubator until use.          
2.4.6 Transfecting neurones 
Hippocampal neurones on 25mm coverslips were transfected around DIV 9-
10. For each transfection, appropriate amount of DNA (as per the experiment) 
was added to 100µl of plain Neurobasal® media in a 1.5ml Eppendorf tube. In 
another 1.5ml Eppendorf tube, 2µl of Lipofectamine® 2000 per µg of DNA was 
added to another 100µl of plain Neurobasal® media. The solutions were 
vortexed briefly and left to incubate in rt for 5 mins. The Lipofectamine® tube 
was added to the DNA tube and vortexed briefly again and allowed to incubate 
in rt for 30 mins.  
Meanwhile, hippocampal neurones on the coverslips were rinsed in warm 
(37oC) plain Neurobasal® media in a 10cm dish and transferred onto a 6-well 
dish containing 1ml of feeding media. After 30 mins incubation of the 
transfection mixture, the tubes were vortexed again and added to the neurones 
on coverslips in a dropwise manner. The transfection was left to incubate at 
37oC for 1.5 hours after which the coverslips were rinsed again in warm (37oC) 
plain Neurobasal® media in a 10cm dish and transferred back to their original 
35mm dish containing the pre-conditioned media. The transfected neurones 
were placed back into the 37oC incubator and treated as appropriate and 
immunostained at DIV 14-15. 




2.4.7 Viral transduction of neurones 
For viral transduction, lentivirus and sindbis aliquots stored at -80oC were 
thawed at rt. The appropriate volume (as optimised) of virus were added to the 
cortical or hippocampal neurones. Sindbis virus was used for GFP 
overexpression to label cell outline and was produced by Dr. K. A. Wilkinson. 
Appropriate amount of sindbis expressing GFP were added to hippocampal 
cultures on coverslips 18h before NMDA and Kainate (KA) treatments. 
Lentivirus for knockdown and knockdown-rescue studies were added to 
neurones at DIV 9 and left to incubate for 5-6 days respectively before the 
stated use.   
2.5 Biochemical methods 
2.5.1 Subcellular fractionation 
All the steps were performed on ice with ice-cold buffers unless stated 
otherwise. Following stated treatments, the cells were washed with 1x PBS 
followed by addition of 250µl of Buffer 1 (150mM NaCl, 50mM HEPES pH 7.4, 
25µg/ml Digitonin (Sigma) and 1x protease inhibitors) per well of a 6-well dish, 
incubated for 20 mins, scraped, homogenised, transferred into a 1.5ml 
Eppendorf tube and centrifuged at 16100g for 30 mins at 4oC. For each 
condition, three wells of cells (500,000 per well) were pooled together. The 
supernatant consisted of the cytosolic proteins and was transferred into a new 
1.5ml Eppendorf tube, while the pellet was resuspended in 40µl of Buffer 2 
(Buffer 1 with 1% triton), incubated for 20 mins and again centrifuged at 
16100g for 30 mins at 4oC. The supernatant consisted of mitochondrial 
proteins and was discarded, while the pellet was resuspended in 40µl of Buffer 
3 (150mM NaCl, 50mM HEPES pH 7.4, 0.5% sodium deoxycholate, 0.1% 
SDS, 1x protease inhibitors and 0.5% triton), incubated for 1 hour on a wheel 
at 4oC and centrifuged at 16100g for 30 mins at 4oC. The supernatant was 
discarded and the pellet, consisting of nuclear proteins, was resuspended in 
40µl of buffer 3. The cytosolic supernatant was transferred into a 15ml falcon 
tube and concentrated using 4 volumes of acetone (kept at -20oC), incubated 
at -20oC for 1 hour and spun for 20 minutes at 3000g and resuspended in 40µl 
of buffer 3. BCA assay was then performed to determine protein 




concentrations to allow equal loading. The workflow is summarised in Figure 
2-1.  
2.5.2 BCA assay 
BCA Assay was performed using PierceTM BCA Protein Assay Kit (Pierce, 
Thermo Scientific) as per manufacturer’s instructions in a clear flat 96-well 
plate. Following 30 minutes incubation with the required mixture at 37oC, the 
samples were read using a plate reader (Versamax Microplate reader, 
Molecular devices) at wavelength of 562nm. The samples were diluted 1:10 in 
the lysis used to lyse the cells initially. Each sample reads were tested in 
triplicates. For blank control, a well with just the lysis buffer and no lysate was 
used to get background read. This was subtracted from other reads. A series 
of dilutions of known concentrations of BSA (included in the kit) (2µg to 
0.0625µg diluted in the lysis buffer) were also prepared and assayed alongside 
the unknown samples to help determine the unknown concentration.  
The values from known BSA concentrations were plotted in an excel sheet 
and best fit straight line was determined to be used as the standard curve. 
Figure 2-1 Schematic of workflow of subcellular fractionation protocol applied.  




Straight-line equation was applied (y=mx+c) to determine the slope (m) and 
the y-intercept (c) from the standard curve. This was then used to determine 
the concentration of the unknown samples (x). Once determined and the 
dilutions were accounted for, the concentrations of each sample were 
calculated, and equal µg of sample was diluted in 2x sample buffer per 
condition and loaded on to an SDS-PAGE gel.   
2.5.3 Cell lysis for sample preparation 
To study the total levels of proteins from cells, the cells were lysed straight into 
1x sample buffer (2% SDS, 5% glycerol, 5% β-mercaptoethanol (β-ME), 
0.002% bromophenol blue, 0.0625M Tris-HCl pH6.4) or in ice cold lysis buffer 
(150mM NaCl, 25mM Tris-HCL pH 7.4, 1% Triton-X 100, 0.01% SDS and 1x 
protease inhibitors (PI)).  
1x Laemmli Sample buffer: After required treatments, the cell media was 
aspirated and 250µl of 1x sample buffer were added into each well of a 6-well 
dish for cortical and hippocampal neurones. For HEK293T cells, 400µl of 1x 
sample buffer were added to each well of a 6-well dish. The cells were scraped 
and transferred into a 1.5ml Eppendorf tube, vortexed briefly and heated at 
95oC on a rotating heat block. After this, the samples were spun down briefly 
and stored at -20oC till used for western blotting purposes.  
Lysis buffer: 250µl of lysis buffer were added to neuronal cells in a well per 6 
well-dish, scraped and transferred into an Eppendorf tube, then incubated on 
ice for 30 minutes and centrifuged at 20,000g at 4oC for 20 mins to pellet 
insoluble debris. Supernatants were dilute 1:1 with 2x Laemmli sample buffer 
(4% SDS, 10% 2-β-mercaptoethanol (β-ME), 10% glycerol, 125mM Tris-HCl 
pH 6.4, 0.004% bromophenol blue). Heating and storing of samples were 
carried out as above.  
2.5.4 Cell surface biotinylation and streptavidin pull 
down  
All steps were performed at 4oC with ice-cold buffers unless stated otherwise. 
Live hippocampal neurones on 6-well dishes post stated treatments, were 
cooled on ice to prevent any further trafficking events before being washed 




twice in 2ml of 1xPBS (10xPBS (Gibco) diluted in ddH2O). Surface proteins 
were live-labelled with 1.5ml of membrane impermeable Sulfo-NHS-SS biotin 
(0.3mg/ml diluted in 1x PBS) for 10 mins with gentle agitation every 2 minutes 
and washed thrice with 2ml of 1x PBS. 1.5ml of 100mM NH4CL diluted in 1x 
PBS was added to quench free biotin-reactive groups for two minutes. The 
cells were washed twice with 2ml of 1x PBS. Cells were then lysed in lysis 
buffer (50mM Tris pH 7.4, 150mM NaCl, 1% triton X-100, 0.1% SDS, Protease 
Inhibitor (X1) in ddH2O) and scraped onto a 1.5ml Eppendorf tube. The lysates 
were vortexed briefly and incubated on ice for 30 mins and centrifuged at 
20,000g, 4oC for 20 mins to get rid of cell debris. A 20µl input sample was 
taken and added to an equal volume of 2x Laemmli sample buffer. 
For pulldown, 30µl PierceTM Streptavidin UltraLinkTM Resin beads per 
pulldown was washed twice with 500µl wash buffer (same as the lysis buffer 
without the protease inhibitor) by centrifuging at 1500g for 2 minutes at rt and 
aspiring the supernatant. 100µl of lysates were added to the beads and rotated 
on a wheel for 90 mins at 4oC. Following three washes with 500µl wash buffer, 
the supernatant was aspirated and resuspended in 40µl 2 x Laemmli sample 
buffer. The input and bead samples in the sample buffer were boiled at 95oC 
on a rotating heat block for 10 mins for western blotting analysis. 
2.5.5 SDS PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
was used to separate proteins based on their molecular weight (MW). 1.5mm 
glass plates were filled with 10% of acrylamide resolving gel solution (375mM 
Tris-HCL pH 8.8, 10% acrylamide, 0.1% SDS, 0.1% APS and 0.01% TEMED) 
and topped with 100% ethanol to ensure even polymerisation of the gel. After 
resolving gel was polymerised, 100% ethanol was washed off with excess 
double distilled water (ddH2O). The resolving gel was stacked with 5% 
stacking gel (125mM Tris-HCL pH 6.8, 5% acrylamide, 0.1% SDS, 0.1% APS, 
0.01% TEMED) and 1.5mm 15-well comb was inserted.  
The polymerised gels were assembled into an electrode and inserted into an 
electrophoresis tank of appropriate size. The tank’s reservoirs were filled with 
SDS-PAGE running buffer (25mM Tris, 250mM glycine and 0.1% SDS in 




ddH2O). Gel loading tips were used to load samples in Laemmli sample buffer 
on to the wells of the gel along with 4µl protein MW marker. The 
electrophoresis was carried out initially at 100V to allow the samples to stack 
onto the stacking gel and were increased up to 150V to allow the proteins to 
separate.  
The separated proteins in the acrylamide gel were then transferred to an 
Immobilin-PVDF membrane. The membrane was cut into appropriate gel sizes 
and activated in 100% methanol for 30 seconds and left to equilibrate in the 
transfer buffer (50mM Tris, 40mM glycine and 20% methanol in ddH2O) for at 
least 10 mins. The membrane, gel, cellulose chromatography papers (cut into 
appropriate gel sizes) and sponges were soaked in transfer buffer and 
assembled in a wet transfer cassette according to manufacturer’s instructions 
and run at 400mA. The acrylamide gel was removed from the glass plates and 
stacking gels were discarded. The sponges and the chromatography papers 
were used to sandwich the gel and the activated membrane. The assembled 
cassette was then placed into the electrode with the membrane facing the 
anode and the gel facing the cathode, which was then transferred into a tank 
filled with transfer buffer. The wet transfer was carried out at 400mA for 70 
mins with constant stirring and cooling with ice packs.   
2.5.6 Western blotting 
2.5.6.1 Immunoblotting 
Once the transfer was completed, the membrane was removed from the wet 
transfer cassette and blocked in 5% non-fat milk powder in PBS-T (PBS 
(recipe: 0.137M NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mM K2HPO4, pH to 7.4 
with HCl) + 0.001% Tween-20) for an hour at rt. The membrane was then 
incubated with primary antibody diluted to appropriate concentration in 2.5% 
milk in PBS-T (see Table 2-2) overnight at 4oC on a shaker. Following 
incubation, the membrane was washed three times with PBS-T for 5 minutes 
at rt on to remove any excess unbound primary antibody. The membrane was 
then incubated with the respective secondary antibodies diluted 1:10,000 in 
5% milk in PBS-T in rt for an hour. Again, the membrane was washed three 




times with PBS-T for 5 mins each to remove excess unbound secondary 
antibodies at rt on a shaker.   
2.5.6.2 Chemiluminescence detection 
For protein visualisation, the membrane was incubated for 2 mins at rt with 
one of the following substrates in order of increasing sensitivity:    
• SuperSignal® West Pico Enhanced Chemiluminescence (ECL) 
• LuminataTM Crescendo 
• LuminataTM Forte 
• West Femto ECL 
Once the excess ECL was removed, the membrane was placed on an 
Odyssey Fc detection system tray and placed in the machine. The ECL 
substrate signal was detected using the chemiluminescence channel for 2-5 
mins and the marker was detected using the 700-fluorescence channel.  
If the machine detection system was not sensitive enough, ECL-incubated 
membrane was sandwiched between sheets of acetate in a developing 
cassette. The ECL substrate signal was then detected in a dark room by 
exposing the X-ray film of appropriate sizes to the membrane (for required 
amount of time) and developing the film in an automatic medical X-ray film 
processor.    
2.5.7 Membrane stripping 
The membranes were stripped and reprobed with different primary antibodies 
as well when needed. For this, the membrane was given three quick washes 
with PBS-T and incubated with 5ml of RestoreTM Stripping buffer (Thermo 
Scientific) for 15 minutes at 65oC and washed three times with PBS-T quickly 
and one 15 mins wash with PBS-T on a shaker at rt. The membrane was then 
re-blocked for 30 mins before incubating with another primary antibody.  
2.5.8 Quantification and analysis of immunoblots 
Western blot data from the Odyssey Fc detection system was quantified as 
pixel signal intensity per protein bands using ImageStudio Lite Version 5.2 (LI-
COR). Data on the X-ray film was scanned using a scanner and analysed by 




measuring densitometry using the Gel Analysis Tool in FIJI ImageJ (NIH). The 
relative pixel intensity was calculated as the area under each peak. The values 
obtained with both systems were transferred to Microsoft Excel and 
normalised to the appropriate bands and statistical significance measured 
[See section 2.10]. 
For all surface biotinylation analysis, the surface pulldown fraction and input 
(total) lysates were always run on the same gel and visualised using LI-COR 
on the same membrane. The pixel signal intensity per protein band was 
determined for both surface and total fraction. Surface/Total ratio was then 
determined by dividing the surface signal values with that of the total.  
2.6 Fixed cell imaging 
2.6.1 Immunocytochemistry 
For fixed cell imaging, hippocampal neurones were plated at 200,000 per 
25mm glass coverslips. After required transfection [see section 2.4.6] or 
transduction [see section 2.4.7], the cells were fixed in 1ml warm to 37oC 4% 
PFA (16% PFA diluted 1:4 in 1 x PBS and 5% sucrose) for 10 minutes at rt. 
All steps after this stage was also carried out in rt unless stated otherwise. 
After 10 mins fixation, the coverslips were washed three times in 2ml of 1x 
PBS (10x PBS diluted in ddH2O). Then, 1ml of 100mM glycine was used to 
quench the PFA for 2 minutes. The coverslips were then washed three times 
with 2ml of 1x PBS again. Neurones were permeabilised and blocked with 
0.1% triton in 3% BSA in 1xPBS for 30 mins. The primary antibodies were 
diluted to appropriate concentration as described in section 2.1.9.1 in 3% BSA 
in 1xPBS. After blocking, neurones were incubated in primary antibody for 1 
hour. For this, the 90µl of the antibody mix was pipetted onto a Parafilm and 
the coverslip was flipped over with cell side down on to the mixture. The 
coverslips were transferred back to their dishes and washed again three times 
in 2ml of 1xPBS for 5 mins each on a gentle shaker. Secondary antibodies 
were then diluted 1:400 in 3% BSA in 1xPBS and the coverslips were 
incubated in it for 45 minutes (same protocol as the primary incubation). After 
three x 5 minutes washes to remove excess secondaries, the coverslips were 




washed once with ddH2O and mounted on a glass microscope slides using 
40µl of Fluoromount-GTM with DAPI (Thermo Fisher) and left to dry at rt 
overnight before storing them at 4oC before imaging.   
2.6.2 Image acquisition 
The coverslips were imaged using Leica SP5-II confocal laser scanning 
microscope attached to a Leica DMI 6000 inverted epifluorescence 
microscope. The confocal images were captured under 63x HCxPL APO CS 
oil-immersion objective, with 1024x1024 pixel resolution and 1x optical zoom 
at 400Hz. Frame average of 2 was taken with a Z-stack of 6-8 Z-planes with 
0.5µM interval. DAPI was excited using a 50 mW 405nm diode laser, Cy2 was 
excited using 150mW Ar laser (488nm), Cy3 using 20mW solid state yellow 
laser (561nm) and Cy5 using a 20mW Red He/Ne (633nm). All the parameters 
with excitation and gain were kept constant for a complete set of experiments. 
Number of neurones imaged are quantified in the figure legends and the 
neurones were acquired from at least three independent dissections as stated.     
2.7 Scaling protocol 
Dyas in Vitro (DIV) 14-15 hippocampal neurones plated for coverslips or 
biochemistry were treated with 1µM TTX (Tocris Bioscience, 1mM stock in 
ddH2O and stored at 4oC) for 24 hours to induce up-scaling process.  
For down-scaling protocol, DIV 16-17 hippocampal neurones were treated 
with 40µM bicuculline (bic) (Sigma, 40mM stock in DMSO, aliquoted and 
stored at -20oC). The control cells were treated with the equal volume of DMSO 
for the longest length of time.  
2.8 Cycloheximide assay 
For cycloheximide assay, cycloheximide (CHX) (Sigma, stored at 4oC) could 
thaw at rt and 25µg/ml was added to cortical neurones and 50µg/ml was added 
to HEK293T cells for the stated lengths of time.  




2.9 Developmental time-course 
For neuronal developmental time course, neurones at indicated Days in vitro 
(DIVs) were washed once with 2ml of 1x PBS at rt. The cells were plated at 1 
million per 35mm cell culture dish. Cells up to DIV 7 were lysed in 150µl of 
lysis buffer and cells between DIV 7-12 were lysed in 250µl volume of lysis 
buffer. Following the lysis buffer protocol, BCA Assay was performed to 
measure protein concentration. Equal amount of protein per DIV was mixed 
with 2x Laemmli Sample Buffer to prepare for western blotting analysis. For 
RNA extraction, RNA extraction protocol was followed as above at the 
indicated DIVs.   
2.10  Statistical analysis and figures 
Statistical Analysis was performed using Graphpad Prism version 7.0. All 
statistical tests are labelled per figure with n (number of cells) or N (number of 
dissections) values along with the p-values and error bars. All the graphs were 
prepared using Graphpad Prism version 7.0 and the results images and 
cartoon schematics were prepared using Microsoft Powerpoint 2013. The 
original figures that were adapted into figures and schematics are cited 
accordingly and copyright permission were obtained for figures taken from 


































 ROLES OF KAINATE RECEPTORS 
IN VARIOUS FORMS OF SYNAPTIC 
PLASTICITY 
  






Previous studies have shown kainate receptor (KAR) involvement in various 
forms of plasticity. More specifically, as set out below KARs have been shown 
to be able to induce synaptic plasticity and undergo plasticity themselves.  
3.1.1 KAR surface expression is bidirectionally 
regulated in response to activity 
KARs can signal through both ionotropic and metabotropic pathways. This 
pertussis-toxin sensitive non-canonical metabotropic signalling from KARs has 
been reported to be involved in its trafficking. Sustained activation of KARs 
decreases surface expressed postsynaptic KARs in a Ca2+ and PKA 
independent but PKC-dependent manner (Martin and Henley 2004). The 
surface GluK2-KARs are internalised and are targeted for lysosomal 
degradation. Similarly, NMDA activation also induces KAR internalisation in a 
Ca2+, PKA and PKC dependent manner but are then recycled back to the 
plasma membrane (Martin and Henley 2004). 
On the other hand, transient/mild agonist stimulation increases postsynaptic 
KARs surface expression, which is thought to enhance synaptic activity and 
promote network development and stabilisation (Martin, Bouschet et al. 2008). 
The kainate evoked increase in surface KARs is dependent on its 
metabotropic signalling, which results in increased recycling of KARs via Rab-
11 dependent, transferrin-positive endosomes to synapses (Gonzalez-
Gonzalez and Henley 2013). This positive KAR feedback system potentially 
allows the adjustment of neuronal responsiveness according to the stimulus 
intensity. 
3.1.2 KARs regulate AMPAR synaptic plasticity 
While NMDAR mediated LTP is the best characterised form of LTP, NMDAR 
independent forms of LTP have also been shown to occur. Hippocampal 
mossy fibre-CA3 synapses, which expresses both pre-and post-synaptic 
KARs, express a NMDAR independent form of LTP (Bortolotto, Clarke et al. 
1999, More, Nistico et al. 2004), which is mediated by the activation of pre-
synaptic KAR signalling facilitating glutamate release (Lauri, Bortolotto et al. 
2001). Initially this was reported to be a GluK1 containing KAR mediated 





signalling mechanism, but subsequent studies revealed that the metabotropic 
action of GluK2 containing KARs is essential to mediate this form of LTP 
(Contractor, Swanson et al. 2000, Breustedt and Schmitz 2004). Thus, 
although the precise KAR subunit/combination of subunits responsible is still 
a point of debate, it is clear that KARs can mediate LTP at these MF-CA3 
synapses. Activation of pre-synaptic KARs by agonist kainate have also been 
shown to decrease glutamate release at CA3-CA1 pyramidal cell synapses 
resulting in decrease in pre-synaptic Ca2+  influx (Chittajallu, Vignes et al. 1996, 
Kamiya and Ozawa 1998). Moreover, the KAR mediated depression of 
glutamate release was shown to be mediated via direct metabotropic action of 
pre-synaptic KARs (Frerking, Schmitz et al. 2001).  
More recently, it has been shown that following transient/mild activation of 
KARs at CA1 synapses, functional AMPA receptor (AMPAR) synaptic 
expression increases, driven by increased AMPAR-receptor recycling. This 
novel form of KAR-dependent, NMDAR-independent LTP at CA1 synapses is 
mediated via metabotropic action of GluK2-containing KARs and subsequent 
activation of G protein, PKC and PLC (Petrovic, Viana da Silva et al. 2017) 
[Figure 3-1]. Moreover, GluK2-/- mice lacked this form of LTP further 
establishing GluK2 to be the important subunit for this novel form of LTP 
(Petrovic, Viana da Silva et al. 2017).   
 
 






Figure 3-1: KARAMPAR-LTP mechanism at CA3-CA1 synapses.  
Stimulation of postsynaptic GluK2 containing KARs leads to the downstream 
metabotropic signalling activating pertussis toxin sensitive G-protein, PLC and PKC 
pathway; leading to increased AMPAR exocytosis from the recycling endosomes. 
Figure taken from (Evans, Gurung et al. 2017).  
In addition, GluK2 Q/R editing deficient mice also displayed a form of NMDAR-
independent LTP at the medial perforant path-dentate gyrus synapse. When 
NMDAR activity was inhibited, the Ca2+ influx through unedited GluK2-
containing KARs were enough to induce NMDAR independent LTP (Vissel, 
Royle et al. 2001). This further shows the importance of KARs in synaptic 
plasticity. 
Together, these findings indicate that KARs play key roles in the induction of 
synaptic plasticity.  
3.1.3 KARs can exhibit plasticity themselves 
Post synaptic GluK2 and GluK5 containing KARs at mossy fibre synapses can 
also undergo LTD (KAR-LTD), which was experimentally induced using low 
frequency stimulation (LFS) (Selak, Paternain et al. 2009) or post-synaptic 
depolarisation (Chamberlain, Gonzalez-Gonzalez et al. 2012). In terms of 
mechanism, SUMOylation of GluK2 at K886 triggered by GluK2 
phosphorylation by PKC was shown to lead to activity dependent KAR-LTD 
(Chamberlain, Gonzalez-Gonzalez et al. 2012). Interestingly, phosphorylation 





at S846 by PKC promotes recycling of GluK2-KARs back to the plasma 
membrane in the absence of SUMOylation while phosphorylation at S868 in 
combination with K886 SUMOylation results in endocytosis of KARs leading 
to KAR-LTD as such SUMOylation is thought to act as a molecular switch that 
regulates this KAR-LTD (Martin and Henley 2004, Martin, Bouschet et al. 
2008, Nasu-Nishimura, Jaffe et al. 2010, Konopacki, Jaafari et al. 2011). 
GluK5 internalisation was also shown to be required for KAR-LTD at mossy 
fibre-CA3 synapses, which was regulated by its interaction with SNAP-25 
(Selak, Paternain et al. 2009). It was thus proposed that during LTD, KARs 
containing both GluK2 and GluK5 are removed from the synapses 
(Chamberlain, Gonzalez-Gonzalez et al. 2012).    
While KARs synaptic responses in mossy fibres are only the minor component 
of mossy fibre-Excitatory Post Synaptic Potentials (EPSPs), it was shown that 
KAR-LTD relieves the inhibition of the slow afterhyperpolarisation (sAHP) 
mediated by KAR metabotropic function (Melyan, Wheal et al. 2002) [section 
1.2.2.8], thus allowing KAR plasticity to regulate cellular excitability 
(Chamberlain, Sadowski et al. 2013).  
3.1.4 KARs in homeostatic scaling 
The role of AMPARs and NMDARs in homeostatic scaling in response to 
chronic suppression and enhancement of synaptic activity is well established 
and characterised (Turrigiano 2012) while very limited reports of KAR scaling 
exists. A study in cerebellar mossy fibre-granule cell synapses showed that 
the loss of synaptic AMPARs increased KAR-mediated synaptic transmission. 
This increase in post synaptic KAR activity was shown to be mediated by the 
increased expression of high affinity GluK5 subunit of KAR (Yan, Yamasaki et 
al. 2013). This indicated a potential role of KARs in homeostatic scaling 
response in the absence of AMPAR signalling.  
Recently, a proteome study in which newly synthesised proteins were 
metabolically labelled, captured and identified during homeostatic scaling, 
GluK2 synthesis was shown to be up-regulated during scaling-up and 
downregulated during scaling-down (Schanzenbächer, Sambandan et al. 
2016). However, while this study captured changes in de novo protein 





synthesis during scaling, it does not account for changes in other cellular 
processes such as recycling or degradation that also play key roles in 
regulating protein levels during activity. Nevertheless, these initial studies 
suggest KARs may be subject to homeostatic scaling. 
3.1.5 KAR assembly and trafficking regulates their 
surface expression 
KARs are thought to favourably oligomerise as heteromers over forming 
homomeric assemblies. Studies on GluK2/GluK5 receptors have shown them 
to initially assemble as heterodimers thus favouring heteromeric assembly 
(Kumar, Schuck et al. 2011, Reiner, Arant et al. 2012). Moreover, high affinity 
subunits GluK4 and GluK5 are only functional as heteromers with low affinity 
subunits GluK1-3 (Ayalon and Stern-Bach 2001). For instance, GluK2 
assembly with GluK5 disrupts the ER retention of GluK5 by reducing its 
binding to COPI thus allowing GluK5 to exit the ER efficiently and express on 
the surface. Increased association of GluK5 with 14-3-3 is also thought to 
contribute to their increased surface expression (Vivithanaporn, Yan et al. 
2006). Interestingly, GluK1 and GluK2 but not necessarily GluK3 is thought to 
predominantly regulate GluK5 surface expression in the hippocampus 
(Darstein, Petralia et al. 2003, Christensen, Paternain et al. 2004, Ruiz, 
Sachidhanandam et al. 2005). However, GluK1-/- mice did not have altered 
GluK5 surface expression, suggesting GluK2 to be the partnering subunit of 
GluK5 (Ball, Atlason et al. 2010). Furthermore, GluK2 Q/R editing that occurs 
in the channel pore region also regulates the surface expression of KAR, 
potentially acting as a rate limiting factor of KAR ER exit whilst also favouring 
heteromeric assembly with GluK5 (Ball, Atlason et al. 2010). In addition, GluK2 
homomers have also been shown to exist alongside GluK2/GluK5 heteromers 
(Barberis, Sachidhanandam et al. 2008, Ma-Hogemeier, Korber et al. 2010). 
Thus, both subunit composition and editing status of subunits can regulate 
membrane delivery of KARs, which could have implications during activity 
mediated trafficking. 






As many lines of evidence point towards the role of KARs in various forms of 
plasticity, my initial objective was to confirm and validate KAR plasticity and 
then investigate the underlying mechanisms. I restricted analysis to GluK2 
containing KARs because GluK2, along with GluK5, are the predominant KAR 
subunits expressed in hippocampal neurones and almost uniquely among the 
KAR subunits high quality GluK2 antibodies are available. Previous studies in 
this lab, on which my work builds, also focused on GluK2 containing KARs. 
Some of my work has also focused on GluK5 containing KARs. More 
specifically, my objectives were to address the following questions: 
1. Can transient KARs stimulation increase AMPAR surface expression 
(LTP)? If so, what are the possible mechanisms? 
2. Can sustained KARs stimulation decrease AMPAR surface expression 
(LTD)? If so, what are the possible mechanisms? 
3. Can KARs themselves undergo homeostatic scaling? 
  





3.2 Materials and methods 
3.2.1 Pharmacological stimulation 
3.2.1.1 Solutions 
• HEPES-buffered Saline (HBS) Buffer 
Table 3-1: Components in HBS Buffer. 








pH was adjusted to 7.4 with NaOH and osmolarity adjusted to match the 
cellular media. Osmolarity was measured with an osmometer (Model 3320, 
Advanced Instruments, Inc). The solutions were warmed to 37oC before 
experiments. 
3.2.1.2 Transient kainate (KA) and NMDA stimulation 
The protocol for transient kainate (KA) stimulation was adapted from (Martin, 
Bouschet et al. 2008, Gonzalez-Gonzalez and Henley 2013, Petrovic, Viana 
da Silva et al. 2017). Following one wash with 1.5ml HBS buffer, DIV 15 
cortical neurones were pre-incubated in 1.5ml of HBS containing 0.5µM TTX 
for 15 minutes (mins) at 37oC. The cells were then treated with 1.5ml HBS 
either containing 10µM kainate (KA) or 25µM NMDA or no drugs (control cells) 
for 3 mins, all in the presence of TTX. The drugs were washed off with 1.5ml 
of HBS+TTX twice and cells were incubated with 1.5ml of HBS+TTX media for 
further 20 mins at 37oC to allow AMPAR trafficking. After 20 mins, the cells 
were allowed to cool on ice for 2-3 mins to stop any further trafficking and 
surface biotinylation was performed (see section 2.5.4).  





3.2.1.3 Sustained kainate (KA) stimulation 
For sustained KA stimulation, the protocol was adapted from (Martin and 
Henley 2004, Martin, Bouschet et al. 2008). The HBS buffer consisted of 
0.5µM TTX and 40µM GYKI throughout the protocol. The cells were 
preincubated as above for 15 mins and the cells were then treated with HBS 
buffer containing 10µM KA or no KA at 37oC for 10 or 20 mins. For the 10 mins 
treatment, the cells were treated with KA for the last 10 mins of incubation. 
Surface biotinylation was then performed for both 10- and 20-mins stimulation 
together.  
3.2.2 Live immunolabelling and surface staining 
Imaging experiments were also performed after transient KA and NMDA 
stimulation. Before the stimulation, the cells were incubated with 10µl of GFP 
Sindbis* virus overnight (no more than 24 hours) to fill the cell with GFP and 
outline the cell structure for imaging. Following stimulation, live cells on 25mm 
coverslips (150,000) were incubated with the N-terminal targeted GluA2 
(Millipore, 1:70) and GluA1 antibody (Millipore, 1:100) for the last 15 mins of 
incubation at 37oC post 3 mins stimulation. The antibodies were diluted in the 
HBS+TTX buffer and 100µl of the antibody solution were placed on a parafilm 
on heated tray and the coverslips were placed on the top with the cell-side 
down. 
Following 15 mins incubation, cells were returned to their dishes and washed 
5 times with 2ml of 1x PBS at room temperature. The cells were then fixed 
with warmed 1ml of 4% paraformaldehyde (16% PFA diluted 1:4 in 1x PBS 
and 5% sucrose) for 10 mins and washed three times with 2ml of 1x PBS, 
quenched with 1ml of 100mM glycine made up in PBS for 2 mins and washed 
again three times with 2ml of 1x PBS. Anti-mouse Cy5 secondary (diluted 
1:400 in 3% Bovine Serum Albumin (BSA in 1x PBS)) was added for 45 mins. 
100µl of diluted secondary antibody was added to parafilm and cells were 
placed on top with cell-side down. The coverslips were returned to their dishes 
after 45 mins and washed three times with 1x PBS and once with distilled 
water. The cells were then mounted on glass slides using Fluoromount-GTM 
with DAPI (Thermo Fisher) with the cell side facing down. The slides were left 
to dry at room temperature overnight and stored at 4oC till imaging. Figure 3-2 





is a schematic depicting timeline at which different stages of drug treatment 
and live immunolabelling was performed.    
*Sindbis-GFP virus was prepared by Dr. K.A. Wilkinson.   
 
Figure 3-2: Timeline of live immunolabelling with drug stimulation.  
The cells were treated with GFP expressing Sindbis virus overnight (~18h) to help 
outline the cell structure before performing the drug (KA or NMDA) stimulation and 
live immunolabelling with N-terminal targeted GluA1 or GluA2 antibody during the last 
15 minutes of post-treatment incubation. The cells were then fixed and 
immunolabelled with the secondary antibodies before mounting.   
3.2.3 Image acquisition and analysis 
Image acquisition was performed as per section 2.6.2. 
The cells were chosen for imaging using 488 channel (GFP) to avoid bias. The 
images were analysed using FIJI ImageJ (NIH). Rectangular boxes were 
drawn at dendrites and GFP channel was used to draw an outline around the 
dendritic structure (Region of Interest (ROI)). Mean intensity per selected area 
(ROI) was determined. Three dendritic regions per neuron were analysed and 
averaged to get the surface intensity per cell (n value). Cells from at least 3 
independent dissections were analysed.   
3.2.4 Electrophysiology 
All electrophysiology experiments were performed by Dr. Ellen Braksator.  
3.2.4.1 Materials 
• Sucrose Solution 





Table 3-2: Components in Sucrose Solution 








• Artificial cerebrospinal fluid (aCSF) 
Table 3-3: Components in aCSF solution. 








• Patch-clamp electrode solution 
Table 3-4: Components in Patch-clamp electrode solution. 








pH was adjusted to 7.2. 





3.2.4.2 Acute slice preparation 
Postnatal day 13-15 male and female Han Wistar rats were anaesthetised with 
4% isoflurane and decapitated. Brains were rapidly removed and placed in 4oC 
oxygenated (95% O2, 5% CO2) sucrose solution. Parasagittal hippocampal 
slices 400µm thick were prepared using a vibratome (7000smz-2, Campden 
Instruments). Slices were kept in a slice holder containing artificial 
cerebrospinal fluid (aCSF) and incubated for 30 mins at 35oC and then for a 
further 30 mins at room temperature before use. 
3.2.4.3 Electrophysiology and analysis 
Hippocampal slices were placed in a submerged holding chamber and 
perfused with 30oC oxygenated aCSF at 2ml.min-1.  Excitatory post-synaptic 
currents (EPSCs) of AMPA transmission were evoked at -70mV by stimulating 
the Schaffer collateral pathway and recorded from CA1 pyramidal neurons. 
Pyramidal neurons were patch-clamped in the whole-cell configuration using 
borosilicate glass (Harvard Apparatus) electrodes with a resistance of 2-5 MΩ 
and were backfilled with electrode solutions. The CA3 area of the hippocampal 
slices was removed using a scalpel blade to minimise epileptic activity. D-AP5 
(50 µM) and picrotoxin (50 µM) were bath applied to isolate AMPA-mediated 
EPSCs. Cells in which the series resistance changed above 20 MΩ or deviated 
by 20% were discarded. 
After a 10 mins stable baseline was achieved, 1µM kainate (KA) was bath 
applied for 10 mins followed by a 30 mins washout period.  
Signals were low-pass filtered at 2 kHz and digitised at 10 kHz using a 
Axopatch 200B amplifier (Molecular Devices) and WinLTP v1.11 acquisition 
software (Anderson and Collingridge 2007).  
3.2.4.4 Statistical analysis 
For statistical analysis GraphPad Prism 7 was used (GraphPad Software, 
Inc.). Results are expressed as mean ± SEM and Student’s t-test was used to 
assess statistical significance. 






3.3.1 Transient kainate (KA) stimulation did not alter 
surface levels of GluK2-KARs or GluA1- and GluA2-
AMPARs 
To study the role of KARs in LTP I first attempted to recapitulate previously 
published work, which showed transient stimulation of KARs increased the 
surface expression of AMPARs. I performed surface biotinylation experiments 
on cortical neurones following 3 mins 10µM kainate (KA) stimulation. However, 
I did not detect any changes in the surface expression of either GluA1 or GluA2 
containing AMPARs or GluK2 containing KARs [Figure 3-3 A, B, C and D]. As 
a control, NMDA mediated LTD was induced in parallel to ensure neuronal 
health was not compromised, which could have resulted in the lack of activity 
induction. NMDA application significantly decreased the surface expression of 
both GluA1 and GluA2-containing AMPARs as expected (Luthi, Chittajallu et 
al. 1999, Beattie, Carroll et al. 2000) and also decreased the surface 
expression of GluK2 containing KARs, which has been shown previously 
(Martin and Henley 2004). Hence, my results showed lack of change in the 
surface expression of AMPARs following kainate (KA) application. EGFR, 
which did not respond to the KA stimulation [Figure 3-3 A and E], was used 
as a non-glutamate surface receptor control to ensure the effect of treatment 
is specific to the surface expression of glutamate receptors.  
 






Figure 3-3: Transient KA stimulation did not change GluA1, GluA2 and GluK2 surface 
expression. Surface biotinylation was performed on DIV 15 cortical neurones 
following 3 mins transient stimulation with KA (10µM) and 3 mins NMDA (25µM) 
stimulation to isolate surface proteins and determine surface/total ratio by western 
blotting.  
A. Representative western blot images of surface and total levels of GluK2, 
GluA2, GluA1 and EGFR post KA or NMDA treatment. EGFR was used as a 
surface expressed non-glutamate receptor control that should not respond to 
stimulation. GAPDH was used as an internal control to determine no internal 
proteins were biotinylated.  
B-E.  Quantification of surface to total ratio of GluK2 (B), GluA2 (C), GluA1 (D) and 
EGFR (E) shown in A. N=6 independent dissections, ns p>0.05, *p<0.05, 
**p<0.01, ***<0.001; One-way ANOVA with Dunnett’s multiple post 
comparisons correction; error bars=S.D.    
 
 












Figure 3-4: Transient KA stimulation did not change GluA1 or GluA2 surface 
expression. Live cell immunolabelling was performed on DIV 15 hippocampal 
neurones following 3 mins transient stimulation with KA (10µM) and 3 mins NMDA 
(25µM) stimulation to determine surface levels of GluA1 and GluA2.  
A. Representative images of surface GluA1 (Cy3-red) on GFP labelled 
neurones. White boxes represent regions of interest, zoom panel underneath 
each image within dendritic regions that were analysed for surface intensity. 
Scale bar=10µm. 
B. Quantification of surface intensity of GluA1 shown in (A). Intensity within three 
regions of interest within dendrites per cell was measured and averaged to 
get a red per cell. n=60-68 cells, N= 3 independent dissections. ns p>0.05, 
**p<0.01; One-way ANOVA with Dunnett’s multiple post comparisons 
correction; error bars=S.D.    
C. Representative images of surface GluA2 (Cy3-red) on GFP labelled 
neurones. White boxes represent regions of interest, zoom panel underneath 
each image within dendritic regions that were analysed for surface intensity. 
Scale bar=10µm. 
D. Quantification of surface intensity of GluA2 shown in (C). Intensity within three 
regions of interest within dendrites per cell was measured and averaged to 
get a red per cell. n=43-47 cells, N= 3 independent dissections; ns p>0.05, 
**p<0.01; One-way ANOVA with Dunnett’s multiple post comparisons 
correction; error bars=S.D.    
Surface biotinylation can only measure changes in the whole surface area of 
neurones, which may mask compartment restricted changes. To assess 
potential compartment specific changes in surface expression of AMPARs, I 
also performed imaging experiments to assess the effects of KA stimulation in 
hippocampal neurones, focusing on regions of interest (ROIs) within dendrites 
[Figure 3-4]. However, I was again unable to see an increase in GluA1 or 
GluA2-containing AMPARs post transient KA stimulation. Similar to the 
surface biotinylation experiments, I did see a decrease in surface levels of 
GluA1 and GluA2 post 3 mins NMDA stimulation. Because there is no reliable 
and effective N-terminal GluK2 antibody available to monitor surface staining 
I could not study the surface levels of GluK2 containing KARs in parallel.  
3.3.2 Sustained KA stimulation alters the surface levels 
of GluK2-KARs and GluA1- and GluA2-AMPARs 
Because I was unable to repeat the previously reported KARAMPAR-LTP 
studies, I started investigating potential role of KARs in AMPAR-LTD. Here, 
cortical neurones were incubated with 10µM KA for 10 or 20 mins in presence 
of 40µM GYKI53655 (an AMPAR antagonist) (Partin and Mayer 1996) and 





surface biotinylation was performed. In this case I did successfully recapitulate 
previous findings where following 20 mins stimulation surface expression of 
GluK2 containing KARs decreased [Figure 3-5 A and B] (Martin and Henley 
2004). In addition, this change in surface expression of KARs was also 
followed by significant decrease in the surface expression of GluA2-containing 
AMPARs post 20 mins treatment [Figure 3-5 A and C]. Post 10 mins 
stimulation, an apparent decrease was observed for both GluK2 and GluA2 
containing AMPARs, although this change was not significant. As these 
experiments were performed in the presence of AMPAR inhibitor 
(GYKI53655), these observations suggest that changes in AMPAR surface 
expression is most likely being regulated by KAR signalling. As expected 
EGFR did not respond to the KA stimulation [Figure 3-5 A and D]. 
 






Figure 3-5: Sustained KA (10µM) stimulation in presence of AMPAR inhibitor 
(GYKI53655) 40µM decreases surface expression of GluK2 and GluA2. Surface 
biotinylation was performed on DIV 15 cortical neurones following 10 or 20 mins of 
sustained KA stimulation to isolate surface proteins and determine surface/total ratio 
by western blotting.  
A. Representative western blot images of surface and total levels of GluK2, 
GluA2 and EGFR post 10 and 20 mins KA treatment. EGFR was used as a 
surface expressed non-glutamate receptor control that should not respond to 
stimulation. GAPDH was used as an internal control to determine no internal 
proteins were biotinylated.  
B-E.  Quantification of surface to total ratio of GluK2 (B), GluA2 (C) and EGFR (D) 
shown in A. N=5-6 independent dissections, ns p>0.05, **p<0.01, ***<0.001; 
One-way ANOVA with Dunnett’s multiple post comparisons correction; error 
bars=S.D.    
 





3.3.3 Sustained KA stimulation evokes initial AMPAR-
EPSC depression in CA1 hippocampal slices 
Since sustained KA stimulation showed a potential role of KARs in AMPAR-
LTD, we decided to follow this study using electrophysiology in CA1 
hippocampal slices. All the electrophysiology studies in this chapter were 
performed and analysed by Dr. Ellen Brakastor.  
During 10 mins application of 1µM KA, we observed an initial depression of 
evoked AMPAR-Excitatory Post Synaptic Currents (EPSCs). Following a 30 
mins washout period, responses remained significantly depressed compared 
to the pre-KA application baseline in the same slice (baseline 100.3 ± 0.27% 
vs KA 73.62 ± 5.67%; p=0.0003). However, a run-down of response was 
observed in the vehicle control group in the last 10 mins of the recording and 
therefore no significant difference was observed between the control slices 
and those treated with KA (vehicle control 85.03 ± 2.55% (n = 10) vs KA 73.62 
± 5.67% (n = 17); p=0.1503) [Figure 3-6 A, B and C].  
UBP310 compound was synthesised as an inhibitor of ionotropic function of 
GluK1 and GluK3 subunit containing KARs (Dolman, More et al. 2007, Perrais, 
Pinheiro et al. 2009) but was later shown to also antagonise ionotropic 
functions of GluK2 and GluK5 containing KARs (Pinheiro, Lanore et al. 2013, 
Petrovic, Viana da Silva et al. 2017) while not affecting the AMPA or NMDA 
receptors (Pinheiro, Lanore et al. 2013). We therefore used UBP310 to 
determine if the changes we observed with the KA application were mediated 
through KAR ionotropic function. When KA was applied in the continuous 
presence of UBP310 (10µM), the initial reduction in AMPAR EPSCs (average 
of first 10 mins washout) was significantly less compared to KA treatment 
alone (KA + UBP310 65.46 ± 6.98% (n = 9) vs KA alone 44.64 ± 3.32 (n = 18); 
(p = 0.0051) but there was no significant difference in AMPA-EPSCs amplitude 
when comparing to the last 10 mins (KA + UBP310 92.2 ± 9.48% vs KA alone 
73.62 ± 5.67%; P = 0.0860) [Figure 3-6 A, D, E and F]. We interpret these 
results to suggest that the initial KA-evoked AMPAR EPSCs depression is 
mediated via KAR ionotropic function, but it seems the changes are not 





sustained long-term (last 10 mins post stimulation), perhaps suggesting this to 
be a form of short-term plasticity (STP).  
 
 





Figure 3-6: 10 mins of 1µM KA application in acute CA1 slices induced initial 
depression of evoked AMPA-EPSCs which was partially inhibited by KAR ionotropic 
inhibitor UBP310. 
A. Graph showing effects of 1µM KA on normalised evoked EPSC amplitudes to 
the baseline (first 10 mins) and sample traces in presence of D-AP5 (50µM) 
and picrotoxin (50µM) from CA1 neurones in rat hippocampal slices. N=9-14 
cells from different animals; error bar=S.E.M.  
B. Quantification of averaged EPSC amplitudes comparing baseline (first 10 
mins reads pre-treatment) to the last 10 mins read in KA treated samples 
shown in A. N=17; Paired t-test, ***p<0.001; error bar = S.D. 
C. Quantification of averaged EPSC amplitudes comparing the last 10 mins post 
KA washout amplitudes between control and KA treated samples shown in A. 
N=10-17; unpaired t-test; error bar=S.D. 
D. Quantification of averaged EPSC amplitudes comparing baseline (first 10 
mins reads pre-treatment) to the last 10 minutes read in UBP310 treated 
samples shown in A. N=9; paired t-test; error bar=S.D. 
E. Quantification of averaged EPSC amplitudes comparing the first 10 mins 
amplitude reads between UBP310 and KA treated samples shown in A. N=9-
18; unpaired t-test, **p<0.01; error bar=S.D. 
F. Quantification of averaged EPSC amplitudes comparing the last 10 mins 
amplitude reads between UBP310 and KA treated samples shown in A. N=9-
17; unpaired t-test; error bar=S.D. 
 
3.3.4 Pre-synaptic KARs mediate initial AMPA-EPSC 
depression 
KARs are present at both pre- and postsynaptic sites (Lerma and Marques 
2013) so to assess if the initial depression of AMPAR-EPSCs caused by KA 
application is of presynaptic origin, the paired pulse ratio (PPR) was 
measured. For this, two stimuli are applied with a 50ms interval and the ratio 
of amplitude of the second response to that of the first is determined. This is 
used as a measure of glutamate release probability, where PPR is inversely 
related to the release probability (Manabe, Wyllie et al. 1993, Debanne, 
Guerineau et al. 1996, Dobrunz and Stevens 1997) and is thought to be of pre-
synaptic origin (Zucker and Regehr 2002, Xu-Friedman and Regehr 2004).  
After a 10 mins KA application, the paired pulse ratio (PPR) significantly 
increased from 1.62 ± 0.07 (baseline levels) to 2.42 ± 0.15 (p< 0.0001) [Figure 
3-7 A]. This means there is a decrease in the glutamate release probability 
which would result in the decreased EPSCs amplitude observed post 10 mins 





KA stimulation. The paired pulse ratio (PPR) returned to baseline levels 10 
mins following KA washout, reaching levels similar to that of the control 
[Figure 3-7 B]. These results suggest that the AMPAR-EPSC depression is 
mediated by a presynaptic mechanism, most likely a pre-synaptic KAR 
signalling function.  
 
Figure 3-7: Initial AMPA-EPSC depression is mediated via pre-synaptic KARs. 
A. Graph of PPR comparing control to KA treated cells (post 10 mins treatment). 
N=10 independent experiments; Paired t-test, ****p<0.0001. 
B. Graph showing timecourse up to 30 mins post KA washout of PPR expressed 
as percentage of the control (100%). N=5-9 cells. Error Bar= SE.M.  
 
3.3.5 Chronic suppression of network activity increases 
surface expression of GluK2 and GluK5 containing 
KARs 
Another fascinating but not as well studied aspect of KAR plasticity is whether 
KARs have a role in homeostatic scaling. I initially wanted to determine if KARs 
can alter their surface expression in response to changes in synaptic activity. 
I performed surface biotinylation experiments to investigate KAR surface 
expression in cultured hippocampal neurones subjected to 1µM tetrotodoxin 
(TTX) treatment for 24 hours (h). TTX when added to the culture inhibits firing 
of action potential by blocking the sodium channels, resulting in chronic 
suppression of network activity (O'Brien, Kamboj et al. 1998, Johnston 2013). 
In response to decreased synaptic activity following TTX treatment (O'Brien, 
Kamboj et al. 1998), there is a significant and robust increase in the surface 





expression (up-scaling) of both GluK2 and GluK5 containing KARs after 24 h 
[Figure 3-8 A, B C]. As expected, this TTX induced suppression of activity also 
increased the surface expression of GluA2 and GluA1 containing AMPARs, 
which were used as a control of scaling response (O'Brien, Kamboj et al. 1998, 
Turrigiano, Leslie et al. 1998) [Figure 3-8 D and E]. In contrast, Epidermal 
growth factor receptor (EGFR), which is widely expressed at synapses 
(Faundez, Krauss et al. 1992), was not affected by TTX treatment [Figure 3-8 
F]. GAPDH was used as a negative control to ensure only surface proteins 
were labelled with biotin.   






Figure 3-8: Chronic Suppression of network activity following 1µM tetrodotoxin (TTX) 
treatment for 24 h increases surface expression of GluK2 and GluK5 containing 
KARs. Surface biotinylation was performed on DIV 15 hippocampal neurones 
following TTX treatment to isolate surface proteins and determine surface/total ratio 
by western blotting.  
A. Representative western blot images of surface and total levels of GluK2, 
GluK5, GluA2, GluA1 and EGFR post 24 h TTX treatment. EGFR was used 
as a surface expressed non-glutamate receptor control that should not 
respond to stimulation. GAPDH was used as an internal control to determine 
no internal proteins were biotinylated.  
B-F. Quantification of surface to total ratio of GluK2 (B), GluK5 (C), GluA2 (D), 
GluA1 (E) and EGFR (F) shown in A. N=5-7 independent dissections, ns 
p>0.05, **p<0.01, ***p<0.001, ****p<0.0001; Unpaired t-test; error bars=S.D.    
 





3.3.6 Chronic enhancement of network activity 
decreases surface expression of GluK2 and GluK5 
containing KARs 
I also investigated KAR responses to chronic enhancement in network activity 
using 40µM bicuculline treatment for 24 or 48 h. Bicuculline is an antagonist 
of inhibitory GABAA receptors and its addition on neurones results in chronic 
enhancement of network activity (Johnston 2013). In response to both 24 and 
48 h bicuculline treatment, there was a significant decrease (down-scaling) in 
the surface expression of both GluK2 and GluK5 containing KARs [Figure 3-9 
A, B and C]. On the other hand, while GluA1 containing AMPARs showed 
similar decrease to KARs, GluA2 containing AMPARs only showed a robust 
decrease after 48h [Figure 3-9 A, D and E]. It seems KAR responses are more 
robust compared to the AMPARs. EGFR, as expected, did not respond to 
changes in synaptic activity [Figure 3-9 A and F].  
These results show for the first time that KARs can both upregulate and down 
regulate in response to chronic suppression and enhancement of network 
activity. 






Figure 3-9: Chronic Enhancement of network activity following 40µM bicuculline 
treatment for 24 and 48 h decreases surface expression of GluK2 and GluK5 
containing KARs. Surface biotinylation was performed on DIV 15 hippocampal 
neurones following bicuculline treatment to isolate surface proteins and determine 
surface/total ratio by western blotting.  
A. Representative western blot images of surface and total levels of GluK2, 
GluK5, GluA2, GluA1 and EGFR post 24h and 48h bicuculline treatment. 
EGFR was used as a surface expressed non-glutamate receptor control that 
should not respond to stimulation. GAPDH was used as an internal control to 
determine no internal proteins were biotinylated.  
B-F.  Quantification of surface to total ratio of GluK2 (B), GluK5 (C), GluA2 (D), 
GluA1 (E) and EGFR (F) shown in A. N=4-7 independent dissections, ns 
p>0.05, *p<0.05, **p<0.01, ***<0.001, ****p<0.0001; One-way ANOVA with 
Dunnett’s multiple post comparisons correction; error bars=S.D.    
 





3.3.7 Q/R editing of KARs are altered in response to 
changes in the network activity 
I next wanted to determine the mechanisms behind TTX and bicuculline 
mediated GluK2 scaling. For this I studied the potential role of Q/R editing 
which has been previously shown to affect the GluK2 subunit assembly and 
trafficking (Ball, Atlason et al. 2010). I performed BbvI digestion analysis 
(Bernard, Ferhat et al. 1999) [see section 2.2.12] post 24 h TTX treatment, 
which showed significantly decreased GluK2 Q/R editing [Figure 3-10]. This 
can also be observed in the representative chromatographs where there is an 
increase in the A peak for treated samples compared to the control at the site 












Figure 3-10: Chronic Suppression of network activity following 1µM tetrodotoxin (TTX) 
treatment for 24 h decreases Q/R editing of GluK2 subunit of KARs. Post 24 h TTX 
treatment, RNA was extracted from the cells and cDNA was synthesised to perform 
PCR assays.  
A. Cartoon description of BbvI restriction enzyme cut assay used to determine 
GluK2 editing. PCR product of 452bp length were amplified using primers 
targeted to the M2 region of GluK2 consisting of the Q/R editing site. The PCR 
products were then digested using endonuclease BbvI restriction enzyme. 
PCR products unedited at the site of Q/R (CAG) codes for 2 BbvI restriction 
sites giving fragmented products of lengths 269, 107 and 76bp post digestion. 
The edited PCR products (CGG) only codes for 1 restriction site giving 
fragmented products of lengths 376 and 76bp post digestion.   
B. Representative image of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluK2 ratio post 24 h TTX 
treatment. 100% edited and unedited GluK2 constructs were used as a control 
to ensure BbvI cut activity and validity of the assay. 
C. Quantification of percentage of edited to unedited ratio of GluK2 population 
present after 24 h TTX treatment as shown in B. N=5 independent dissections; 
*p<0.05; Unpaired t-test; error bars=S.D. 
D. Representative chromatographs of PCR products comparing control to 24 h 
TTX treated samples. The undigested PCR products were also sent for 
sequencing to determine changes in the dual peaks obtained at the site of 
editing as indicated by the green arrow. A peak (green) represents the 
unedited base while the G peak (black) represents the edited base. The image 
is representative of 3 repeats. 
 





Similar analysis was also performed on bicuculline treated samples, which 
resulted in higher Q to R editing compared to DMSO treated for 48 h (vehicle 
control added at the same volume as that of bicuculline) treated samples 
[Figure 3-11]. These results strongly suggest a role of GluK2 Q/R editing in 
KAR scaling.
 
Figure 3-11: Chronic enhancement of network activity following 40µM bicuclline for 
48 h increases Q/R editing of GluK2 subunit of KARs. Post 48 h bicuculline treatment, 
RNA was extracted from the cells and cDNA was synthesised to perform PCR assays.  
A. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluK2 ratio post 48 h bic 
treatment. 100% edited and unedited GluK2 constructs were used as a control 
to ensure BbvI cut activity and validity of the assay. 
B. Quantification of percentage of edited to unedited ratio of GluK2 population 
present after 48 h TTX treatment as shown in B. N=5 independent dissections; 
*p<0.05; Unpaired t-test; error bars=S.D. 
 
3.3.8 Q/R editing of GluA2 is not altered during chronic 
changes in the network activity 
GluA2 subunit of AMPARs are also known to undergo this Q/R editing process 
(Sommer, Kohler et al. 1991, Kuner, Beck et al. 2001) and GluA2 themselves 
can undergo both up-scaling [Figure 3-8] and down-scaling process [Figure 
3-9]. So, I wanted to determine if GluA2 editing levels were also altered in TTX 
treated samples. Using similar BbvI restriction enzyme assay, I observed no 
changes in the editing status of GluA2 [Figure 3-12]. Furthermore, 





chromatographs data further validate these results where no A peak at the site 
of editing can be detected in either conditions Figure 3-12 C]. 
 
Figure 3-12: Chronic Suppression of network activity following 1µM TTX treatment for 
24 h does not alter the Q/R editing of GluA2 subunit of AMPARs. Post 24 h TTX 
treatment, RNA was extracted from the cells and cDNA was synthesised to perform 
PCR assays.  
A. Cartoon description of BbvI restriction enzyme cut assay used to determine 
GluA2 editing. PCR product of 231bp length were amplified using primers 
targeted to the M2 region of GluA2 consisting of the Q/R editing site. The PCR 
product was then digested using endonuclease BbvI restriction enzyme. PCR 
products unedited at the site of Q/R (CAG) codes for 1 BbvI restriction site 
giving fragmented products of lengths 137 and 94bp post digestion. The 
edited PCR products does not code for any BbvI restriction sites giving intact 
product of 231bp post digestion.   
B. Representative image of the PCR products separated on a 4% agarose gel 
post BbvI digestion. 100% edited and unedited GluA2 constructs were used 
as a control to ensure BbvI cut activity and validity of the assay. 
C. Representative chromatographs of PCR products of GluA2 comparing control 
to 24 h TTX treated samples at the editing site. The undigested PCR products 
were sent for sequencing to determine any changes in the dual peaks 
obtained at the site of editing as indicated by the green arrow. A peak (green) 
represents the unedited base while the G peak (black) represents the edited 
base. The image is representative of 3 repeats. 
GluA2 unlike that of GluK2 is almost fully edited (>99%) by birth (Paschen and 
Djuricic 1995, Hamad, Ma-Hogemeier et al. 2011). So, unedited GluA2 was 





not detected in either the BbvI or the chromatograph assays. With this in mind, 
I did not expect to see any further increase in GluA2 editing during the down-
scaling process with bicuculline and therefore did not pursue this line of 
investigation.  
Taken together these data indicate that Q/R editing changes during scaling 
selectively alters the GluK2 KAR subunit compared to GluA2 subunit of 
AMPAR. 
3.3.9 GluK5 levels are not affected by GluK2 loss 
GluK5 unlike GluK2 cannot form homomers and needs to oligomerise with one 
of the low affinity KAR subunits (GluK1, GluK2 or GluK3) to be released from 
the ER and express on the surface (Hayes, Braud et al. 2003, Ma-Hogemeier, 
Korber et al. 2010). As the surface expression of GluK5 containing KARs were 
also changed in response to the changes in synaptic activity [Figure 3-8 and 
Figure 3-9], I speculated if changes in GluK2 surface expression leads to the 
changes in GluK5 surface expression by forming GluK2/GluK5 heteromeric 
receptors.  
To test this hypothesis, I initially performed shRNA GluK2 knockdowns (KD) 
in my cultures to study the effect of loss of GluK2 on GluK5 expression. As 
shown in Figure 3-13 A, B and C, endogenous surface and total GluK2 was 
reduced by >50% with the GluK2 KD. However, this loss of GluK2 did not affect 
the surface or the total levels of GluK5 [Figure 3-13 A, D and E]. These results 
seem to suggest that GluK2 loss does not necessarily affect the surface 
expression of GluK5 in my cultures. This could potentially be due to 
compensation from other high affinity KAR subunits i.e. GluK1 and GluK3.     






Figure 3-13: Loss of total and surface GluK2 does not alter the total or surface levels 
of GluK5. Surface biotinylation was performed on DIV 15 hippocampal neurones post 
5 days GluK2 KD to isolate surface proteins and determine surface and total GluK2 
and GluK5 levels by western blotting.  
A. Representative western blot images of surface and total levels of GluK2 and 
GluK5 post 5 days GluK2 KD. GAPDH was used as an internal control to 
determine no internal proteins were biotinylated.  
B-E.  Quantification of separate surface and total protein levels of GluK2 total (B), 
GluK2 surface (C), GluK5 total (D) and GluK5 surface (E) shown in A. The total 
levels of proteins were normalised to respective GAPDH levels. Surface/Total 
ratio was determined to obtain surface reads. N=7 independent dissections, ns 
p>0.05, ****p<0.0001; Unpaired t-test; error bars=S.D.    
3.4 Discussion 
3.4.1 Transient KAR stimulation did not induce AMPAR-
LTP 
The initial aim of my PhD was to extend previous studies and define the 
mechanisms behind KAR mediated increase in synaptic AMPARs, and hence 
KARAMPAR-LTP (Petrovic, Viana da Silva et al. 2017). I started by attempting to 
replicate the data where increased AMPAR surface expression was shown 
following transient KA stimulation. Unfortunately, I could not replicate this 
[Figure 3-3] even though the control, NMDA mediated long term depression 





(LTD), was induced in parallel to ensure neuronal health was not 
compromised, which could have resulted in the lack of activity induction. 
NMDA application significantly decreased the surface expression of both 
GluA1 and GluA2-containing AMPARs, thus inducing AMPAR-LTD (Beattie, 
Carroll et al. 2000). Interestingly, NMDA application also resulted in the 
decrease of surface expression of GuK2-containing KARs. This is in 
agreement with a previous report showing decrease in the surface expression 
of KARs following NMDA application (Martin and Henley 2004).  
I reasoned that measuring whole surface changes using surface biotinylation 
may mask neuronal compartment restricted changes. In order to assess 
compartment specific changes in surface expression of AMPARs, imaging 
experiments in hippocampal neurones were also performed, focusing on 
potential alterations within dendrites. However, I was again unable to replicate 
previous data [Figure 3-4]. Hence, in my hands, these results suggested lack 
of change in the surface expression of AMPA receptors following transient 
KAR activation. 
While the precise reasons for this remain elusive, possible explanations for 
this lack of reproducibility of KARAMPAR-LTP in my hands include subtle 
differences in experimental protocols, variability in the health and 
responsiveness of the primary neurones, issues with different batches of KA 
and/or the possibility that the KA-evoked changes were too erratic and small 
to reliably detect any changes. Regardless of the reasons, after several 
months of concerted effort and systematically changing variables, the lack of 
replicability led me to discontinue these experiments and develop new, but 
closely related, lines of investigation.  
3.4.2 Sustained KAR stimulation decreased AMPAR and 
KAR surface expression 
It was shown previously that following sustained stimulation of KARs, their 
surface expression decreases. I set out to determine if this change in KARs 
surface expression also resulted in changes in surface expression of 
AMPARs. 





While there was a decreasing trend in the surface expression of GluK2 
containing KARs after both 10 and 20 mins of KA application, the surface 
levels decreased significantly after 20 mins application [Figure 3-5]. 
Interestingly, the surface biotinylation data also showed a decrease in GluA2-
containing AMPARs post 20 mins treatment but not in EGFRs, suggesting this 
change to be selective for glutamate receptors. Following published protocols, 
KA concentration of 10µM was chosen for these experiments (Martin, 
Bouschet et al. 2008, Petrovic, Viana da Silva et al. 2017). However, because 
AMPARs can be activated by KA at concentrations above 3µM (Bureau, 
Bischoff et al. 1999), we inhibited AMPAR activation using the well 
characterised AMPAR antagonist GYKI53655 (Donevan, Yamaguchi et al. 
1994, Partin and Mayer 1996). Therefore, our data suggest the changes in 
AMPAR surface expression are specifically mediated by alterations in KAR 
signalling. Together our results indicate that KARs can directly regulate 
AMPAR surface expression which has striking implications for the, as yet 
almost completely unexplored, roles of KARs in the induction and regulation 
of AMPAR-mediated synaptic plasticity.  
3.4.3 Potential role of pre-synaptic KARs in initial AMPA 
EPSCs depression 
Electrophysiology experiments were carried out to investigate the effects of 
KA application on hippocampal slices on AMPAR EPSCs in the CA1 region 
[Figure 3-6]. As we were measuring AMPAR EPSCs, we could not use 
GYKI53655 to inhibit AMPAR signal. So, we instead used KA at concentration 
of 1µM, a concentration at which KA effect is shown to be selective to KARs 
(Bureau, Bischoff et al. 1999). Following 10 mins KA application, there was an 
initial depression in the AMPAR EPSCs compared to the control slices. 
Moreover, following 30 mins washout period, the reads were significantly 
depressed compared to its own baseline within individual KA treated slices. 
However, confusingly, KA-treated slices were not significantly different to non-
KA-treated control slices because there was a marked run-down in AMPAR-
EPSCs in the vehicle control group after 30 mins, perhaps suggesting the 
health of the slices were compromised by the long stimulation protocol.  





We also used UBP310 compound to specifically inhibit ionotropic function of 
KARs. It should be noted that there is a controversy around whether this 
compound inhibits GluK1 (Dolman, More et al. 2007), GluK2/GluK5 KARs 
(Pinheiro, Lanore et al. 2013) or all KAR compositions. Nevertheless, the 
application of UBP310 significantly inhibited the extent of initial depression 
caused by KA application. This suggests that the initial AMPAR EPSC 
depression observed with KA stimulation is partly mediated by KAR ionotropic 
function. However, these changes are not sustained over 30 mins.  
Furthermore, there was also a decrease in the release probability of glutamate 
release as shown by the increase in the paired pulse ratio (PPR) following 10 
mins of KA application [Figure 3-7]. This low release of glutamate can lead to 
decreased AMPAR-EPSCs observed thus suggesting that the initial 
depression is potentially caused by pre-synaptic KARs. 
Because KARs occur at both pre- and post-synapses (Lerma, Paternain et al. 
2001), these results are most consistent with a role of pre-synaptic KAR 
function. Indeed, there is evidence of functional pre-synaptic KARs mediating 
NMDAR-independent form of AMPAR-LTP (Bortolotto, Clarke et al. 1999, 
Lauri, Bortolotto et al. 2001). It is also evident that presynaptic KARs can 
bidirectionally regulate to either inhibit (Kidd, Coumis et al. 2002) or facilitate 
(Contractor, Swanson et al. 2001) glutamate release. Moreover, activation of 
presynaptic KARs has been shown to result in long lasting inhibition of 
glutamate release, resulting in depression of excitatory transmission (Frerking, 
Schmitz et al. 2001). Thus, the simplest explanation of our electrophysiology 
experiments is that at CA1 synapses, pre-synaptic KARs facilitate 
transmission inhibition potentially leading to pre-synaptic LTD/short-term 
plasticity (STP). However, while potentially interesting my main focus was on 
determining the roles and regulation of postsynaptic GluK2-containing KARs, 
so I did not pursue these observations further into my PhD. 
3.4.4 Novel role of GluK2 and GluK5 containing KARs in 
homeostatic scaling 
The study and analysis of neuronal circuits and network activity is an emergent 
and extensively studied area of neuroscience. At a molecular level, changes 





in networks rely on the modification, connectivity and different forms of 
synaptic plasticity. In particular, synaptic scaling is important to maintain 
neuronal network integrity and is critical for neuronal circuit development 
(Contractor, Mulle et al. 2011). As there were very limited reports of KAR in 
homeostatic scaling [see section 3.1.4], I next decided to study if KARs 
respond to chronic alterations in network activity. Here I show that GluK2 and 
GluK5 containing KARs can both up-scale and down-scale in response to 
chronic suppression (TTX) and enhancement (bicuculline) of synaptic activity 
as shown by the alterations in their surface expression [Figure 3-8 and Figure 
3-9]. Interestingly, to some extent these changes parallel changes in AMPARs 
surface expression. However, if these occur within same synapses is not 
known. Indeed, it is not clear if AMPARs and KARs colocalise at the same post 
synapses (Sheng, Shi et al. 2015). Nevertheless, our data demonstrate that 
KARs undergo up- and down-scaling in response to changes in synaptic firing 
rates indicating that they are finely tuned in response to overall network 
activity. 
3.4.5 Chronic changes in synaptic activity alters GluK2 
editing status 
To establish a mechanism for these activity dependent changes in 
postsynaptic KARs we investigated Q/R editing within the M2 channel pore 
region of GluK2 (621aa). Q/R editing has been shown to play a role in GluK2-
containing KAR channel conductance and ion channel properties (Egebjerg 
and Heinemann 1993). Moreover, it was also shown that this GluK2 editing 
influences KAR assembly, ER exit and delivery to cell surface. More 
specifically, edited GluK2(R) is more likely to form monomer/dimer and be ER 
retained (Ball, Atlason et al. 2010, Evans, Gurung et al. 2017). Here, I show 
that changes in Q/R editing of GluK2 can be activity dependently regulated. 
Following 24 h TTX treatment, there is a decrease in the Q to R editing of 
GluK2 while the 48 h bicuculline treatment increased this editing activity 
[Figure 3-10 and Figure 3-11]. A similar concept of RNA editing regulating 
activity dependent receptors delivery to surface has also been reported for 
NMDARs where its mRNA splicing event at the C2/C2’ site of NR1 subunit 





was shown to be activity dependently regulated during homeostatic scaling 
(Mu, Otsuka et al. 2003).  
This mechanism to regulate the amount of KARs reaching the cell surface 
likely plays a key role in controlling neuronal excitability. 
3.4.6 Chronic changes in synaptic activity does not alter 
GluA2 editing status 
I also speculated if GluA2 upscaling can be mediated via changes in their Q/R 
editing status as previous findings have shown unedited GluA2 (Q) at 607aa 
site to result in its rapid release from ER causing their increased surface 
expression (Greger, Khatri et al. 2002, Greger, Khatri et al. 2003). 
Interestingly, GluA2 upscaling response seems to be independent to that of its 
Q/R editing as TTX treatment did not affect their Q/R editing ratio [Figure 
3-12]. Previous reports suggests that TTX mediated change in ADAR2 levels 
altered the R/G site editing of GluA2 subunits (Balik, Penn et al. 2013), which 
has not been investigated here. Moreover, this also suggests that GluA2 Q/R 
editing is more tightly regulated than that of GluK2. Furthermore, various 
reports have linked changes in Q/R editing status of GluA2 (mediated via 
changes in ADAR2 levels) and hence increased Ca2+ permeability during 
excitotoxicity (Mahajan, Thai et al. 2011) and diseases such as ALS 
(Hideyama, Yamashita et al. 2012) and ischaemia (Peng, Zhong et al. 2006) 
as such ensuring maintenance of GluA2 editing status is important for cell 
survival. This shows the need for maintaining GluA2 editing status i.e. ensure 
GluA2 is completely edited at the Q/R site.  
3.4.7 GluK5 surface expression is not altered following 
GluK2 loss 
Both TTX and bicuculline treatment showed decrease in GluK2 and GluK5 
containing KARs [Figure 3-8 and Figure 3-9]. As it is also known that GluK5 
is only functional as a heteromeric complex and needs to form heteromers with 
GluK1/2/3 to traffic out of the ER (Hayes, Braud et al. 2003), I hypothesised if 
changes in GluK5 are mediated due to its oligomerisation with GluK2. 
Moreover, GluK5 has higher ligand affinity than that of GluK1-3 (Herb, 
Burnashev et al. 1992). Perhaps, increasing or decreasing surface expression 





of GluK5 allows increased sensitivity of KARs in response to the dampening 
or enhancement of synaptic activity. 
To test this, I initially performed GluK2 KD to determine if loss of GluK2 can 
decrease GluK5 surface levels. I hypothesised that the lack of GluK2 would 
result in GluK5 not being able to form heteromeric assemblies, causing them 
to build up in the ER and potentially get degraded. So, I also tested whether 
total GluK5 levels post GluK2 KD is altered. However, loss of GluK2 did not 
alter either GluK5 surface or total levels [Figure 3-13]. This was surprising as 
GluK2 and GluK5 are the most abundant KAR subunit composition in the brain 
(Petralia, Wang et al. 1994, Kumar, Schuck et al. 2011, Evans, Gurung et al. 
2017). Possible explanations could be the lack of complete removal of 
endogenous GluK2 with the shRNA target used. Only ~50% loss of total GluK2 
levels compared to scrambled was achieved and the remaining GluK2 could 
still be enough for GluK5 to heteromerise with and traffic out of the ER. 
Secondly, there may be other KAR subunits (GluK1 and GluK3) present in our 
cultures that can oligomerise with GluK5 and this could be compensating for 
the lack of GluK2. As the tools to study these subunits are limited, it is difficult 
to determine this. Finally, the antibody I used can recognise both GluK2 and 
GluK3, so the remaining GluK2 signal I see post knockdown could potentially 
be GluK3 in our cultures, which can also oligomerise with GluK5.  
With all this in mind, it is not fully conclusive if changes in GluK2 surface levels 
post activity treatment can lead to subsequent changes in GluK5 surface. So, 
the rest of my PhD focused on unravelling mechanisms behind GluK2 scaling.       
3.5 Conclusions 
In conclusion, my initial investigation could not repeat published work showing 
changes in KAR mediated AMPAR-LTP. Though, KAR could be mediating 
AMPAR-LTD however, this seems to be potentially mediated by pre-synaptic 
KARs and more likely to be a form of short term plasticity (STP).  
Finally, I show novel KAR scaling responses. GluK2 and GluK5 containing 
KARs surface expression can increase or decrease in response to chronic 
changes in network activity like that of AMPARs and NMDARs. Moreover, the 





Q/R editing of GluK2 is a potential selective mechanism of GluK2 scaling. 
Given these intriguing results I subsequently focused on studying the role of 
Q/R editing in GluK2 containing KARs scaling and the enzyme known to 
regulate this post-transcriptional editing process. 
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ADAR2 is the enzyme that deaminates adenosine to inosine (A-to-I), which is 
then read as guanosine by the cellular machinery. This results in change in 
the codon read from glutamine (Q) (CAG) to arginine (R) (CGG) when 
translated, which affects the functional properties and subcellular distribution 
of the resultant proteins. Moreover, such editing mediated changes have also 
been shown to occur during neuronal activity.    
4.1.1 Activity dependent regulation of A-to-I RNA editing 
It is becoming increasingly evident that RNA editing can be regulated during 
changes in the neuronal network activity. Initial evidence of this involved the 
serotonin 2C (5-HT2C) receptor that can be A-to-I edited in a serotonin 
dependent manner, in early life stress and also following application of 
antidepressant fluoxetine (Gurevich, Englander et al. 2002, Englander, 
Dulawa et al. 2005, Bhansali, Dunning et al. 2007). Subsequent genome wide 
studies on cortical neuronal cultures revealed various RNA editing sites that 
were regulated by synaptic activity (Sanjana, Levanon et al. 2012). 
Interestingly, the majority of these changes were shown to occur in ADAR 
substrates including the GluK2 Q/R editing site which decreased following 6 h 
potassium (60mM) treatment and following suppression of synaptic activity 
(Sanjana, Levanon et al. 2012). Interestingly, editing of the AMPAR subunit 
GluA2 Q/R was not altered with either of the treatments. This study did, 
however, identify alterations in the GluA2 R/G editing, which was also 
supported by another independent study showing similar changes in cultured 
hippocampal slices (Balik, Penn et al. 2013). These changes were shown to 
be cell-type specific, occurring in the CA1 region of the hippocampus but not 
the CA3. These observations were also accompanied with concurrent 
changes in ADAR2 transcript levels but not of any other ADARs, showing the 
specific importance of ADAR2 in neuronal activity dependent RNA editing 
(Sanjana, Levanon et al. 2012, Balik, Penn et al. 2013).     
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4.1.2 Q/R editing of KARs and AMPARs regulate their 
surface expression 
As detailed in the Introduction section 1.5, Q/R editing occurs in the GluK1 and 
GluK2 subunit of KARs and GluA2 subunit of AMPARs. Having either edited 
or unedited forms of these subunits is a key determinant of their ionotropic 
functional properties. In addition, this Q/R editing also affects the surface 
delivery of the resultant multimeric complex.  
4.1.2.1 Evidence that Q/R editing of GluA2 regulates AMPAR 
assembly and expression 
The role of Q/R editing in the surface delivery of glutamate receptors was 
initially shown for GluA2 containing AMPARs (Greger, Khatri et al. 2002). 
While GluA1 containing AMPARs could exit the ER and traffic to the surface 
efficiently, a pool of GluA2 subunits of AMPARs were retained in the ER. Most 
of this retention was attributed to the Q/R editing of GluA2 subunit since 
reverting to the unedited version of GluA2 (R607Q) led to rapid release of 
GluA2 from the ER. This also resulted in their increased surface expression. 
Consistent with this, another study also showed higher surface expression of 
unedited forms of GluA2 compared to the edited form (Ma-Hogemeier, Korber 
et al. 2010). Interestingly, mutating corresponding Glutamine in GluA1 to 
Arginine (Q600R) also reduced the mutant GluA1 surface expression (Greger, 
Khatri et al. 2002), further strengthening the role of editing in trafficking.   
4.1.2.2 Evidence that Q/R editing of GluK2 regulates KAR assembly 
and expression 
Studies on the GluK2-containing KARs showed differential subunit assembly 
and subcellular distribution of the edited (R) and unedited (Q) forms of GluK2, 
like that for GluA2 in AMPARs. The unedited forms of GluK2 were more likely 
to assemble as tetramers allowing them to be released from the ER whereas 
the edited form of GluK2 accumulated primarily as monomer/dimer causing 
them to be predominantly ER retained (Ball, Atlason et al. 2010).  
However, another study reported no such differences with either the edited or 
unedited forms of GluK2 (Ma-Hogemeier, Korber et al. 2010). These opposing 
observations could be due to the differences in sensitivity of the assays applied 
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as changes in GluK2 containing KAR oligomerisation and trafficking are 
relatively moderate compared to GluA2. It should also be noted that these 
studies were performed in an over-expressed system over 72 h time course. 
So, changes in the ER assembly and export are more likely to be prominent in 
the earlier timepoints (24 h) to prevent saturation of the system which may 
mask the Q/R effect on assembly and trafficking (Ball, Atlason et al. 2010). 
Equally, EndoH assays used to mark the intracellular immature proteins in 
both GluK2 and GluA2 Q/R editing studies, has also been questioned in a 
recent study where it was shown that EndoH-sensitive proteins can be 
abundant at the neuronal surface as well (Hanus, Geptin et al. 2016).  
Nevertheless, in line with the studies showing differential expression of edited 
and unedited GluK2, recent study from our lab also showed unedited form of 
GluK2 to have higher surface expression compared to the edited form (Evans, 
Gurung et al. 2017). 
4.1.2.3 Proposed model of Q/R editing regulation of surface delivery 
The Q/R editing of both GluA2 and GluK2 occurs in its transmembrane II (TMII) 
region which lines the channel pore forming loop [see section 1.5]. AMPARs 
studies have shown oligomerisation of ionotropic glutamate receptors to be a 
two-step process: dimerisation of dimers (Kuusinen, Abele et al. 1999, 
Armstrong and Gouaux 2000, Ayalon and Stern-Bach 2001, Mansour, 
Nagarajan et al. 2001, Sun, Olson et al. 2002). Likewise, KAR assembly also 
involves an initial dimerisation process mediated by their N-terminal Domains 
(NTD) (Ayalon and Stern-Bach 2001, Kumar, Schuck et al. 2011). Forming 
tetrameric assembles would require these pore regions of the subunits to 
come in close proximity to each other. Having positively charged arginine 
group in the pore region potentially brings charge repulsion and/or steric 
hindrances disfavouring multimeric assemblies, in particular homomeric 
assemblies (Greger, Khatri et al. 2003, Greger, Ziff et al. 2007).  
It has also been previously proposed, using separate studies on ATP-sensitive 
K+ channel trafficking, that the properties of ion channels may act as functional 
checkpoints in the ER to regulate the export of complexes out of the ER 
(Zerangue, Schwappach et al. 1999). The reduced channel conductance of 
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edited subunits (Swanson, Feldmeyer et al. 1996, Burnashev and Rozov 
2000, Cull-Candy, Kelly et al. 2006) may act as a disadvantage in ensuring 
efficiency of synaptic transmission. Favouring this hypothesis, it has been 
reported that downstream checkpoints potentially exists in ER which allows 
sensing of gating motions to prevent ER export of glutamate receptor channels 
with blocked desensitisation (Priel, Selak et al. 2006). However, the identity of 
these checkpoints is as of yet not known.  
Hence, charge repulsion, steric hindrance and/or ER checkpoints are all 
potentially contributing to the altered surface delivery of Q/R edited and 
unedited receptors. 
4.1.3 Q/R editing role in regulation of protein expression 
and stability 
Beyond their role in trafficking and ion channel properties, Q/R editing has also 
been shown to regulate protein expression via an interplay between GluA2 
Q/R editing and splicing. GluA2 editing was reported to be positively coupled 
to the pre-mRNA splicing efficiency. The edited GluA2 pre-mRNA transcripts 
were preferentially spliced compared to the unedited transcripts (Brusa, 
Zimmermann et al. 1995), which is thought to act as a ‘safe-guard’ mechanism 
to ensure high-editing of GluA2 is maintained basally and also during periods 
of ADAR2 fluctuations (Schoft, Schopoff et al. 2007, Hideyama, Yamashita et 
al. 2012, Penn, Balik et al. 2013). Furthermore, this splicing regulation of 
editing provides a mechanism to ensure tight regulation of GluA2 Q/R editing 
because unedited GluA2 pre-mRNA transcripts are less likely to be 
successfully transcribed and expressed. Supporting this, ADAR2 knockout 
mice showed nuclear accumulation of incompletely spliced GluA2 pre-mRNA 
transcripts and reduced GluA2 expression levels (Higuchi, Maas et al. 2000).  
If this is also the case for GluK2 is not known, although GluK2 Q/R assembly 
studies have shown an increased degradation of edited form of GluK2 (Ball, 
Atlason et al. 2010). The build-up of intracellular edited GluK2 subunits due to 
their lack of ability to form heteromeric complexes was thought to lead to 
increased degradation of these unassembled edited GluK2 subunits. This 
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suggests that Q/R editing at least indirectly can alter the protein stability and 
hence the levels of GluK2 containing KARs.  
4.1.4 Objectives 
It is becoming increasingly evident that changes in neuronal activity regulates 
RNA editing, in particular ADAR2 mediated RNA editing, that can result in 
changes in receptor properties. Q/R editing of GluK2 and GluA2, in addition to 
affecting their ionotropic functional properties, also changes their assembly, 
ER export and their surface delivery.  
My work in Chapter 3 showed novel role of KAR receptors in homeostatic 
scaling. Chronic suppression and enhancement of network activity resulted in 
up-scaling and down-scaling of GluK2-containing KARs as demonstrated by 
their increase and decrease in surface expression following 24 h tetrodotoxin 
(TTX) treatment and 48 h bicuculline treatment respectively. Furthermore, 
suppression of network activity decreased Q/R editing of GluK2 leading to an 
increase in unedited GluK2 (Q) population and vice-versa with enhancement 
in the network activity.  
This led to my hypothesis that changes in ADAR2 mediated Q/R editing of 
GluK2 plays a key role in GluK2 scaling response. So, my objectives for the 
next phase of my project were to: 
1. Determine if ADAR2 levels alter in response to chronic changes in 
network activity. 
2. Apply ADAR2 KD strategies to comparatively test ADAR2 regulation of 
GluK2 and GluA2 Q/R editing. 
3. Apply ADAR2 KD strategies to determine if ADAR2 can induce KAR 
scaling.  
4.2 Materials and methods 
All techniques used in this section are covered in the general Materials and 
methods section.  
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4.3.1 ADAR2 but not ADAR1 total levels decrease post 
24 h TTX treatment 
To investigate the role of ADAR2 mediated GluK2 Q/R editing in KAR scaling 
I tested the effects of chronic suppression of network activity with 24 h TTX 
treatment on ADAR2 levels (Higuchi, Maas et al. 2000). As shown in Figure 
4-1 A and B, incubation with TTX for 24 h decreased total ADAR2 levels by 
~50% compared to the untreated control. Q/R site editing in glutamate 
receptors are predominantly mediated by ADAR2 (Higuchi, Maas et al. 2000). 
However, ADAR1 can also to an extent edit Q/R sites (Dabiri, Lai et al. 1996, 
Herb, Higuchi et al. 1996) and is the only other functionally active enzyme 
(Melcher, Maas et al. 1996) in this family so I also probed for ADAR1 levels to 
determine if it too is regulated by synaptic activity. Following 24 h TTX 
treatment, ADAR1 levels were unchanged [Figure 4-1 C and D]. Both bands 
obtained for ADAR1 were quantified here as ADAR1. These data indicate that 
ADAR2 is preferentially lost following chronic suppression of network activity. 
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Figure 4-1: ADAR2 but not ADAR1 total levels decrease post 24h 1µM TTX treatment.  
A. Representative western blot images of total levels of ADAR2 and GAPDH 
levels post 24h TTX treatment.  
B. Quantification of total ADAR2 levels normalised to GAPDH levels post 24h 
TTX treatment shown in A. N=5 independent dissections, Unpaired t-test; 
****p<0.0001, error bar=S.D. 
C. Representative western blot images of total levels of ADAR1 and GAPDH 
levels post 24h TTX treatment.  
D. Quantification of total ADAR1 levels normalised to GAPDH post 24h TTX 
treatment shown in C. Both bands were quantified. N=8 independent 
dissections, Unpaired t-test; ns p>0.05, error bar=S.D.  
 
4.3.2 Both ADAR1 and ADAR2 total levels are unchanged 
post bicuculline treatment 
GluK2 containing KARs are susceptible to chronic enhancement of synaptic 
activity following both 24 h and 48 h bicuculline treatment. As the Q/R editing 
of GluK2 also increased significantly following bicuculline treatment, I next 
determined if either ADAR1 or ADAR2 levels were also altered. In contrast to 
the TTX treatment, ADAR2 levels remained unchanged [Figure 4-2 A and B] 
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following both 24 and 48 h of bicuculline treatment. Similarly, ADAR1 levels 
also remained unchanged [Figure 4-2 C and D]. 
 
Figure 4-2: Both ADAR2 and ADAR1 total levels are unchanged post 24 and 48 h 
40µM bicuculline treatment.  
A. Representative western blot images of total levels of ADAR2 and GAPDH 
levels post 24h and 48h bicuculline treatment.  
B. Quantification of total ADAR2 levels normalised to GAPDH post 24h and 48h 
bicuculline treatment shown in A. N=6 independent dissections, Unpaired t-
test; ns p>0.05, error bar=S.D.  
C. Representative western blot images of total levels of ADAR1 and GAPDH 
levels post 24h and 48h TTX treatment.  
D. Quantification of total ADAR1 levels normalised to GAPDH post 24h and 48h 
bicuculline treatment shown in C. Both bands were quantified. N=8 
independent dissections, Unpaired t-test; ns p>0.05, error bar=S.D.  
These results indicate that in contrast to TTX-evoked up-scaling, the levels of 
ADAR2 are not altered during bicuculline-evoked down-scaling, suggesting 
that other mechanism(s) potentially regulates GluK2 Q/R editing during KAR 
downscaling. I therefore focused on the role of ADAR2 during GluK2 up-
scaling. 
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4.3.3 Longer exposure to TTX does not decrease ADAR2 
levels further 
I next wanted to determine if ADAR2 levels are altered in a time-dependent 
manner by TTX treatment. Studies using TTX to mediate suppression of 
network activity have varied from 6 to 48 h (Craig, Jaafari et al. 2012, 
Schanzenbächer, Sambandan et al. 2016, Schaukowitch, Reese et al. 2017). 
Therefore, I treated hippocampal neurones with 1µM TTX for 6, 12, 24, 36 and 
48 h and determined ADAR2 levels. While there was a decreasing trend in 
ADAR2 levels following 12 h TTX treatment, there was significant reduction 
only after 24h, with no further significant decrease in ADAR2 levels at 36 or 
48h [Figure 4-3]. This suggests basal level of ADAR2 must be maintained 
throughout long-term suppression of synaptic activity to ensure editing of other 
ADAR2 substrates including that of GluA2. 
 
Figure 4-3: Longer lengths of 1µM TTX treatment do not decrease total ADAR2 levels 
further. 
A. Representative western blot images of total levels of ADAR2 and GAPDH 
levels post 6, 12, 24, 24, 36 and 48 h TTX treatments.  
B. Quantification of total ADAR2 levels normalised to GAPDH post stated lengths 
of TTX treatment shown in A. N=6 independent dissections, One-way ANOVA 
with Dunnett’s multiple post comparisons correction; **p<0.01, ***p<0.001, 
error bar=S.D. 
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4.3.4 ADAR2 is localised in the nucleus and the nuclear 
levels are decreased following TTX treatment 
ADAR2 is a nuclear protein (Desterro, Keegan et al. 2003, Sansam, Wells et 
al. 2003) where it interacts with its dsRNA substrates (Higuchi, Single et al. 
1993, Herb, Higuchi et al. 1996, Wahlstedt and Ohman 2011). I first confirmed 
that ADAR2 is expressed in the nucleus in my neuronal cultures and then 
determined the effect of 24 h TTX treatment within the nucleus. As expected, 
subcellular fractionation of neuronal cultures shows that ADAR2 is entirely 
expressed in the nucleus [Figure 4-4] and that TTX treatment decreased 
levels of ADAR2 in the nucleus by ~50%, consistent with the total ADAR2 
decrease observed.  
 
Figure 4-4: Subcellular fractionation show nuclear localisation of ADAR2 which is 
decreased following 24 h 1µM TTX treatment. Cytosolic and nuclear compartments 
were isolated to determine ADAR2 localisation and levels post 24 h TTX treatment.  
A. Representative western blot images of levels of ADAR2 in the cytosol and the 
nucleus post 24 h TTX treatment. RhoGDI was used as a cytosolic marker 
(Maurya, Sundaram et al. 2009) and Lamin B as a nuclear marker (Olins, 
Rhodes et al. 2010).   
B. Quantification of nuclear ADAR2 levels normalised to Lamin B post 24 h TTX 
treatment shown in A. N=3 independent dissections, Unpaired t-test; 
**p<0.01; error bar=S.D. 
To further confirm the data obtained from subcellular fractionation, I also 
performed fixed immunocytochemistry experiments. DAPI was used to stain 
the nucleus and the cells to be imaged were selected under this channel to 
avoid bias. Fibrillarin, a nucleolar RNA methyltransferase, was used as a 
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nucleolar specific marker (Lafontaine and Tollervey 2000, Shubina, Musinova 
et al. 2016) as ADAR2 has been reported to predominantly localise within the 
nucleolus (Desterro, Keegan et al. 2003, Sansam, Wells et al. 2003). 
Consistent with previous studies ADAR2 in hippocampal neurones were 
localised in the fibrillarin positive nucleoli structures. Moreover, 24h TTX 
treatment caused a decrease in the overall nuclear ADAR2 signal [Figure 4-5 
A and B]. 
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Figure 4-5: Fixed immunolabelling show nucleolar localisation of ADAR2. The 
intensity of ADAR2 signal and the percentage of cells expressing ADAR2 were both 
decreased following 24h 1µM TTX treatment.  
A. Representative images showing predominantly nucleolar localisation of 
ADAR2 in the nucleus stained with DAPI (blue) and imaged for ADAR2 (red-
Cy3) and fibrillarin (cyan-Cy5, nucleolar marker). White boxes in the top panel 
represent zoomed images below showing decreased ADAR2 intensity and red 
arrows show cells positive for ADAR2 expression. Scale bar=10µm.   
B. Quantification of nuclear intensity of ADAR2 following 24h TTX treatment 
shown in A. DAPI channel was used to draw regions of interest around the 
nucleus and average intensity was calculated. n=60-62 cells, N= 3 
independent dissections, Unpaired t-test; ****p<0.0001, error bar=S.D. 
C. Quantification of percentage of cells expressing ADAR2 post 24h TTX 
treatment per field of view as shown in A (red arrows). N=15 fields of view, 
Unpaired t-test; *p<0.05, error bar=S.D. 
 
Surprisingly not all cells expressed ADAR2 with approximately 80% of cells 
within a field of view positive for ADAR2 signal (indicated by red arrows). 
Dispersed neuronal cultures are thought to possess predominantly CA1 
pyramidal cell properties (Lerma, Morales et al. 1997, IM, FA et al. 2011). 
Previous work has suggested that the CA1 does not express ADAR2 as highly 
as the CA3 hippocampal region (Balik, Penn et al. 2013). This may explain 
why ~20% of cells do not express ADAR2. Other possibilities include that the 
ADAR2-lacking cells are non-neuronal e.g. glial cells, which do not highly 
express ADAR2 (Jacobs, Fogg et al. 2009). It may also be the case that these 
cells express isoforms of ADAR2 (Dracheva, Lyddon et al. 2009) not detected 
by our antibody. While further investigation will be needed to distinguish 
between these possibilities, TTX treatment also caused the percentage of cells 
expressing ADAR2 to decrease significantly from ~80% to ~50% [Figure 4-5 
A and C].  
4.3.5 Creating and validating knockdown tools against 
ADAR2 
I reasoned that the decrease in ADAR2 following 24h TTX treatment was a 
causal factor in reduced GluK2 Q/R editing. To test this hypothesis, I 
generated lentiviruses expressing either shRNAs targeted to ADAR2 or non-
specific scrambled shRNA control. I synthesised two different shRNAs against 
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ADAR2. Serendipitously, one shRNA completely removed endogenous 
ADAR2, which I named ‘Complete’ ADAR2 KD whereas second shRNA 
reduced ADAR2 levels to ~50% of the scrambled control, which I named 
‘Partial’ ADAR2 KD [Figure 4-6 A and B].  
Fixed imaging analysis also showed absolute loss of ADAR2 signal when 
infected with ‘Complete’ ADAR2 KD. On the other hand, the ‘Partial’ ADAR2 
KD had significantly reduced ADAR2 intensity signal along with significantly 
reduced percentage of cells expressing ADAR2, similar to those elicited by 
TTX treatment [Figure 4-6 C, D and E]. 
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Figure 4-6: Validating knockdown tools against ADAR2. Lentiviral delivery system 
was used to target two different shRNAs against ADAR2. ‘Complete ADAR2 KD’ 
completely removes endogenous ADAR2 whereas ‘Partial ADAR2 KD’ removes 50% 
of the endogenous ADAR2 compared to the scrambled. 
A. Representative western blot images of ADAR2 and GAPDH levels post 5 days 
infection with either Complete ADAR2 KD or Partial ADAR2 KD.  
B. Quantification of total ADAR2 levels normalised to GAPDH shown in A. N=5 
independent dissections, One-way ANOVA with Tukey’s multiple post 
comparisons correction; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; error 
bar=S.D. 
C. Representative images of ADAR2 levels post 5 days infection with either 
Complete ADAR2 KD or Partial ADAR2 KD. The cells were stained with DAPI 
(blue) and imaged for GFP (green-Cy2), ADAR2 (red-Cy3) and fibrillarin 
(cyan-Cy5, nucleolar marker). White boxes in the top panel represent zoomed 
images below showing decreased ADAR2 intensity and red arrows show cells 
positive for ADAR2 expression. Scale bar=10µm. 
D. Quantification of nuclear intensity of ADAR2 shown in C. DAPI channel was 
used to draw regions of interest around the nucleus and average intensity was 
calculated. n=75-99 cells, N=3 independent dissections, One-way ANOVA 
post Tukey’s multiple post comparisons correction; ***p<0.001, ****p<0.0001; 
error bar=S.D. 
E. Quantification of percentage of cells expressing ADAR2 per field of view as 
shown in C (red arrows). n=11-13 fields of view; N=3 independent dissections, 
One-way ANOVA post Tukey’s multiple post comparisons correction; 
****p<0.0001; error bar=S.D. 
 
4.3.6 Complete and Partial ADAR2 knockdown 
differentially alter GluK2 editing 
I next tested if removing endogenous ADAR2 reduces the GluK2 Q/R editing. 
As expected, ‘Complete’ ADAR2 KD reduced GluK2 editing by over 60% 
whereas ‘Partial’ ADAR2 KD reduced GluK2 editing by ~20% compared to the 
scrambled control [Figure 4-7 A and B]. Consistent with this, chromatographs 
of neurones treated with ‘Complete’ ADAR2 KD showed a dramatic change in 
the base read of the editing site to A (unedited) rather than G (edited). In 
contrast, the editing site in the neurons treated with the ‘Partial’ ADAR2 KD 
predominantly read G but had an increased peak read for A and decreased 
peak read for G compared to the scrambled control [Figure 4-7 C]. 
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Figure 4-7: Complete and Partial removal of ADAR2 differentially alters GluK2 editing. 
5 days after knockdown virus infection, RNA was extracted from the cells and cDNA 
was synthesised to perform PCR assays.  
A. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluK2 ratio after 
knockdowns infection. 100% edited and unedited GluK2 constructs were used 
as a control to ensure BbvI cut activity and validity of the assay. 
B. Quantification of percentage of edited to unedited ratio of GluK2 population 
present after 24 h TTX treatment as shown in A. n=4 independent dissections; 
One way ANOVA with Tukey’s multiple post comparisons correction; *p<0.05, 
**p<0.01, ****p<0.0001; error bars=S.D. 
C. Representative chromatographs of PCR products comparing scrambled 
infected cells with the knockdowns infected cells at the Q/R editing site. The 
undigested PCR products were sent for sequencing to determine changes in 
the dual peaks obtained at the site of editing as indicated by the green arrow. 
A peak (green) represents the unedited base while the G peak (black) 
represents the edited base. The image is representative of 3 repeats. 
 
4.3.7 Complete and Partial ADAR2 knockdown 
differentially alter GluA2 editing 
ADAR2 KO mice are deficient in both GluA2 and GluK2 editing (Higuchi, Maas 
et al. 2000) and the majority of the functional studies on ADAR2 mediated Q/R 
editing have focused on the GluA2 AMPAR subunit. With this in mind, I wanted 
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to determine the effect of the two ADAR2 shRNA knockdowns on GluA2 
editing.  
 
Figure 4-8: Complete and Partial knockdown of ADAR2 differentially alters GluA2 
editing. 5 days after knockdown virus infection, RNA was extracted from the cells and 
cDNA was synthesised to perform PCR assays.  
A. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluA2 ratio. 100% edited 
and unedited GluA2 constructs were used as a control to ensure BbvI cut 
activity and validity of the assay. 
B. Quantification of percentage of edited to unedited ratio of GluA2 population 
present after 24 h TTX treatment as shown in A. n=4 independent dissections; 
One way ANOVA with Tukey’s multiple post comparisons correction; 
****p<0.0001; error bars=S.D. 
C. Representative chromatographs of PCR products comparing scrambled 
infected cells with the knockdowns infected cells at the Q/R editing site. The 
undigested PCR products were sent for sequencing to determine changes in 
the dual peaks obtained at the site of editing as indicated by the green arrow. 
A peak (green) represents the unedited base while the G peak (black) 
represents the edited base. The image is representative of 3 repeats. 
Interestingly, ‘Complete’ ADAR2 KD only reduced GluA2 editing by ~30% 
while the ‘Partial’ ADAR2 KD did not have any effect on the Q/R editing of the 
AMPAR subunit GluA2 [Figure 4-8 A and B]. The changes are also visible in 
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the chromatographs where in scrambled control there is no dual peak at the 
editing site (green arrow), consistent with GluA2 being edited over 99% pre-
birth (Jacobs, Fogg et al. 2009). This remains unchanged with the ‘Partial’ 
ADAR2 KD however, with the ’Complete’ ADAR2 KD, there is an increased A 
to G peak ratio [Figure 4-8 C]. 
4.3.8 ADAR2 knockdown can be rescued by lentiviral 
infection 
Removing endogenous ADAR2 reduced the editing status of both GluK2 and 
GluA2 to varying degrees. I next determined if this editing deficiency could be 
rescued by expression of exogenous shRNA insensitive WT ADAR2 rescue 
construct to confirm the specificity of the ADAR2 KD and establish proof of 
concept for rescue with mutant forms of ADAR2. I generated two separate 
lentiviruses using the same backbone vector; one contained the ‘Complete’ 
ADAR2 KD shRNA expressing GFP and another consisted of the N-terminally 
HA tagged shRNA insensitive WT ADAR2 rescue. The knockdown virus 
(250µl) completely ablated endogenous ADAR2 while adding (100µl) of HA 
tagged ADAR2 rescue virus alongside the knockdown restored ADAR2 to 
levels comparable to the control [Figure 4-9 A]. Both viruses were added to 
the cells on the same day. Moreover, adding two separate viruses successfully 
infected same cells as shown by colocalization of GFP and HA markers in the 
rescue panel in [Figure 4-9 B]. 
I also wanted to ensure there were comparable number of cells expressing 
ADAR2 with the volume of rescue virus used. Fixed imaging analysis [Figure 
4-9 B and C] showed that ~80% of cells expressed exogenous ADAR2 after 
knockdown and rescue, similar to the percentage of cells expressing 
endogenous ADAR2 in the scrambled control. Hence, I determined the 
optimum volume of viruses to obtain rescue at comparable levels to the 
endogenous.   
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Figure 4-9: ADAR2 loss can be rescued by lentiviral overexpression after complete 
ADAR2 knockdown in hippocampal neuronal cultures. 
A. Representative western blot images of ADAR2, HA and GAPDH levels of cells 
infected with either scrambled, Complete ADAR2 KD or complete ADAR2 KD 
with WT HA-ADAR2 at DIV 9 for 6 days.  
B. Representative images of cells stained with DAPI (blue) and imaged for GFP 
(green-Cy2), ADAR2 (red-Cy3) and fibrillarin (cyan-Cy5). The cells were 
infected with either scrambled, Complete ADAR2 KD or Complete ADAR2 KD 
with WT HA-ADAR2 at DIV 9 for 6 days. Thus, the GFP panels shows cells 
expressing knockdown while HA and ADAR2 panels show the cells 
expressing the rescue constructs. Red arrows show cells positive for ADAR2 
expression. Scale bar=10µm.  
C. Quantification of percentage of cells expressing ADAR2 per field of view as 
shown in B (red arrows). n=12-14 fields of view; N=3 independent dissections, 
Unpaired t-test; ns p>0.05; error bar=S.D. 
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4.3.9 ADAR2 rescue restores the editing deficiency 
following ‘Complete’ and ‘Partial’ ADAR2 KDs 
With the rescue system in place, I determined if the editing deficiency 
observed with ADAR2 loss was rescued when ADAR2 levels are rescued. 
Following 6 days of knockdown and rescue, I performed RNA extraction and 
cDNA synthesis and analysed the editing ratio. As shown in Figure 4-10 A 
and B, GluK2 editing was significantly rescued for both ‘Complete’ and ‘Partial’ 
ADAR2 KDs.  
GluA2 editing was unaffected by ‘Partial’ ADAR2 knockdown but the increase 
in unedited GluA2 population following ‘Complete’ ADAR2 KD was reversed 
by rescue with expression of shRNA insensitive WT ADAR2 rescue [Figure 4-
10 D and E]. This data confirms GluK2 and GluA2 editing deficiency is a direct 
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Figure 4-10: Rescuing ADAR2 levels rescues editing levels of GluK2 and GluA2 
following Complete and Partial ADAR2 KD. 6 days after knockdown and rescue virus 
infections, RNA was extracted from the hippocampal cells and cDNA was synthesised 
to perform PCR assays.  
A. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluK2 ratio. 100% edited 
and unedited GluK2 constructs were used as a control to ensure BbvI cut 
activity and validity of the assay. 
B. Quantification of percentage of edited to unedited ratio of GluK2 population 
present as shown in A. N=4 independent dissections; One way ANOVA with 
Tukey’s multiple post comparisons correction; *p<0.05, **p<0.01, 
****p<0.0001; error bars=S.D. 
C. Representative chromatographs of PCR products comparing scrambled 
infected cells with the knockdowns and knockdown rescue infected cells at 
the Q/R editing site of GluK2. The undigested PCR products were sent for 
sequencing to determine changes in the dual peaks obtained at the site of 
editing as indicated by the green arrow. A peak (green) represents the 
unedited base while the G peak (black) represents the edited base. The image 
is representative of 3 repeats. 
D. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluA2 ratio. 100% edited 
and unedited GluA2 constructs were used as a control to ensure BbvI cut 
activity and validity of the assay. 
E. Quantification of percentage of edited to unedited ratio of GluA2 population 
present as shown in A. N=4 independent dissections; One way ANOVA with 
Tukey’s multiple post comparisons correction; ns p>0.05, ****p<0.0001; error 
bars=S.D. 
F. Representative chromatographs of PCR products comparing scrambled 
infected cells with the knockdowns and knockdown rescue infected cells at 
the Q/R editing site of GluA2. The undigested PCR products were sent for 
sequencing to determine changes in the dual peaks obtained at the site of 
editing as indicated by the green arrow. A peak (green) represents the 
unedited base while the G peak (black) represents the edited base. The image 
is representative of 3 repeats. 
 
4.3.10 Complete and Partial ADAR2 KD differentially 
alter total GluA2 and GluK2 levels 
As loss of ADAR2 editing function has been suggested to lead to eventual loss 
of total protein expression at least in case of GluA2 (Higuchi, Maas et al. 2000), 
I next tested if the ADAR2 KDs affected the total protein expression of GluK2 
and GluA2. Interestingly, ‘Complete’ ADAR2 KD decreased the total protein 
levels of both GluA2 and GluK2. ‘Partial’ ADAR2 KD also significantly 
decreased total GluA2 levels although to a lesser extent than ‘Complete’ 
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ADAR2 KD. On the other hand, total protein levels of GluK2 were unaffected 
[Figure 4-11]. Thus, ‘Partial ADAR2 KD’ does not affect total GluK2 levels.
 
Figure 4-11: Complete and Partial knockdown of ADAR2 differentially alter GluA2 and 
GluK2 total levels. 5 days after knockdown virus infection, cells were harvested and 
analysed using western blotting.  
A. Representative western blot images of total levels of GluK2 and GluA2 post 
5 days infection with complete and partial ADAR2 KD. 
B-C.  Quantification of GluK2 (B) and GluA2 (C) normalised to GAPDH shown in 
A. N=10 independent dissections. One-way ANOVA with Tukey’s multiple 
post comparisons correction; ns p>0.05, **p<0.01, ****p<0.0001; error 
bars=S.D.    
 
4.3.11 Partial ADAR2 KD phenocopies and occludes 
GluK2 scaling 
Intriguingly, the levels of ADAR2 loss observed with Partial ADAR2 KD were 
comparable to the levels obtained following 24 h TTX treatment. The shift in 
proportions of edited to unedited GluK2 were also similar. Moreover, ‘Partial’ 
ADAR2 KD did not affect the total expression of GluK2 unlike the ‘Complete’ 
ADAR2 KD.  
I therefore determined if ‘Partial’ loss of ADAR2 is enough to mediate GluK2 
up-scaling. As shown in Figure 4-12 A and B, 24 h TTX treated neurones and 
neurones infected with Partial ADAR2 KD, both significantly increased GluK2 
surface expression compared to the neurones infected with scrambled 
shRNA, with no effect on the EGFR surface expression [Figure 4-12 A and 
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C]. However, TTX treatment in combination with Partial ADAR2 KD had no 
additive effects consistent with partial ADAR2 loss phenocopying and 
occluding GluK2 up-scaling.   
 
Figure 4-12: Partial ADAR2 KD phenocopies and occludes GluK2 scaling. Surface 
biotinylation was performed on DIV 15 hippocampal neurones following infections 
with either scrambled or Partial ADAR2 KD for 5 days with or without 24 h TTX 
treatment to isolate surface proteins and determine surface/total ratio by western 
blotting.  
A. Representative western blot images of surface and total levels of GluK2 and 
EGFR. EGFR was used as a surface expressed non-glutamate receptor 
control that should not respond to the stimulation. GAPDH was used as an 
internal control to determine no internal proteins were biotinylated.  
B-C.  Quantification of surface to total ratio of GluK2 (B) and EGFR (C) shown in A. 
N=10 independent dissections. One-way ANOVA with Tukey’s multiple post 
comparisons correction; ns p>0.05, *p<0.05, **p<0.01, ***<0.001; error 
bars=S.D.    
Interestingly, however, in ‘Partial ADAR2 KD’ neurons treated with 24 h TTX 
there was a further decrease in ADAR2 levels [Figure 4-13], indicating that 
even when already depleted, ADAR2 levels are still subject to activity-
dependent regulation. 
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Figure 4-13: Partial ADAR2 KD combined with 24 h TTX treated elicits further 
decrease in ADAR2 levels. DIV 15 hippocampal neurones following infected with 
either scrambled or Partial ADAR2 KD for 5 days with or without 24h TTX treatment 
were blotted for total ADAR2 levels.  
A. Representative western blot images of total levels of ADAR2 and GAPDH.  
B. Quantification of ADAR2 normalised to GAPDH shown in A shown in A. N=10 
independent dissections. One-way ANOVA with Tukey’s multiple post 
comparisons correction; *p<0.05, ****p<0.0001; error bars=S.D.    
 
4.3.12 No further reduction in GluK2 editing in 
neurones treated with both Partial ADAR2 KD and 
TTX 
As there was further loss of ADAR2 when cells were infected with ‘Partial 
ADAR2 KD’ and treated with 24 h TTX, I tested if GluK2 editing was also 
decreased further in this condition. As shown in Figure 4-14, despite the 
summative decrease in ADAR2 levels, Partial ADAR2 KD combined with 24 h 
TTX treatment did not further decrease GluK2 Q/R editing compared to either 
treatment alone, consistent to no additive increase in GluK2 surface 
expression in combined TTX and ADAR2 KD condition.  
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Figure 4-14: No further reduction in GluK2 editing in neurones treated with both Partial 
ADAR2 KD and 24 h TTX.  
A. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluK2 ratio in cells treated 
with either scrambled or partial ADAR2 KD or 24 h TTX or both partial KD and 
24 h TTX. 100% edited and unedited GluK2 constructs were used as a control 
to ensure BbvI cut activity and validity of the assay. 
B. Quantification of percentage of edited to unedited ratio of GluK2 population 
present as shown in A. N=5 independent dissections; One way ANOVA with 
Tukey’s multiple post comparisons correction; **p<0.01, ***p<0.001; error 
bars=S.D. 
 
4.3.13 Decreased stability of unedited GluK2 (Q) 
compared to the edited GluK2 (R) 
It has been previously suggested that edited GluK2 is less stable than the 
unedited GluK2 (Ball, Atlason et al. 2010). Therefore, I determined if 
exogenously expressed tagged unedited (Q) and edited (R) GluK2 (YFP-myc 
tagged in the N-terminus) have altered stability. Edited and unedited forms of 
GluK2 were overexpressed in HEK293T cells for 24 h and then subjected to 
cycloheximide (CHX) treatment, which blocks translation (Schneider-Poetsch, 
Ju et al. 2010). Cycloheximide was added for 0, 4 or 8 h to measure the GluK2 
stability.  
In contrast to published findings, my results show the total protein levels of 
unedited GluK2 (Q) were decreased significantly by 8 h of CHX addition 
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suggesting decreased stability. In contrast, the edited form of GluK2 (R) was 
stable even after 8 h of CHX addition [Figure 4-15].  
 
Figure 4-15: Unedited GluK2 (Q) showed less stability than edited GluK2 (R). 
HEK293T cells transfected with either edited or unedited forms of GluK2. 24h after 
transfection to overexpress GluK2, cells were treated with translation blocker 
cycloheximide (CHX) for 0h (same volume of DMSO as CHX for 8h), 4h and 8h and 
then lysed to determine total GluK2 levels by western blotting. 
A. Representative western blot images of the total GluK2 and actin levels after 
0, 4 and 8 h CHX treatment. 0 h CHX treated cells were treated with same 
volume DMSO for 8 h.   
B. Quantification of edited or unedited GluK2 as shown in A. Each GluK2 
constructs were normalised to their respective 0h control. N=5 independent 
passages; One way ANOVA with Tukey’s multiple post comparisons 
correction; **p<0.01; error bars=S.D. 
4.4 Discussion 
4.4.1 ADAR2 levels are not regulated bi-directionally 
during chronic suppression and enhancement of 
synaptic activity 
Reports in the literature have indicated that ADAR2 levels are susceptible to 
both acute and chronic changes in synaptic activity (Sanjana, Levanon et al. 
2012, Balik, Penn et al. 2013). Here I show that ADAR2, but not ADAR1, 
protein levels decrease following chronic suppression of synaptic activity with 
24 h TTX treatment [Figure 4-1]. Subcellular fractionation and imaging data 
confirmed the nuclear localisation of these proteins [Figure 4-4 and Figure 
4-5]. Following 24 h TTX treatment along with the intensity, the percentage of 
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cells expressing ADAR2 also decreased. Moreover, longer durations of TTX 
treatment (up to 48 h) did not further decrease ADAR2 levels. 
Surprisingly, chronic enhancement of network activity with 48 h bicuculline 
treatment did not increase ADAR2 or ADAR1 protein levels [Figure 4-2]. While 
ADAR1 has been shown to be unresponsive to changes in the synaptic 
activity, ADAR2 levels have been reported to be susceptible to both up-scaling 
and down-scaling of network activity (Sanjana, Levanon et al. 2012, Balik, 
Penn et al. 2013). While further analysis will be required, we speculate that 
these different findings could be due to the use of different experimental 
systems and outcome measures. In particular, both studies monitored 
alterations in ADAR2 transcripts levels rather than the protein levels, as I have 
done here. RNA transcripts are not necessarily a true indication of the total 
protein levels. Furthermore, the genome-wide studies were performed in 
cerebral cortical cultures (Sanjana, Levanon et al. 2012) whereas my studies 
were performed in hippocampal neurones. It may be that hippocampal 
neurones respond differently to cortical cultures. Consistent with this another 
study reporting changes in response to bicuculline treatment were region 
specific favouring CA1 to CA3 (Balik, Penn et al. 2013). My studies were 
performed on dispersed cultures which are generally thought to have a more 
CA1 phenotype however mixture of various hippocampal subtypes in 
dispersed cultures could mask subtle changes.  
Nonetheless, I did observe increase in GluK2 editing following bicuculline 
treatment [see section 3.3.7]. Perhaps either ADAR2 (or even ADAR1) could 
have had increased editing ability. This could be due to changes in their activity 
domains (deaminase domain) or changes in their ability to bind their substrates 
either due to lesser substrate sequestration or changes in enzyme subcellular 
localisation. While interesting, this was not pursued any further. 
Perhaps most interestingly, my observation that ADAR2 levels are altered in 
up-scaling but not in down-scaling shows that opposing changes in network 
activity are likely governed by distinct underlying mechanisms. Thus, my 
results suggest that ADAR2 levels are not bi-directionally regulated during 
chronic suppression and enhancement of network activity.  
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4.4.2 Differential sensitivity of GluK2 and GluA2 to 
alterations in ADAR2 levels 
Following 24 h TTX treatment, I observed robust up-scaling of both KARs 
(GluK2) and AMPARs (GluA2). Moreover, I detected a significant decrease in 
GluK2 Q/R editing, most likely due to the loss of ADAR2 levels. However, no 
such editing changes were observed in GluA2 AMPARs following TTX 
treatment. This suggested a specific role of Q/R editing in GluK2 up-scaling.  
To study this further, I created two different knockdown tools for ADAR2, one 
that completely removed endogenous ADAR2 ‘Complete ADAR2 KD’ and 
another that partially removed endogenous ADAR2 ‘Partial ADAR2 KD’ 
[Figure 4-6]. This allowed me to study the comparative effects of varying levels 
of ADAR2 in both GluK2 and GluA2 and determine if ADAR2 can selectively 
alter GluK2 editing. 
Complete loss of ADAR2 decreased GluA2 editing by ~30% and GluK2 
editing by >60%, whereas partial ADAR2 loss decreased editing of GluK2 by 
~20% but had no discernible impact on the editing of AMPAR subunit GluA2 
[Figure 4-7 and Figure 4-8].  Furthermore, editing deficiencies for both 
GluK2 and GluA2 is rescued upon expression of shRNA insensitive WT 
ADAR2 rescue, showing specificity of ADAR2 role in Q/R editing for both 
GluK2 and GluA2 [Figure 4-10].   
These findings suggest that GluA2 is preferentially and almost completely 
edited at Q/R site, even when only low levels of ADAR2 are available. GluK2 
mRNA, on the other hand, is more sensitive to fluctuations in ADAR2 levels. It 
has been reported that GluA2 Q/R editing is robustly regulated by maintaining 
less efficient splicing of unedited GluA2 mRNA transcripts (Penn, Balik et al. 
2013). Thus, it seems that GluA2 editing is protected and maintained at ‘all 
costs’ since failure to edit GluA2 is lethal. This is exemplified by the 
observation that expression of edited GluA2 in ADAR2 KO mice rescues their 
lethality (Higuchi, Maas et al. 2000). This infers that control of GluA2 is less 
nuanced than the regulation of GluK2 by changes in ADAR2 levels.  
Interestingly, the ADAR2 KO mice had a build-up of unedited GluA2 pre-
mRNA transcripts resulting in the reduction of total GluA2 protein levels 
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(Higuchi, Maas et al. 2000). In line with this, following even partial loss of 
ADAR2 there is a decrease in total GluA2 levels [Figure 4-11]. This is probably 
due to the accumulation of immature unedited transcripts that are not spliced 
efficiently. Hence there is a lack of detectable unedited GluA2 population with 
‘Partial’ ADAR2 KD. The loss of total GluA2 is further amplified with total loss 
of ADAR2. Thus, rather than express excess amounts of unedited GluA2 
neurons compensate by reducing total levels of GluA2. I also speculate that 
the lack of further loss of ADAR2 with longer times of TTX treatment is a 
mechanism to ensure that sufficient numbers of edited GluA2 are maintained 
to constrain AMPAR Ca2+ permeability and ensure cell survival [Figure 4-3]. 
Interestingly, with the complete loss of ADAR2, there is 30% increase in the 
unedited mature GluA2 transcripts. This suggests that while coupling editing 
with splicing acts as a ‘safeguard’ mechanism to ensure editing levels of GluA2 
are maintained, some of the unedited transcripts can still be spliced to form 
mature transcripts.  
In contrast, partial loss of ADAR2 did not decrease GluK2 levels which 
suggests that the neurones have higher tolerance to unedited GluK2 
compared to GluA2. The fact that only 85% GluK2 population are edited in 
adults compared to 99.9% in GluA2 further supports the higher tolerance of 
neurones to unedited GluK2 (Paschen and Djuricic 1995, Bernard, Ferhat et 
al. 1999). However, there was a significant loss of total GluK2 protein levels 
following complete loss of ADAR2. This begs the question if the unedited 
GluK2 can also undergo similar safeguard mechanism to that of GluA2 at 
higher levels. While GluK2 transcript and total levels were not mentioned in 
the ADAR2 KO mice, the GluK2 editing deficient mice did not show such 
phenotype. Therefore, it is not known the mechanism behind the loss of GluK2 
total levels following decrease in its editing.  
Taken together, my studies show that Q/R editing of GluK2 is more flexible 
and responsive to changes in ADAR2 levels compared to GluA2. This explains 
how GluK2 editing, but not GluA2, changes following ADAR2 loss after TTX 
treatment. In summary, I interpret these data to indicate that the Q/R editing 
of KARs is more dynamically and activity-dependently regulated than 
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AMPARs, and reason that this provides a rapidly tunable system to control 
KAR forward trafficking and scaling.  
4.4.3 Selective ADAR2 mediated Q/R editing of GluK2 
containing KARs regulates their up-scaling 
One of the main aims of my project was to determine if ADAR2 loss mediated 
decrease in Q/R editing plays a role in GluK2 up-scaling. Partial ADAR2 KD 
mimicked the decrease in ADAR2 levels observed after TTX induced scaling 
and importantly did not alter GluA2 editing. Moreover, this knockdown tool did 
not alter total GluK2 levels compared to complete knockdown of ADAR2. I 
therefore used this tool to further study the role of ADAR2 mediated changes 
in GluK2 editing in inducing GluK2 up-scaling in response to TTX treatment.  
Here I show that the partial loss of ADAR2 is sufficient to induce an increase 
in GluK2 surface expression mimicking the surface levels achieved post 24h 
TTX treatment [Figure 4-12]. Further addition of 24 h TTX in partial ADAR2 
knockdown treated neurones however, did not increase the surface 
expression any further. Interestingly in Partial ADAR2 knockdown neurons, 
TTX treatment did elicit a further decrease in ADAR2 levels, indicating that 
even when already depleted, ADAR2 levels are still subject to activity-
dependent regulation [Figure 4-13]. However, despite the summative 
decrease in ADAR2 levels, GluK2 editing status did not decrease any further 
[Figure 4-14], which perhaps explains the occlusive effect of ‘Partial’ ADAR2 
loss on TTX treatment and strongly suggests that reduced KAR editing 
underpins KAR up-scaling. EGFR used a negative control in this instance was 
not significantly affected in their surface expression with the ‘Partial’ 
knockdown or TTX treatment.  
Hence, I conclude that the ‘Partial’ loss of ADAR2 phenocopies and occludes 
GluK2 scaling. Taken together, my data is consistent with the activity-
dependent loss of ADAR2 leading to the alterations in KAR editing which, in 
turn, directly mediates KAR up-scaling as unedited GluK2(Q) has been shown 
to increase KAR assembly and ER exit compared to edited GluK2(R) (Ball, 
Atlason et al. 2010, Evans, Gurung et al. 2017).   
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4.4.4 Potential role of Q/R editing in GluK2 stability 
A particularly interesting observation was the loss of GluK2 following complete 
loss of ADAR2. To investigate the mechanisms involved I tested if unedited 
GluK2 is less stable than edited GluK2. Following 8 h cycloheximide treatment, 
the unedited GluK2 transfected in HEK293T cells for 24h were degraded at a 
significantly higher rate compared to the edited GluK2, consistent with 
increased rapid turnover of unedited GluK2 [Figure 4-15]. As more unedited 
GluK2 would exit the ER and express on the surface, there is likely a higher 
turnover and degradation from the surface. However, this contrasts with a 
previous report suggesting that the edited GluK2 are more likely to be 
degraded rapidly than unedited GluK2 due to their ER build up and lack of 
ability to form homomers (Ball, Atlason et al. 2010). Further work will be 
required to resolve this apparent discrepancy. As both these studies are 
performed in isolation (overexpressed in HEK293T cells, which do not express 
any KARs), the kinetics may be different in presence of other KAR subunits.  
Therefore, my preliminary work here suggests that the Q/R editing may play a 
role in GluK2 containing KARs stability. 
4.5 Conclusion 
In summary of this chapter, I have shown ADAR2 levels are regulated during 
chronic suppression of network activity leading to a selective decrease in 
GluK2 Q/R editing but not that of GluA2 editing. This allows more unedited 
GluK2 to be formed which assembles into tetramers and exits the ER more 
efficiently leading to an increase in their surface expression and hence GluK2 
containing KARs up-scaling. However, similar mechanism does not seem to 
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For the final part of my PhD I wanted to determine the possible mechanisms 
behind ADAR2 loss during 24 h TTX mediated suppression of synaptic activity. 
The changes in ADAR2 levels could be due to alterations in mRNA 
transcription, translation or protein degradation. While not much is known 
about ADAR2 regulation, here I have summarised the factors that are thought 
to regulate ADAR2 levels and function.   
5.1.1 Transcription 
As discussed in section 4.1, ADAR2 transcript levels are susceptible to 
changes in both the acute and chronic changes in synaptic activity.   
5.1.1.1 CREB 
One of the potential regulators of ADAR2 transcription is cAMP-response -
element-binding protein (CREB). It was reported that during transient ischemic 
insults, ADAR2 gene expression can be regulated in a CREB dependent 
manner, where ADAR2 transcription and gene expression was positively 
regulated by constitutively active CREB expression (Peng, Zhong et al. 2006). 
Complementing this, ADAR2 promoter region consists of CREB binding site 
that regulates ADAR2 expression in pancreatic cells in response to glucose 
uptake via JNK-1 kinase pathway (Yang, Huang et al. 2012). It has also been 
suggested that Ca2+ signalling through L-type voltage-gated Ca2+ channels can 
regulate activity-dependent ADAR2 expression (Wheeler, Barrett et al. 2008). 
Interestingly, this signalling can also activate nuclear CREB pathway which 
could be mediating alterations in ADAR2 levels (Balik, Penn et al. 2013).  
5.1.1.2 Epigenetic Regulation 
Studies in neuronal SH-SY5Y cells suggested ADAR2 mRNA expression can 
be differentially regulated by epigenetic modifying enzymes DNA 
methyltransferase (DNMT) and histone deacetylase (HDAC). Inhibiting either 
of these epigenetic modifying enzymes elicited an increase in ADAR2 mRNA 
expression. Furthermore, blocking transcription using actinomycin D, 
prevented the mRNA increase in ADAR2, suggesting these epigenetic 
modifying enzymes regulate ADAR2 expression by regulating ADAR2 
transcription (Uchida and Ito 2015). 
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ADAR2 is an interesting protein as it can self-regulate its own expression 
levels by editing itself. ADAR2 self-edits its own pre-mRNA leading to 
alternative splicing at various sites. This can generate several ADAR2 
alternatively spliced variants, though functional consequences for all the 
identified forms of auto-edited transcript variants are not known (Li, Tian et al. 
2015, Fu, Zhao et al. 2016) [see section 1.4.3].  
One such editing event occurs between the exons 1 and 2 of ADAR2 which 
results in the addition of 47 nucleotides (nt) at the 5’ end of exon 2 during 
subsequent splicing [Figure 5-1]. The resultant alternatively spliced ADAR2 
variant codes for a premature stop codon giving rise to truncated 9kDa ADAR2 
protein which lacks both the dsRNA binding domain and the deaminase 
domain and is hence non-functional (Rueter, Dawson et al. 1999). The auto-
editing at this site has been shown to increase during development in both rat 
and mouse brains and in cortical cultured neurones (Hang, Tohda et al. 2008, 
Wahlstedt, Daniel et al. 2009, Behm, Wahlstedt et al. 2017). Moreover, 
transgenic mice lacking this autoregulation were shown to have increased 
ADAR2 protein expression at several tissues and had subsequent increase in 
the editing of various ADAR2 substrates such as the R/G editing of GluA2 
(Feng, Sansam et al. 2006).  
Moreover, auto-editing of ADAR2 at this site has also been shown to be altered 
during various cellular insults. Thiamine (vitamin B1) deficiency (TD) in cortical 
cultured neurones and brain tissue resulted in decreased ADAR2 auto-editing 
(Lee, Yang et al. 2010). This was regulated by stress-activated protein kinase 
c-Jun N-terminal kinases (JNK1) and inhibiting this pathway resulted in 
decreased ADAR2 auto-editing (Yang, Huang et al. 2012). On the other hand, 
elevated self-editing was observed following glucose stimulation in INS-1 β-
cells (Gan, Zhao et al. 2006). Furthermore, less ADAR2 self-editing after 48 h 
activity-deprivation with TTX has also been shown and the opposite was 
observed with enhanced network activity (Balik, Penn et al. 2013), however 
functional consequences of these changes in auto-editing are not known. 
Hence, ADAR2 auto-editing at this site can act as a potential mechanism to 
regulate ADAR2 levels and function during neuronal activity. 
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Figure 5-1: ADAR2 can edit its own pre-mRNA.  
This generates a new 3’ splice site extending the second coding exon by 47 
nucleotides (nt). This then results in a frameshift coding for a premature stop codon. 
This self-editing process can be tested by designing forward and reverse primers 
spanning the adjacent exons to intron 2 and performing PCR amplification of the 
region of interest (ROI). The resultant PCR products produces two bands when 
separated by agarose gel electrophoresis. 
5.1.3 Subcellular Localisation 
The subcellular localisation of ADAR2 can also regulate ADAR2 function and 
activity. ADAR2 import into the nucleus is regulated by the family of alpha 
importins; karyopherin subunit alpha 1 (KPNA1) and 3 (KPNA 3) (Maas and 
Gommans 2009). Moreover, it was shown that importin alpha-4 (KPNA3) 
levels increase during neuronal maturation in cultured cortical neurones and 
increasingly associate with ADAR2, enhancing their import into the nucleus 
thus contributing to the editing efficiency of ADAR2 (Behm, Wahlstedt et al. 
2017). 
Interestingly, ADAR2 activity can be regulated in the nucleus via functional 
sequestration of ADARs in the nucleolus. While the editing is thought to occur 
mostly in the nucleoplasm where ADAR2 can be present, ADAR2 are 
predominantly concentrated in the nucleolus (Desterro, Keegan et al. 2003, 
Sansam, Wells et al. 2003). It has been suggested that ADAR2 can shuttle in 
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and out of nucleolus to the nucleoplasm, which is regulated by substrate 
availability and specificity. This functional sequestration by the nucleolus 
potentially occurs through binding of abundant dsRNA structures associated 
with small nucleolar RNAs. Moreover, inhibiting ribosomal RNAs increased 
translocation of ADAR2 to nucleoplasm and resulted in increased substrate 
editing (Desterro, Keegan et al. 2003). However, a separate study showed that 
ADAR2 can be functionally active in the nucleolus as well and that specific 
nucleolar specific mechanisms exists to limit ADAR2 activity there (Sansam, 
Wells et al. 2003). Taken together, nucleolar sequestration adds another level 
of cellular mechanism to prevent accidental editing activity in nucleoplasm for 
ADAR2.   
5.1.4 Pin1 mediated ADAR2 phosphorylation 
Peptidyl-prolyl isomerase NIMA interacting protein 1 (Pin1) is a 
phosphorylation dependent peptidyl-prolyl cis/trans isomerase. The WW 
domain, 38 to 40 amino acid (aa) residues in a triple-stranded β-sheets (Lu, 
Hanes et al. 1996), present in Pin1 mediates protein-protein interactions by 
binding to a phosphorylated serine (S) or threonine (T) preceding a proline 
residue in the target substrates. They catalyse the cis/trans isomerisation of 
the substrate’s peptide bond altering substrate stability, subcellular localisation 
and/or catalytic activity (Lu, Zhou et al. 1999, Lu and Zhou 2007).    
ADAR2 was shown to be post-translationally regulated by Pin1. This binding 
occurs via phosphorylation of the threonine 32 (T32) residue on the N-terminus 
of ADAR2. Pin1 binding to ADAR2 regulates ADAR2 nuclear localisation, 
stability and hence editing activity (Marcucci, Brindle et al. 2011) [Figure 5-2]. 
Further to this, another study in mouse cortical cultured neurones also showed 
the Pin1 and ADAR2 interaction to be important during development. More 
specifically, this interaction was important in maintaining ADAR2 stability after 
its import into the nucleus (Behm, Wahlstedt et al. 2017). This allowed 
increased editing of ADAR2 substrates during neuronal maturation.  
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Figure 5-2: Pin1 and WWP2 mediated regulation of ADAR2.  
Cartoon diagram of potential Pin1 mediated regulation of ADAR2, altering the stability 
and activity of ADAR2 within the nucleus. This interaction is phosphorylation mediated 
where phosphorylated ADAR2 dimerises and binds to the dsRNA. Pin1 binds at the 
phosphorylated site at Threonine 32 (T32) and stabilises ADAR2 in the nucleus. Upon 
lack of this phosphorylation mediated interaction, ADAR2 is exported out of nucleus 
into the cytoplasm, where it is targeted for ubiquitination by WWP2 and hence 
proteasomal degradation.  
 
5.1.5 WWP2 mediated ADAR2 degradation 
WWP2; a HECT (homologous to the E6-AP C terminus) is an E3 ubiquitin 
ligase (Pirozzi, McConnell et al. 1997) and was shown to bind and negatively 
regulate ADAR2 levels and activity. It binds to ADAR2 via a conserved PPxY 
motif in both amino- and carboxyl terminus of ADAR2 resulting in ADAR2 poly-
ubiquitination. This targets them for proteasomal degradation in the cytosol, 
hence acting as another post-translational regulator of ADAR2 (Marcucci, 
Brindle et al. 2011) [Figure 5-2]. However, physiological relevance of this 
interaction is not known yet.  
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5.1.6 Other ADAR2 regulators 
5.1.6.1 AIMP2 
Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 
(AIMP2) was recently identified as a negative regulator of A-to-I editing. AIMP2 
is a scaffolding component of the aminoacyl t-RNA synthetase complex 
required for the complex assembly and stability (Kim, Kang et al. 2002). AIMP2 
interacted with both ADAR1 and ADAR2 and overexpression of AIMP2 protein 
decreased both ADAR1 and ADAR2 protein levels without affecting their 
transcript levels (Desterro, Keegan et al. 2003). This indicated a non-
translational role of AIMP2 in ADAR regulation. Interestingly, AIMP2 has been 
shown to have a non-canonical function in regulating protein stability by 
mediating ubiquitination of target proteins for degradation (Kim, Park et al. 
2003). Thus, AIMP2 could potentially be playing a role in post-translational 
modification of ADAR2 via ubiquitination targeted degradation of ADAR2.  
5.1.6.2 FMRP 
Fragile-X-Mental Retardation Protein (FMRP) is an RNA binding protein which 
can regulate RNA metabolism by altering mRNA translation (Napoli, Mercaldo 
et al. 2008). However, evidence is accumulating to suggest that FMRP can 
further regulate post-transcriptional modifications by interacting with ADAR 
proteins. Studies in drosophila initially showed dFMRP1 can interact with 
dADAR in the nucleus and alter their editing ability on several common RNA 
targets (Bhogal, Jepson et al. 2011). Following this, studies in zebrafish 
(Shamay-Ramot, Khermesh et al. 2015) and fmr1 KO mice (Filippini, Bonini et 
al. 2017) have shown an interplay between FMRP and ADAR2 enzymes, 
implying FMRP’s negative role in ADAR2 editing function. It is thought that 
ADAR2 and FMRP can also potentially interact in an RNA independent 
manner and can co-localise in the nucleus (Filippini, Bonini et al. 2017). 
However, it is not fully understood how FMRP can regulate ADAR2 function.  
5.1.6.3 ADAR3 
Unlike other ADARs, ADAR3 is expressed exclusively in the brain (Melcher, 
Maas et al. 1996) but it has not been shown to have any catalytic activity 
(Chen, Cho et al. 2000). Nonetheless, it consists of both single and double-
Chapter 5  Studying Mechanisms regulating 
ADAR2 level and function during scaling 
182 
 
stranded RNA binding domains so ADAR3 can bind to other ADAR family 
targets and potentially sequester them, thereby altering the availability of 
substrates and playing a regulatory role in ADAR2 function. Consistent with 
this, ADAR3 was shown to inhibit activities of ADAR2 in vitro (Chen, Cho et al. 
2000). A recent study also reported ADAR3 as an important regulator of GluA2 
Q/R editing in glioblastoma tumours by directly competing with ADAR2 for 
substrate binding (Oakes, Anderson et al. 2017). However, a recent study in 
ADAR3 deficient mice showed no considerable differences in editing of target 
substrates of ADAR1 or ADAR2 (including the R/G and Q/R site of GluA2), 
suggesting lack of significant inhibitory function of ADAR3 on other functional 
ADARs in vivo (Mladenova, Barry et al. 2018). Hence, the role of ADAR3 in 
the brain is a mystery.   
5.1.6.4 SRSF9 
Serine and Arginine Rich Splicing Factor 9 (SRSF9), which belongs to family 
of pre-mRNA splicing factors rich in serine/arginine, has also been shown to 
repress ADAR2 editing activity (Tariq, Garncarz et al. 2013, Shanmugam, 
Zhang et al. 2018). In particular, SRSF9 has been shown to interact with 
ADAR2 in the nucleus in the presence of RNA substrate and interfere with 
ADAR2 editing function by disrupting ADAR2 dimerisation. Moreover, this 
inhibition of ADAR2 function was highly enriched in the brain specific sites 
(Shanmugam, Zhang et al. 2018).  
5.1.7 Objectives 
The results in Chapter 4 showed that ADAR2 levels are modulated by changes 
in synaptic activity. In this chapter I investigated how loss of ADAR2 levels and 
hence its function is mediated during chronic suppression of network activity 
following 24h TTX treatment. My main objectives were to address the following 
questions: 
1. Is the loss mediated via changes in ADAR2 mRNA transcription? 
2. Are there alterations in ADAR2 auto-editing? 
3. Is Pin1 mediated ADAR2 stabilisation altered during activity? 
4. Is ADAR2 targeted for increased degradation following TTX 
treatment? 
Chapter 5  Studying Mechanisms regulating 
ADAR2 level and function during scaling 
183 
 
5.2 Materials and Methods 
5.2.1 RT-qPCR 
For RT-qPCR, 2µl of the cDNA samples per condition were mixed with 
PowerUp SYBR green Master Mix ((Life Technologies) containing Dual-
Lock™ Taq DNA Polymerase) and forward and reverse primers targeting 
ADAR2 and GAPDH: 
1. PowerUp SYBR green Master Mix: 10µl (Final concentration:1x) 
2. Forward + Reverse Primer: 1µl (Final concentration: 0.25 µM each) 
3. Sample: 2µl 
4. ddH2O: 7µl  
The primers used were:  
ADAR2 Forward: 5’- TCCCGCCTGTGTAAGCAC-3’ 
ADAR2 Reverse: 5’- TGGGCTTGGTGATCTTGG-3’ 
GAPDH Forward: 5’- CAAGGTCATCCATGACAACTTTG -3’ 
GAPDH Reverse: 5’- GTCCACCACCCTGTTGCTGTAG -3’ 
The mixture was then amplified quantitatively using Real Time PCR System 
(MiniOpticon, BioRAD) for 40 cycles using following conditions:  
1. 95oC for 3 minutes to activate the Hot Start Polymerase.  
2. 95oC for 20 seconds to break the double strands. 
3. 60oC for 30 seconds to anneal the primers.  
4. 72oC for 30 seconds for extension. 
5. Repeat steps 3-4, 39 times. 
6. 95oC for 10 seconds for final extension. 
7. 65oC for 5 seconds + 0.5oC every 5 seconds up to 95oC for melt curve. 
Ct values were recorded for each reaction. Each reaction was performed in 
triplicate and average Ct was measured per condition. The values were 
exported to Microsoft Excel. ADAR2 Ct values were normalised to GAPDH Ct 
values and ADAR2 mRNA fold difference value of TTX treated conditions was 
normalised against the untreated control. Melting curve of the primers were 
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also determined to ensure the specificity of primers used and lack of primer 
dimer formation. No Reverse Transcriptase control and water only control was 
also run, and Ct values were compared to ensure there was no genomic DNA 
contamination. 
5.2.2 Auto-editing Assay 
For the auto-editing assay, primers were designed using the exonic regions 
flanking the editing site in ADAR2 as shown in Figure 5-1. Following primers 
were used: 
Forward primer: 5’-GCCAGTCAAGAAGCCCTCAAAAG-3’ 
Reverse primer: 5’-TGTCCAGATTGCGGTTTTCTTTAAC-3’ 
The resultant PCR products were run on a 4% agarose gel to separate the two 
PCR products formed of 150nt (edited to include extra 47nt) and 103nt 
(unedited). GAPDH was also amplified using PCR and run on a 1.5% agarose 
gel to produce 496bp PCR product using following primers: 
Forward: 5’-CAAGGTCATCCATGACAACTTTG-3’ 
Reverse: 5’-GTCCACCACCCTGTTGCTGTAG-3’ 
The agarose gel was visualised under UV transilluminator.  
The bands were quantified by measuring densitometry using the Gel Analysis 
Tool in FIJI ImageJ (NIH). The relative pixel intensity was calculated as the 
area under each peak. The values obtained were transferred in Microsoft 
Excel. Both edited and unedited bands were quantified separately and 
normalised to the GAPDH values.  
ADAR2 self-editing percentage calculation: 
Total ADAR2= (edited+unedited) / GAPDH 
ADAR2 self-editing percentage= (Edited/Total ADAD2) * 100 
Statistical significance was then measured. 
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5.2.3 HEK293T transfection and GFP Trap 
HEK293T cells were plated at a density of 1x106 per 10cm dish, and 
transfected the next day using LipofectamineTM3000 and the optimised 
amount (in µg) of each construct to ensure even expression.  
All subsequent steps were performed at 4oC on ice using ice-cold buffers. 48h 
post-transfection, cells were washed with 1x PBS once. 500µl of lysis buffer 
was added to each dish, scraped and harvested in lysis buffer (20mM Tris pH 
7.4, 137mM NaCl, 2mM sodium pyrophosphate, 2mM EDTA, 1% triton X-100, 
0.1% SDS, 25mM β-glycerolphosphate, 10% glycerol, protease inhibitors 
(Roche), phosphatase inhibitor cocktail 2 (1:100, Sigma)). The lysates were 
left to incubate for 30 mins on ice and centrifuged at 16100g for 20 minutes at 
4oC to remove any cell debris. The supernatant was transferred into a fresh 
1.5ml tube. 
Meanwhile, 5µl of GFP-trap beads per condition was added to separate 1.5ml 
tubes. The beads were washed twice with 500µl wash buffer (lysis buffer 
without protease or phosphatase inhibitors) at rt (1500g spin for 2 mins and 
aspirate the supernatant) (Chromotek). 480µl of the supernatant was then 
added to the washed beads, incubated on wheel at 4oC for 90 mins. The 
remaining 20µl of the lysate was mixed with 20µl of 2x Laemmli sample buffer 
(Input samples). After incubation, the beads were washed 3x with wash buffer. 
After the last wash, the supernatant was fully aspirated, and the samples were 
then lysed in 2x Laemmli sample buffer and then heated at 95oC for 10 mins 
on a rotating heat block (along with the input samples). Samples were then 
analysed using SDS-PAGE and western blot. 
5.2.4 Bortezomib (BTZ) treatment 
For proteasomal degradation assay, bortezomib (BTZ) (Cell Signalling, stock 
in DMSO at 1mM, stored at -20oC) was thawed at rt and was added to the 
hippocampal neurones to get final concentration of 1µM for 20h. The control 
cells were treated with equal volume of DMSO for the same length of time. 
The cells were then either lysed straight into 1x Laemmli sample buffer or 
surface biotinylation was performed.  
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5.3.1 ADAR2 transcription is not altered following 24 h 
TTX treatment 
I first wanted to determine if changes in ADAR2 levels following 24 h TTX 
treatment were due to changes in the transcription of ADAR2 mRNA. I 
measured ADAR2 mRNA levels by RT-qPCR and did not see any changes in 
the overall mature mRNA transcripts post 24 h TTX treatment [Figure 5-3]. 
Hence, in my cultures, ADAR2 transcription is not altered following 
suppression of synaptic activity. This was surprising as previous studies had 
shown altered transcript levels following chronic TTX treatment (Sanjana, 
Levanon et al. 2012, Balik, Penn et al. 2013). I speculate the differences in 
observations could be due to use of different systems where the genome wide 
study was performed in cerebral cortical cultures (Sanjana, Levanon et al. 
2012) and the second study was performed specifically on the CA1 
hippocampal region (Balik, Penn et al. 2013). Nevertheless, my data suggests 
that ADAR2 loss during TTX treatment is not due to decrease in ADAR2 
mRNA transcription.  
 
Figure 5-3: ADAR2 transcription is not 
affected following TTX treatment.  
The fold change in mRNA levels of 
ADAR2 after 24h TTX treatment 
compared to their respective control 
treated samples. ΔΔCT method of 
analysis was used to measure the fold 
change in ADAR2 levels. RT-qPCR 
was used to measure the ADAR2 
expression and the reads were 
normalised to the GAPDH reads. N=7 
independent dissections; Unpaired t-test; ns p>0.05, error bar=S.D. 
 
5.3.2 ADAR2 self-editing is altered following 24 h TTX 
treatment 
ADAR2 can undergo self-editing process, which acts as a negative feedback 
mechanism to control ADAR2 expression and activity [See section 5.1.2].  
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I therefore wanted to determine if ADAR2 self -editing was altered after 24 h 
TTX treatment. There was a small but significant decrease in the self-editing 
of ADAR2 [Figure 5-4 A and B] with no change in ADAR2 total mRNA levels 
[Figure 5-4 A and C]. This suggests an increased pool of functional ADAR2 is 
being translated. While surprising, this may act as a mechanism to counteract 
the loss of ADAR2 following activity deprivation to prevent the complete loss 
of ADAR2 levels and function.  
 
Figure 5-4: ADAR2 auto-editing decreases following 24 h TTX treatment. Post mRNA 
extraction and cDNA synthesis, the exonic and intronic regions consisting of this 47nt 
insertion site was amplified and separated on a 4% agarose gel and visualised under 
UV light.   
A. Representative agarose gel image of RT-PCR analysis of alternatively spliced 
ADAR2 mRNA with or without 47nt insertion as indicated post 24 h TTX 
treatment.  
B. Quantification of edited to unedited ratio of ADAR2 mRNA post 24 h TTX 
treatment as shown in A. N=10 independent dissections; Unpaired t-test; 
*p<0.05, error bar=S.D. 
C. Quantification of total ADAR2 mRNA levels (edited ADAR2 + unedited 
ADAR2) and normalised to GAPDH shown in A. N=10 independent 
dissections, Unpaired t-test; ns p>0.05, error bar=S.D.  
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5.3.3 Loss of ADAR2 during scaling is not dependent on 
Pin1 interaction 
As neither transcription nor self-editing of ADAR2 contributed to ADAR2 loss, 
I next determined if post-translational modifications of ADAR2 were altered. I 
therefore tested if destabilisation of Pin1-ADAR2 interaction underpinned 
ADAR2 loss [See section 5.1.4].  
5.3.3.1 Pin1 levels are unchanged following 24 h TTX treatment 
I first studied total Pin1 levels following 24 h TTX treatment as Pin1 loss can 
alter ADAR2 editing activity (Marcucci, Brindle et al. 2011). However, Pin1 
levels were unchanged [Figure 5-5] showing that Pin1 is not reduced during 
synaptic upscaling.   
 
Figure 5-5: Pin levels do not decrease post 24 h TTX treatment.  
A. Representative western blot images of total levels of Pin1 and GAPDH levels 
post 24 h TTX treatment.  
B. Quantification of total Pin1 levels normalised to GAPDH post 24 h TTX 
treatment shown in A. N=9 independent dissections, Unpaired t-test; ns 
p>0.05, error bar=S.D. 
5.3.3.2 GFP-Trap Assays show increased interaction of T32D ADAR2 
with Pin1 
I next determined if ADAR2 interaction with Pin1 was decreased during TTX 
treatment. ADAR2 interaction with Pin1 is primarily mediated via 
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phosphorylation of threonine 32 (T32) site in ADAR2 preceding the proline (P) 
(Marcucci, Brindle et al. 2011).  
 
Figure 5-6: Phosphomimetic (T32D) ADAR2 interacts strongly with Pin1. GFP tagged 
Pin1 (rat construct) was co-transfected with HA tagged WT ADAR2, T32D ADAR2 or 
T32A ADAR2 (all rat constructs) in HEK293T cells and 48h post transfection GFP-
trap assays were performed and analysed using western blotting.  
A. Representative western blot images showing strong interaction of T32D 
ADAR2 to Pin-GFP compared to WT ADAR2 and T32A ADAR2. GFP only 
control was used to determine any non-specific interactions with the GFP.  
B. Quantification of HA-ADAR2 interactions with GFP-Pin1 as shown in A. The 
HA signal in the GFP trap lanes were normalised to their respective GFP 
signal. N=4 independent experiments, One way ANOVA with Tukey’s multiple 
post comparisons correction, ***p<0.001, ****p<0.0001, error bar=S.D. 
I created N-terminus HA tagged WildType (WT), phosphonull (T32A) and 
phosphomimetic (T32D) mutant forms of rat ADAR2, co-transfected each of 
them in HEK293T cells with a C-terminus GFP tagged Pin1 and performed 
GFP-traps to determine Pin1-ADAR2 interaction. As shown in Figure 5-6, 
phosphomimetic (T32D) version of ADAR2 has significantly stronger 
interaction with Pin1 compared to the phosphonull (T32A) or WT or GFP only 
control. Surprisingly, the WT ADAR2 did not show any interaction with Pin1. 
One possible explanation for this may be that phosphorylation at this site does 
not occur basally to allow ADAR2 binding to Pin1. Another possibility is that 
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these experiments were performed in HEK293T cells which may not have the 
required kinase(s), which are currently unknown, to phosphorylate this 
threonine site in the rat ADAR2. Nevertheless, when constitutively 
phosphorylated, ADAR2 showed a strong interaction with Pin1.  
5.3.3.3 WT, T32D and T32A ADAR2 are equally sensitive to the 24 h 
TTX treatment 
As phosphomimetic (T32D) ADAR2 showed stronger interaction with Pin1, I 
performed knockdown rescue experiments in cultured hippocampal neurones 
to determine if T32D ADAR2 is resistant to TTX mediated loss. For this, I used 
the knockdown rescue strategy I had already optimised [see section 4.3.8] to 
remove endogenous ADAR2 and replace with either WT, phosphonull or 
phosphomimetic ADAR2 (all HA tagged N-terminally and ‘complete’ shRNA 
insensitive) and subjected them to further 24 h TTX treatment. Similar to the 
section 4.3.8, the ‘complete’ knockdown and the shRNA insensitive ADAR2 
rescues were expressed using two separate viruses. Western blot analyses 
probing for both ADAR2 and HA showed all three WT, T32D and T32A ADAR2 
were significantly decreased by TTX treatment [Figure 5-7]. These data 
suggest that Pin1 interaction with ADAR2 does not play a role in loss of ADAR2 
during suppression of neuronal activity.  
I also performed confocal imaging analysis with the WT and phosphomutants 
(T32D and T32A) ADAR2. Consistent with the western blot analysis, fixed cell 
imaging analysis also showed significant loss of ADAR2 intensity and 
decrease in the percentage of cells expressing ADAR2 following 24 h TTX 
treatment [Figure 5-8]. The intensity was analysed using both ADAR2 and HA 
signal.  
Surprisingly, the nuclear localisation of ADAR2 was not altered with the 
phoshphonull (T32A) ADAR2. Pin1 is important for ADAR2 nuclear localisation 
(Marcucci, Brindle et al. 2011) which makes it surprising that in these 
experiments. ADAR2 nuclear localisation was not altered despite the loss of 
Pin1 interaction. One potential explanation is that this interaction is important 
for ADAR2 to be stabilised in the nucleus but not necessarily for it to be 
imported in the nucleus. The loss of ADAR2 interaction with Pin1 could lead it 
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to be translocated to the cytosol and degraded rapidly and hence is not 
observed. Taken together, my results suggest that Pin1 mediated ADAR2 
stabilisation does not play a role in activity mediated loss of ADAR2. 
 
Figure 5-7: WT, T32D and T32A forms of ADAR2 are all equally sensitive to 24 h TTX 
treatment. Endogenous ADAR2 in hippocampal neurones were replaced with either 
WT ADAR2 or T32D ADAR2 or T32A ADAR2 using lentiviral knockdown replacement 
strategy along with scrambled infected control. The cells were then treated with 24 h 
TTX and lysed and analysed with western blotting. Blue control, pink TTX. 
A. Representative western blot images of ADAR2 and GAPDH with or without 24 
h TTX treatment.  
B. Quantification of ADAR2 normalised to the GAPDH shown in A. Each TTX 
treated reads were normalised to their respected non-treated controls. N=6 
independent dissections, Unpaired t-test for each normalised condition, 
*p<0.05, **p<0.01, ****p<0.0001, error bar=S.D. 
C. Representative western blot images of HA (replaced ADAR2 were tagged with 
HA) and GAPDH with or without 24 h TTX treatment.  
D. Quantification of HA normalised to the GAPDH shown in C. Each TTX treated 
reads were normalised to their respected non-treated controls. N=6 
independent dissections, Unpaired t-test for each normalised condition, 
*p<0.05, ****p<0.0001, error bar=S.D. 
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Figure 5-8: Fixed immunolabelling show WT, T32D and T32A forms of ADAR2 are all 
equally sensitive to 24 h TTX treatment. Endogenous ADAR2 in hippocampal 
neurones were removed and replaced same as 5-7 and then treated with 24 h TTX, 
lysed after and analysed with confocal imaging.  
A. Representative images labelled with antibodies against GFP (Cy2-green), 
ADAR2 (Cy3-red) and HA (Cy5-cyan) and stained with DAPI (blue). White 
boxes in the top panel represent zoomed images below showing decreased 
ADAR2 intensity and red arrows show cells positive for ADAR2 expression. 
Scale bar=10µm.   
B. Quantification of nuclear intensity of ADAR2 per condition as shown in A. 
DAPI channel was used to draw regions of interest around the nucleus and 
average intensity was calculated. Each TTX treated reads were normalised to 
their respected non-treated controls. n=81-92 cells; N=3 independent 
dissections, Unpaired t-test for each normalised condition, *p<0.05, **p<0.01, 
****p<0.0001, error bar=S.D.  
C. Quantification of nuclear intensity of HA per condition as shown in A. DAPI 
channel was used to draw regions of interest around the nucleus and average 
intensity was calculated. Each TTX treated reads were normalised to their 
respected non-treated controls. N=81-92 cells, N=3 independent dissections, 
Unpaired t-test for each normalised condition, *p<0.05, **p<0.01, 
****p<0.0001, error bar=S.D.  
D. Quantification of percentage of cells expressing ADAR2 post 24 h TTX 
treatment per field of view as shown in A. n=14-16 fields of view, N=3 
independent dissections, Unpaired t-test; *p<0.05, **p<0.01, error bar=S.D. 
 
5.3.4 Comparing basal stability of phosphomutants 
ADAR2 to WT ADAR2 
While both ADAR2 phosphomutants were equally sensitive to the TTX 
treatment, I wanted to determine if phosphomimetic ADAR2 has increased 
basal stability. For this, I again removed endogenous ADAR2 and replaced 
with shRNA insensitive WT, T32A and T32D ADAR2 rescue constructs in 
cortical cultured neurones for 5 days and performed cycloheximide time-
course assays sampling at 0, 4 and 8 h. Cycloheximide (CHX) is a drug that 
blocks translation and allows analysis of protein stability/degradation 
(Schneider-Poetsch, Ju et al. 2010).  
Surprisingly, both phosphomimetic (T32D) and phosphonull (T32A) ADAR2 
showed decreased stability within 4 h of CHX treatment while WT ADAR2 
showed a decreasing trend at 4 h and was significantly decreased by 8 h 
[Figure 5-9]. This suggests that in contrary to previous findings (Marcucci, 
Brindle et al. 2011) the ADAR2 interaction with Pin1 does not play a role in 
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ADAR2 stability at basal levels. However, it should be noted that these 
experiments were performed in rat neuronal cultures whereas previous reports 
were based on work on human cell lines. Nevertheless, comparing within the 
rescued groups, phosphomimetic ADAR2 did not show increased stability 
compared to either WT or phosphonull ADAR2.  
 
Figure 5-9: All WT, T32A and T32D ADAR2 show comparable level of basal stability. 
Endogenous ADAR2 in cortical neurones were replaced with either WT ADAR2 or 
T32D ADAR2 or T32A ADAR2 same as 5-7. Post 6 days of knockdown and 
replacement translation blocker cycloheximide (CHX) were added to cells for 0 (same 
volume of DMSO as CHX for 8h), 4 and 8h, were lysed to determine total ADAR2 
levels by western blotting. 
A. Representative western blot images of the total WT, T32A and T32D HA-
ADAR2 and actin levels after 0, 4 and 8h CHX treatment. 0h CHX treated cells 
were treated with same volume DMSO for 8h.  
B. Quantification of conditions shown in A normalised to their respective 0h 
controls. N=5 independent dissections; error bars=S.D. 
C. Same quantifications as B but each ADAR2 mutants shown separately for 
clarity with the statistical analysis. N=5 independent dissections; One-way 
ANOVA with Dunnett’s multiple post comparisons correction; *p<0.05, 
**p<0.01, ***p<0.001; error bars=S.D.  
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5.3.5 All forms of ADAR2 rescue both GluA2 and GluK2 
editing equally 
Finally, I tested if the ADAR2 phosphomutants (T32A and T32D) had altered 
ability to edit two key substrates (GluK2 and GluA2) using the BbvI restriction 
enzyme assay. The ability of ADAR2 to edit was not altered by any of the 
ADAR2 mutants, equally rescuing both GluK2 and GluA2 editing [Figure 5-10] 
following complete loss of ADAR2. The chromatographs confirm these 
findings from the BbvI digestion assay [Figure 5-10 C and F].  
While these results contradict previous reports of Pin1 interaction loss leading 
to loss of ADAR2 editing ability (Marcucci, Brindle et al. 2011), it is entirely 
consistent with my findings showing that neither the phosphomimetic or 
phosphonull ADAR2 have altered localisation and can actively edit their 
substrates in the nucleus. 
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Figure 5-10: WT, T32A and T32D ADAR2 can rescue both GluK2 and GluA2 editing 
equally. Endogenous ADAR2 in hippocampal neurones were replaced with either WT 
ADAR2 or T32D ADAR2 or T32A ADAR2. Post 6 days of knockdown and 
replacement, RNA was extracted, and cDNA synthesised to perform PCR assays.  
A. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluK2 ratio after either 
scrambled or knockdown and knockdown rescues infection. 100% edited and 
unedited GluK2 constructs were used as a control to ensure BbvI cut activity 
and validity of the assay. 
B. Quantification of percentage of edited to unedited ratio of GluK2 population 
shown in A. n=5 independent dissections; One way ANOVA with Tukey’s 
multiple post comparisons corrections; ****p<0.0001; error bars=S.D. 
C. Representative chromatographs of PCR products comparing scrambled 
infected cells with the knockdowns infected cells at the Q/R editing site of 
GluK2. The undigested PCR products were sent for sequencing to determine 
changes in the dual peaks obtained at the site of editing as indicated by the 
green arrow. A peak (green) represents the unedited base while the G peak 
(black) represents the edited base.  
D. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluA2 ratio after either 
scrambled or knockdown and knockdown rescues infection. 100% edited and 
unedited GluA2 constructs were used as a control to ensure BbvI cut activity 
and validity of the assay. 
E. Quantification of percentage of edited to unedited ratio of GluA2 population 
shown in A. n=5 independent dissections; One way ANOVA with Tukey’s 
multiple post comparisons corrections; ****p<0.0001; error bars=S.D. 
F. Representative chromatographs of PCR products comparing scrambled 
infected cells with the knockdowns infected cells at the Q/R editing site of 
GluA2. The undigested PCR products were sent for sequencing to determine 
changes in the dual peaks obtained at the site of editing as indicated by the 
green arrow. A peak (green) represents the unedited base while the G peak 
(black) represents the edited base.  
 
5.3.6 TTX mediated scaling enhances proteasomal 
degradation of ADAR2 
ADAR2 has been shown to be targeted for ubiquitination mediated 
proteasomal degradation (Marcucci, Brindle et al. 2011). So, I next wanted to 
determine if this post-translational modification plays a role in ADAR2 loss 
during 24 h TTX treatment.  
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5.3.6.1 ADAR2 loss following TTX treatment can be rescued by 
inhibiting proteasomes 
I used Bortezomib (BTZ) a reversible inhibitor of 26S proteasome (Chen, 
Frezza et al. 2011) to block proteasomal activity. I tested the effects of 24h 
TTX up-scaling protocol on ADAR2 stability in the presence or absence BTZ. 
Accumulation of ubiquitinated products acted as a positive control to show that 
BTZ worked [Figure 5-11 A and C]. Consistent with the suppression of 
synaptic activity leading to enhanced proteasomal degradation (Ehlers 2003), 
incubation with BTZ prevented the TTX-evoked decrease in ADAR2 levels 
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Figure 5-11: ADAR2 loss following 24 h TTX treatment is rescued by inhibiting 
proteasomes following 20 h 1µM BTZ treatment.  
A. Representative western blot images of total levels of ADAR2, ubiquitin 
conjugates and GAPDH levels post 24h TTX treatment and 20h 1µM BTZ 
treatment.  
B. Quantification of total ADAR2 levels normalised to GAPDH shown in A. N=6 
independent dissections, Two-way ANOVA with Tukey’s multiple post 
comparisons correction; ns p>0.05, **p<0.01, ****p<0.0001, error bar=S.D. 
C. Quantification of total ubiquitin conjugates normalised to GAPDH shown in A. 
N=6 independent dissections, Two-way ANOVA with Tukey’s multiple post 
comparisons correction; ns p>0.05, ****p<0.0001, error bar=S.D. 
5.3.6.2 ADAR2 is rescued in both the nucleus and the cytosol 
I next performed nuclear and cytoplasmic fractionations to determine if ADAR2 
is exported from the nucleus for degradation in the cytosol. As expected, in the 
presence of BTZ the 24h TTX treatment caused ADAR2 to accumulate in the 
cytosol [Figure 5-12 A and C]. These data indicate that either ADAR2 is 
exported in the cytosol to be ubiquitinated or that it is ubiquitinated in the 
nucleus and exported to the cytosol to be degraded. Moreover, the TTX-
induced decrease in the levels of nuclear ADAR2 was prevented by BTZ 
[Figure 5-12 A and B], further suggesting that the TTX-induced loss of ADAR2 
is mediated by proteasomal degradation of ADAR2. 
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Figure 5-12: ADAR2 loss following 24 h TTX treatment is rescued in both nucleus and 
cytosol by inhibiting proteasomes following 20h 1µM BTZ treatment. Subcellular 
fractionation was performed to isolate cytosolic and nuclear compartments to 
determine ADAR2 localisation and levels.  
A. Representative western blot images of levels of ADAR2 in the cytosol and the 
nucleus. Lamin B was used as a nuclear specific marker while RhoGDI was 
used as cytosolic marker.   
B. Quantification of nuclear ADAR2 levels normalised to Lamin B shown in A. 
N=6 independent dissections, Two-way ANOVA with Tukey’s multiple post 
comparisons corrections; ns p>0.05, *p<0.05, **p<0.01; error bar=S.D. 
C. Quantification of cytosolic ADAR2 levels normalised to RhoGDI shown in A. 
N=6 independent dissections, Two-way ANOVA with Tukey’s multiple post 
comparisons corrections; ns p>0.05, *p<0.05, **p<0.01, ****p<0.0001; error 
bar=S.D. 
5.3.6.3 Preventing ADAR2 loss prevents GluK2 upscaling 
Based on these data I hypothesised that, in the presence of BTZ, ADAR2 
accumulates in the cytosol. Since it cannot degrade, it undergoes further 
rounds of nuclear import and export, which results in a functional pool of 
ADAR2 being maintained in the nucleus. I therefore tested if preventing 
ADAR2 degradation with BTZ is enough to prevent GluK2 up-scaling with 24h 
TTX treatment. Consistent with this hypothesis, surface biotinylation showed 
that blocking ADAR2 proteasomal degradation with BTZ prevents TTX-
induced GluK2 upscaling [Figure 5-13 A and B] with no change in the EGFR 
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surface levels [Figure 5-13 A and C]. 
 
Figure 5-13: Preventing loss of ADAR2 prevents GluK2 upscaling. Partial ADAR2 KD 
phenocopies and occludes GluK2 scaling. Following 24 h TTX treatment and 20 h 
1µM BTZ treatment, surface biotinylation was performed on DIV 15 hippocampal 
neurones to isolate surface proteins and determine surface/total ratio by western 
blotting.  
A. Representative western blot images of surface and total levels of GluK2, and 
EGFR. EGFR was used as a surface expressed non-glutamate receptor 
control that should not respond to stimulation. GAPDH was used as an internal 
control to determine no internal proteins were biotinylated.  
B-C.  Quantification of surface to total ratio of GluK2 (B) and EGFR (C) shown in A. 
N=5 independent dissections; Two-way ANOVA with Tukey’s multiple post 
comparisons corrections; ns p>0.05, *p<0.05; error bars=S.D.    
These results demonstrate that the availability of nuclear ADAR2 mediates 
upscaling of GluK2 containing KARs.    
5.3.7 Creating knockdown tools to study WWP2 
WWP2 is an E3 ubiquitin ligase and was previously shown to ubiquitinate 
ADAR2 (Marcucci, Brindle et al. 2011). I hypothesised if WWP2 mediated 
ubiquitination plays a role in ADAR2 ubiquitination during TTX treatment. I first 
generated shRNA knockdown tools to study WWP2 in rat cultures to validate 
antibodies against WWP2. I cloned rat WWP2 in HA (N-terminally tagged) 
pcDNA3 vector and co-expressed HA-WWP2 (rat) and shRNA mediated 
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WWP2 knockdown vectors (pSUPER) in HEK293T cells. I designed shRNA 
tools against two different sites within the rat WWP2 sequence. This would 
allow me to validate the knockdown tools against WWP2 and determine if the 
antibody can recognise rat WWP2. As seen in Figure 5-14 A, the antibody 
recognised the overexpressed rat WWP2 construct in HEK293T cells. 
Moreover, the WWP2 knockdown 1 showed slight loss of overexpressed 
WWP2 but the knockdown 2 showed robust WWP2 loss.  
I then cloned the knockdown shRNA sequences into pXLG3-wpre vector and 
generated lentiviruses to infect cortical neurones. Firstly, the antibody was 
able to recognise endogenous WWP2 from cortical neurones. Upon infection 
with the WWP2 shRNA knockdowns, the knockdown 1 mediated slight loss of 
endogenous wwp2 while the knockdown 2 showed robust loss of endogenous 
WWP2 [Figure 5-14 B]. This was similar to the observations obtained in 
HEK293T cells.  
Interestingly, the antibody showed double bands for WWP2 recognition, both 
of which seems to be targeted by the knockdowns. I speculate them to 
potentially be different isoforms of WWP2. With these tools in place, I would 
next determine whether removing endogenous WWP2 in hippocampal 
neurones, rescues ADAR2 loss during chronic suppression of network activity 
and if so, whether GluK2 upscaling is inhibited upon the loss of WWP2. Thus, 
this will allow me to study the molecular regulators of ADAR2 ubiquitination 
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Figure 5-14: Studying and validating tools to study WWP2 in rat neuronal cultures. 
Validating shRNA mediated knockdown tools and commercial antibody against 
WWP2 in HEK293T cells and rat neuronal cortical cultures.  
A. Representative western blot images of total levels of overexpressed HA-
WWP2 and actin. HA-WWP2 (rat) and shRNA against rat WWP2 was co-
transfected in HEK293T cells for 3 days and lysed and analysed using western 
blotting. Levels of WWP2 KD achieved and validity of the antibody were 
tested. 
B. Representative western blot images of total levels of endogenous WWP2 and 
GAPDH in rat cortical neurones. Two shRNAs against rat WWP2 were added 
to the cells using lentiviral delivery system. The cells were infected for 6 days 
and lysed and analysed using western blotting. Levels of WWP2 KD achieved 
and validity of the antibody were tested.  
5.4 Discussion 
As ADAR2 transcript levels were not altered post 24 h TTX treatment [Figure 
5-3], I concluded that the ADAR2 decrease was not occurring at the 
transcription level. It is also important to note that previous studies on 
transcript levels of ADAR2 post TTX treatment used 48 h time length of TTX 
treatment, while my study uses 24 h time length. Whether there could be a 
difference in responses of loss of ADAR2 depending on the length of activity 
reduction is not known.  Nevertheless, I studied other potential mechanisms 
by which ADAR2 levels could be altered during scaling. 
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5.4.1 Self-editing of ADAR2 is altered following 24 h TTX 
treatment 
ADAR2 self-editing has been shown to be a mechanism that can regulate 
ADAR2 editing activity [See section 5.1.2]. One of these auto-editing process 
results in a frameshift, coding for an immature stop codon producing a non-
functional 9kDa protein (Rueter, Dawson et al. 1999). Thus, increased auto-
editing could play a role in ADAR2 loss during activity. However, following 24h 
TTX treatment I observed a small but significant decrease in ADAR2 self-
editing in this region [Figure 5-4]. This indicates increased functional ADAR2 
is potentially being translated following 24 h TTX treatment.  
While surprising, this could perhaps be acting as a regulatory mechanism to 
prevent any further loss of ADAR2 protein and ADAR2 function. This could 
allow maintenance of the editing status of other ADAR2 substrates such as 
GluA2, needed for cellular survival (Higuchi, Maas et al. 2000). I had also 
previously shown that any further loss of ADAR2 is prevented when TTX is 
added for longer lengths of time (up to 48 h) [see section 4.3.3]. Hence, this 
auto-editing process could be acting as a mechanism to maintain threshold 
ADAR2 levels.  
Equally, it can also be argued that the TTX treatment is potentially decreasing 
ADAR2 enzymatic activity. In other words, loss of ADAR2 is consequentially 
decreasing its self-editing activity, thus acting as a negative self-regulation 
mechanism. In line with this, previous studies also showed decrease in ADAR2 
self-editing following loss of neuronal activity (Sanjana, Levanon et al. 2012, 
Balik, Penn et al. 2013). Studying ADAR2 self-editing levels at earlier time-
points (6-24 h) could provide initial indication if this is the case.  
While the exact role of decreased ADAR2 self-editing in this instance is not 
fully known, it does not seem to play a causative role in ADAR2 loss during 
scaling. 
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5.4.2 Pin1 does not play a role in ADAR2 stability or 
function during scaling 
ADAR2 is functionally active in the nucleus where it has been reported to be 
stabilised by binding to the protein Pin1. Loss of the ADAR2-Pin1 interaction 
leads to ADAR2 export into cytosol where it is ubiquitinated and degraded 
(Marcucci, Brindle et al. 2011). It was also recently reported that this Pin1 
mediated stabilisation is important for ADAR2 editing activity during 
development in cortical neurons (Behm, Wahlstedt et al. 2017). So, I 
hypothesised this pathway could be altered during TTX mediated loss of 
ADAR2. While no change in Pin1 levels were observed [Figure 5-5], I 
hypothesised that ADAR2 phosphorylation at T32 site that mediates its 
interaction with Pin1 [Figure 5-6] could be altered either by preventing kinase 
(identity unknown) activity or increased phosphatase (identity unknown) 
activity.  
However, both phosphonull (T32A) and phosphomimetic (T32D) mutants of 
ADAR2, which decrease or enhance binding to Pin1 respectively [Figure 5-6], 
were equally susceptible to the TTX mediated loss [Figure 5-7]. Furthermore, 
imaging experiments also showed nuclear localisation of both phosphonull 
and phosphomimetic ADAR2 and both the intensity of ADAR2 and percentage 
of cells expressing ADAR2 decreased following TTX treatment for each 
condition [Figure 5-8].  
Hence, my experiments suggest that Pin1 mediated ADAR2 stabilisation in the 
nucleus does not play a role in ADAR2 loss during up-scaling mediated by the 
suppression of synaptic activity. 
5.4.3 Loss of Pin1 interaction did not alter basal stability 
of ADAR2 
While Pin1 mediated stabilisation did not play a role in activity mediated loss 
of ADAR2, I wanted to determine if basal stability of ADAR2 was altered. 
Contrary to the previous reports (Marcucci, Brindle et al. 2011, Behm, 
Wahlstedt et al. 2017), my cycloheximide experiments suggest that the basal 
stability of ADAR2 is not altered for any of the mutants [Figure 5-9]. This was 
further confirmed by imaging experiments which showed no change in the 
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localisation of any of these mutants as they were all nuclear localised despite 
the supposed loss of interaction with Pin1 [Figure 5-8].  
Similarly, the editing assays also showed all three WT, phosphomimetic and 
phosphonull ADAR2 can equally rescue both GluK2 and GluA2 editing [Figure 
5-10]. Thus, the ability of these mutants to interact with and edit its substrates 
were not affected. Hence, my results contradict previous findings that suggest 
ADAR2-Pin1 interaction play a role in ADAR2 stability and function.  
The published studies were performed by overexpressing human ADAR2 and 
Pin1 (Marcucci, Brindle et al. 2011) proteins in HEK293T cells. So, the 
interactions could be different in rat cultured neurones or perhaps there is 
another Pin1 interaction site in ADAR2. Equally, there may be other ADAR2 
protein interactors compensating for the loss of Pin1 interaction to stabilise it 
in the nucleus. Similarly the reported role of Pin1 mediated nuclear 
stabilisation of ADAR2 were performed in mouse cortical cultured neurones 
(Behm, Wahlstedt et al. 2017). However, these studies only showed increased 
colocalisation of ADAR2 with Pin1 during development. So, to further study 
this, I would remove endogenous Pin1 in my cultures and see if that does 
change ADAR2 stability and localisation. I also want to perform colocalisation 
experiments of these ADAR2 mutants with Pin1 in neuronal cultures to ensure 
Pin1 interaction is indeed lost with these mutants as suggested by the GFP-
trap experiments in HEK293T cells. 
Hence, my results so far suggest that Pin1 does not play any role in the basal 
stability and localisation of ADAR2. 
5.4.4 ADAR2 loss during activity is mediated via 
ubiquitination targeted degradation 
I next wanted to determine if ADAR2 loss during activity is mediated by 
increased degradation of ADAR2 as ADAR2 has been previously suggested 
to be ubiquitinated in the cytosol. My results show that TTX treatment does 
induce the degradation of ADAR2 as the loss can be blocked by the 
proteasome inhibitor BTZ [Figure 5-11].  
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While it is not known whether the ubiquitination occurs in the cytosol or in the 
nucleus, subcellular fractionation data show that the rescued ADAR2 
accumulates in the cytosol. Interestingly, ADAR2 levels are also rescued in 
the nucleus [Figure 5-12]. We speculate that owing to the accumulation of 
ADAR2 in the cytosol, which cannot be removed due to inhibition of the 
proteasomes, it can be re-imported into nucleus, maintaining the functional 
pool of ADAR2. If this is the case, TTX may enhance the overall turnover rate 
of ADAR2 but the increase in the rate of export and degradation outweighs the 
increase in translation and nuclear localisation. Interestingly, increased 
translation of ADAR2 following TTX treatment has been reported 
(Schanzenbächer, Sambandan et al. 2016).  
I also note that blocking general proteasomal function will lead to accumulation 
of many ubiquitinated products that cannot be degraded. Hence, the rescue of 
ADAR2 loss following TTX treatment could be indirectly mediated by rescue 
of potential other interactors of ADAR2 that could target it for import and 
stability in the nucleus. To study this, I would determine if the rescued ADAR2 
following BTZ treatment is indeed ubiquitinated. It would also be interesting to 
determine if there is increased import of ADAR2 from cytosol into the nucleus 
in presence of BTZ by increased association with importin alpha-4 (KPNA3), 
association of which has been shown to be responsible for increased ADAR2 
nuclear accumulation during development (Behm, Wahlstedt et al. 2017).    
Nevertheless, when ADAR2 degradation is blocked it leads to the 
maintenance of a functional pool in the nucleus. Consistent with this, blocking 
proteasomal degradation of ADAR2 prevents TTX induced GluK2 up-scaling 
[Figure 5-14]. Together, these data demonstrate that the loss of ADAR2, and 
the consequent reduction in GluK2 Q/R editing, are both necessary and 
sufficient to support homeostatic scaling of GluK2 containing KARs.  
5.4.5 Developing and validating tools to study WWP2 
role in ADAR2 ubiquitination 
My next aim was to determine molecular pathways behind ADAR2 
ubiquitination. As mentioned above, WWP2 has been shown to be potentially 
regulate ADAR2 ubiquitination and I wanted to determine if this played a role 
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during scaling. For this I created knockdown tools firstly to validate the 
antibodies as not many tools are available to study this protein in rat cultures. 
Comparing the two shRNA knockdown tools, knockdown 2 targeted 
overexpressed rat WWP2 HEK293T cells more robustly than knockdown 1 
[Figure 5-14 A]. However, I struggled to detect endogenous WWP2 in 
HEK293T cells with the antibody.  
Nevertheless, I moved into rat cortical cultures firstly in order to determine if 
the antibody can recognise endogenous WWP2. The antibody did recognise 
a band around the height expected (same as that with the overexpressed 
construct in HEK293T cells) ~110kDa [Figure 5-14 B]. This band was 
decreased in the knockdown lanes, suggesting it to be WWP2 specific band. 
However, the antibody signal was generally very weak which could be due to 
presence of less WWP2 in my cultures or lack of a good recognition from the 
antibody.  
So, to further study this in future I want to test other commercially available 
antibodies against rat WWP2. The eventual goal is to see whether WWP2 
levels themselves are altered during TTX treatment and/or altering ADAR2 
interaction with WWP2 results in altered levels of ADAR2 basally and during 
activity.  
5.5 Conclusion 
In conclusion, my work suggests that ADAR2 loss during TTX mediated up-
scaling is mediated by targeting ADAR2 for ubiquitination and degradation but 
not due to loss of Pin1 mediated stability or reduction in transcription or 
alterations in auto-editing.  
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6.1 Summary of research 
I started my PhD with the aim to explore the potential roles of KARs in various 
forms of synaptic plasticity. I approached this by initially studying AMPAR 
regulation by KAR signalling in both LTP and LTD. I also determined whether 
KARs themselves can undergo homeostatic plasticity i.e. scale up and down 
in response to the chronic changes in network activity. My next aim was to 
study the molecular mechanisms behind regulation of KARs in these forms of 
plasticity, adding to the wealth of knowledge that currently exists on activity 
dependent regulation of KARs expression and function. Below I summarise 
the main findings from my PhD.  
6.1.1 KARs regulation of AMPAR surface expression and 
plasticity  
Previous studies from the lab had shown that along with undergoing plasticity 
themselves, KARs can also regulate AMPAR surface expression and function. 
The activity dependent regulation of KAR surface expression following KAR 
activation can in turn regulate AMPAR surface expression, inducing a novel 
form of KARAMPAR-LTP (Martin, Bouschet et al. 2008, Gonzalez-Gonzalez and 
Henley 2013, Petrovic, Viana da Silva et al. 2017). Furthermore, metabotropic 
signalling via GluK2 subunit of KARs was shown to mediate AMPAR regulation 
by KARs. This non-classical form of LTP presented an opportunity for an 
exciting project and I was keen to extend on these studies and define the 
downstream signalling pathways and players that mediate this increase in 
synaptic AMPARs. One particularly interesting aspect of the study would be to 
determine if NMDAR-LTP and KAR-LTP share common pathways and 
whether the effect of both forms of LTP would be summative or occlusive. 
Unfortunately, lack of reproducibility of KARAMPAR-LTP in cultures in my hands, 
led me to discontinue this project and develop other avenues of investigation 
within KAR plasticity. 
The idea of KARAMPAR-LTP was initiated by the findings that the transient 
stimulation of KAR can increase KAR surface expression (Martin, Bouschet et 
al. 2008, Gonzalez-Gonzalez and Henley 2013). Based on these data I 
hypothesised that KAR signalling could also play a role in KARAMPAR-LTD, as 
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sustained KAR stimulation was shown to induce KAR endocytosis and 
degradation (Martin and Henley 2004). Indeed, sustained KAR stimulation not 
only decreased KAR surface expression but also decreased AMPAR surface 
expression and electrophysiological studies on CA1 synapses suggested 
induction of KARAMPAR-LTD following sustained KAR activation. Further study 
suggested the pre-synaptic KARs to be responsible for this phenomenon 
partially through their ionotropic function. Hence, this is more likely to be a 
form of pre-synaptic LTD/short term plasticity (STP) as the depression in 
AMPAREPSCs were not sustained long term. This finding possibly adds to the 
understanding of the functions of pre-synaptic KARs in plasticity (Jiang, Xu et 
al. 2001, Andrade-Talavera, Duque-Feria et al. 2013).  
Application of the ionotropic KAR inhibitor (UBP310) partially inhibited the 
initial decrease in AMPAREPSCs.  However, since this was only partial block it 
would be interesting to investigate the potential role of metabotropic signalling 
from pre-synaptic KARs as pre-synaptic KARs have been shown to modulate 
GABA release and glutamate release by their metabotropic signalling 
(Rodriguez-Moreno and Lerma 1998, Frerking, Schmitz et al. 2001). While 
interesting, I did not pursue this any further as I wanted to study the function 
and plasticity of postsynaptic GluK2 containing KARs. 
Nevertheless, KARs like NMDARs can regulate AMPAR surface expression 
and function thereby regulating synaptic plasticity itself. 
6.1.2 KARs undergo homeostatic scaling in response to 
chronic activity changes 
Homeostatic plasticity maintains network stability and function in response to 
input-specific changes (Pozo and Goda 2010). The very limited study of the 
role of KARs in this form of plasticity made this an intriguing area to explore. 
My study showed that GluK2 and GluK5 containing KARs undergo 
homeostatic up and down scaling in response to chronic suppression (TTX) 
and enhancement (bicuculline) of synaptic activity respectively. Intriguingly, 
TTX treatment decreased, whereas bicuculline treatment increased GluK2 
Q/R editing. Oligomerisation, ER exit and surface expression of GluK2 
containing KARs are all affected by GluK2 Q/R editing (Ball, Atlason et al. 
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2010), Therefore, I formulated the hypothesis that Q/R editing of GluK2 
regulates KAR surface expression during chronic changes in network activity.      
6.1.3 ADAR2 mediated Q/R editing of GluK2-KARs 
regulates KAR upscaling 
Q/R editing of KARs is predominantly regulated by the enzyme ADAR2 
(Higuchi, Maas et al. 2000).  Furthermore, ADAR2 is activity dependently 
regulated in neurones (Sanjana, Levanon et al. 2012, Balik, Penn et al. 2013). 
My data show that following 24 h TTX treatment, ADAR2 levels decrease 
significantly while the ADAR1 levels remain unchanged. Interestingly, 
however, levels of ADAR2 did not change following bicuculline treatment, 
suggesting a mechanism separate to that of upscaling.  
To demonstrate that the loss of ADAR2 causes the decrease in Q/R editing of 
GluK2, I created shRNA targeted knockdown tools against ADAR2. Partial 
ablation of ADAR2 (50% decrease compared to the scrambled control) caused 
a ~20% decrease in GluK2 editing, the same levels observed with the TTX 
treatment. Importantly, total levels of GluK2 remained unchanged. Moreover, 
replacing endogenous ADAR2 with an exogenously expressed shRNA 
insensitive mutant (knockdown-rescue) restored GluK2 editing. 
The knockdown of 50% of ADAR2 was sufficient to increase the GluK2 surface 
expression, mimicking the surface levels of GluK2 post TTX treatment. 
Furthermore, this surface increase following TTX treatment is occluded in the 
Partial ADAR2 KD cells. Interestingly, while there is further loss of ADAR2 in 
cells treated with both Partial ADAR2 KD and 24 h TTX, there is no further 
decrease in the GluK2 editing itself, consistent with the occluding effect.  
These data support my hypothesis that the decrease in GluK2 editing following 
24 h TTX treatment is mediated by the reduced levels of ADAR2. This in turn 
causes increased oligomerisation and ER exit of GluK2 containing KARs, 
resulting in their increased surface expression and upscaling [Figure 6-1]. 
These findings provide a novel functional role of ADAR2 mediated Q/R editing 
of KARs in synaptic plasticity. 
 





Figure 6-1: Schematic of ADAR2 mediated Q/R editing regulating GluK2 containing 
KARs homeostatic up-scaling.  
Under basal conditions unedited GluK2 transcripts are edited at their Q/R site by 
ADAR2 enzyme resulting in ~80% edited mature GluK2 transcripts. The resultant 
edited and unedited GluK2 subunits oligomerise in the ER and traffic into the surface. 
Under conditions of synaptic activity suppression with TTX treatment, ADAR2 
undergoes proteasomal degradation in the cytosol (1). This results in less ADAR2 
editing of GluK2 pre-mRNA transcripts (2) and increased levels of unedited GluK2 
mature transcripts (3). The subsequent increase in the proportion of unedited 
GluK2(Q) allows enhanced oligomerisation and ER exit (4) to increase surface 
expression of GluK2 containing KARs on the surface (5).  
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6.1.4 Q/R editing of GluK2 and GluA2 by ADAR2 is 
differentially regulated 
Another interesting finding was the differential sensitivity of GluA2 and GluK2 
mRNA to varying levels of endogenous ADAR2. ADAR2 KO mice have 
profound deficits in editing of both GluA2 and GluK2 (Higuchi, Maas et al. 
2000). However, my experiments show that only the Q/R editing of GluK2 was 
altered by the reduced levels of ADAR2 following 24 h TTX treatment. The 
very high levels of GluA2 Q/R editing were maintained despite the partial 
ADAR2 loss. These findings were reiterated in the ADAR2 KD experiments, 
where the partial loss of ADAR2 resulted in the editing loss of GluK2 but not 
of GluA2. Only after the complete loss of ADAR2, GluA2 unedited status 
increased by ~30%, while GluK2 unedited population increased by over ~60%. 
These results suggest that GluA2 is preferentially and almost completely 
edited at the Q/R site even when low levels of ADAR2 are present.  
Complementing this finding, my results also show that ADAR2 levels do not 
decrease any further when treated for longer times with TTX, suggesting 
threshold levels of ADAR2 are preserved by the cell to maintain editing status 
of GluA2. This is likely because editing of GluA2 is essential for neuronal 
survival. 
GluK2, on the other hand, is susceptible to relatively small changes in ADAR2 
levels. This is consistent with the observations that a relatively larger 
proportion of GluK2 remains unedited in adult rat brain (>15%) whereas GluA2 
is almost entirely edited, with <1% unedited (Burnashev, Monyer et al. 1992, 
Bernard, Ferhat et al. 1999). This means that there is a higher tolerance of 
neurones to unedited GluK2 population than that of GluA2. This is also evident 
in studies from GluA2 unedited mice and ADAR2 KO mice which, due to 
presence of significantly higher unedited GluA2 population, are extremely 
seizure prone and die soon after birth (Higuchi, Maas et al. 2000). GluK2 
editing deficient mice, on the other hand, are completely viable and show much 
subtler changes in phenotype, including their plasticity and have increased 
susceptibility to induced seizures (Vissel, Royle et al. 2001). 
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Taken together, my results demonstrate that GluK2 Q/R editing site is 
regulated by changes in ADAR2 levels, to preferentially regulate GluK2 
expression and function in response to alterations in neuronal activity.   
6.1.5 Pin1 does not mediate ADAR2 regulation basally or 
during activity 
Pin1 was previously identified as a regulator of ADAR2 localisation and activity 
(Marcucci, Brindle et al. 2011, Behm, Wahlstedt et al. 2017). Pin1 interacts 
with ADAR2 in a phosphorylation dependent manner.  Phosphorylation of 
threonine 32 (T32) stabilises ADAR2 in the nucleus and prevents degradation 
in the cytosol. GFP trap assays in HEK293T cells showed significantly stronger 
interaction of constitutively phosphorylated (T32D) ADAR2 to Pin1. To 
determine whether altered ADAR2 interaction with Pin1 resulted in the ADAR2 
loss following 24 h TTX treatment I performed knockdown rescue experiments.  
I determined ADAR2 susceptibility to TTX treatment in WT, phosphomimetic 
(T32D) or phosphonull (T32A) mutants using knockdown-rescue experiments. 
Surprisingly, all the mutant forms of ADAR2 were equally vulnerable to the 
TTX mediated loss. I interpret these data to indicate that the phosphorylation 
of T32 in ADAR2 does not play a role in the Pin1-ADAR2 interaction and does 
not regulate ADAR2 stability during homeostatic scaling. Interestingly, 
immunocytochemistry experiments with the phosphomutants did not show 
altered localisation of phosphonull ADAR2, which was surprising as it was 
previously shown that the loss of ADAR2 interaction with Pin1 regulates their 
nuclear localisation (Marcucci, Brindle et al. 2011, Behm, Wahlstedt et al. 
2017). Moreover, WT and both the phosphomutant versions of ADAR2 could 
equally rescue GluA2 and GluK2 editing. Finally, cycloheximide stability 
assays showed that WT and both phosphomutant versions of ADAR2 are 
equally stable as well. Hence, these data suggest that Pin1 does not play a 
role in ADAR2 stability, localisation or function in neurones both basally or 
during TTX mediated activity.       
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6.1.6 ADAR2 ubiquitination could play a role in 
homeostatic scaling 
ADAR2 is targeted for degradation via the ubiquitin-proteasome pathway. I 
tested to see whether inhibiting the proteasomal pathway would prevent this 
TTX facilitated ADAR2 loss. Addition of bortezomib (BTZ), a specific inhibitor 
of the proteasome (Chen, Frezza et al. 2011), caused a build-up of 
ubiquitinated products following 20 h drug treatment. Interestingly, application 
of drug alongside 24 h TTX rescued the loss of ADAR2. Moreover, subcellular 
fractionation experiments showed that ADAR2 is rescued in both nucleus and 
in the cytosol in presence of BTZ. I speculate that the build-up of ubiquitinated 
but not degraded ADAR2 results in the nuclear import and export recycling of 
ADAR2, which maintains a functional pool in the nucleus. In line with this, TTX-
induced GluK2 up-scaling is inhibited in the presence BTZ. These data 
suggest ADAR2 loss following TTX treatment is mediated by its ubiquitination 
mediated degradation [Figure 6-1].   
6.2 Future work 
The findings outlined above open interesting questions and numerous 
research avenues, some of which are outlined below.  
6.2.1 How does GluK2 Q/R editing lead to KAR 
upscaling? 
Previous studies have shown that unedited GluK2 containing KARs form 
oligomers more readily than edited GluK2. This means unedited GluK2-
containing KARs are more efficiently released from the ER allowing their 
increased surface expression (Ball, Atlason et al. 2010). However, it is not 
known, whether there are also variations along the secretory pathway 
trafficking of unedited KARs and/or recycling and degradation rates between 
edited and unedited GluK2 due to their altered oligomerisation.  
We have shown previously that KAR forward traffic through the secretory 
pathway is subject to multiple regulatory checkpoints (Evans, Gurung et al. 
2017). It would be interesting to study if unedited GluK2 also have increased 
surface expression due to enhanced KAR forward trafficking. The 
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cycloheximide assay performed in HEK293T cells suggested that the unedited 
GluK2 are less stable than the edited GluK2. This begs a question whether 
unedited KARs have enhanced internalisation from the surface leading to 
enhanced degradation or do these unedited receptors also have altered 
recycling rates to the surface. Addressing these questions can provide further 
understanding as to how Q/R editing leads to KAR upscaling.   
Furthermore, using strategies such as removing endogenous GluK2 and 
replacing with either completely edited and unedited forms of GluK2, would be 
interesting to determine if unedited GluK2 express more on the surface and 
whether the cultures expressing completely unedited GluK2 would be 
insensitive to TTX mediated and partial ADAR2 mediated GluK2 upscaling. 
This would further emphasise the role of Q/R editing in GluK2 scaling.  
6.2.2 Functional relevance of unedited KARs during 
scaling 
What is the functional relevance of increased unedited KARs on surface during 
synaptic scaling? Co-localisation with post synaptic markers, calcium imaging 
and electrophysiology experiments can help determine if the increase in GluK2 
occurs at synapses. Furthermore, determine the ionic properties of these 
synaptic KARs and how changes in Q/R editing of the incorporated receptors 
impacts on Ca2+ permeability and synaptic function will be interesting to study.  
Moreover, KARs signal via both metabotropic and ionotropic signalling 
pathways. It is completely unknown, however, whether the increase in surface 
KARs following scaling/partial ADAR2 loss alters the metabotropic functions 
of KARs. This is important because synaptic activation of postsynaptic 
metabotropic KARs can inhibit slow AHP that regulates neuronal excitability 
(Melyan, Wheal et al. 2002, Chamberlain, Sadowski et al. 2013).  
Moreover, metabotropic function of GluK2 have been implicated in KAR-
LTPAMPAR (Petrovic, Viana da Silva et al. 2017). Would the increase in GluK2-
KARs following scaling/partial ADAR2 loss, affect the threshold for induction 
of KAR-LTPAMPAR? If the increase in KARs occurs at synapses, would these 
receptors have altered excitability. Determining such signalling pathways, 
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could provide profound new insights into the regulation, roles and signalling 
pathways of KARs. 
6.2.3 Crosstalk between other forms of RNA editing 
Is ADAR2 loss selectively altering GluK2 Q/R editing over other editing sites 
of GluK2, GluK1 and GluA2 or this selectiveness is towards KARs in general?  
The presence of other potential editing sites in GluK2 (I/V and Y/C sites), which 
can also be edited by ADAR2, begs the question if these sites are targeted 
during homeostatic up-scaling. Editing at these sites along with the Q/R site 
regulates the ion permeability of the GluK2 containing KARs. Together they 
can alter the channel properties of KARs on synapses following scaling 
(Köhler, Burnashev et al. 1993, Burnashev, Zhou et al. 1995). Equally, the Q/R 
editing site at GluK1 could also be altered with ADAR2 loss during scaling.  
Future experiments could address whether R/G editing sites in GluA2 are 
altered by TTX treatment. While R/G editing does not alter the GluA2 
trafficking properties, it does affect their desensitisation kinetics (Lomeli, 
Mosbacher et al. 1994). As GluA2 have been shown to be have increased 
surface expression during homeostatic upscaling this would help us 
understand whether the GluA2 expressed on the surface have altered ionic 
properties.  
6.2.4 GluK2 Q/R editing deficient mice 
GluK2 Q/R editing deficient mice offer an invaluable in vivo and ex vivo tool to 
study functional implications of unedited GluK2 receptors. Only one study on 
these mice have been published (Vissel, Royle et al. 2001). However, there 
are many interesting questions that can be addressed in this model, which will 
shed light into the function and importance of unedited KARs. These mice 
have recently been shipped to Bristol providing us with an opportunity to work 
with them. They have deleted ECS region within the intron, resulting in the loss 
of ability of GluK2 pre-mRNA to be edited [Figure 6-2] as dsRNA cannot be 
formed at the Q/R site for ADAR2 to bind and deaminate the site.  




Figure 6-2: Genotyping GluK2 Q/R editing deficient mice.  
The Editing site Complementary sequence (ECS) in the adjacent intronic region is 
~1900nt downstream of the exonic sequence consisting of the Q/R editing site, 
between exon 12 and 13 (A). The WT mice have this ECS site intact, while the 
homozygous ECSΔ mice have 600bp intronic region between exon 12 and 13 deleted 
which consists of the ECS site. This results in lack of ability of ECS mice to edit its 
GluK2 pre-mRNA at Q/R site as such all the GluK2 translated are unedited. Mice 
were genotyped to determine whether they are homozygous, heterozygous or WT 
using primers targeting the deleted region as shown in (A) indicated by numbers 1, 2 
and 3. Figure B shows an example of PCR products obtained. With primers 1, 2 and 
3 combined heterozygous genomic DNA gives band at 450bp (PCR product of 
primers 1 and 2) and 350bp (PCR product of primers 1 and 3) while from homozygous 
DNA only the at 350bp (PCR products from primers 1 and 3) is obtained. No PCR 
product is obtained from Primer combinations 1 and 2 from homozygous mouse 
genomic DNA.    
While no alterations in the total GluK2 protein or transcript levels were 
reported, whether there are changes in overall surface expression of GluK2 
and whether there is presence of increased synaptic KARs in these mice has 
not been studied. Using dissociated cultures, we can perform surface 
biotinylation experiments and measure KAR mEPSCs using 
electrophysiology. Region specific changes in GluK2 levels could also be 
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studied using slice electrophysiology. This can be extended into studying the 
ionotropic and metabotropic functions of unedited KARs, determining whether 
the synaptic KARs have altered inhibition of slows AHP and have reduced 
threshold for KARAMPAR-LTP. Interestingly, these mice have also been 
reported to induce a form of LTP in the absence of NMDAR activity. 
Homeostatic scaling studies can also be performed to determine whether 
these mice display TTX mediated KAR increase on the surface.  
6.2.5 ADAR2 regulators 
There have been studies indicating various regulators of ADAR2 function and 
localisation [summarised in Chapter 5]. While I have shown that ubiquitination 
mediated degradation of ADAR2 plays a role in scaling, I am keen to define 
molecular regulators in this activity dependent pathway. Studying the potential 
role of ubiquitin ligase WWP2 as a mediator of activity dependent ADAR2 
regulation (Marcucci, Brindle et al. 2011) will be the starting point as the tools. 
I have made and validated the relevant tool, and these are ready to use.  
If WWP2 is the ligase, we can define the binding sites, design WWP2 non-
binding ADAR2 mutants and use knockdown replace strategies to study 
WWP2 role. If this is not the case, co-immunoprecipitation and proteomics 
approach can be taken to systematically search for the ubiquitin ligase 
responsible. This would also allow us to search for unidentified new regulators 
of ADAR2 while also providing us with an opportunity to explore potential 
ADAR2 regulators during downscaling process (bicuculline treatment), where 
ADAR2 function was potentially shown to be increased but not its levels.  
6.2.6 GluK2 Q/R editing in development  
As unedited KARs are predominant early in life, it is thought that they play an 
important role during development (Bernard, Ferhat et al. 1999). Moreover, at 
certain synapses the contribution of KARs to transmission decreases in an 
activity dependent manner during development and they are replaced by 
AMPARs (Kidd and Isaac 1999).  
Could the increase in GluK2 editing be playing a role in decreased KAR 
transmission? Is having increased unedited GluK2 during scaling reverting the 
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neurones to an immature state, perhaps allowing GluK2-KARs to increasingly 
contribute to the synaptic transmission. Interestingly, my dissociated 
hippocampal cultures mimic the studies in brain where there is an increased 
proportion of unedited GluK2 up to DIV5, after which the editing is increased 
up to DIV 12 to reach a stable level [Figure 6-3]. This also correlates with 
increasing ADAR2 levels, further showing ADAR2 role in GluK2 editing during 
development. This puts forward an interesting idea if KARs are increasing at 
the synapses and potentially contributing to the synaptic transmission and 
whether the increase of both KARs and AMPARs occur at the same synapses 
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Figure 6-3: Developmental increase in ADAR2 levels and GluK2 Q/R editing in 
hippocampal cultures. 
A. Representative images of the PCR products separated on a 4% agarose gel 
post BbvI digestion to determine edited to unedited GluK2 ratio at indicated 
Days in vitro (DIV). 100% edited and unedited GluK2 constructs were used as 
a control to ensure BbvI cut activity and validity of the assay. RNA extraction 
was performed on hippocampal cells at indicated DIVs, cDNA synthesised, 
and PCR performed.  
B. Quantification of percentage of edited to unedited ratio of GluK2 population 
as shown in A. N=3 independent dissections; One way ANOVA with Dunnett’s 
multiple post comparisons corrections; **p<0.01, ***p<0.001; error bars=S.D. 
C. Representative chromatographs of PCR products comparing hippocampal 
cells at DIV 1, 5 and 12 at the Q/R editing site. The undigested PCR products 
were sent for sequencing to determine changes in the dual peaks obtained at 
the site of editing as indicated by the green arrow. A peak (green) represents 
the unedited base while the G peak (black) represents the edited base. The 
image is representative of 3 repeats. 
D. Representative western blot images of ADAR2 and GAPDH levels at indicated 
DIVs. Hippocampal cells were lysed at indicated DIVs, proteins extracted, 
protein quantification performed, and equal amount was loaded per condition.  
E. Quantification of total ADAR2 levels normalised to GAPDH shown in D. N=3 
independent dissections, One-way ANOVA with Dunnett’s multiple post 
comparisons corrections; **p<0.01, ****p<0.0001; error bar=S.D. 
 
6.2.7 GluK2 Q/R editing and disease  
ADAR2 and GluK2 (including unedited GluK2) have all been implicated in 
diseases principally in epilepsy (Kortenbruck, Berger et al. 2001, Wondolowski 
and Dickman 2013). Additionally, the unedited GluK2 transgenic mice were 
shown to have increased seizure susceptibility compared to the WT mice 
(Vissel, Royle et al. 2001). Intriguingly, dysregulation of homeostatic synaptic 
plasticity is thought to play a role in excitation/inhibition imbalances that 
underlies the pathogenic epileptogenic states, however molecular links for this 
have been elusive (Wondolowski and Dickman 2013). Perhaps, increases in 
GluK2 editing during development act as a regulatory mechanism to reduce 
seizure vulnerability in adults. Hence, it would be of immense interest in the 
field to test the related questions:  
• Does increased unedited GluK2 generate a pathogenic epileptic 
phenotype?  
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• Does increasing edited GluK2 provide a mechanism for cells to avoid 
epileptic states?  
Moreover, we have recently received rat brain samples from pilocarpine 
induced epileptic rat brains extracted at various timepoints of pilocarpine 
injection and epileptic induction, from collaborators in University of Aston 
[Figure 6-4]. The Reduced Intensity Status Epilepticus (RISE) model of 
pilocarpine-induced temporal lobe epilepsy (TLE) was used, which features 
low mortality compared to other forms of epileptic models and allows for 
detection of subtler changes that is potentially leading to the epileptogenic 
states (Modebadze, Morgan et al. 2016). This model gives us an opportunity 
to determine levels of ADARs and KARs and the editing status of both KAR 
and AMPAR subunits at different stages of epilepsy induction to investigate if 
they are causative factors of epileptic induction.  
 
Figure 6-4: Timelines at which rat brains were obtained.  
RISE model of epilepsy involved pilocarpine injection at 0h, causing the initial seizure 
activity. Rat brains were obtained 24 h post injection (Timepoint 1), control brains 
were subjected to sham injection. The latent phase is 1 week post injection where the 
rats show no symptoms or seizure activities. Chronic stage (Timepoint 3) is 4 weeks 
post injection, where the rats have recurrent spontaneous recurrent seizures. 
6.2.8 Other potential questions and directions 
Along with GluK2 subunit of KARs, GluK5 also scaled up and down. Moreover, 
removing endogenous GluK2 did not affect GluK5 total or surface expression. 
This led me to speculate if the involvement of low affinity KAR subunits (such 
as GluK5) is required to form heteromers to allow their traffic out of ER 
Chapter 6  General Discussion 
225 
 
(Gallyas, Ball et al. 2003, Vivithanaporn, Yan et al. 2006). This opens many 
interesting questions such as:  
• Do other KAR subunits GluK1, GluK3 and GluK4 also respond to 
changes in the network activity?  
• Are other interacting proteins that are involved in KAR trafficking and 
that stabilise KARs on the surface and synapses also involved in 
surface increase of not just GluK5 but also GluK2? (Pahl, Tapken et al. 
2014, Evans, Gurung et al. 2017).  
While I showed GluK2 editing plays a major role in GluK2 scaling, do 
processes such as post translational modifications and interactions also 
contribute to aid and maintain these changes. If so, are these mechanisms 
shared in both upscaling and downscaling of KARs? Screening for changes 
that occur during scaling with KAR interactors and/or modifications can allow 
us to understand mechanisms that are involved in scaling. Furthermore, 
studying whether similar mechanisms play role in both up-scaling and down-
scaling will also be an equally interesting aspect to follow.   
Finally, KAR function in inhibitory transmission is becoming increasingly 
evident with its role in regulating GABA release (Rodriguez-Moreno and Lerma 
1998) and regulating KCC2 surface expression (Pressey, Mahadevan et al. 
2017). Here I initially explored the role of KARs in both upregulation and 
downregulation of AMPARs to study their function in excitatory 
neurotransmission. But following questions are also of interest: 
• Do KARs regulate inhibitory transmission by altering surface 
expression of KCC2 during these transient and sustained KAR 
activations?  
• Do KARs have a role as a mediator of excitation and inhibition 
signalling?  
This would add a new direction to the study of KAR function and further 
implement KAR importance in synaptic plasticity.   
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6.3 Conclusion and Significance 
There is substantial and increasing evidences for key roles of KARs in certain 
forms of synaptic plasticity, both by autoregulation of their own plasticity and 
by regulating the plasticity of AMPARs. In the first part of my PhD, I showed a 
potential role of pre-synaptic KARs in regulating short term plasticity by 
regulating AMPAR surface expression. Moreover, I showed a novel role of 
KARs in homeostatic scaling by demonstrating that KARs can scale up and 
down on the surface in response to the changes in the network activity. 
Furthermore, I highlighted the importance of Q/R editing of GluK2 in this 
upscaling process.  
While unedited GluK2 had been shown in the past to be efficiently released 
from the ER and traffic to the surface, here I establish the physiological 
relevance of this increased ER export and surface expression of unedited 
KARs in scaling. With this, I also demonstrate an important role of ADAR2 in 
neuronal activity, which has been alluded to before. ADAR2 seems to undergo 
proteasomal degradation following chronic decrease in the network activity, 
which in turn alters its editing activity. While ADAR2 studies have 
predominantly focused on its function of regulating GluA2 Q/R and R/G editing, 
here I have shown that alterations in ADAR2 levels functions to regulate GluK2 
upscaling by regulating GluK2 Q/R editing. How ADAR2 is mechanistically 
regulated during scaling, understanding the functional relevance of upscaling 
unedited KARs and how the interplay between editing, KAR and homeostatic 
plasticity can potentially lead to pathological phenotypes will be an important 
subject for future studies.   
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Abstract
Kainate receptors (KARs) are glutamate-gated ion channels that play fundamental roles in regulating neuronal excitability 
and network function in the brain. After being cloned in the 1990s, important progress has been made in understanding the 
mechanisms controlling the molecular and cellular properties of KARs, and the nature and extent of their regulation of wider 
neuronal activity. However, there have been significant recent advances towards understanding KAR trafficking through the 
secretory pathway, their precise synaptic positioning, and their roles in synaptic plasticity and disease. Here we provide an 
overview highlighting these new findings about the mechanisms controlling KARs and how KARs, in turn, regulate other 
proteins and pathways to influence synaptic function.
Keywords Kainate receptors · GluK2 · Trafficking · RUSH · Synaptic transmission · Synaptic plasticity
Introduction
Glutamate is the major excitatory neurotransmitter in the 
CNS and participates in nearly all aspects of brain function. 
There are three major subclasses of ionotropic glutamate 
receptors, kainate receptors (KARs), AMPA receptors and 
NMDA receptors. KARs are widely distributed throughout 
the brain and, depending on the cell type in question, they 
can be localised at pre-, post- and/or extrasynaptic sites. In 
general, presynaptic KARs modulate both excitatory and 
inhibitory neurotransmitter release, postsynaptic KARs 
contribute to excitatory neurotransmission and extrasynap-
tic KARs play a role in determining neuronal excitability 
(for reviews of KAR physiology see [1–4]). For reasons 
that remain unclear, compared to AMPARs and NMDARs, 
synaptic KAR ionotropic responses are highly restricted 
to subsets of excitatory synapses. For example, some neu-
rons, including CA1 pyramidal neurons and dispersed hip-
pocampal cultures display robust KAR currents following 
kainate application [5, 6] but they lack synaptically-evoked 
ionotropic postsynaptic excitatory post-synaptic currents 
 KAR(EPSCs) [6–8]. Intriguingly, it has been proposed that 
 KAR(EPSCs) are present only at synapses that do not contain 
 AMPAR(EPSCs) [9, 10].
Remarkably, despite their classical ion channel structure, 
KARs can also signal via a non-canonical G-protein cou-
pled metabotropic cascade [11]. In contrast, postsynaptic 
metabotropic KAR signalling is much more widespread than 
ionotropic KAR signalling [12, 13] and recent discoveries 
have highlighted their previously unsuspected roles in neu-
romodulation. For example, they regulate inhibitory trans-
mission by controlling surface expression of the chloride 
transporter KCC2 [14] and mediate certain forms of synaptic 
plasticity [15, 16]. For extensive reviews of metabotropic 
KARs see [4, 17].
Our aim here is to provide an overview of recent advances 
in understanding the cellular regulation of KARs and their 
interacting proteins, and how these processes influence 
KAR-mediated synaptic transmission and plasticity. We 
highlight what is known, what remains to be established, 
and outline the future perspectives for KAR research and 
how it will impact on our understanding of brain function 
and dysfunction in disease.
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Since their initial cloning [18, 19] the names of specific 
KAR subunits have changed to conform to a simpler, more 
systematic naming system. This can lead to considerable 
confusion in the field since many seminal early papers use 
the old nomenclature. Nonetheless, since 2009, the Interna-
tional Union of Basic and Clinical Pharmacology (IUPHAR) 
naming system has been almost universally adopted. Briefly, 
the subunits formerly most commonly referred to as GluR5, 
GluR6, GluR7, KA1 and KA2 are now named GluK1, 
GluK2, GluK3, GluK4 and GluK5, respectively, and the 
genes encoding these proteins are named GRIK1-5 [20].
KARs from Birth to Maturity
KAR Structure and Assembly
KARs are heteromeric assemblies containing four subu-
nits. Each subunit has a large extracellular N-terminal 
domain (NTD), helical transmembrane domains (TMD) 
including three membrane spanning domains (M1, M3 
and M4) and a membrane re-entrant domain (M2), and 
an intracellular C-terminal domain (CTD). The latter part 
of the NTD (the last ~ 150 amino acids, S1) together with 
the extracellular loops between M3 and M4 (S2) form the 
ligand-binding domain (LBD) [21]. Recently, detailed 
structural information has been gained by solving the 
crystal structure of kainate receptor subunits and this is 
reviewed in detail elsewhere [22–25].
Heteromeric Assembly
Following protein synthesis, the NTDs initiate receptor 
assembly in the endoplasmic reticulum (ER) by facilitat-
ing dimer formation, and the dimerization of two dimers 
then leads to the formation of tetrameric receptors. Based 
on affinity for their ligand, KAR subunits have been grouped 
into low affinity (GluK1-3) and high affinity (GluK4-5) 
receptors. Studies on recombinant systems have shown 
that low affinity GluK1-3 subunits can form ion channels 
as both homomers and heteromers but high affinity GluK4 
and GluK5 subunits can only form heteromeric functional 
ion channels when complexed with the low-affinity subunits 
[19, 26, 27]. The most abundant subunit combination in the 
brain comprises GluK2 and GluK5. This occurs, at least in 
part, because widely distributed contacts within the NTD of 
GluK2 and GluK5 favour the assembly of functional hetero-
meric receptors over homomeric receptors [28].
Alternative Splicing
Regions within the N- and C- terminal domains of KAR 
subunits can undergo alternative RNA splicing. For instance, 
the extracellular N-terminal domain of GluK1 can produce 
two variants,  GluK11 and  GluK12 [29], while the C-termi-
nus has four splice variants, GluK1a, GluK1b, GluK1c and 
GluK1d [30, 31]. Splice variants have also been reported at 
the C-termini of both GluK2 and GluK3; GluK2a/GluK2b/
GluK2c and GluK3a/GluK3b, respectively [32–34]. C-ter-
minal alternative splicing of KAR subunits has been shown 
to greatly affect the ability of receptors to exit the ER and 
accumulate at the cell surface. Furthermore, different C-ter-
mini facilitate distinct protein–protein interactions and it is 
likely they provide mechanisms for nuanced tuning of spe-
cific KARs at particular locations [35–37].
RNA Editing
In addition to splicing, further diversity arises from varying 
degrees of RNA editing in GluK1 and GluK2 subunits [38, 
39]. For example, Q/R editing in the pore-lining region of 
GluK2 results in a change from the genomically encoded 
glutamine residue to an arginine. This change alters the 
properties of the resultant KAR from calcium permeable to 
calcium impermeable and also alters the biophysical prop-
erties of the channel [40]. Furthermore, GluK2 Q/R editing 
reduces its ability to assemble with other subunits, leading to 
its accumulation as monomers and dimers that are retained 
in the ER [41].
It is well established that GluK1/GluK2 editing is devel-
opmentally controlled through regulation of the enzyme that 
also catalyses GluK1/2 RNA editing, ADAR2 [42–44]. For 
an excellent recent review see [45]. ADAR2 levels are low 
in embryonic brain and during development ADAR2 levels 
increase [46]. After birth ~ 80% of GluK2 and 40% GluK1 
are edited, which leads to fewer surface KARs and lower 
conductance and  Ca2+ permeability [47]. Furthermore, 
recent evidence has suggested that the ADAR2 dependent 
Q/R editing of GluK2 is also dynamically regulated during 
homeostatic scaling [48]. Suppression of synaptic activity 
with TTX results in upscaling of KAR surface expression, 
which is, at least in part, due to reduced Q/R editing of 
GluK2 [48]. Therefore, this developmental and homeostatic 
regulation of GluK2 Q/R editing likely control processes 
such as synaptogenesis [49, 50], plasticity [40] and pathol-
ogy [47].
KAR Trafficking Through the Secretory Pathway
The accurate and timely delivery of KARs to specific pre-, 
post- and extrasynaptic locations is fundamental to many 
aspects of neuronal function. Most research efforts have 
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focused on the processes of transcription, endocytosis, recy-
cling and degradation (for reviews see [4, 51]). However, 
after assembly, tetrameric KARs need to traffic through the 
secretory pathway to reach the cell surface and be appropri-
ately targeted. Until recently, it was unknown whether these 
early KAR trafficking steps occur locally in dendrites and, 
importantly, how these processes are regulated.
Local Dendritic Translation and Secretory Pathway 
Trafficking
In neurons, mRNAs can be trafficked to distant sites in axons 
and dendrites for local translation and processing [52–57]. 
A range of neuronal transmembrane proteins, including 
AMPARs, NMDARs and  GABABRs, can be translated using 
both somatic and dendritically localised ribosome patterned 
rough ER. They then traffic from the ER using dendritic ER 
exit sites and utilise the somatic Golgi or dendritic Golgi 
outposts for mature glycosylation [48, 58–62]. Importantly, 
all of the secretory pathway machinery appears to be pre-
sent in neurites as iGluRs can mature in isolated dendrites 
[63]. For example, AMPAR mRNAs traffic into dendrites, 
under the control of synaptic activity, to create local utiliz-
able pools of mRNA for local translation [64].
Recently, using the RUSH system, which allows the syn-
chronous release and visualization of cargo proteins traf-
ficking through the secretory pathway [65, 66], it has been 
demonstrated that GluK2-containing KARs utilise these 
local secretory pathway systems for their delivery to the cell 
surface [48] (Fig. 1). However, the functional consequences 
that result from KARs utilising these local secretory path-
way systems remain to be established.
Activity Dependent Secretory Pathway Trafficking
Although there is a strong base of knowledge about the 
activity-dependent regulation of KAR endocytosis and 
recycling [13, 15, 67–71], compared to AMPARs [72] 
and tsVSVG cargo [73], little is known about the activity-
dependence of secretory pathway trafficking of KARs. A 
very recent study reported that secretory pathway KAR traf-
ficking is indeed highly regulated in multiple different cellu-
lar activity contexts [48]. Activation of surface KARs results 
in a decrease in secretory pathway trafficking of de novo 
GluK2-containing KARs from the ER to the cell surface, 
demonstrating that KAR secretory pathway trafficking is 
subject to a negative feedback mechanism controlling KAR 
surface levels. Mechanistically, this pathway is dependent 
on the PDZ ligand of GluK2, since a mutant lacking this 
Fig. 1  Control of KAR trafficking through the secretory pathway. 
KAR trafficking is controlled at multiple levels under basal and activ-
ity-dependent conditions. PKC phosphorylation of the GluK2 subu-
nit at S846 and S868 reduces ER exit of GluK2-containing recep-
tors. Activation of surface KARs leads to a feedback mechanism that 
reduces forward trafficking of KARs from the ER, via a mechanism 
that requires the PDZ ligand of GluK2. Furthermore, induction of 
synaptic scaling via inhibiting neuronal activity with TTX leads to 
upscaling of KARs, at least in part via reduced RNA editing of the 
GluK2 subunit, favouring forward trafficking of GluK2-containing 
KARs. Finally, in addition to using somatic Golgi for post-ER pro-




protein interaction site is insensitive to the effects of kainate 
on secretory pathway trafficking, however the GluK2 inter-
acting partner responsible remains to be determined [48].
Roles of GluK5 in Trafficking
As well as interactions with the GluK2 subunit, interactions 
with GluK5 also determine flux through the secretory path-
way. ER retention sequences in the C-terminus of GluK5 
facilitate its interaction with the COPI coat complex, driving 
retrograde Golgi to ER trafficking of KARs, and acting as an 
ER retrieval mechanism [74]. This interaction is disrupted 
by the heteromerization of GluK2 with GluK5 and bind-
ing to 14-3-3ζ, which promotes forward trafficking to the 
cell surface, both driving ER exit and favouring assembly 
of heteromeric KARs [74].
Post‑translational Modifications
Further tight control of the ER exit and secretory pathway 
trafficking of KARs is also provided by post-translational 
modifications, most notably PKC phosphorylation of GluK2 
at residues S846 and S868 [48, 75], which act to restrict 
forward trafficking of GluK2-containing KARs.
Thus, far from being a passive process, ER exit of KARs 
and flux through the secretory pathway is emerging as a 
major point of regulation in determining the surface expres-
sion of KARs under basal and activity-dependent conditions 
(summarised in Fig. 1).
Synaptic Positioning and Function of KARs
Given the highly-ordered targeting and localisation of KARs 
at distinct synaptic and sub-synaptic compartments, a key 
question in the field relates to how KARs are targeted to, 
and retained at, specific pre- or postsynaptic locations. While 
many of the factors that mediate this distribution are yet to 
be determined, as discussed below, recent data suggest that 
structural aspects of the receptor subunits, the presence of 
Neto auxiliary proteins in the KAR complex and the secreted 
C1q-like proteins play important roles in these processes 
(Fig. 2).
Postsynaptic KARs
Role of the GluK2 C‑Terminus in Synaptic Localisation
In the cerebellum, KARs are located post-synaptically on 
cerebellar granule cells, which receive inputs from mossy 
fibres. These receptors comprise GluK2/5 and the auxiliary 
subunit Neto2 [76] (see below). Synaptic localisation of this 
complex is dependent on the GluK2 subunit, since ablation 
of GluK5 or Neto2 has no effect on levels of GluK2/Neto2 
or GluK2/GluK5, respectively, in the postsynaptic density 
(PSD) fraction [76, 77]. Furthermore, knock-in mice in 
which the intracellular C-terminus of GluK2 is replaced with 
the C-terminus of the AMPAR subunit GluA1 do not exhibit 
synaptic KAR responses in cerebellar slices [77]. Notably, 
whole cell KAR currents were unaffected, demonstrating a 
specific role for the GluK2 C-terminus in synaptic incor-
poration of KARs at cerebellar synapses but not in recep-
tor surface expression [77]. Furthermore, these mice show 
reduced postsynaptic KAR responses at MF-CA3 synapses 
in the hippocampus, the prototypical KAR-containing syn-
apse in the brain, but no reduction in total KAR responses, 
again indicating a specific role for the GluK2 C-terminus in 
synaptic incorporation, but not surface expression, of KARs 
[77].
Roles of GluK4 and GluK5 in the Synaptic Specificity of KARs
While the C-terminus of GluK2 seems to be necessary 
for synaptic incorporation, synapse specificity in the hip-
pocampus has been shown to be dependent on the GluK4 
and GluK5 subunits. Postsynaptic KARs at MF-CA3 syn-
apses are lost in mice lacking both of these subunits [78]. 
Moreover, in GluK4/5−/− mice there is a redistribution of 
GluK2 immunolabelling to more distal dendrites in CA3 
pyramidal neurons [77], suggesting GluK4/5 are crucial 
determinants of the synapse specificity of KARs in the hip-
pocampus. Interestingly, viral re-expression of GluK5 in the 
Fig. 2  Mechanisms of KAR synaptic localisation. At mossy fibre-
CA3 (MF-CA3) synapses, presynaptically released C1ql proteins 
cluster KARs through binding to KAR subunit extracellular domains, 
and forming a tripartite trans-synaptic complex with presynaptic 
neurexin 3. KAR synaptic incorporation is also promoted through 
interactions between the GluK2 C-terminus and the trans-synaptic 
adhesion molecule N-cadherin, and through interactions between the 




hippocampus of GluK4/5−/− mice rescued GluK2 signal in 
stratum lucidum, but this did not occur for a GluK5 chimera 
in which the extracellular N-terminus was replaced with that 
of GluK2 [77], which the authors attribute to the ability of 
the N-terminus of GluK5 to bind to the mossy fibre-enriched 
C1q-like proteins (see below).
Proteins that Interact with KARs to Define 
Postsynaptic Localisation
N‑Cadherin
The fact that MF-CA3 synapses in  GluK2−/− mice lack post-
synaptic KAR responses [79] has allowed examination of the 
factors required for their effective synaptic positioning by re-
expressing wild-type or mutant GluK2 in CA3 neurons. The 
last 20 amino acids of GluK2 are required for KAR incor-
poration at MF-CA3 synapses [80] and this region mediates 
interactions between GluK2 and the neuronal cell adhesion 
molecule N-cadherin [81]. At MF-CA3 synapses in wild-
type mice, expression of a dominant-negative N-cadherin 
reduced KAR EPSCs, as did knockdown of N-cadherin 
mediated by expression of Cre recombinase in CA3 cells 
from N-cadherin floxed mice [80]. Together, these findings 
demonstrate GluK2 binding to N-cadherin is a key determi-
nant of GluK2 recruitment to MF-CA3 synapses.
PSD95
The synaptic scaffold protein PSD95 binds to the C-terminal 
PDZ ligands of the core KAR subunits GluK1, GluK2 and 
GluK5 [82, 83]. PSD95 also binds to the auxiliary subu-
nit Neto1 [84], and accelerates the recovery of GluK2 from 
desensitisation [85]. The KAR component of the EPSC at 
MF-CA3 synapses is reduced in PSD95 knockout mice, sug-
gesting a role for this interaction in KAR synaptic localisa-
tion [86]. However, whether this is due to direct binding of 
KARs to PSD95 and, if it is, which subunits are responsible, 
remains to be determined. Moreover, as discussed below, 
regulation of the interaction between GluK5 and PSD95 
is required for long-term depression (LTD) of KARs at 
MF-CA3 synapses [87].
C1ql
The C1q-like proteins are a family of secreted synaptic 
organisers [88]. Two members of this family, C1ql2 and 
C1ql3, are highly expressed by hippocampal mossy fibres 
and contribute to the localisation of KARs to mossy fibre 
synapses in CA3 neurons [77, 89]. In heterologous cells, 
C1ql2 and 3 bind to the N-terminal domains of GluK2 and 
GluK4 [89], although another study instead observed bind-
ing to GluK5 [77]. C1ql2 and 3 are present at MF-CA3 
synapses, and their levels are reduced in slices from 
 GluK2−/− or  GluK4−/− mice, suggesting GluK2 and GluK4 
act as binding sites for C1ql2/3 [89]. Moreover, GluK2/3 
immunoreactivity is markedly decreased in CA3 stratum 
lucidum in C1ql2/3 knockout mice, and KAR EPSCs at 
MF-CA3 synapses are reduced to levels similar to those 
observed in  GluK2−/− mice. The presynaptic adhesion 
molecule neurexin 3 binds to secreted C1ql2/3 and a neu-
rexin 3-C1ql-KAR complex was isolated in co-cultures 
of HEK293 cells expressing neurexin 3 and C1ql2/3 and 
neurons [89]. Thus, specific secretion of C1ql proteins at 
mossy fibres provides the basis for a trans-synaptic complex 
that clusters KARs postsynaptically at MF-CA3 synapses 
(Fig. 2).
Neto1 and Neto2
Neto1 and Neto2 are single pass transmembrane proteins 
that associate with KAR complexes through binding to the 
GluK1-3 subunits [90, 91]. Neto1 is expressed abundantly in 
the hippocampus and is a component of postsynaptic KARs 
at MF-CA3 synapses [91] whereas Neto2 is more highly 
expressed in the cerebellum [90]. The effects of Neto pro-
teins on KAR channel properties have been studied exten-
sively (reviewed in [92–95]), but, briefly, Neto proteins 
generally slow the deactivation kinetics of KARs, which 
accounts for their different properties in vivo compared to 
exogenously expressed KARs in cell lines that do not con-
tain Netos. Furthermore, it has also recently been shown that 
Neto proteins control the function of both somatodendritic 
and presynaptic KARs in somatostatin, cholecystokinin/can-
nabinoid receptor 1, and parvalbumin-containing interneu-
rons to regulate neuronal network inhibition [96]. However, 
as outlined below, how Neto proteins affect the trafficking 
and synaptic incorporation of KARs is less well established 
with the current literature containing apparently contradic-
tory results.
Netos and GluK2
Initial studies observed no effect of Neto1 or Neto2 in 
mediating surface expression of GluK2 in heterologous 
systems [90, 91] nor any effects on the abundance of GluK2 
or GluK5 in PSD fractions from Neto1 knockout mice 
[91]. Furthermore, co-expression of Neto1 or Neto2 did 
not enhance exogenous KAR responses in CA1 pyramidal 
neurons, which normally lack postsynaptic KAR EPSCs, 
arguing against a role for Netos in synaptic incorporation 
of GluK2-containing KARs [9]. Other studies, however, 
reported a reduction in synaptic GluK2 in the hippocam-
pus of Neto1 knockout mice [97, 98], and from cerebellar 
PSD fractions from Neto2 knockout mice [99], supporting 
a role for Neto proteins in the synaptic targeting of GluK2. 
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Moreover, recent studies have reported that Neto1 and Neto2 
enhance GluK2 surface expression in HEK293 cells [100] 
and that injection of Neto2 with GluK2 into oocytes potenti-
ates GluK2 surface expression [77]. Given these apparently 
contradictory results, the precise roles of Neto proteins in the 
trafficking and targeting of GluK2-containing KARs remains 
to be defined.
Netos and GluK1
Neto proteins have also been reported to be involved in the 
trafficking of GluK1-containing KARs. Transfection of 
Neto2 with GluK1 promotes GluK1 surface expression in 
both COS-7 cells and cultured hippocampal neurons, and 
drives the synaptic incorporation of GluK1-containing 
KARs [101]. Consistent with this role, co-transfection of 
either Neto1 or Neto2 with GluK1 in CA1 pyramidal cells in 
hippocampal slice cultures enhances GluK1 surface expres-
sion and synaptic targeting [9, 102]. It should be noted, how-
ever, that since these studies rely on overexpression of KAR 
subunits in cells that do not usually express GluK1 [6, 103] 
or exhibit synaptic KAR responses [6–8], the relevance of 
Neto proteins to GluK1 trafficking in vivo requires further 
examination.
Overall, although there is not yet a clear consensus, 
accumulating evidence suggests Neto proteins do influ-
ence surface expression and synaptic targeting of KARs 
under some circumstances. The apparently conflicting data 
regarding the roles of Netos in KAR trafficking and synap-
tic positioning can, at least in part, be attributed to the use 
of different model systems, clonal cell lines and neuronal 
subtypes, and experimental conditions. Thus, the current 
inconsistencies may reflect a complex relationship between 
Netos and KARs, which can be affected differential subunit 
expression and the availability of cell type-specific interact-
ing proteins. Moreover, GluK2 is subject to multiple, coor-
dinated post-translational modifications (PTMs) including 
phosphorylation [75], SUMOylation [67, 69], ubiquitina-
tion [104, 105] and palmitoylation [71, 106], each of which 
could potentially directly or indirectly influence the actions 
of Netos. Clearly, further work is required to will determine 
the molecular mechanisms, under what circumstances, and 
for which subunit combinations Netos regulate KAR traf-
ficking and targeting in vivo.
KAR Post‑translational Modifications 
and Post‑synaptic Localisation
CaMKII Phosphorylation of GluK5
LTD of KARs at MF-CA3 synapses is induced by a spike 
timing-,  Ca2+ influx-, and CaMKII-dependent plasticity 
mechanism, which is absent in slices from  GluK5−/− mice 
[87]. CaMKII phosphorylates the C-terminal domain of 
GluK5 in vitro and a phosphomimetic mutation enhances 
surface expression, but reduces synaptic localisation, in 
neurons. GluK5 phosphorylation enhances lateral mobil-
ity and reduces the interaction between GluK5 and PSD95. 
Moreover, while re-expression of GluK5 in  GluK5−/− slices 
restored KAR-LTD, expression of a non-phosphorylatable 
GluK5 did not, demonstrating that direct phosphorylation 
of GluK5 by CaMKII is required for this form of KAR LTD 
[87]. Thus, these data indicate that CaMKII phosphorylation 
of GluK5-containing KARs regulates their synaptic locali-
sation by antagonising the interaction between GluK5 and 
PSD95 (Fig. 3).
Fig. 3  Mechanisms of 
KAR-LTD. a At MF-CA3 
synapses, LTD induction 
leads to CaMKII-mediated 
phosphorylation of the GluK5 
subunit, reducing its ability 
to bind PSD95. This reduced 
anchoring of GluK5-containing 
KARs promotes their lateral 
mobility and diffusion away 
from the postsynapse, resulting 
in LTD of KAR EPSCs. b An 
alternative LTD mechanism 
results in PKC-dependent 
phosphorylation (not shown) 
and subsequent SUMOylation 
of the GluK2 subunit. This 
then leads to endocytosis of 
GluK2-containing KARs and 





PKC phosphorylation of GluK2 at S846 and S868 regulates 
the surface expression of GluK2-containing KARs at several 
levels. It affects both GluK2 transit through the secretory 
pathway [48, 75] and KAR endocytosis and recycling back 
to the plasma membrane [15, 75]. Phosphorylation of S846 
promotes basal internalisation of GluK2-containing KARs in 
both HeLa cells and neurons [75], potentially via regulating 
the interaction between GluK2 and 4.1 proteins [71]. Fur-
thermore, phosphorylation of both sites occurs in response 
to kainate stimulation of cultured neurons, and phosphoryla-
tion at S868 is required for agonist-induced endocytosis of 
GluK2, by promoting SUMOylation at lysine 886 [15, 69, 
107] (see below). It should be noted, however, that PKC 
phosphorylation of S868 also appears to be involved in recy-
cling of endocytosed GluK2 back to the plasma membrane 
[15], suggesting that whether phosphorylation of S868 pro-
motes insertion or removal of GluK2 from the plasma mem-
brane is likely to be context-dependent.
SUMOylation
SUMOylation is a post-translational modification that results 
from the conjugation of a member of the ~ 11kD SUMO 
family to lysine residues in substrate proteins [108]. GluK2 
is SUMOylated at a single lysine residue in its intracellu-
lar C-terminus, K886, resulting in agonist-induced inter-
nalisation of GluK2-containing KARs [67]. Infusion of the 
catalytic domain of the deSUMOylating enzyme SENP1 
increases KAR currents at MF-CA3 synapses, highlighting 
SUMOylaton as an endogenous regulator of the number of 
synaptic KARs [67]. Subsequent studies have demonstrated 
that SUMOylation of GluK2 is enhanced by prior PKC-
mediated phosphorylation of serine 868 and is required for 
LTD of kainate receptors at MF-CA3 synapses [15, 69].
Ubiquitination
One major functions of protein ubiquitination is to target 
proteins for lysosomal or proteasomal degradation [109]. 
A recent study identified that the Parkinson’s disease-
associated ubiquitin ligase Parkin directly interacts with 
and ubiquitinates the C-terminus of GluK2 [105]. Parkin 
ubiquitinates GluK2 in both heterologous cells and cultured 
neurons, and knockdown of Parkin increased GluK2 sur-
face expression and increased vulnerability of hippocampal 
neurons to kainate-induced excitotoxicity. Furthermore, in 
a mouse model of autosomal recessive juvenile Parkinson’s 
expressing a truncated form of Parkin, there are increased 
levels of GluK2 in substantia nigra and corresponding 
increases in cortex samples from human patients express-
ing mutations in Parkin [105]. Thus, GluK2 is a Parkin target 
that may contribute to the excitotoxic cell death of substantia 
nigra neurons in Parkinson’s disease.
KARs in Plasticity
KARs are involved in both excitatory and inhibitory neuro-
transmission, controlling both short and longer-term plas-
ticity. These properties have been extensively reviewed [2, 
11] and we confine our discussion largely to the most recent 
findings relating to the role of postsynaptic KARs as induc-
ers of long-term plasticity.
KAR Regulation of Excitatory Neurotransmission
Presynaptic KARs decrease glutamate release at CA3-CA1 
pyramidal cell synapses [110–112]. Intriguingly, however, 
KARs have also been shown to facilitate glutamate release 
upon application of nanomolar concentrations of kainate. 
This facilitation of glutamate release requires KAR activa-
tion resulting in the accumulation of presynaptic calcium, 
the production of  Ca2+–calmodulin complexes and the 
activation adenylate cyclase and PKA [113–115]. Thus, at 
certain synapses, KARs can exert bidirectional modulatory 
actions on glutamate release related to the extent of their 
activation (for recent review see [3]).
Postsynaptic KARs at MF-CA3 synapses undergo plas-
tic changes, and exhibit several forms of LTD that can 
be induced by different stimulation protocols [15, 87]. 
Chamberlain et al. showed that SUMOylation of GluK2 
is required for activity-dependent long-term depression 
of kainate receptor-mediated synaptic transmission (KAR 
LTD). They We further demonstrated that a critical trig-
ger for SUMOylation is GluK2 phosphorylation by protein 
kinase C (PKC) and that this sequence of events is required 
for KAR LTD and that SUMOylation can act as the switch 
between enhanced or decreased surface expression of KARs 
after PKC phosphorylation [15].
Furthermore, in cultured neurons, activity-dependent 
up- or down-regulation of surface KARs can be induced by 
differential agonist application protocols [13, 68]. KAR sur-
face expression is also subject to homeostatic plasticity and 
can be ‘scaled’ by manipulating neuronal excitability [48]. 
Intriguingly, beyond being regulated by plasticity them-
selves, there is a growing appreciation that KARs also func-
tion as postsynaptic inducers of synaptic plasticity (Fig. 3).
Recently, a novel form of AMPAR-LTP was discovered 
at CA3-CA1 synapses that is mediated by activation of 
postsynaptic KARs (KAR-LTPAMPAR [16]). Despite the fact 
that CA1 pyramidal cells exhibit essentially no postsynaptic 
KAR EPSCs [6, 8, 9, 102, 116], activation of postsynaptic 
KARs by high-frequency stimulation of Schaffer collaterals 
inhibits a slow after-hyperpolarization current that regulates 
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excitability in hippocampus (IsAHP) through a metabotropic 
cascade [117, 118], suggesting receptors are postsynaptically 
localised. Remarkably, however, at these synapses, KARs, 
which have a classical ion channel structure, signal primar-
ily through a G protein-dependent pathway (for review see 
[17]).
Consistent with this, stimulation protocols that acti-
vate postsynaptic KARs on CA1 neurons induce LTP 
of AMPARs via a metabotropic signalling pathway [16]. 
 GluK2−/− mice lack this novel form of plasticity, indicat-
ing an absolute requirement for this subunit in induction of 
KAR-LTPAMPAR (Fig. 4). Similar to inhibition of IsAHP, 
KAR-LTPAMPAR is mediated by activation of pertussis 
toxin-sensitive G-proteins, and requires activation of PKC 
and PLC. Furthermore, similar to LTP induced by activation 
of NMDARs, KAR-LTPAMPAR is mediated by an increase 
in surface AMPARs supplied by recruitment of recycling 
endosomes to spines and also leads to structural plasticity, as 
determined by an increase in spine size and maturation [16].
Thus, although the exact mechanisms are still to be deter-
mined, it is clear that KAR metabotropic signalling plays 
a key role in directly mediating certain forms of AMPAR-
mediated plasticity at CA1 synapses.
KAR Regulation of Inhibitory Neurotransmission
KAR Regulation of GABA Release
An important facet of KAR physiology is that they coordi-
nate and regulate neuronal and network activity via regula-
tion of both excitatory and inhibitory transmission. Presyn-
aptic KARs downregulate GABA release from interneurons 
in the hippocampus through a metabotropic PKC and PLC 
dependent pathway that reduces inhibitory postsynaptic cur-
rents (IPSCs) [119].
KARs and  GABAARs
Moreover, postsynaptic KAR metabotropic signalling 
depresses synaptic  GABAARs while at the same time poten-
tiating extrasynaptic  GABAARs, in a process that decreases 
synaptic inhibitory drive to facilitate synaptic plasticity, 
while simultaneously protecting against neuronal over-exci-
tation by promoting extrasynaptic inhibition [120].
KARs and KCC2
In addition to this direct effect on  GABAAR-mediated trans-
mission, KARs separately regulate the potassium-chloride 
cotransporter KCC2. KCC2 is crucial because it establishes 
the electrochemical chloride gradient for postsynaptic inhi-
bition through  GABAARs [121, 122] and its dysregulation 
is implicated in autism spectrum disorder (ASD; [123]) 
and epilepsy [124]. KCC2 interacts with both Neto2 [125] 
and GluK2 [126], which increase the total abundance and 
enhance surface expression of KCC2 [14]. KCC2 and GluK2 
form macromolecular assemblies that traffic together, and 
this complex regulates intraneuronal chloride homeostasis 
to support  GABAAR-mediated transmission [126]. In addi-
tion, this process is further controlled by phosphorylation of 
serines 846 and 868 in GluK2 to determine surface KCC2 
levels [14]. These findings establish clear roles for KARs as 
modulators of postsynaptic inhibitory transmission.
KARs in Disease
Dysregulation of common molecular pathways underlies 
multiple neurological and neurodegenerative diseases and 
there is mounting evidence that KAR dysfunction could be 
one such feature (reviewed in [127, 128]).
Epilepsy
KAR dysfunction is particularly closely associated with 
temporal lobe epilepsy (TLE) [129], and  GluK2−/− mice 
exhibit significantly fewer seizures than wild-type counter-
parts [79]. TLE is associated with abnormal sprouting of 
recurrent mossy fibres, which synapse onto dentate gyrus 
cells [130–132] and this abnormal sprouting is also reduced 
in  GluK2−/− mice [133]. Consistent with the requirement 
for recruitment of KARs to postsynaptic sites for seizure 
activity, despite induction of MF sprouting in an animal 
model of TLE, C1ql2/3 double KO mice are resistant to sei-
zures [89] and genetic silencing of KARs at CA3 synapses 
attenuates kainate-induced seizures [134]. Together, these 
Fig. 4  Mechanism of KAR-LTPAMPAR. At CA3-CA1 synapses, acti-
vation of postsynaptic KARs leads to LTP of AMPAR-mediated syn-
aptic transmission. This occurs through KAR-mediated activation of 
a pertussis toxin-sensitive G protein, activation of phospholipase C 




studies suggest that recurrent synaptic activity, mediated 
by postsynaptic KARs, drives seizure activity in TLE, and 
highlights KARs as an attractive therapeutic target in the 
treatment of this disorder.
KARs and Other Neurological Disorders
In addition to TLE, both gain [135] and loss [136, 137] of 
GluK2 have been reported to lead to ASD-like phenotypes. 
Furthermore, duplication of the GluK4 gene has been associ-
ated with autism [138] and, consistent with this, overexpres-
sion of GluK4 in the forebrain of mice causes severe anxiety 
and ASD-like behaviours [139]. Additionally, GluK4 has 
been linked with treatment-resistant depression [140], and 
disruption of the gene encoding GluK4 has been observed 
in a patient with schizophrenia and mental retardation [141].
Most recently it has been reported that complete ablation 
of all KAR subunits results in disrupted corticostriatal func-
tion and dramatic obsessive-compulsive-like behaviour with 
severe self-grooming [142]. Together with the previous stud-
ies, these new observations support the notion that KAR-
mediated control of network activity is a key determinant of 
higher brain function, and that disruption of these pathways 
can lead to multiple neurological disorders.
Perspectives
Although historically much less studied than AMPARs 
or NMDARs, there is a currently a renaissance in KAR 
research fuelled by the realisation that they are multifunc-
tional neuronal modulators that have roles in health and dis-
ease far beyond those previously appreciated.
To understand how KARs exert these regulatory effects, it 
is necessary to define how KARs themselves are controlled 
and how they interact with, and regulate, other proteins and 
systems. Furthermore, while there is a growing apprecia-
tion of the multifaceted roles played by KARs, a number 
of fundamental questions remain unanswered. For example, 
while it is widely-accepted that KARs can signal both iono-
tropically and metabotropically through G-proteins, how this 
dual signaling occurs, and what determines which ‘mode’ 
of signaling an individual KAR complex utilizes remains 
almost entirely unexplored. In addition, while we are begin-
ning to understand the molecular events that control the spe-
cific distribution and synaptic localization of KARs, how 
these mechanisms cooperate to orchestrate the highly selec-
tive distribution of KARs in the brain remains an important 
unanswered question. Finally, although KARs can induce 
plasticity of AMPARs, exactly how this occurs, how wide-
spread this form of plasticity is in the brain, and whether 
postsynaptic KARs can direct other forms of bidirectional 
synaptic plasticity remain unknown.
We expect that further studies examining how KAR local-
isation and signalling at pre- and postsynaptic sites impacts 
on neuronal function will answer many of these remaining 
questions, and will transform our understanding of the roles 
KARs play in development, plasticity and disease.
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Ionotropic glutamate receptor (iGluR) trafficking and
function underpin excitatory synaptic transmission
and plasticity and shape neuronal networks. It is
well established that the transcription, translation,
and endocytosis/recycling of iGluRs are all regulated
by neuronal activity, but much less is known about
the activity dependence of iGluR transport through
the secretory pathway. Here, we use the kainate re-
ceptor subunit GluK2 as a model iGluR cargo to
show that the assembly, early secretory pathway
trafficking, and surface delivery of iGluRs are all
controlled by neuronal activity. We show that the
delivery of de novo kainate receptors is differentially
regulated by modulation of GluK2 Q/R editing,
PKC phosphorylation, and PDZ ligand interactions.
These findings reveal that, in addition to short-term
regulation of iGluRs by recycling/endocytosis and
long-term modulation by altered transcription/trans-
lation, the trafficking of iGluRs through the secretory
pathway is under tight activity-dependent control to
determine the numbers and properties of surface-
expressed iGluRs.INTRODUCTION
The morphological complexity of neurons presents unique chal-
lenges for the timelyandappropriatesupplyofproteins todynamic
and metabolically active synapses. The ionotropic glutamate re-
ceptor (iGluR) family comprising N-methyl-D-aspartate (NMDA),
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA),
and kainate receptors (NMDARs, AMPARs, and KARs, respec-
tively) are critical for synaptic transmission and plasticity, and
the mechanisms by which iGluRs are delivered to, retained at,
and removed from synapses under basal, stimulated, and patho-
logical conditions have been the focus of intense investigation for
decades (Huganir and Nicoll, 2013; Granger and Nicoll, 2013;
Lerma and Marques, 2013; Henley and Wilkinson, 2016).Cell
This is an open access article undThe transcription (Liu et al., 2010; Jia et al., 2006; Grooms
et al., 2006), RNA editing (Sanjana et al., 2012), translation (Schu-
man et al., 2006), post-translational modification (Martin et al.,
2007; Copits and Swanson, 2013; Lussier et al., 2015; Wilkinson
et al., 2012; Chamberlain et al., 2012; Konopacki et al., 2011),
and surface endocytosis/recycling (Glebov et al., 2015; Boehm
et al., 2006; Palmer et al., 2005; Beattie et al., 2000; Kennedy
and Ehlers, 2011) of iGluRs are all activity-dependently regu-
lated. Surprisingly, however, relatively little is known about
whether and how the delivery of newly synthesized iGluRs
through the secretory pathway is controlled by neuronal activity.
Studies using temperature-sensitive vesicular stomatitis virus G
transmembrane protein (tsVSV-G) as a cargo marker for the en-
domembrane system have reported that endoplasmic reticulum
(ER) exit sites (ERESs) are both present and utilized in dendrites
and that some VSV-G cargo subsequently colocalizes at den-
dritic Golgi outposts (Torre and Steward, 1996; Presley et al.,
1997; Horton and Ehlers, 2003). Using mRNA trafficked from
the soma, postsynaptic proteins can be locally translated and
post-translationally modified (Cajigas et al., 2012; Holt and
Schuman, 2013; Na et al., 2016). Furthermore, transmembrane
proteins with an immature glycosylation profile can be surface-
expressed, suggesting that not all secretory pathway cargo
needs to be processed within the Golgi prior to plasma mem-
brane insertion (Hanus et al., 2016).
Despite its widespread use, the fact that tsVSV-G is an exog-
enous viral protein and that temperature shifts are required
to release it from the ER raise important questions about its
fidelity as a reporter for endogenous neuronal proteins. Despite
these caveats, neuronal activity can increase VSV-G-containing
vesicle delivery through the secretory pathway to the cell surface
(Hanus et al., 2014), suggesting, but not directly demonstrating,
that the secretory pathway trafficking of endogenous cargos
such as iGluRs is likely to be activity-dependently regulated.
Furthermore, the secretory pathway trafficking of AMPARs can
be regulated by interactions with coat protomer II (COPII)
components following activation of metabotropic glutamate re-
ceptors (Pick et al., 2017).
To directly monitor iGluR processing and progression through
the secretory pathway under basal and stimulated conditions,
we adapted the retention using selective hooks (RUSH) system
that allows the synchronous release and visualization of theReports 19, 2613–2626, June 20, 2017 ª 2017 The Author(s). 2613
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Construction and Validation of
RUSH Glutamate Receptor Subunits in
HeLa and Primary Hippocampal Neuronal
Cells
(A) Schematic of a RUSH ionotropic glutamate re-
ceptor subunit. SBP, streptavidin-binding peptide.
(B) Representative confocal images of the AMPAR
subunits SBP-mCherry-GluA1 and SBP-EGFP-
GluA2 and the KAR subunit SBP-EGFP-GluK2 in
HeLa cells. Receptors are retained in the ER (0 min)
and synchronously released by biotin addition,
allowing trafficking to the cell surface (60 min after
biotin addition). Total, green; surface anti-SBP, red.
(C) Quantification of the data represented in (B);
three independent experiments, n = 80 cells/con-
dition. ****p < 0.0001, Welch’s t test.
(D) Representative still frames of the TIRF micro-
scopy video (Figure S1B; Movie S1), showing the
time course of trafficking and analysis of cell
surface delivery of SBP-SEP-GluK2 after biotin
addition. Arrows indicate sites of exocytosis.
Quantification of surface delivery over time is also
shown. See also Figure S1B.
(E) Representative confocal images of primary hip-
pocampal neurons showing the differential secre-
tory pathway trafficking rates of SBP-EGFP-GluK2,
SBP-mCherry-GluA1, and SBP-EGFP-GluA2 con-
taining KARs and AMPARs, respectively. Surface-
expressed receptorswerevisualizedusinganti-SBP
(red) at the indicated times (minutes) after biotin
release. White boxes positioned on the merged
panels indicate the region of the zoom panel.
(F) Quantification of the data shown in (E); three
independent experiments, n = 20–24 for each re-
ceptor per time point. ***p < 0.001, **p < 0.01,
Welch’s t test.
Scale bars, 10 mm.trafficking of cargo through the secretory pathway (Boncompain
et al., 2012). We used the KAR subunit GluK2 as a prototypic
iGluR cargo. KARs are present at both pre- and postsynaptic
membranes, where they perform distinct roles in modulating
synaptic transmission, neuronal excitability, and network activity
(Contractor et al., 2011; Lerma andMarques, 2013), and they are
implicated in processes ranging from neuronal development and2614 Cell Reports 19, 2613–2626, June 20, 2017differentiation to neurodegeneration and
neuronal cell death (Contractor et al.,
2011; González-González et al., 2012).
We show that KARs can use a local
dendritic secretory pathway. GluK2 edit-
ing is activity-dependently controlled,
resulting in modulation of KAR assembly
(Ball et al., 2010) and subsequent in-
creases in unedited GluK2-containing,
calcium-permeable KARs at the cell sur-
face (Egebjerg and Heinemann, 1993).
Under basal conditions, the secretory
pathway trafficking of GluK2-containing
KARs is regulated by protein kinase C
(PKC) phosphorylation. In a distinct regu-
latory process, surface KAR activationslows the progression of newly synthesized KARs through the
secretory pathway by modulating interactions at the C-terminal
PDZ ligand of GluK2. Together, these data reveal that the
delivery of de novo KARs to the cell surface is dynamically regu-
lated in a sophisticated, multilayered manner. These mecha-
nisms provide additional flexibility to neuronal responses to
changing cellular environments and network activity.
Figure 2. KARs Use Local Secretory Pathway Systems
(A) Schematic of dendritic local secretory pathways in neurons, focusing on ER exit sites.
(B) Representative fixed confocal images of dendritic ERESs (using the marker mRuby-Sec23a) and SBP-EGFP-GluK2 10 min after biotin addition. White arrows
in the merged panel indicate colocalization.
(C) Kymograph (Movie S2) of SBP-EGFP-GluK2 and mRuby-Sec23a up to 24 min 50 s after biotin addition, with a frame being taken every 10 s. White boxes on
the merged panel show the duration of colocalization.
(D) Schematic of dendritic local secretory pathways in neurons, focusing on the Golgi.
(E) Representative fixed confocal images of SBP-EGFP-GluK2 colocalization with the Golgi marker Sialyltransferase-mCherry (Golgi) before biotin release and a
line trace illustrating lack of colocalization along the line indicated in white in the merged image.
(F) Representative fixed confocal images of SBP-EGFP-GluK2 30 min after biotin-induced release with Sialyltransferase-mCherry (Golgi) and line trace quan-
tification.
(G) Kymograph (Movie S3) of SBP-EGFP-GluK2 and GalT-mCherry (Golgi) after biotin addition up to 59min 50 s, with a frame being taken every 10 s.White boxes
on the merged panel show colocalization duration.
Scale bars, 10 mm.
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RESULTS
Using RUSH to Assay iGluR Secretory Pathway
Trafficking
We utilized the RUSH system by tagging the GluK2 KAR subunit
and both the GluA1 and GluA2 AMPAR subunits at the N termi-
nus with a streptavidin-binding peptide (SBP) and a fluorescent
tag. When these constructs are coexpressed with a streptavi-
din-KDEL ‘‘hook’’ that localizes to the lumen of the ER, the
SBP-tagged subunits are anchored at the ER membrane (Fig-
ure 1A). The retained SBP-tagged receptors can then be syn-
chronously released by biotin addition to monitor their trafficking
through the secretory pathway (Figure S1A; Boncompain and
Perez, 2012).
We first validated these RUSH constructs in HeLa cells. As ex-
pected, the SBP-tagged receptors are efficiently retained in the
ER (0 min), and, upon addition of biotin, they are released and
move through the secretory pathway, reaching the cell surface
after 60 min (Figures 1B and 1C). Interestingly, each of the three
different subunits had different kinetics, with much more GluK2
than GluA1 or GluA2 present at the cell surface after 60 min.
Because GluK2 trafficsmost rapidly, wemeasured the dynamics
of surface expression using super-ecliptic pHluorin (SEP)-
tagged GluK2 (SBP-SEP-GluK2) (Ashby et al., 2004; Wilkinson
et al., 2014) and total internal reflection fluorescence (TIRF)
microscopy. GluK2 starts accumulating at the surface 30 min
after biotin-induced release from the ER (Figure 1D; Figure S1B;
Movie S1).
Consistent with the results from HeLa cells, we observed
different rates of secretory pathway trafficking for GluK2,
GluA1, and GluA2 in hippocampal neurons (Figures 1E and 1F).
In agreement with previous reports using endogenous subunits
(Greger et al., 2002), SBP-mCherry-GluA1 traffics through the
secretory pathway quicker than SBP-EGFP-GluA2. These data
show that the RUSH system allows synchronized release of
KARs and AMPARs from the ER in both clonal cell lines and neu-
rons and that it provides a powerful tool to investigate the early
trafficking steps of iGluRs.
KARs Use Dendritic ER Exit Sites and Golgi Outposts
VSV-G and NMDARs have been reported to use dendritic ERESs
and Golgi outposts (Figures 2A and 2D) for post-translational
modification, which is facilitated by the interacting proteins
CASK and SAP97 (Horton and Ehlers, 2003; Jeyifous et al.,
2009). Although KARs bind to both CASK and SAP97 through
a PDZ ligand/domain interaction (Coussen et al., 2002; Hirbec
et al., 2003), it is unknown whether KARs use local secretory
pathways. We therefore investigated this using SBP-EGFP-
GluK2 in neurons. SBP-EGFP-GluK2 colocalizes with mRuby-
Sec23A-labeled ERESs (Budnik and Stephens, 2009; Hughes
and Stephens, 2010) in dendrites after biotin-induced release
(Figures 2B and 2C; Figure S2A; Movie S2).
VSV-G colocalizes with local Golgi outposts after release from
dendritic ERESs (Horton and Ehlers, 2003; Figure 2D). Before
release, SBP-EGFP-GluK2 is retained in the ER and does not co-
localize with dendritic Golgi outposts (Figure 2E). However,
30 min after ER release by biotin, SBP-EGFP-GluK2 strongly co-
localized at Golgi outposts (Figures 2F and 2G; Figure S2B;2616 Cell Reports 19, 2613–2626, June 20, 2017Movie S3), demonstrating that KARs utilize local secretory
pathway systems.
Assembly and Surface Delivery of Newly Synthesized
KARs Is Controlled by Chronic Changes in Synaptic
Activity and Mediated by Changes in the RNA Editing
of GluK2
NMDAR and AMPAR surface expression scales in response to
chronic down- or upregulation of synaptic activity (Rao and
Craig, 1997; Shepherd et al., 2006; Turrigiano, 2012). To address
whether KARs also scale, we chronically suppressed synaptic
activity in hippocampal neurons with tetrodotoxin (TTX) for
24 hr. As expected, TTX significantly increased GluA1-contain-
ing AMPAR surface expression and also increased GluK2-con-
taining KARs at the cell surface with no change in surface
epidermal growth factor receptors (EGFRs) (Figures 3A and
3B), indicating that chronic blockade of activity upscales
GluK2-containing KARs.
The pre-mRNAs encoding GluA2 and GluK2 can undergo
editing at a site within the channel pore that changes a
glutamine (Q) residue to an arginine (R) in the translated sub-
unit (Sommer et al., 1991). This Q/R editing alters the calcium
permeability of surface-expressed AMPARs (Burnashev et al.,
1992) and KARs (Köhler et al., 1993). Q/R editing also regu-
lates AMPAR and KAR subunit assembly and ER exit (Greger
et al., 2002; Ball et al., 2010). We generated RUSH variants of
edited and unedited GluK2, and, consistent with previous
observations (Ball et al., 2010), the edited (R) form of SBP-
EGFP-GluK2 exhibited lower levels of surface expression
compared with the unedited Q form in HeLa cells after 24 hr
of biotin-induced release (Figures 3C and 3D; Figure S3A).
Furthermore, TTX decreases Q/R editing of GluK2 (Figures
3E and 3F). We hypothesized that this change in GluK2 editing
will promote KAR assembly and ER exit, resulting in increased
surface expression. To test this, we knocked down ADAR2,
the enzyme responsible for GluK2 editing (Nishikura, 2016;
Figure S3B). ADAR2 knockdown reduced GluK2 editing similar
to TTX treatment (Figure S3C) and upscaled surface GluK2 in
the absence of TTX (Figures 3G and 3H), indicating that KAR
scaling is mediated, at least in part, by activity-dependent
regulation of GluK2 Q/R editing.
PKC Phosphorylation Regulates Basal KAR Trafficking
through the Secretory Pathway
To measure the secretory pathway trafficking and surface
expression of de novo KARs without confounding issues from
endocytosis and recycling of KARs, we modified the RUSH pro-
tocol to measure all subunits that reach the cell surface by live
labeling (Figure 4A). To ensure that this live labeling protocol
faithfully reports only secretory pathway trafficking to the cell
surface and is not affected by rates of endocytosis, we exposed
SBP-EGFP-GluK2-expressing HeLa cells to kainate to promote
KAR endocytosis (Figure S4A). Comparable surface delivery
levels of SBP-EGFP-GluK2 were observed with and without kai-
nate, confirming that this procedure only reports de novo KARs
delivered by the secretory pathway (Figures 4B and 4C).
Serines 846 and 868 in the C terminus of GluK2 are phosphor-
ylated by PKC, and phosphomimetic mutations of these residues
Figure 3. KAR ER Exit Is Regulated by Activity-Dependent Changes in RNA Editing of GluK2
(A) Representative western blots of surface-biotinylated KAR and AMPAR subunits and EGFR in hippocampal neurons. The blots show surface and total levels of
subunits with or without 24-hr treatment with 1 mM TTX to suppress synaptic activity.
(B) Quantification of immunoblots and comparison of surface-to-total ratios from six (GluA1 and EGFR) and seven (GluK2) independent experiments. *p < 0.05,
Wilcoxon matched pairs signed-rank test.
(C) SBP-EGFP-GluK2 unedited (Q) or edited (R) RUSH constructs transfected into HeLa cells with addition of biotin at the time of transfection to allow basal
expression. Surface RUSH KARs were labeled with anti-SBP for a duration of 5 min. See also Figure S3A.
(D) Quantification from (C), representative of three independent experiments (n = 90). ****p < 0.0001, Welch’s t test.
(E) RT-PCR and digestion analysis of levels of unedited and edited GluK2 with or without TTX treatment. Black arrows indicate unedited forms of GluK2.
(F) Quantification of unedited and edited GluK2 with or without TTX treatment (n = 5). *p < 0.05, Welch’s t test.
(G) Representative western blots of surface-biotinylated GluK2 and EGFR after lentiviral infection of primary hippocampal neurons with either scrambled or
ADAR2-targeting shRNA. The blots show both total and surface levels of GluK2 and EGFR after 5 days of knockdown. See also Figure S3B.
(H) Quantification of immunoblots and comparison of surface-to-total ratios from six independent experiments. *p < 0.05, Wilcoxon matched pairs signed-rank
test.
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cause ER retention (Konopacki et al., 2011). We therefore used
the RUSH assay to assess the role of GluK2 phosphorylation in
KAR trafficking through the secretory pathway. We mutated
both S846 and S868 to non-phosphorylatable alanines (SBP-
EGFP-GluK2-AA) or to phosphomimetic aspartic acid residues
(SBP-EGFP-GluK2-DD). As predicted, the AA phospho-null mu-
tant traffics more and the DD phosphomimetic mutant traffics
less efficiently to the cell surface than the wild-type SBP-EGFP-
GluK2 under non-stimulated conditions. In parallel, we tested
the effect of the PKC activator phorbol 12-myristate 13-acetate
(PMA) on surface accumulation. Consistent with the mutant
data, PMA decreased the surface expression of SBP-EGFP-
GluK2, whereas SBP-EGFP-GluK2-AA was unaffected (Figures
4D and 4E; Figure S4B). Our interpretation of these results is
that a proportion of GluK2 is basally phosphorylated by PKC in
the ER and that this provides a mechanism to regulate the ER
exit and supply of de novo KARs for delivery to the cell surface.
Activation of Surface-Expressed KARs Regulates De
Novo KAR Delivery to the Cell Surface
Our data demonstrate that, rather than being a constitutive pro-
cess, the secretory pathway trafficking of KARs is subject to strict
regulation. Under basal conditions, PKC phosphorylation limits
the supply of GluK2-containing KARs, and chronic suppression
of synaptic activity reduces Q/R editing, which promotes KAR as-
sembly and ER exit. Therefore, we next tested the effects of direct
activation of surface-expressed KARs on SBP-EGFP-GluK2 traf-
ficking.We used our previously described transient kainate appli-
cation protocol (5min, 10 mMkainate + TTX followed bywashout),
which increases KAR surface expression (Martin et al., 2008;
González-González and Henley, 2013). This transient kainate
application prior to biotin-induced SBP-EGFP-GluK2 release
from the ER caused a significant reduction in trafficking through
the secretory pathway to the cell surface (Figures 5A and 5B). In
contrast, the secretory pathway trafficking of SBP-EGFP-GluA1
was unaffected (Figures 5C and 5D). These results indicate that
transient activation of surface KARs can selectively reduce the
trafficking of de novo KARs through the secretory pathway to
control the supply of receptors available for insertion at the cell
surface (FigureS5).We initially hypothesized that phosphorylation
of S846 and S868 may mediate the kainate-evoked reduction in
the surface delivery of de novo KARs (Nasu-Nishimura et al.,
2010; Konopacki et al., 2011). Contrary to our expectations, how-
ever, secretory pathway trafficking of the non-phosphorylatable
SBP-EGFP-GluK2-AA was also significantly reduced by transient
kainate stimulation (Figures 5E and 5F). Thus, kainate regulation
of KAR secretory pathway trafficking appears to be mediated
via a mechanism other than PKC phosphorylation.
The GluK2 PDZ Ligand Is Involved in Basal and Activity-
Dependent Delivery of De Novo Receptors to the Cell
Surface
The GluK2 PDZ ligand (905ETMA908) interacts with multiple PDZ
domain-containing proteins, including SAP97, PICK1, PSD95,
GRIP, syntenin, and CASK (Coussen et al., 2002; Hirbec et al.,
2002), and inhibition of PDZ interactions using a competing pep-
tide leads to a rundown in KAR excitatory postsynaptic currents
(EPSCs) (Hirbec et al., 2003). We therefore mutated the extreme2618 Cell Reports 19, 2613–2626, June 20, 2017C-terminal PDZ ligand of SBP-EGFP-GluK2 from the wild-type
sequence ETMA to EPAS, which cannot interact with PDZ
domain-containing proteins (Hirbec et al., 2003).
In HeLa cells, secretory pathway trafficking for both wild-type
SBP-EGFP-GluK2-ETMA and the PDZ ligand mutant SBP-
EGFP-GluK2-EPAS was comparable (Figures 6A and 6B; Fig-
ure S6A). Similarly, there was no difference between the wild-
type and EPAS mutant when expressed in neurons with addition
of biotin at the same time as transfection to allow continuous
release of the receptor from the ER to determine their steady-
state localization (Figures 6C and 6D; Figure S6B).
We next performed experiments corresponding to those
shown in Figure 5, where biotin was added to elicit synchronized
release of SBP-EGFP-GluK2 or SBP-EGFP-GluK2-EPAS with or
without a transient kainate stimulation prior to biotin application.
This transient kainate stimulation significantly decreased the
secretory pathway trafficking of wild-type SBP-EGFP-GluK2-
ETMA (Figures 6E and 6F). Interestingly, the secretory pathway
trafficking of SBP-EGFP-GluK2-EPAS was significantly reduced
compared with SBP-EGFP-GluK2-ETMA under basal condi-
tions. Furthermore, the secretory pathway trafficking of SBP-
EGFP-GluK2-EPAS was not further decreased by kainate appli-
cation, indicating that preventing PDZ interactions occludes the
kainate-induced reduction in secretory pathway trafficking (Fig-
ures 6Eand6F; Figure S6B). Together, these results demonstrate
that, although the GluK2 PDZ interactions do not affect the
steady-state localization of GluK2-containing KARs, they regu-
late their activity-dependent secretory pathway trafficking.
DISCUSSION
Here we show that GluK2-containing KARs use a local secretory
pathway system close to their sites of membrane delivery.
Rather than being a constitutive process, KAR traffic through
the secretory pathway is tightly and differentially regulated
under chronically suppressed, basal, and transiently stimulated
conditions.
Validation of the RUSH System in Neurons
RUSH provides a powerful system for investigating the dynamics
ofAMPARandKAR trafficking to thecell surface.Weshowthat the
RUSHGluA1 andGluA2AMPARsubunits andGluK2KAR subunit
are effectively retained at the ERmembrane and can be synchro-
nously releasedondemandbyadditionofbiotin inbothclonal cells
and primary neurons. Importantly, the rates of traffic through the
secretory pathway we measured for GluA1 and GluA2 agree well
with rates reported for endogenous AMPAR subunits monitored
by pulse-chase radiolabeling, with GluA1 trafficking more rapidly
than GluA2 (Greger et al., 2002; Greger and Esteban, 2007).
KAR Scaling Is Mediated by GluK2 Editing
AMPARs and NMDARs scale in response to a prolonged
decrease or increase in synaptic activity (Turrigiano, 2012).
Given their importance in neuronal circuit development and
both pre- and postsynaptic function (Contractor et al., 2011;
Lerma and Marques, 2013) we reasoned that it is likely that
KARs also need to be tuned in response to overall activity
changes. Consistent with this, KARs are scaled by chronic
Figure 4. Basal PKC Phosphorylation Suppresses Surface Delivery of KARs
(A) Schematic illustrating the live labeling protocol used to exclude any contribution of changes in endocytosis. 1: hooked RUSH receptor before the addition of
biotin. 2: live label with anti-SBP antibody. 3: addition of biotin allows release of receptors and accumulation at the cell surface. 4: anti-SBP antibodies bind to
newly exposed SBP-tagged receptors. 5: a proportion of receptors internalize, but cells are permeabilized and labeled with a secondary antibody labeling all
receptors that have been surface-exposed.
(B) Representative images of the live labeling protocol showing that 100 mMKA does not change the secretory pathway delivery and extent of surface expression
of SBP-EGFP-GluK2 in HeLa cells 35 min after biotin addition. See also Figure S4A.
(C) Quantification of the data shown in (B); two independent experiments, n = 80. p > 0.05, Welch’s t test.
(D) Representative images of hippocampal neurons expressing SBP-EGFP-GluK2 WT, SBP-EGFP-GluK2 S846A/S868A, or SBP-EGFP-GluK2 S846D/S868D
30 min after biotin in the presence or absence of PMA. Total receptor distribution was measured using the EGFP tag, and surface-expressed receptors were
determined using live labeling with anti-SBP. See also Figure S4B.
(E) Quantification of three independent experiments (n = 17–22). ***p < 0.0005, **p < 0.01, *p < 0.05; Welch’s t test.
Scale bars, 10 mm.
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suppression of synaptic activity (Yan et al., 2013). We propose a
mechanism analogous to NMDAR scaling whereby changes in
RNA editing regulate the ER exit and, consequently, the availabil-
ity of new NMDARs for delivery to the surface (Mu et al., 2003).
We show that chronic suppression of synaptic activity decreases
Q/R editing of GluK2, which promotes KAR assembly, ER exit,
and delivery to the cell surface (Figure 7). This mechanism to
restrict the amount of KARs reaching the cell surface likely plays
a key role in controlling neuronal excitability, and it is notable
that transgenic mice deficient in Q/R editing display increased
seizure vulnerability (Vissel et al., 2001).
PKC Phosphorylation of GluK2 Controls Basal
Trafficking through the Secretory Pathway
Agonist activation of surface-expressed KARs causes PKC
phosphorylation of GluK2 at S846 and S868, which promotes
SUMOylation and KAR endocytosis (Martin et al., 2007;
Konopacki et al., 2011; Chamberlain et al., 2012). Further-
more, phosphomimetic serine-to-aspartate mutations of resi-
dues 846 and 868 in GluK2 impede KAR traffic to the cell sur-
face (Nasu-Nishimura et al., 2010; Konopacki et al., 2011).
Here we show that these PKC phosphorylation sites are
involved in ER exit of KARs and that preventing PKC phos-
phorylation of GluK2 by mutating S846 and S868 to alanine in-
creases basal rates of secretory pathway trafficking. Thus,
PKC phosphorylation of S846 and S868 in GluK2 exerts mul-
tiple levels of control over KAR trafficking, including regulating
the number of GluK2-containing KARs that can exit the ER and
enter the secretory pathway (Figure 7).
Transient Kainate Receptor Activation Downregulates
the Delivery of Newly Synthesized KARs
Transient KAR activation can elicit a lasting upregulation of KARs
at the cell surface because of increased recycling back to the sur-
face (Martin et al., 2008; González-González and Henley, 2013),
and this form of KAR activation can also induce long-term poten-
tiation (LTP)ofAMPARs (Petrovicet al., 2017;Sanjanaetal., 2012).
Here we show that transient kainate stimulation decreases the
supply of de novo KARs through the secretory pathway.We inter-
pret these results to indicate a negative feedbackmechanism that
can limit the extent of the increase in KAR surface expression.
Thus, following a kainate-induced increase in surface expression
of locally available KARs, the supply of new receptors is restricted
to prevent positive feedback, leading to further increases in KAR
surface expression and uncontrolled neuronal excitability and ex-
citotoxicity. This agonist-mediated regulation of KAR secretory
pathway trafficking is not due to changes in the phosphorylation
status of S846 and S868 because secretory pathway traffic of
the PKC non-phosphorylatable GluK2 mutant was also reduced
by transient kainate application. Furthermore, this regulatory sys-
tem isKAR-specificbecausekainate stimulationdoesnot regulate
the secretory pathway traffic of AMPARs.
GluK2 PDZ Interactions and the Activity-Controlled
Secretory Pathway
The PDZ ligand of GluK2 binds to an array of interacting proteins,
including PSD95, SAP97, PICK1, GRIP, CASK, and syntenin
(Coussen et al., 2002; Hirbec et al., 2003) that control many as-2620 Cell Reports 19, 2613–2626, June 20, 2017pects of KAR localization and function. C-terminal truncations of
GluK2 that removed the PDZ ligand did not result in major de-
fects in trafficking in heterologous cells, indicating that the PDZ
ligand is not required for folding or ER exit (Yan et al., 2004).
Consistent with this, secretory pathway trafficking is similar for
GluK2 containing either the wild-type (ETMA) or mutated non-
binding (EPAS) PDZ ligand. Furthermore, the steady-state local-
ization of PDZ ligand mutants was also unchanged, suggesting
that, although PDZ interactions are important for the dynamics
of secretory pathway trafficking, they are not required for correct
localization of GluK2.
Disruption of the GluK2 PDZ ligand did, however, significantly
decrease basal secretory pathway trafficking in neurons, which
occluded the kainate-induced reduction of secretory pathway
trafficking. This is consistent with our previous observation that
a peptide corresponding to the PDZ ligand of GluK2 can out
compete endogenous interactions and, consequently, causes
rundown of KAR-mediated EPSCs (Hirbec et al., 2003) and
long-term depression of kainate receptor-mediated synaptic
transmission (Park et al., 2006). Both of these reductions in
KAR-mediated transmission are sustained over long periods,
and we propose that they are attributable, at least in part, to
the activity-dependent reductions in KAR secretory pathway
trafficking we describe here.
In summary, the secretory pathway trafficking of KARs occurs
through local secretory pathways using ERES in distal dendrites
and Golgi outposts. We note, however, that it has recently been
reported that KARs with an immature glycosylation state
accumulate at the cell surface, suggesting that not all KARs are
processed within the Golgi (Hanus et al., 2016). Like long-term
regulation of iGluR synthesis by transcription and translation
and short-term regulation by endocytosis and recycling of sur-
face-expressed iGluRs, the intermediate-term processes of traf-
ficking through the secretory pathway are also under tight activ-
ity-dependent control. These additional medium-term regulatory
mechanisms add further flexibility and subtlety to neuronal excit-
ability and network activity. Consistent with this general idea, the
secretory pathway trafficking of the GluA2 AMPAR subunit can
be regulated by an activity-dependent interaction with COPII
vesicle proteins during mGluR-mediated, long-term depression
(Pick et al., 2017). These findings open exciting avenues of
research into how defects in this local secretory trafficking of
KARs contribute to diseases such as epilepsy and autism, in
which misregulation of KARs have been strongly implicated.
EXPERIMENTAL PROCEDURES
Primary Neuronal Culture
Embryonic hippocampal neurons were isolated from E18 Wistar rats as
described previously (Martin and Henley, 2004). The cells were then plated
out at various densities and cultured for up to 2 weeks. Plating medium was
left on the cells for the first 24 hr: Neurobasal (Gibco) medium supplemented
with horse serum (10%), GS21 (GlobalStem), and 2 mM Glutamax. Then this
was changed to feeding medium (lacking horse serum) for the duration of
the culture. Animal care and all experimental procedures were conducted in
accordance with UK Home Office and University of Bristol guidelines.
DNA Construct Generation and Transfection
All RUSH iGluR constructs were assembled in the RUSH vector system as
described previously (Boncompain and Perez, 2013). Briefly, glutamate
Figure 5. KAR Progress through the Secretory Pathway Is Regulated by Transient KAR Stimulation
(A) Representative images of SBP-EGFP-GluK2 without biotin (0), with biotin for 30 min (30), or with a transient 5-min pre-treatment with 10 mM kainate before
biotin addition (30+KA). Total SBP-EGFP-GluK2 was visualized with EGFP, and the surface-expressed SBP-EGFP-GluK2 was live-labeled with anti-SBP.
(B) Quantification of five independent experiments (n = 24–40). ****p < 0.0001, Welch’s t test.
(C) Representative images of SBP-EGFP-GluA1 without biotin (0), with biotin for 45 min (45), or with a transient 5-min pre-treatment with 10 mM kainate
before biotin addition (45+KA). Total SBP-EGFP-GluA1 was visualized with EGFP, and the surface-expressed SBP-EGFP-GluA1 was live-labeled with anti-SBP
antibody.
(D) Quantification of three independent experiments; n = 24 for all conditions. p > 0.05, Welch’s t test.
(E) Representative images of SBP-EGFP-GluK2 S846A/S868A, 30 min after biotin (AA 30), or with a transient 5-min pre-treatment with kainate before biotin
addition (AA 30+KA). Total SBP-EGFP-GluK2 S846A/S868Awas visualizedwith EGFP, and surface-expressed SBP-EGFP-GluK2 S846A/S868Awas live-labeled
with anti-SBP antibody.
(F) Quantification of three independent experiments; n = 15–30. ****p < 0.0001, ***p < 0.001, Welch’s t test.
Scale bars, 10 mm.
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Figure 6. The PDZ Ligand of GluK2 Is
Involved in Both Basal and Activity-Depen-
dent Progression of KARs through the
Secretory Pathway
(A) Representative images of HeLa cells showing
the distributions of exogenously expressed SBP-
EGFP-GluK2-ETMA or SBP-EGFP-GluK2-EPAS
before and 30 min after addition of biotin. In
all cases, EGFP was used to visualize total
receptors, and surface-expressed KARs were
visualized by live labeling with anti-SBP antibody.
(B) Quantification of two independent experiments;
n = 40 for 0 and n = 80 for 30. p > 0.05, Welch’s t
test. See also Figure S6A.
(C) Representative images of hippocampal neu-
rons expressing SBP-EGFP-GluK2-ETMA or SBP-
EGFP-GluK2-EPAS 24 hr after addition of biotin.
EGFP was used to visualize total receptors, and
surface-expressed KARs were visualized by live
labeling with anti-SBP antibody.
(D) Quantification of three independent experi-
ments; n = 22–24. p > 0.05, Welch’s t test.
(E) Representative images of hippocampal neu-
rons expressing SBP-EGFP-GluK2-ETMA or SBP-
EGFP-GluK2-EPAS before or 30 min after addition
of biotin, with or without a transient 5-min pre-
treatment of 10 mM kainate. EGFP was used to
visualize total receptors, and surface-expressed
KARswere visualized by live labeling with anti-SBP
antibody. See also Figure S6B.
(F) Quantification of four independent experi-
ments; n = 21–32. ****p < 0.0001, ***p < 0.001,
Welch’s t test.
Scale bars, 10 mm.receptors were cloned so that the fluorescent protein (FP) and the SBP were
positioned immediately after an N-terminal signal peptide (in all cases, the
interleukin-2 signal peptide was used). The structure is therefore SP-SBP-
FP-glutamate receptor. All GluK2 constructs had an additional myc tag on
the N terminus, and all SBP-EGFP-GluK2 constructs used, unless specified
otherwise, were Q-edited versions (Martin et al., 2007). The R-edited version
of SBP-EGFP-GluA2 was used throughout. For each iGluR construct, a for-2622 Cell Reports 19, 2613–2626, June 20, 2017ward primer was designed with an FseI restriction
site and the reverse primer with a PacI site,
followed by cloning of the PCR product using stan-
dard molecular biology techniques. QuikChange
mutagenesis was used to introduce point muta-
tions. Fluorescent tags were switched using for-
ward and reverse primers with SbfI and FseI sites,
respectively. DH5a was used to clone and amplify
DNA. A Lipofectamine 2000 method from Invitro-
gen was used to introduce DNA into hippocampal
neurons (days in vitro [DIV] 13–14) and HeLa cells.
Cells were incubated at 37C and 5% CO2 for
18–24 hr before fixation or live imaging (Boncom-
pain et al., 2012).
Virus Generation and shRNA
For ADAR2 knockdown experiments, a short
hairpin RNA (shRNA)-targeting ADAR2 (target
sequence AACAAGAAGCTTGCCAAGGCC) under
the control of an H1 promoter was cloned into a
modified form of the lentiviral vector pXLG3. Lenti-
viruses were then produced using HEK293T cells,harvested, and added to DIV 9/10 hippocampal cells for 5 days, followed by
surface biotinylation (Rocca et al., 2017).
Live Cell Surface Labeling and Fixation
All experimentswith surface stainingwere performed using a live imaging proto-
col. RUSH-transfected hippocampal neuronsorHeLacellswere live-labeled us-
ing an anti-SBP (Millipore, monoclonal, clone 20, MAB10764) primary antibody.
Figure 7. Model
Shown is a schematic summarizing our results.
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For activity experiments, cells were incubated for 5 min in 1 mM TTX with or
without 10 mM kainate (Tocris Bioscience) and then washed with PBS.
GYKI53655 (40 mM, Abcam) was included to block AMPARs. The PKC acti-
vator PMA (12-O-tetradecanoylphorbol-13-acetate [TPA], Cell Signaling Tech-
nology) was used at 1 mM, and DMSOwas used as a vehicle. HEPES-buffered
saline (HBS) (NaCl, 140 mM; KCl, 5mM; glucose, 15 mM; HEPES, 25 mM;
CaCl2, 1.5 mM; and MgCl2, 1.5 mM) containing D-biotin (40 mM, Sigma) was
added to the cells in the presence of the anti-SBP antibody (1/500 dilution)
for different times. The 0 time point was incubated with just anti-SBP and no
biotin but always for the longest time being tested. After completion, cells
were washed with PBS multiple times before fixing in 4% paraformaldehyde
(PFA) for 8–10 min and quenched in 100 mM glycine (Severn Biotech). Cells
were then incubated with PBS + 3% BSA (Sigma) with 0.1% Triton X-100
(Fisher Scientific) for 10 min and then with PBS + 3% BSA for a further 10 min.
For all non-live labeling experiments, themediumwas removed from cells on
the day of fixation. The cells were then washed with PBS, and methanol
(20C) was added to the cells and incubated at 20C for 4 min. The cells
were then washed in PBS.
Fixed Immunostaining and Secondary Antibody Labeling
After fixation, the cells were washed in PBS before addition of primary anti-
bodies diluted in PBS + 3% BSA for an incubation time of 60 min.
Cells were washed in PBS before adding secondary antibodies (Jackson
ImmunoResearch Laboratories), which were used at 1:400 dilution in PBS +
3% BSA. The cells were then washed again in PBS and mounted onto glass
slides using Fluoromount-G with DAPI (eBioscience).
Imaging and Analysis
A Leica SP5 confocal microscope was used to image both the total (EGFP/
mCherry) and surface (anti-SBP) fluorescence, and a surface-to-total ratio
was calculated after analysis. ImageJ was used to analyze surface-to-total ra-
tios. Multiple boxes were drawn onto proximal and secondary dendrites that
had an EGFP/mCherry signal present. The total fluorescence was measured,
and then the channel was switched to surface fluorescence to measure the
surface. A surface-to-total ratio was measured, and then an average of the
multiple box measurements gave a cell surface-to-total ratio. At least eight
cells were analyzed per experiment, and experiments were repeated at least
three times using cells from independent dissections. TIRF analysis was
done using the mCherry signal to mark the cell surface. ImageJ was used to
thenmeasure the accumulation of SEP fluorescence. Prism and eitherWelch’s
t tests (direct comparison of two time points/conditions/receptors) orWilcoxon
matched-pairs signed-rank (normalized control sample) tests were used to
determine statistical significance. Data are represented as mean, and SEM
values are used for error bars. Kymograph live imaging representations and
colocalization line traces were made using ImageJ. The scale bars used
throughout all figures represent 10 mm.
RUSH Wide-Field Imaging
A Nikon Ti microscope with a Plan Apo VC 603 oil differential interference
contrast (DIC) lens and an Andor DU-885 camera were used to acquire live
wide-field RUSH images. The heated stage was pre-heated to 37C. The cell
medium was replaced with 1 mL pre-warmed HBS. When RUSH-transfected
cells were found, biotin was added to the cells by diluting biotin to a 23working
solution inHBS. 1mLof this 23 biotin working solutionwas added to the original
1 mL of imaging medium already on the cells. The cells were imaged over time
periods of up to 60 min, with a frame being taken every 5 or 10 s.
RUSH TIRF Imaging
A Leica AM TIRF MC system attached to a Leica DMI 6000 inverted epifluor-
escence microscope was used to image the surface of cells. A 633 oil lens
was used. HBS was added to the cells, and the cells were found and focused,
and the cell surface plane (mCherry) was found using automated TIRF angles.
Frames were taken every 30 s.
Scaling, Surface Biotinylation, and Western Blot
Hippocampal neurons (DIV 14–15) plated at a density of 500,000 per well of a
6-well dish were treated with 1 mM TTX for 24 hr. All steps were performed on2624 Cell Reports 19, 2613–2626, June 20, 2017ice with ice-cold buffers unless stated otherwise. After the stated treatments,
hippocampal neurons were washed twice in PBS. Surface proteins were
labeled with membrane-impermeable Sulfo-NHS-SS biotin (0.3 mg/mL,
Thermo Scientific) for 10 min on ice and washed three times with PBS.
50 mM NH4Cl was added to quench free biotin-reactive groups, and cells
were extracted with lysis buffer (50 mM Tris [pH 7.4], 150 mMNaCl, 1% Triton,
0.1% SDS, and protease inhibitor [Complete, Roche]), incubated on ice for
30 min, and centrifuged (15,000 3 g, 4C, 20 min) to remove insoluble cell
debris. For isolation of surface proteins, samples were incubated with strepta-
vidin beads (Sigma) for 90 min at 4C. Following three washes, the samples
were boiled with 23 sample buffer at 95C for 10 min, resolved by SDS-
PAGE, and immunoblotted. Antibodies used were as follows: GluA1 and
GluK2 (Millipore), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
EGFR (Abcam), and ADAR2 (Sigma). Western blots were imaged and quanti-
fied using LI-COR Biosciences Image Studio software. The surface levels of
GluA1, GluK2, and EGFR were normalized to their respective total levels to
determine surface expression. Treated samples were normalized to their con-
trol samples.
RNA Extraction and RT-PCR
RNA samples were extracted from DIV 14 hippocampal neurons after the
stated treatments using the RNeasy Mini RNA extraction kit (QIAGEN)
following the manufacturer’s protocol. 1 mg of RNA was used per condition
and reverse-transcribed to cDNA using the RevertAid First Strand cDNA Syn-
thesis Kit following the manufacturer’s protocol (Thermo Scientific). The
following primers (spanning the M2 region of GluK2) were used, giving a
PCR product of 452 bp: GluK2 F, 50-GGTATAACCCACACCCTTGCAACC-30;
GluK2 R, 50-TGACTCCATTAAGAAAGCATAATCCGA-30. To determine the
level of GluK2 RNA editing, BbvI (New England Biolabs) digestion was used
(Bernard et al., 1999). Digestion of the PCR product was performed at 37C
for 2 hr. All of the digested product was run on 4% agarose gel, and the
ethidium bromide-stained bands were imaged using a UV transilluminator
and quantified using NIH ImageJ. To determine the level of editing, the
following formula was used: (intensity of 376 [edited] / intensity of [376 (edi-
ted) + 269 (unedited)]) 3 100. The band at 76 bp was used to determine equal
loading.
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Figure S1. RUSH GluK2 receptor leaving the ER and exocytosing into the cell surface. 
Related to Figure 1. (see Supplemental Movie S1) 
 
A) Primary hippocampal neurons were transfected with SBP-EGFP-GluK2 and an ER 
marker UBC6-mCherry (Wozniak et al., 2009). Frames were takien every 5 seconds after 
biotin addition. Still frames are shown demonstrating that before biotin there is colocalisation 
between SBP-EGFP-GluK2 and UBC6-mCherry and then a seperation after biotin addition 
(white arrows indicate seperation). 
B) Movie from Figure 1D. HeLa cells were transfected for 20-24 hours with SBP-SEP-GluK2 
and mCherry (to outline the cell). The bottom of the cell was found using TIRF imaging and 
biotin was added to release the ‘hooked’ receptor. Time is indicated in HR:MN:SC and split 
panels are shown for both SBP-SEP-GluK2, mCherry and a merged panel is also shown. 
Scale bars in all panels = 10µm. 
 
Reference 
Wozniak, M.J., Bola, B., Brownhill, K., Yang, Y.C., Levakova, V. & Allan, V.J. 2009. Role of 
kinesin-1 and cytoplasmic dynein in endoplasmic reticulum movement in VERO cells. J Cell 





Figure S2: SBP-EGFP-GluK2 uses a local dendritic secretory pathway. Related to Figure 2. 
 
A) Still image from the Kymograph shown in Figure 2C, please see Supplemental Movie S2. 
Primary hippocampal neurons were cotransfected for 20-24 hours with SBP-EGFP-GluK2 
and mRuby-Sec23a to mark ER exit sites. Time is indicated in HR:MN:SC after the addition 
of biotin at the beginning of the movie. 
B) Still image Kymograph shown in Figure 2G, please see Supplemental Movie S3. Primary 
hippocampal neurons were cotransfected for 20-24 hours with SBP-EGFP-GluK2 and GalT-
mCherry to mark dendritc Golgi ouposts. Time is indicated MN:SC after the addition of biotin 
at the beginning of the movie. 




Figure S3: The GluK2 unedited (Q) and edited (R) are expressed at comparable levels and 
ADAR2 shRNA knocks down ADAR2 resulting in a decrease in GluK2 editing in primary 
neuronal culture. Related to Figure 3. 
 
A) Total EGFP measurements (from Figure 3C, D) are compared from HeLa cells 
transfected for 20-24 hours with either SBP-EGFP-GluK2 (Q) or SBP-EGFP-GluK2 (R). This 
is to ensure there is no difference in the expression levels of the two different DNA 
constructs. 3 independent experiments and n=90. p>0.05, Welch’s T Test. 
B) Primary hippocampal neurons were infected with lentivirus expressing either scrambled 
or ADAR2 targeting shRNA, lysed and immunoblotted for ADAR2 and GAPDH. Graph 
shows quantification from 6 independent experiments. *=p<0.05, Wilcoxon matched-pairs 
signed rank test. 
C) Primary hippocampal neurons were infected with lentivirus expressing either scrambled 
or ADAR2 targeting shRNA. Black arrows indicate unedited forms of GluK2. RT-PCR was 
performed on samples and digestion analysis of levels of unedited and edited GluK2 are 
displayed with quantification. **=p<0.01, Welch’s T Test. 
 
 
Figure S4: Kainate causes kainate receptor internalisation in HeLa cells and GluK2, GluK2 
AA and GluK2 DD are all expressed at comparable levels. Related to Figure 4. 
 
A) HeLa cells were transfected with SBP-mCherry-GluK2 (no hook, non RUSH variant) for 
20-24 hours. Cells were untreated or exposed to kainate (100µM) and surface GluK2 
labelled with Anti-SBP for 5 minutes. Cells were fixed in 4% PFA and not permeablised 
allowing labelling of just the receptors that remain at the cell surface and not the internilised 
population. Scale bars = 10µm. n=44-50, 2 independent experiments. *=p<0.05, Welch’s T 
Test. 
B) Total EGFP measurements (from Figure 4D, C) are compared from neurons transfected 
for 20-24 hours with SBP-EGFP-GluK2, SBP-EGFP-GluK2-AA or SBP-EGFP-GluK2-DD. 
This is to ensure there is no difference in the expression levels of the three different DNA 





Figure S5: The transient kainate-mediated decrease in secretory pathway trafficking of de 
novo KARs is not mediated by activation of AMPARs. Related to Figure 5. 
 
Primary hippocampal neurons were transfected with SBP-EGFP-GluK2 and released with 
biotin with or without a pre-biotin stimulation with 10µM KA or 10µM KA with 40µM GYKI-
52466. KA still causes a decrease in de novo receptor surface delivery of KARs even in the 





Figure S6: The GluK2 WT and EPAS mutant are expressed at comparable levels in both 
HeLa cells and neurons. Related to Figure 6. 
 
A) Total EGFP measurements (from Figure 6A, B) are compared from HeLa cells 
transfected for 20-24 hours with either SBP-EGFP-GluK2 or SBP-EGFP-GluK2 EPAS. This 
is to ensure there is no difference in the expression levels of the two different DNA 
constructs. 3 independent experiments, n=80. p>0.05, Welch’s T Test. 
B) Total EGFP measurements (from Figure 6E, F) are compared from neurons transfected 
for 20-24 hours with either SBP-EGFP-GluK2 or SBP-EGFP-GluK2 EPAS. This is to ensure 
there is no difference in the expression levels of the two different DNA constructs. 4 
independent experiments and n=82-92. p>0.05, Welch’s T Test. 
 
 
